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Abstract 
 
Health Technology Assessment (HTA) relies on evidence-based medicine to inform 
drug coverage recommendations about the most efficient use of resources.  Despite 
appraising the same evidence based on similar methodological approaches, HTA 
recommendations for the same drug differ across countries.  This thesis aimed to 
understand the reasons for these differences, and based on cross-national comparisons, 
whether they are a consequence of methodological challenges in HTA.  A mixed 
methods research design was used to develop a methodological framework that allows 
to breakdown these complex processes in a comparable and understandable manner, by 
considering: (a) the evidence appraised, (b) its interpretation, and (c) how this 
influenced the final decision.  Ten orphan drug-indication pairs appraised in four 
countries (England, Scotland, Sweden and France (N=35)) were systematically 
analysed and compared on this basis.  Results present the criteria accounted for at each 
stage of the process in the decisions, the reasons for differences across countries, and 
how HTA bodies are dealing with issues relating to orphan drugs.  Quantitative 
analysis of these provided information about agency-specific risk and value 
preferences, and measured agreement in interpreting the same evidence.  There was 
heterogeneity within and across countries in the criteria accounted for and reasons for 
cross-country differences.  Interviews to competent authorities provided insights about 
these differences and implications for HTA.  Although agreement was seen in the 
evidentiary requirements or preferences, there were subtle differences in the 
circumstances where uncertain evidence may be considered acceptable, partly 
explaining diverging HTA recommendations.  The three main contributions of this 
thesis are: (1) the development of a methodological framework to understand what 
criteria feed into HTAs, which can be applied to other drugs and countries; (2) through 
its application, the identification of a full taxonomy of criteria considered in decision-
making; and (3) the ability to understand the differences in HTA recommendations 
across countries.  A better understanding of HTA in different settings may help 
advance these processes, and, ultimately, improve access to treatments.  
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1. Introduction 
 
Health care decision-makers are currently facing major challenges in providing equal, 
effective and high quality care subject to budget constraints.  This is partly due to 
increased drug expenditure accounting for a significant and ever rising proportion of 
national health care budgets as a consequence of population ageing (Drummond, 
Evans, LeLorier, Karakiewicz, Martin, Tugwell, & MacLeod, 2009a; NIH, 2011) and 
rising cost of new medicines (Bach, 2009; Congressional Budget Office, 2006; Light 
& Kantarjian, 2013).  In order to control the level of expenditures and use resources 
more efficiently, a variety of mechanisms have been implemented to target 
pharmaceutical price, volume, use, and distribution methods.  The focus of this 
doctoral thesis is on one such mechanism: health technology assessment (HTA) used 
for value assessments and coverage decisions.  
 
Since its introduction in 1967 in the US, the increasing uptake of HTA has been driven 
by the need to control expenditures by seeking to obtain value for money (Banta, 
2003).  The US Congressional Office of Technology was the first to introduce and 
define HTA as “a comprehensive form of policy research that examines the short- and 
long-term social consequences of the application or use of technology” (United States 
Congress, 1976).  It was first implemented in Europe in the 1980s with the creation of 
the Swedish Council on Technology Assessment in Health Care (SBU), followed by 
many countries in Europe and around the world (Banta & Jonsson, 2009).  With its 
maturation and expansion over time, the definitions of HTA are defined more broadly 
and go beyond the synthesis of evidence about efficacy, safety and cost-effectiveness.  
It has been more recently defined as “a form of policy research that examines short- 
and long-term consequences of the application of a health-care technology.  Properties 
assessed include evidence of safety, efficacy, patient-reported outcomes, real world 
effectiveness, cost and cost-effectiveness as well as social, legal, ethical, and political 
impacts” (ISPOR, 2003) 
 
The rationale for having such a mechanism is to allow for a systematic identification of 
treatments which have clinical and cost-effectiveness or that provide additional 
therapeutic benefits when compared to existing standards of care, and to set priorities 
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accordingly.  Theoretically, this should shift resources from cost-ineffective treatments 
or those with relatively inferior clinical benefit, and result in a more efficient use of 
health care resources under which greater value for money and access are achieved 
(Department of Health, 2010).  
 
Although it is assumed that HTA outcomes are likely to be similar across settings 
because the clinical and safety evidence considered is - in the majority of cases - 
similar for the same drug-indication pair, in practice evidence from the literature 
suggests that HTA outcomes vary greatly across settings.  HTA is a complex process 
that operates within a multidisciplinary field with differences at each stage.  These 
variations are a consequence of disparities in the HTA processes (e.g. evidence 
considered, methods used for the assessment, interpretation of the evidence), their 
national context (e.g. budget constraints, prioritization of disease areas), the timing of 
the appraisals, the level of stakeholder involvement, and their implementation in 
practice (e.g. advisory or regulatory role) (Cairns, 2006; Clement, Harris, Li, Yong, 
Lee, & Manns, 2009; Drummond et al., 2009a; Kanavos, Manning, Taylor, Schurer, & 
Checchi, 2010a; Kanavos, Nicod, Van den Aardweg, & Pomedli, 2010b; Morgan, 
McMahon, Mitton, Roughead, Kirk, Kanavos, & Menon, 2006; Nicod, 2010; Pomedli, 
2010; Richards, 2010; Sorenson, 2009; Sorenson, Drummond, & Kanavos, 2008; Van 
den Aardweg, 2010; Velasco-Garrido, Borlum Kristensen, Palmhoj Nielsen, & Busse, 
2008; Velasco-Garrido & Busse, 2005).  It may also be that some of these differences 
are a consequence of weaknesses in HTA methods and their application, possibly 
resulting in resources not being used optimally.  If this were the case, patients would 
have access to certain treatments in some countries or regions and not in others. 
Patients would also incur the negative consequences of resources not being used 
optimally if their treatment was not reimbursed because of insufficient funds spent 
inefficiently elsewhere. 
 
Consequently, in order to ensure that these cross-country differences are legitimate and 
not a consequence of weaknesses in HTA methods and their application, to increase 
transparency between regulators and other stakeholders to improve the quality of the 
submissions, and to improve HTA methods, there is a need to understand why they 
occur.  The objectives of this thesis are in line with this need. 
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This thesis begins by discussing the European pharmaceutical regulatory environment 
and introducing the role of HTA amongst other market interventions (Chapter 2.1).  
The drug development process, followed by an overview of HTA and the 
characteristics of HTA bodies are then explained (Chapter 2.2-2.3).  The subsequent 
chapter (Chapter 3) synthesises the findings from selected literature reviews conducted 
around four topics of interest: (a) HTA as a value assessment tool, which presents the 
different approaches to using HTA as a value assessment tool (Chapter 3.1); (b) the 
HTA framework and its main limitations, which outlines the methods used to 
undertake HTA and their limitations (Chapter 3.2); (c) the factors that distinguish 
orphan drugs from other disease areas (Chapter 3.3); and (d) HTA in different settings, 
which summarises the existing evidence that compared HTA recommendations across 
more than one country and therapy area (Chapter 3.4).  These were used to identify the 
gaps in the literature and derive the hypotheses and research questions of this thesis, 
outlined in Chapter 4 together with the plan of the PhD.  Chapter 5 summarises the 
methodological approaches used, while Chapters 6-10 are the empirical chapters of the 
thesis.  Chapter 6 sets the scene for the remainder of the thesis by quantifying the 
extent and contradictory nature of the differences in HTA recommendations issued 
across countries, highlighting the need to query why they occur.  Chapter 7 develops 
and pilots a methodological framework enabling to systematically compare HTA 
decision processes as reported in the HTA reports across countries.  Chapter 8 then 
applies this framework to a larger sample of ten orphan drugs, providing a more 
structured and fuller understanding of the reasons for differences across countries.  
Chapter 9 focuses specifically on one aspect of the decision-making process: the 
scientific and social value judgments.  It aimed to understand how the decision-
makers’ value judgments influenced the decisions and to further the debate as to 
whether orphan drugs deserve special status.  Building on the findings from the 
previous empirical chapters, Chapter 10 aimed to develop a broader perspective about 
how value is assessed for orphan drugs and how differences affect reimbursement 
decisions based on interviews of representatives of the four European HTA bodies.  
The main contributions and conclusions of this thesis, policy implications, limitations 
and future research agenda are presented in the final chapter (Chapter 11). 
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2. The Pharmaceutical Environment and Health Technology 
Assessment  
 
This chapter provides the conceptual background to this thesis and describes the 
pharmaceutical regulatory environment, the drug development process and where HTA 
stands in this process, and the characteristics of HTA bodies.  
 
2.1. The European Pharmaceutical Regulatory Environment 
 
Pharmaceutical expenditure accounts for a large proportion of the total health care 
budget estimated at an average of 16.6% of total health expenditures in European 
OECD countries in 2011 (OECD, 2014), and continues to rise every year (Figure 2-1).  
The main drivers of expenditure are the increasing volume of drugs being consumed 
and the high cost of the new medicines being marketed (Mousnad, Shafie, & Ibrahim, 
2014).  For pharmaceutical expenditures to remain sustainable, policymakers recognise 
that costs should be contained within budgets and used more efficiently while 
continuing to incentivise innovation.  As a consequence, the European pharmaceutical 
market is heavily regulated for both on-patent and off-patent medicines (e.g. generics). 
 
Pharmaceutical markets are imperfect and require a number of interventions.  There 
are various factors that are responsible for this (McGuire, Drummond, & Rutten, 
2002).  First, patients with a given disease may receive different treatments due to 
variable symptoms, variable levels of tolerance to treatment, and various medical 
habits of patients and physicians.  This results in an inconsistent demand for any 
particular medication.  Second, the use of any particular medication is generally not 
decided by the consumer, but by the health provider, generating a so called “agency 
relationship” (Folland, Goodman, & Stano, 2013).  This is due to the asymmetry of 
information existing between the provider and consumer, where the consumer 
generally trusts the choice of the provider given his lack of knowledge regarding his 
health status and treatment options.   
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Figure 2-1. Average annual growth rate of GDP per capita, in real terms, and annual growth rate per capita in real terms of total 
health care expenditure (%, USD PPP) 
 
Source: (OECD Health Statistics, 2013). 
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Third, the existence of a third party payer, e.g. health insurance, introduces additional 
complications.  Consumers may want to get as many and as expensive medications for 
themselves, if they do not cost them money (moral hazard) (Folland et al., 2013).  
Physicians can also make moral hazard worse, through the so-called “supplier-induced 
demand”.  On the other hand, the third party payer may restrict the use of medications 
by developing a list of accepted medications (positive list) or by limiting indications, 
among others.  Fourth, the market may also be biased by the fact that some patients are 
willing to pay more money for a treatment that they believe will be superior.  This 
introduces the concept of “elasticity of the demand”: consumption of a given 
medication may be more or less affected by a change of price.  If price increase results 
in a minor decrease in demand, the elasticity is considered low (inelastic).  On the 
other hand, if a price increase results in a substantial change of consumption, the 
elasticity is considered high (elastic).  
 
In such an imperfect market, regulatory interventions are needed to protect consumers 
and have been implemented both on the demand and supply-side and drive market 
access (Figure 2-2).  On the demand-side comprising the consumers (e.g. patients) and 
providers (e.g. prescribers and dispensers), measures can be financial and non-
financial.  For the consumer, measures such as co-payment, co-insurance, a deductible 
or a flat fee per prescription have been implemented with positive and negative effects 
depending on their personal wealth.  For example, high levels of co-payment can 
impoverish certain patients, whereas including a maximum amount to be paid by the 
consumer (deductibles or exoneration) may limit the amount of co-payments 
particularly for patients with chronic conditions.  For the provider, prescription 
budgets, including compulsory generic prescription, can encourage physicians to 
prescribe generic drugs.  Generic substitution and flat fee combined with regressive 
margins are measures encouraging pharmacists to dispense cheaper products.  
 
On the supply-side, patent protection grants exclusive rights to a patented molecule 
from being used, copied or traded for a period of up to 20 years.  This is to protect and 
reward innovation.  In Europe, the Supplementary Protection Certificate (SPC) 
prolongs this period up to 5 years depending on the product’s novelty.
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Figure 2-2. Pricing and reimbursement pharmaceutical policies for market access 
 
Source: The author. 
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During this time, the manufacturer benefits from a monopolistic position.  This is 
countered by policies targeting pricing and reimbursement to ensure that excessive 
profits are not made from this monopolistic position.  A variety of pricing mechanisms 
exist, where the price is based on: the expected returns (e.g. cost-plus pricing), the 
average price of a basket of countries (e.g. reference pricing), or the value of the 
treatment (e.g. value-based pricing).  Prices can also be driven by negotiations between 
the manufacturer and the payer (e.g. price-volume agreements).  Pricing is 
complemented by the conditions for reimbursement, which determines whether the 
treatment is reimbursed, at what price and with what level of co-payment.  In parallel, 
a number of generic policies may facilitate generic penetration once patents expire 
(e.g. Bolar provision) (Kanavos, Costa-Font, & Seeley, 2008).   
 
National drug policy objectives in Europe are relatively uniform and include: 
“universal access for all citizens, effective care for better health outcomes, efficient use 
of resources, high-quality services and responsiveness to patient concerns” (McGuire 
et al., 2002).  Given the complexities of this market and its imperfections, we have 
seen that it is highly regulated and includes contradictory or complementary measures 
in order to reach a reasonable balance to achieve these goals.  Despite these and due to 
the increasing (pharmaceutical) expenditures, we are facing issues around affordability 
where current budgets are insufficient to cover population needs.  Therefore, decisions 
about which drugs national health care budgets cover have to be made.  HTA is 
increasingly being used to support such decisions across Europe, Canada and 
Australia, and is increasingly used elsewhere in the world as it aims to ensure that 
health care resource allocation decisions are efficient.  In this respect, it has recently 
been recognised during the World Health Assembly as a means towards universal 
health care (Sixty-seventh World Health Assembly, 2014). 
 
The focus of this thesis is on HTA and its application across different Member States 
for new patented prescription drugs (given they are one of the main drivers of health 
care expenditures), with an orphan designation by the European Medicines Agency 
(given they are often high cost medicines and can be viewed as outliers for HTA).  The 
next section describes the drug development process and where and why HTA fits in 
this process. 
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2.2. Drug Development Process  
 
Across the drug development pipeline, very few drugs make it past clinical testing and 
only one in 57 drugs developed actually make it to the market (Portfolio Management 
Solutions).  R&D costs are estimated to range from $800 million to $1.3 billion 
dollars, including the cost of failures (DiMasi & Grabowski, 2007; DiMasi, Hansen, & 
Grabowski, 2003; Vernon, Golec, & Dimasi, 2010).  One recent study argues that this 
is an overestimate and is based on unknown factors (Light et al., 2013).  This may be 
due to the true R&D cost that cannot be fully observed because of the cross-subsidy 
existing between successful and unsuccessful products and the uncertainties regarding 
innovative processes (McGuire et al., 2002).  Nevertheless, high drug prices are often 
explained by the high attrition rates and the strict evidence standards required to pass 
regulatory hurdles.  Additionally, very few of the new drugs entering the market are 
breakthrough or first-in-class: as little as 45% of drugs being tested in phase III trials 
are first-in-class, and may still potentially be unsuccessful (Long & Works, 2013).  In 
cancer, one study showed that only twelve drugs approved in 2012 provided a survival 
benefit of more than two months (Light et al., 2013).  Recently, the market is shifting 
from blockbuster to more niche and specialised markets, such as personalised 
medicines.  One of these niche and specialized markets is for rare diseases, discussed 
in Chapter 3.3. 
 
During the drug discovery, once a potential drug has been developed and appears 
promising, it can take up to ten years or more to perform the necessary clinical trials to 
generate evidence about its safety, quality and efficacy, which are requirements for 
marketing authorisation.  In Europe, the marketing authorisation process occurs either 
at European level (“centralised procedure”) through the European Medicines Agency 
(EMA), or at national level (“decentralised procedure”).  For example in the UK, the 
national regulatory body is the Medicines and Health care Products Regulatory 
Agency (MHRA). 
 
Marketing authorization is not sufficient to ensure patient access to these new drugs.  
Once market authorization is granted for a new drug, the marketing authorization 
holder (MAH) (e.g. the manufacturer or sponsor) then files an application to obtain 
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coverage by the national health systems in each individual country to their local 
Pricing and Reimbursement authorities (Figure 2-3).  Therefore, access to these 
treatments largely depends on the outcome of the pricing and reimbursement decisions, 
because such decisions drive both their affordability and availability.  This consists of 
the reimbursement decision (e.g. yes/no), the coverage rate (e.g. % of the drug price 
covered), and the final drug price (e.g. cost-effectiveness pricing).  In countries with 
HTA, these decisions are supported by whether the drug under review is considered to 
provide value for money, where the value of using this drug in real world settings in 
terms of costs and benefits is assessed, while considering the related social, ethical and 
legal implications.  
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Figure 2-3. Drug development process and orphan designation 
 
Source: The author. 
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2.3. The characteristics of different HTA bodies  
 
HTA bodies are generally in charge of deciding or making recommendations for the 
pricing and/or reimbursement of a technology, and are either at arm’s length or 
integrated with other activities.  The former includes England & Wales, Scotland, 
Sweden and France, (Appendix A), and the Dutch Health Care Insurance Board 
(Zorginstituut Nederland, ZIN) advising the government on the statutory health 
package while being responsible for risk equalisation and other activities.  Another 
example of the latter is the AIFA in Italy, which is the Italian Medicines Agency in 
charge of marketing authorisation, reimbursement, and pricing of drugs through 
negotiations with manufacturers.  HTA activities are generally funded with public 
monies (direct or indirect taxation, user fees, or other contributions), though this varies 
depending on the country.   
 
Responsibilities and memberships depend on whether the HTA body is regulatory 
(with legally binding coverage recommendations), or advisory (who issues a 
recommendation to the final decision-maker (e.g. Health Ministry)).  The general 
objective of the HTA will define the responsibilities in how it is conducted.  The scope 
is generally outlined before initiation of the HTA process, and defines the aim of the 
review and the evidence required (e.g. stage of the HTA, perspective adopted) 
(Drummond, Schwartz, Jonsson, Luce, Neumann, Siebert, & Sullivan, 2008).  Topic 
selection is a priority setting process about the technologies to be appraised, and are 
based on a number of criteria and types of technologies (Sorenson et al., 2008).   
 
The burden of proof of value for money rests with the manufacturer, who is asked to 
submit an application outlining their product for review by the HTA bodies.  Unlike 
marketing authorisation, HTA bodies may then conduct additional analyses in-house 
or by independent analysts (e.g. universities or expert groups), and focus on verifying 
the assumptions in the manufacturer’s submission or in generating additional evidence 
and redoing an HTA.  Each HTA body has their own HTA methodological 
requirements summarised in their submission guidelines, which may differ across 
countries.  For example, the appropriate comparator may be the treatment that is 
intended to be replaced by the new drug or the most cost-effective standard of care.  
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The final outcome of HTA is in the form of a recommendation or decision about 
whether to reimburse, reimburse under certain conditions, or not reimburse the drug 
under review.  
 
Even with a common objective in assessing whether new health technologies provide 
value for money, HTA bodies may vary in their responsibilities and membership, in 
the assessment procedures and methods, in the type and timing of the HTA, and in its 
dissemination and implementation (Chalkidou, Tunis, Lopert, Rochaix, Sawicki, 
Nasser, & Xerri, 2009; Sorenson et al., 2008).  In this respect, while cross-national 
differences in the HTA coverage recommendations made are legitimate due to these 
contextual considerations, they may also be a consequence of how HTA is applied in 
different settings and its methodological limitations.  Therefore, it is essential to 
understand and differentiate the reasons behind such cross-national differences, given 
that these have direct implications for patient access and indirect implications for 
society as a whole if resources are used inefficiently.  This is in line with the research 
questions and objectives of this PhD, further discussed in Chapter 4.  Beforehand, a 
selected review of the literature was performed in order to frame the problem and 
identify in a more systematic manner the gaps in the literature used to derive the 
research questions of this thesis.  Four areas were explored and synthesised in the next 
chapter: (a) how HTA works as a value assessment tool, (b) the HTA framework and 
its limitations, (c) factors that distinguish orphan drugs from other drugs, and (d) the 
application of HTA in different settings. 
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3. Conceptual Background on HTA 
 
3.1. HTA as a Value Assessment Tool  
 
This section discusses the fundamental role of HTA as a value assessment tool in the 
health system placing it into context based on a comprehensive review of the health 
services research, health policy, health economics, and medical literatures.  
 
Given that the main goal of policymakers in the health care sector is to maximise 
health within a given budget, HTA aims to ensure that the price paid for a technology 
reflects its value and provides value for money (Hurley, 2000).  Fundamental to the 
definition of HTA is the concept of “value” and how different stakeholders perceive it 
differently within and across health care systems.  Value can be perceived within the 
context of efficiency, where only the most efficient technologies would be reimbursed 
within an allowable budget.  This approach would not necessarily account for what 
really matters to society and to those being treated (Caro, 2009).  Generally, there is 
agreement that HTA is an appropriate tool to measure value.  The main issue is 
whether the notion of “value” captures what is valued by patients, carers and society.  
“Value” could then reflect specific attributes such as innovation, which may have 
direct implications for the patient (e.g. improved prognosis or quality of life) and 
society (e.g. better productivity and ability to contribute to society), but also potential 
spill-over effects that could benefit other patients and disease areas (e.g. new molecule 
or mechanism of action that could work in other disease areas).  Therefore, value can 
be regarded as an umbrella concept that encompasses a range of facets relating to 
different stakeholder perspectives and capturing different attributes of interest (e.g. 
innovation). 
 
The definition of HTA outlined in Chapter 1 captures well this multidisciplinary and 
multidimensional approach, as does the conceptualisation of a “full HTA” proposed by 
David Eddy, which can be completed in up to four –ordered- stages (Figure 3-1): (a) 
the analysis of evidence (e.g. evidence-based medicine), (b) the outcomes analysis 
(e.g. benefit-risk ratio), (c) the analyses of cost and cost-effectiveness, and (d) the 
analysis of ethical and legal implications of the technology (Eddy, 2009).   
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Figure 3-1. Relationship of evidence-based medicine and technology assessment  
 
Source: (Eddy, 2009) 
 
Evidence-based medicine is the basis of HTA.  It is a way to synthesise and formulate 
in a clear way the best available evidence for a specific health problem based on a 
systematic and critical appraisal of this evidence (HTAglossary.net, 2015).  This is 
then used to measure the benefit-risk ratio for the specific health problem of interest, 
typically comparing two interventions (e.g. the new treatment against standard 
practice).  Including cost considerations allows for an estimation of the cost-
effectiveness of these two treatment interventions (e.g. whether one is more cost-
effective than the other).  This is done using economic evaluation, which can take a 
number of forms.  Therefore, HTA measures the incremental benefits and the 
incremental costs between the technology of interest with existing options, usually 
standard care used as a benchmark (HTAI Policy Forum Meeting, 2013), and is 
modelled using economic evaluation techniques to account for certain assumptions, 
such as extrapolating the known effects into the long-term.  Deciding on whether the 
outcome of this economic model demonstrates adequate value for money for the 
technology can be deliberated while accounting for ethical and social considerations, 
where certain outcomes may be more or less acceptable given these contextual 
considerations.   
 
The ordering of these four steps signifies that the second cannot be done without 
having accomplished the first step, and so forth.  Further, not all HTAs are full HTAs, 
whereby some may stop at the assessment of incremental value (step two), others at 
the cost-effectiveness analysis (step three), and the most advanced will complete all 
four steps (Eddy, 2009).  For example, the Haute Autorité de Santé (HAS) in France 
did not, at the time work on this thesis commenced, account for costs and cost-
effectiveness but focused solely on incremental benefit translated into an ASMR 
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(Amélioration du Service Médical Rendu) rating.  This allows for drugs across all 
therapy areas to be compared using this single measure which encompasses a range of 
attributes in order to decide on its coverage.  Recently, it has implemented a 
requirement for economic evaluation for those drugs considered to provide additional 
clinical benefits (ASMR I-III) or costing more than 20 million euros to the health care 
system (HAS, 2012).  In England, the National Institute for Health and Care 
Excellence (NICE) relies on cost-effectiveness and accounts for equality issues or end-
of-life treatments.  HTA bodies may use different attributes to valuing benefit (e.g. 
survival, health-related quality of life (HRQol).  NICE, for example, requires that these 
health effects be expressed in QALYs (“quality adjusted life years”), which is a 
composite measure of improvement in length of life and in HRQol (NICE, 2013).  This 
is not the case for the other HTA bodies. 
 
Many different methods, both quantitative and qualitative, are being used to devise 
these measures of value on the basis of evidence-based medicine.  The outcomes of 
interest for the health benefit include measures of therapeutic effect (e.g. effectiveness, 
safety) and/or of HRQol.  Quantitative methods include, for example, the analysis of 
survival data or the calculation of average costs.  In terms of qualitative methods, 
outcomes could be measured through interviews, focus groups, surveys, etc. and aim to 
elicit preferences, priorities or broader aspects not covered by quantitative methods 
(HTAI Policy Forum Meeting, 2013).  
 
The “three-step HTA” can be summarised by the cost-effectiveness formula (Box 1).  
The ratio of incremental costs and incremental benefits demonstrates the incremental 
cost-effectiveness ratio (ICER), providing information about the extra cost to be paid 
for an extra unit of effect.  This represents a measure of value of this new treatment 
compared to standard care.  It is worth paying for (or is cost-effective) if it is within 
the decision-maker’s maximum willingness-to-pay (WTP) threshold.  The fourth step 
(e.g. analysis of ethical and legal implications of the technology) would be accounted 
for when deliberating about the ICER. 
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Despite its fundamental role in value assessment, HTA is not without its controversies.  
In addition to the issues discussed previously around defining “value”, these decision-
making processes most often rely on incomplete or imperfect evidence, referred to as 
“uncertainty”.  Value judgments are being made about the acceptability of this 
uncertainty.  Different methods exist to deal with uncertainty, as discussed in the next 
section, but the decision about its acceptability relies on the decision-maker 
Committee’s own (scientific) judgment.  These decisions may also be influenced by 
the Committee Members’ social value judgments about considerations related to living 
with a disease and taking a course of treatment, which may also influence their 
judgment based on their own experience or on what they believe society would prefer.  
This is illustrated in Figure 3-2.   
 
Figure 3-2. Visual model of the decision making process 
 
Source: The author. 
 
Box 1: The cost-effectiveness formula (≈ 3 step HTA) 
∆cost/∆effect = ICER < WTP 
Legend: ∆cost = difference between the cost of a new treatment and its comparator; ∆effect = 
difference between the effect of a new treatment and its comparator; ICER = incremental cost 
effectiveness ratio; WTP = willingness-to-pay threshold. 
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Generally, the uncertain estimates of clinical benefit and costs accounted for in the 
cost-effectiveness model result in uncertain ICER estimates.  The acceptability of this 
uncertainty depends on the decision-makers’ value judgments during the deliberative 
process.  However, the higher and more uncertain, the more likely they are to lead to a 
negative coverage recommendation.  In such cases, patients are being told they will not 
receive a treatment that could provide some benefit to them because it is not “cost-
effective”.  This is often misunderstood and interpreted as putting a monetary value on 
life.  Some decisions have led to strong reactions from different stakeholders and the 
media.  For example, NICE’s decision against the use of Arbiterone for advanced 
prostate cancer before chemotherapy was heavily criticised: “NICE decision on 
prostate cancer drug is a 'kick in the teeth' for patients” say UK Prostate Cancer 
(Prostate Cancer UK, 2014).  Similarly was their decision to deny access to Herceptin 
to treat breast cancer due to a high cost per QALY: "It has given me back my normal 
life.  You just can't put a price on it" (Orr, 2014).   
 
Several important questions arise in light of these controversies around whether 
current HTA approaches sufficiently capture the attributes of value that matter most to 
patients, their carers and society.  These include, for example, patient preferences (e.g. 
preference for certain side effects over others), considerations of additional attributes 
of value (e.g. innovation), or whether benefits beyond health gains are to be considered 
(e.g. productivity losses).  There is no consensus around how these are accounted for 
across HTA bodies.  These issues reflect the previous discussion about capturing 
value.  The next section discusses some of these key issues pertaining to the use of 
HTA in assessing the value of a drug. 
 
3.2. The HTA Framework and its Main Limitations  
 
Despite the extensive and continuously increasing use of HTA as a decision-making 
tool, its methods and processes present significant challenges; these are often a 
consequence of issues around evidence generation, the outcomes to measure 
effectiveness, costs or cost-effectiveness, the extent to which willingness-to-pay 
thresholds (WTP) are used explicitly, and how they are interpreted.  This section 
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portrays the main challenges and their implications on the final HTA recommendation, 
and focuses on each of the components of a “full HTA”.   
 
3.2.1. Evidence-based medicine & comparative effectiveness 
 
HTA relies on evidence-based medicine to measure the comparative effectiveness of a 
set of treatment interventions in real world settings, and assess the clinical benefit of 
the treatment under consideration.  This differs from the requirements for marketing 
authorisation, where the focus is solely on the treatment’s efficacy, quality and safety 
compared to placebo in a controlled environment.  At the time of an HTA, information 
about the treatment’s effectiveness - in real world settings – is rarely available since 
HTA is often conducted soon after market authorisation (Figure 2-3).  Therefore, HTA 
relies mainly on imperfect or incomplete – or uncertain - evidence from clinical trials 
conducted in controlled environments, which most likely do not capture the full effects 
of the treatment since the trial period is often inferior to the time horizon during which 
the treatment produces its effects (Sculpher, Claxton, Drummond, & McCabe, 2006).  
Uncertainty refers to the fact that we can never know for certain what the mean 
(expected) costs and effects would be if the treatment is provided for a particular 
population of patients, even if they have the same observed characteristics” (Claxton 
2008).  Decision-makers make scientific value judgments about the extent to which 
this uncertain evidence is acceptable.  This includes judgments about whether the 
evidence presented captures the effect of the intervention, whether it is generalizable to 
the local context of the decision, whether quality of life changes are accurately 
captured, or whether it is appropriate to impose restrictions to population subgroups 
(Rawlins 2014).  Assessing uncertainty is important in terms of using a correct 
estimate of costs and effects, of determining if existing evidence is sufficient, and to 
assess the consequences of an uncertain decision (Claxton 2008). Part of this 
uncertainty relates to the estimates of costs and effect used, where no two different 
individuals will have the same response to treatment or way of living the disease. It 
may be greater in some cases (e.g. cancer) or less in others (e.g. cardio-vascular), and 
the evidence produced will aim to capture this effect in the best way possible but will 
always have some degree of uncertainty.   
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NICE defines three types of uncertainty: structural, parameter and uncertainty around 
the choice of data sources (NICE 2009a): structural uncertainty relates to the 
assumptions made to construct a model (e.g. treatment pathway), parameter 
uncertainty relates to the mean values of the parameters considered (e.g. clinical 
endpoints, utilities), whereas uncertainty about the choice of data sources that provide 
the values for the key parameters (e.g. sufficient to capture the full effects of the 
treatment).  The type of uncertainty discussed throughout this thesis relates to both 
parameter uncertainty and uncertainty about the sources of data, however they were 
not distinguished as such but similarly to how they were reported or discussed during 
the interviews.  
 
Consequently, uncertainties are inevitable and making a decision failing to account for 
them can be misleading (Rawlins, 2008).  Different statistical mechanisms exist to 
address this issue, such as probabilistic or deterministic sensitivity analysis (Claxton, 
2008).  The main question continues to be around appropriate methods to tackle these 
uncertainties, and whether the estimates or the methods used capture sufficient 
information about the expected benefits and costs.   These decisions therefore rely on 
the decision-makers scientific and social value judgments about the acceptability of 
this imperfect or incomplete evidence and about certain treatment and disease 
considerations that may not have been captured in the evidence presented (Rawlins 
2014). 
 
The debate around uncertainty also opens further discussions about when requirements 
for the generation of additional evidence should be made to manufacturers after a 
positive or “only in research” HTA recommendation (e.g. marketing authorisation 
under exceptional circumstances) (Claxton, 2008).  From a more ethical perspective, 
there are on-going debates about whether patients should be given early access to a 
treatment that is being evaluated within a clinical trial and shows positive interim 
results at the cost of producing lower quality evidence.  For example, interim results 
for sorafenib (2nd line treatment for renal cell cancer) were positive and the decision 
was taken to unblind the trial participants and provide treatment to all.  This resulted in 
uncertain evidence generation since the control group was unblinded before the end of 
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the trial, which impacted negatively on the reimbursement decision (Drummond et al., 
2009a). 
 
Many different types of studies contribute to demonstrating effectiveness (e.g. RCTs, 
observational studies).  Systematic reviews or meta-analyses are often required for 
HTA submissions in order to account for all existing evidence and avoid bias in 
selecting only a subset of studies when considering relevant information for a decision 
problem.  Direct comparisons are often considered the gold standard or preferred type 
of evidence for HTA bodies; though indirect comparisons or placebo-controlled trials 
are usually also accepted.  Evidence suggests that direct comparisons also have their 
limitations (e.g. often carried out as open trials), and can be addressed by combining 
all levels of evidence (e.g. direct and indirect comparative evidence) (Lu & Ades, 
2004; Madan, Stevenson, Cooper, Whyte, & Akehurst, 2011; Sutton, Ades, Cooper, & 
Abrams, 2008); though this may not be recognized across the board. 
 
Hierarchy of evidence is common practice, where RCTs are considered the gold 
standard despite their limitations.  For example, multi-drug interactions may not be 
identified in RCTs since patients with multiple morbidities are often excluded.  Some 
argue that non-controlled studies enable to capture elements that are not identified in 
RCTs (e.g. less common adverse effects) and consequently all levels of evidence are 
crucial for the evaluation of a technology (Rawlins, 2008).  Many questions about 
what constitutes evidence of sufficient quality remain, and as such HTA bodies may 
have different perceptions about the acceptable levels of evidence.   
 
The estimates of effectiveness capture two aspects of the treatment: 1) how well it 
works (e.g. life years gained), and 2) what impact it has on the patient’s HRQol.  
“HRQol includes physical and mental health perceptions (e.g. energy level, mood) and 
their correlates—including health risks and conditions, functional status, social 
support, and socioeconomic status” (CDC, 2016).  Symptoms alleviation would be 
considered a HRQol improvement.  A set of generic and disease-specific tools exist to 
measure the impact on HRQol, the most common and also often preferred method is 
the generic EQ-5D instrument enabling comparisons across disease areas.  This is 
summarized in a measure referred to as “utility” to the patient.  Current debate exists 
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around whether these HRQol measures really capture patient preferences and compare 
HRQol across disease areas accurately, considering that they are measured from 
healthy individuals (Ghislandi, Apolone, Garattini, & Ghislandi, 2002).  In some 
countries, the preferred metric for expressing both the duration and health-related 
quality of life is the QALY (“quality adjusted life years”), where one QALY represents 
one year of life gained in full health.  In other countries, the clinical effect is 
considered as a hard endpoint and HRQol as a soft endpoint.  Consequently and 
similarly to the above, many different methods, each with their own recognised 
advantages and disadvantages, exist to measure HRQol and effectiveness, and in the 
key question for HTA remains whether they accurately reflect the impact of a disease 
or treatment on a patient and their carers (Brazier, 2008). 
 
In summary, differences are seen in the way common HTA methods to estimate the 
treatment’s benefit are applied (e.g. QALY or clinical benefit of the treatment), which 
are likely to result in differing HTA outcomes.  Indeed, methods can take many 
different forms, and there is no clear understanding about what constitutes evidence of 
sufficient quality.  These decisions therefore rely on the evidence presented and 
methods used for its interpretation, as well as the decision makers’ judgments about 
the acceptability and plausibility of this evidence made during the deliberative process 
and influenced by their own experience or what they believe society would prefer, as 
well as additional contextual considerations (e.g. political context). 
 
3.2.2. Costs (direct and indirect) and cost-effectiveness 
 
A similar scenario is seen for costs and cost-effectiveness.  Indeed, HTA often 
includes the economic consequences of different treatment alternatives (“3-step 
HTA”), referred to as comparative costs (Chalkidou et al., 2009).  The costs collected 
are either direct medical or non-medical costs (e.g. hospitalisation or carer services, 
respectively), or indirect costs to the health care system (e.g. productivity losses or 
informal carers).  Generally, costs vary depending on the context.  The cost of GP 
visits or hospitalization differs in different settings.  The perspective adopted will also 
determine which costs are included in the analysis.  For example, direct costs to the 
NHS and Personal Social Services are considered in England and Wales and in only 
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exceptional cases will costs outside this scope be considered (Sculpher, 2008).  In 
contrast, TLV in Sweden adopts a societal approach and considers both direct and 
indirect costs.  Cost can be measured using different methodological approaches from 
average per diem costs to micro-costing.  Consequently, cost estimates are also likely 
to differ across countries depending on the approach used (Hughes, Tilson, & 
Drummond, 2009). 
 
Once the costs and benefits of a new treatment and its comparator(s) are estimated, the 
next step is to determine whether the new treatment provides value for money; this is 
often done through an economic evaluation.  Economic evaluation uses decision 
analysis to model the different treatment paths from taking this new treatment or its 
alternative comparator, and account for the different events occurring (e.g. full health, 
death) and their probability of occurring.  These models allow for a number of 
assumptions to be made, such as to extrapolate short-term costs and effects over the 
long run, or under a set of assumptions (e.g. treatment is taken for 2 years, natural risk 
of death within different age groups is accounted for, probability of the event depends 
on the health state, etc.).  
 
Many different methods of economic evaluation exist, the most common being: cost-
utility analysis (CUA), which compares QALYs and costs of alternative treatments; 
cost-effectiveness analysis, which compares health outcomes (e.g. life years gained) 
and costs of alternative treatments, and cost-minimisation analysis, which compares 
the cost associated with two “identical” treatment alternatives.  Each HTA body has 
different preferences and requirements for economic evaluation modelling, which may 
also be one of the explanatory factors for different HTA outcomes, discussed later.  
Results from economic modelling are the incremental cost-effectiveness ratio (ICER), 
which provides information about the cost per extra unit of effect.  Whether or not it is 
cost-effective depends on whether it is within the limits of what is considered to 
provide value for money.  
 
3.2.3. Willingness-to-pay and “Other considerations” 
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The willingness-to-pay (WTP) is the maximum amount a payer is willing to pay for an 
extra unit of health benefit, which is specific to each country depending on national 
preferences and affordability.  High ICER estimates, which represent a high cost per 
unit of health benefit, are more likely to be rejected than lower ICER estimates.  
Evidence shows that the WTP threshold ranges between £20,000 and £30,000 per 
QALY in England and Wales, and increases with disease severity and need in Sweden 
(McCabe, Claxton, & Culyer, 2008; Pearson & Rawlins, 2005; Webb, 2009).  When a 
treatment’s ICER is less than the threshold, it is expected to receive a positive 
reimbursement recommendation, and when higher, it is expected to receive a negative 
recommendation.  Despite this, evidence suggests that decisions are not always 
consistent with WTP thresholds and may vary depending on the disease characteristics 
(e.g. disease severity) and level of progression, as well as on the treatment’s 
characteristics (e.g. curative or symptomatic) (Dolan, Shaw, Tsuchiya, & Williams, 
2005).  This may suggest that “other considerations” beyond ICER estimates are likely 
to have an impact on the final HTA recommendation.   
 
This is illustrated in a number of studies that identified variable WTP levels depending 
on the therapy areas being appraised.  Dupont and van Wilder compared the Belgian 
HTA recommendations for a sample of orphan and non-orphan drugs considered 
equally severe and innovative.  Orphan drugs received a higher rate of positive 
recommendations despite the less robust nature of the evidence considered for orphan 
conditions (Dupont & Van Wilder, 2011).  Another study showed that 43% of the 
orphan drugs appraised in Scotland had an ICER greater than the £30,000 informal 
WTP threshold and almost all were rejected for reimbursement; suggesting that more 
flexibility in accepting high and uncertain ICERS may not be given to orphan drugs 
(Vegter, Rozenbaum, Postema, Tolley, & Postma, 2010).  Simoens and colleagues 
(2011) demonstrated that SMC and NICE have higher WTP levels for cancer drugs 
(including orphan indications) than for other disease areas (Simoens & Dooms, 2011).   
 
Such disparities in accepting different levels of ICER may reflect social value 
judgments or preferences, where the decision makers prioritise certain treatments 
because of considerations around living with the disease or taking a treatment.  Such 
social values may either be elicited from a representative sample of society (e.g. 
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disease severity in Sweden, where it is recognised that higher ICERs are accepted for 
patients with high disease severity), or non-elicited and relies on the personal judgment 
of the decision-maker.  There is a need to better understand the value judgments made 
throughout these processes and the weight they have on decisions.  The lack of 
consistency and transparency in accounting for these “other considerations” were 
highlighted by Earnshaw and colleagues (Earnshaw & Lewis, 2008). 
 
3.3. Factors that distinguish orphan drugs from other drugs  
 
Rare diseases affect small patient numbers, less than five in 10,000 in Europe and less 
than 200,000 people in the US.  There are currently between 5,000 and 8,000 rare 
diseases; put together they affect six to eight per cent of the European population.  
These conditions are often life-threatening, debilitating and frequently genetic 
(European Commission, 2015b).   
 
In the past, R&D for the development of treatments against rare diseases was not 
sufficiently attractive, given the modest returns from a small number of patients.  
Based on the principle of equality, where all patients are entitled the same quality of 
care, incentives were implemented at the marketing authorisation level to stimulate 
research and development (European Union, 1999).  According to recent regulations, 
all medicinal products treating a rare disease are eligible to receive an orphan 
designation and benefit from these incentives.  In Europe, incentives are granted at the 
marketing authorisation level by the EMA and include free regulatory advice for 
clinical development, accelerated marketing authorization review procedures, a 50% 
fee reduction on the regulatory procedure and marketing exclusivity for ten years after 
marketing approval.  Orphan recognition and similar incentives are implemented in the 
US, Japan, Canada, and Australia.  Another characteristic is the willingness to grant 
early access to these treatments through the exceptional circumstances or conditional 
approval processes, depending on the Member State and under specific circumstances 
(e.g. treatment of a serious or life-threatening disease, no alternative treatment 
available, treatment being tested in clinical trials and in an active phase of marketing 
approval) (Orphanet, 2015).  These incentives have successfully stimulated the 
development of orphan drugs, as demonstrated by the increasing number of medicinal 
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products receiving orphan designations over the past decade compared to before 
(Kesselheim, 2011; US Food and Drug Administration, 2015).   
 
Despite the unique nature of marketing authorization procedures for orphan drugs, 
HTA processes are similar to other drugs.  Once these orphan drugs are granted the 
authorisation to be marketed, the MAH seeks coverage in each individual country in 
the same manner as those drugs for more prevalent conditions.  Given the substantial 
uptake of HTA in Europe and around the world, there is a high probability that the 
decision is evidence-based and informed by HTA.   
 
However, unlike other (non-rare) conditions, challenges exist in producing robust 
evidence for rare conditions.  Rarity implies that there is a lack of knowledge about the 
natural history of the disease, and a scarcity of scientific literature and of experienced 
clinical investigators around the world.  This is even more accentuated for those 
diseases with no existing treatments, where there is no knowledge about the clinical 
development path (Vickers, 2013).  The lack of knowledge about these diseases and 
their heterogeneous nature creates issues in designing, recruiting and conducting 
appropriate clinical trials.  Issues around trial design pertain to selecting the 
appropriate endpoints, treatment pathway(s) and trial duration; during the trial period, 
there may be difficulties in recruiting sufficient patient numbers from small patient 
populations and in generating meaningful trial results from scarce clinical experts; 
trials are often conducted on multi-sites requiring high fixed costs for each site and 
delays (Kesselheim, Myers, & Avorn, 2011; Vickers, 2013).  Additionally, trials for 
rare diseases are often smaller than those for more common conditions (Kesselheim et 
al., 2011), whereby treatment effects should be much greater to attain statistical 
significance, which may not be representative of the added benefit of some of these 
treatments for very rare conditions (Boudes, 2013).  This was shown in one study that 
compared the evidence for orphan and non-orphan cancer drugs, where trials for rare 
cancers were less likely to be randomized and double-blinded, and more likely to 
assess a surrogate outcome rather than a hard endpoint compared to trials for more 
common cancers (Kesselheim et al., 2011).  A number of innovative trial designs exist 
to deal with small patient trial populations, which minimize the number of patients 
included in the trial (e.g. with longer trials or innovative trial designs such as factorial 
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designs), or maximize on-treatment participants (e.g. N of 1 cross-over trial design) 
(Gagne, Thompson, O'Keefe, & Kesselheim, 2014), but their use is not often yet seen 
in practice (Kesselheim et al., 2011).   
 
This has implications for HTA, as the evidence for a treatment for a rare disease is 
likely to be subject to a high degree of uncertainty compared to the more common 
conditions; additionally, the price of orphan drugs are usually very high in order to 
recoup R&D investments from small patient populations.  As a consequence, an 
orphan drug is hardly cost-effective (Clarke, 2006; Denis, Mergaert, Fostier, 
Cleemput, & Simoens, 2010a; Drummond, Wilson, Kanavos, Ubel, & Rovira, 2007), 
as illustrated in Figure 3-3.  The main question therefore relates to whether we are 
willing-to-pay more for these conditions or whether we are willing to accept greater 
uncertainty in the evidence.  This is further discussed in the next section. 
 
Figure 3-3. HTA and cost-effectiveness 
 
Source: The author. 
 
3.4. HTA in Different Settings  
 
Even if the reasons for using HTA are similar across countries, David Eddy argues that 
differences across countries are inevitable because of the methodological approaches 
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used and the stages of the HTA carried out, often relying on the social and political 
circumstances in that particular setting (Eddy, 2009).  This was further emphasised in 
the last section, which highlighted the variety of ways to conduct HTA, even when 
similar methodological approaches are being used.  This section discusses evidence 
that compared HTA recommendations across countries and identified differences 
(Section 3.4.1), including cases when they related to decisions for orphan drugs 
(Section 3.4.2). 
 
3.4.1. Differences in HTA coverage recommendations across countries 
 
Cross-national differences in the HTA coverage recommendations made exist and are 
generally recognised, mainly because of the complexity of these processes and the 
context in which they operate (Banta, 2003).  Each country sets its own objectives for 
conducting HTA reflecting its values, preferences (e.g. population disease profile) and 
constraints (e.g. budget constraints, structure of the health care system), and 
consequently differences across countries in the HTA outcomes are inevitable (Banta, 
2003; Busse, Orvain, Velasco, Perleth, Drummond, Gurtner, Jorgensen, Jovell, 
Malone, Ruther, & Wild, 2002).  This is further emphasized in a recent systematic 
review of the literature that aimed develop a framework describing and comparing 
features of HTA bodies.  Substantial differences in the stages of an HTA process were 
identified: only 38% of the scope of HTA were similar across the four study countries 
(Germany, France, England, Sweden), 26% in the process, 29% in the methods, 40% 
in the dissemination, and in only 19% of the decisions (Schwarzer & Siebert, 2009).   
 
Variations across settings may be a consequence of national considerations, reflecting 
different priorities or preferences, but also a consequence of differences in HTA 
processes or other factors considered in the appraisals, possibly also reflecting 
weaknesses in HTA methods.  In the latter case, implications are that value for money 
may not be obtained for some of the treatments covered or that access to these 
treatments across countries may also differ, especially considering that HTA 
recommendations have shown to be fairly consistent with the final reimbursement 
decision (McMahon, Morgan, & Mitton, 2006; Wonder, Neville, & Parsons, 2006).  
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As a result, the need to understand the reasons for these differences and increase 
transparency is recognized.  A number of initiatives exist to increase collaboration and 
establish methods for the harmonization of methodological approaches to HTA (e.g. 
EUnetHTA, Pharmaceutical Forum).  The European Network for Health Technology 
Assessment (EUnetHTA), for example, aims to improve HTA methods and avoid 
duplication of efforts.  It has developed an HTA framework (the “HTA Core Model”) 
that enables the sharing of information across countries, and is piloting EU-level 
HTAs.  It has also developed a common methods for HTA through collaborative work 
between Member States, focusing on the clinical effectiveness of a treatment 
(EUnetHTA, 2015).  This research complements such initiatives in generating a better 
understanding of the causes for variation and areas where HTA methods may be 
improved and potentially result in a common agreement about their appropriateness. 
 
At the time this thesis began, eight studies comparing HTA recommendations across 
more than one country were identified. They identified important variations (Table 
3-1) (Clement et al., 2009; Kanavos et al., 2010b; Lexchin & Mintzes, 2008; Morgan 
et al., 2006; Nicod, 2010; Pomedli, 2010; Shah, Mestre-Ferrandiz, Towse, & Smyth, 
2013; Van den Aardweg, 2010).  Their research designs were generally in the form of 
retrospective descriptive or cohort analyses.  The level of agreement in the HTA 
recommendations issued across countries was measured in three of these studies and 
ranged between poor and moderate, further emphasising the extent of these differences 
(Clement et al., 2009; Lexchin et al., 2008).  Countries included in the comparisons 
were Canada, Australia, England, Scotland, France, and New Zealand.  
 
Morgan and colleagues compared coverage recommendations for the seventeen top 
selling drugs in four countries with a centralised drug review process (England, 
Australia, Canada, New Zealand), and evaluated their impact on use and spending.  
They showed that listing decisions differed substantially and may indicate differences 
in appraising and interpreting the evidence, in the alternatives covered, or in price 
negotiations (Morgan et al., 2006).  The manner in which these potential explanations 
for differences were identified was not described nor did it appear to have been 
explored systematically.  The main objective of the research was to discuss challenges 
relating to the centralised drug review process rather than identify cross-national 
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differences in a systematic manner, and – through these - derive recommendations so 
that these processes become more transparent and rigorous. 
 
Lexchin and colleagues also conducted a retrospective analysis of all HTA 
recommendations issued in Canada, Australia and Scotland until September 2006.  
They compared the HTA recommendations made for 51 drugs and analysed the 
clinical and pharmacoeconomic assessments made for individual drugs with diverging 
recommendations.  Results showed poor to moderate agreement in the 
recommendations issued across agencies (0.19 < k < 0.44), and differences in the 
clinical and pharmacoeconomic assessments in nine cases with diverging 
recommendations (Lexchin et al., 2008).  While the reasons for differences were 
explored in more depth compared to previous studies, they were considered 
meaningful and described in only nine cases, which potentially suggests that the depth 
of the analysis was insufficient to systematically capture the reasons for differences.  
This may be due to the nature of the comparison that focused on the clinical and 
pharmacoeconomic assessment, which may not be sufficient to capture the subtleties 
of how different agencies are dealing with uncertainty and how their concerns are dealt 
with across settings (e.g. means through a concern was deemed acceptable).  This 
would allow for a more extensive understanding of the application of HTA across 
settings, which could contribute to furthering the debate around how HTA bodies are 
dealing with uncertainty resulting from limitations in the HTA approach (which is one 
of the objectives of this thesis).  
 
Clement and colleagues conducted a retrospective analysis of all HTA 
recommendations issued in Canada, Australia, and England and Wales until 2008.  
Similar to the previous study, poor to moderate agreement (0.13 < κ < 0.55) in the 
recommendations issued across agencies was also demonstrated.  They also identified 
key issues known in these assessments, such as clinical and economic uncertainty, and 
to what extent such characteristics were identified in each of the study countries.  For 
example, clinical uncertainty was present in more than 40% of the submissions, but 
was lower for NICE reflecting its willingness to narrow down the indication to more 
effective and cost-effective niche groups of patients.  Three case studies were selected 
to illustrate some of the differences and similarities identified across countries.  They 
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concluded that listing variations were more likely to be a consequence of HTA 
processes than of the subjective interpretation of the evidence by each agency.  The 
study limitations recognise that differences exist in the way HTA bodies use clinical 
and/or cost-effectiveness, but that more research is needed to understand the reasons 
for these differences (Clement et al., 2009).  While this study identified a number of 
key issues, and illustrated similarities and differences through three case studies, they 
recognise that further research is needed to identify the reasons for these cross-national 
differences.  This would require a more systematic and in depth approach in the 
analysis made across a greater sample of compounds. 
 
A more recent study by Shah compared HTA decisions for seventy-six decisions in 
two oncologic areas: breast and colorectal cancer, and highlight important variations 
(Shah et al., 2013).  They then conducted a thorough review of those drugs that 
received diverging recommendations in order to understand the reasons for 
differences.  They identified three key recurring issues around surrogate endpoints, 
patient voice and comparator selection.  They also recognise other aspects influencing 
these processes, such as the different ways agencies are using the available evidence or 
dealing with uncertainty, but these were not further explored (Shah et al., 2013).  
While a more thorough and in depth analysis was undertaken compared to the 
previously reported studies, the level of detail in the methodological approach used 
(thematic analysis) was not sufficient for its transferability, nor was it clear to what 
extent the analysis was systematic, encompassing all factors captured in the decision 
reports influencing these decisions (including during the deliberative process), or 
allows for cross-country comparisons.  The study also lists a number of potential 
reasons explaining differences.  A more systematic and in-depth approach could 
constitute a stronger case to understand more comprehensively the limitations in the 
application of HTA and how these are dealt with across settings. 
 
Additionally, there were a number of studies that investigated the drivers of HTA 
decisions in a more systematic manner by focusing on one specific country (Devlin & 
Parker, 2004; Dakin, Devlin, & Odeyemi, 2006). These have not been covered in the 
literature review but are reflected upon in the Conclusion chapter together with any 
additional comparative studies published until 2016. 
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Table 3-1. Summary of existing evidence focusing on cross-national comparisons of HTA recommendations 
Author 
Year 
Objectives Method Countries Main findings Reasons for cross-country 
differences in the HTA 
recommendations 
How these studies differ from 
this thesis 
Morgan 
2006 
To explore 
features of the 
centralised review 
processes across 
countries, and 
compare the HTA 
processes and 
recommendations, 
and the impact of 
the decisions on 
cost and use  
Comparison of 17 
top selling drugs 
(2003) and 
reimbursement 
processes in the 
four countries 
Australia, 
Canada, New 
Zealand, UK 
Different HTA 
processes, and 
HTA 
recommendations 
across countries 
Differences in:  - what is appraised; - interpretation of the evidence; - coverage of therapeutic 
alternatives; - negotiation with suppliers 
 
The approach used to identify the 
reasons for different HTA 
recommendations was not described.  
The differences were presented as 
potential reasons.  They are 
considered not to have been examined 
systematically.  This is because the 
main objective was to discuss 
challenges relating to the centralised 
drug review process rather than 
systematically examining cross-
national differences 
Lexchin 
2008 
To compare HTA 
recommendations 
across countries 
Retrospective 
cohort analysis. 
To compare HTA 
recommendations 
across countries 
and explore the 
reasons when 
these were 
different 
Canada, 
Scotland, 
Australia 
Different 
recommendations: 
PBAC-CDR: 
moderate 
agreement  
CDR-SMC: poor 
agreement 
(Kappa score 
0.19<k<0.44)  
Potential reasons for differences in: - proposed price and effectiveness 
of competing products in the 
national markets;  - hospitalisation and physician 
visit costs; 
other considerations: disease 
prevalence and severity, perceived 
need, composition of the panel 
making the recommendation, the 
scientific rigor and relevance of the 
evidence for comparative safety and 
effectiveness 
The reasons for differences were 
explored in more depth compared to 
previous studies, however, they were 
considered meaningful and described 
for only nine cases.  This may suggest 
that the depth of the analysis was 
insufficient to systematically capture 
the reasons for differences.  This may 
be due to the nature of the comparison 
that focused on the clinical and 
pharmacoeconomic assessment, 
which may not be sufficient to capture 
the subtleties of how different 
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agencies are dealing with uncertainty 
and how their concerns are dealt with 
across settings (e.g. means through a 
concern was deemed acceptable)  
Clement 
2009 
To describe how 
clinical and cost-
effectiveness are 
used in coverage 
decisions, and 
identify common 
issues in the study 
countries 
Descriptive 
analysis of 
retrospective data 
England and 
Wales, 
Australia, 
Canada 
Different rates of 
positive 
recommendations:  
poor to moderate 
agreement (Kappa 
score 0.13<k<0.55) 
Most common causes of variation:  - narrowing down of indication 
(NICE); - price negotiations (PBAC); - different attitude towards drugs 
with little or no therapeutic 
benefit (CDR and PBAC); - cost-effectiveness data; - approaches to assessing low 
quality evidence (CDR, PBAC, 
NICE) 
While this study identified a number 
of key issues, and illustrated 
similarities and differences through 
three case studies, they recognise that 
further research is needed to identify 
the reasons for these cross-national 
differences.  This would require a 
more systematic and in depth 
approach in the analysis made across 
a greater sample of compounds 
Shah 
2013 
The aims are to 
identify key 
drivers of 
decisions and to 
understand the 
similarities and 
differences in the 
requirements of 
different agencies 
Qualitative 
thematic analysis  
Australia, 
Canada, 
England and 
Wales, 
Scotland, 
France 
Different 
recommendations 
across countries for 
cancer drugs, and 
reasons for these 
Main causes of variation : 
- interpretation of clinical endpoints ; 
- differing levels of patient input ; 
- issues around appropriate 
comparators. 
Other aspects listed but not explored 
in depth (e.g. ways agencies are 
using the available evidence or 
dealing with uncertainty) 
While a more thorough and in depth 
analysis was undertaken compared to 
the previously reported studies, the 
level of detail in the methodological 
approach used (thematic analysis) was 
not sufficient for its transferability, 
nor was it clear to what extent the 
analysis was systematic, 
encompassing all factors influencing 
these decisions (including during the 
deliberative process), or allows for 
cross-country comparisons   
Sources: (Clement et al., 2009; Lexchin et al., 2008; Morgan et al., 2006; Shah et al., 2013) 
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In summary, inter-country variability in HTA recommendations are well known to 
scientists preoccupied with comparative research because they may reflect weaknesses 
in the application of HTA.  This problem, together with its implications, has been 
identified and possible explanations examined.  The above mentioned studies all have 
in common that they highlight the extent of these differences, by comparing the HTA 
coverage recommendations across a sample of drugs and countries.  They differ in that 
some of the countries included were not common, nor were the therapy areas being 
compared.    
 
The reasons for cross-national differences were also explored, but with varying levels 
of thoroughness.  Morgan and colleagues focus more on the process, transparency and 
rigour of these processes, rather than on case-specific reasons for diverging 
recommendations (Morgan et al., 2006).  In contrast, the three other studies investigate 
these differences in a more thorough manner (Clement et al., 2009; Lexchin et al., 
2008; Shah et al., 2013).  Nevertheless, the reasons, or similarities and differences, 
across countries relied on a few cases or potential reasons, and may not encompass the 
full picture and subtleties of these processes.  First, no clear picture of the key 
determinants and of the structure of the decision-making problem is outlined in any of 
these studies, where consequently, the reasons set forth may not constitute the full 
picture.  Second, issues relating to the clinical and pharmacoeconomic assessments 
also referred to as clinical and economic uncertainty or key issues, were identified.  
However, the level of detail provided did not differentiate the type of concern raised 
(e.g. trial duration or uncertain magnitude of the benefit?), how these were dealt with 
across countries (e.g. acceptable by some and not by others?), and what were the 
factors influencing these processes (e.g. “other considerations” accounted for during 
the deliberative process?).  Third, the methodological approaches used, even if 
thorough, were not sufficiently detailed for these approaches to be transferable.  One 
exception may be the paper from Lexchin and colleagues, which does describe in 
detail how the variables were categorised (Lexchin et al., 2008).  This was accounted 
for when setting up the coding scheme in this thesis.  Given that these decision 
processes are complex and understanding what happened for one same drug in 
different countries may be challenging, a more systematic, structured, and 
comprehensive approach to identifying and comparing differences would be required.  
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Additionally, understanding how similar scenarios are dealt with across settings may 
also constitute a way forward to identifying some of the limitations in the applications 
of HTA and for cross-country learning about how these were dealt with across settings. 
 
In 2010, a series of papers was published in the EuroObserver, which looked at the 
impact of HTA on an international level (Kanavos et al., 2010b; Nicod, 2010; Pomedli, 
2010; Van den Aardweg, 2010).  Having been part of this project and collaborated 
with the three co-authors, this project formed the motivation for this thesis, which 
resulted in the recognition about the need to further explore the differences across 
countries.  The database compiled during this preliminary stage was further leveraged 
and developed, and contributed to the first empirical paper of this thesis (Chapter 6).   
 
3.4.2. Differences in access to orphan drugs  
 
The literature focusing on orphan drugs is more limited in scope and only a few studies 
evaluated the level of variability in access to orphan drugs across different countries 
(Blankart, Stargardt, & Schreyogg, 2011; Kanters, Hakkaart, Rutten-van Molken, & 
Redekop, 2015; Michel & Toumi, 2012; Stolk, Heemstra, Leufkens, Bloechl-Daum, & 
Heerdink, 2009).  Two studies identified such differences, where disease and treatment 
characteristics have shown to play a significant role (Denis et al., 2010a; Vegter et al., 
2010).  Indeed, rarity translates into difficulties to produce evidence of sufficient 
quality because of challenges in recruiting an adequate number of patients into RCTs 
(Clarke, 2006; Denis et al., 2010a; Denis, Mergaert, Fostier, Cleemput, & Simoens, 
2010b; Drummond et al., 2007; Dupont et al., 2011; Joppi, Bertele, & Garattini, 2009; 
Kanavos & Nicod, 2012; Simoens et al., 2011; Vegter et al., 2010), together with the 
nature of the disease that can pursue highly variable clinical courses (Clarke, 2006), as 
discussed in section 3.3.   
 
Different studies demonstrate that orphan drugs are more likely to receive the same or 
a higher level of acceptance for reimbursement compared to other, more common 
disease areas (Dupont et al., 2011; Simoens et al., 2011; Stolk et al., 2009).  This 
suggests that coverage decisions for orphan drugs are based on the decision-makers’ 
willingness to accept high and uncertain cost-effective drugs while taking into account 
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other considerations related to the disease and treatment characteristics, such as disease 
severity or the availability of treatment alternatives. 
 
There is ongoing debate as to whether greater flexibility should be given to orphan 
drugs compared to drugs for more common diseases, based on the principle of equality 
and on the fact that these drugs by nature are likely not cost-effective (Drummond et 
al., 2007; McCabe, 2010; McCabe, Stafinski, & Menon, 2010; McCabe, Tsuchiya, 
Claxton, & Raftery, 2006, 2007; Simoens, 2011; Simoens et al., 2011).  Both positive 
and negative arguments are put forward, and both parties agree that societal 
preferences (about whether or not society is willing to pay more for rarity) need to be 
elicited.  The arguments for having greater flexibility for orphan drugs are the 
following: recoupment of R&D costs, equity in access, lack of existing treatment 
alternatives, potentially catastrophic levels of out-of-pocket costs to the patient, and 
societal preferences.  The latter is based on the assumption that society puts more 
value on rare diseases due to the severe, life-threatening and disabling nature of these 
diseases. 
 
Currently, with the exception of SMC in Scotland and HAS in France, HTA bodies in 
other countries do not make a differentiation in their processes for orphan drugs 
(Garau & Mestre-Ferrandiz, 2009a; Panju & Bell, 2010).  The SMC accounts for 
additional treatment and disease characteristics referred to as the “SMC modifiers” 
(e.g. life-threatening, curative, life-extending, quality of life, no alternative treatments).  
In France, orphan drugs and rare diseases are recognised as a national priority under 
the 2004 Public Health Act (Ministere des Affaires Sociales et de Sante, 2004), though 
it is yet unclear how and whether this has any influence in the HTA coverage 
recommendation.  Orphan drugs are generally subject to the same HTA evaluation 
processes, with some exceptions where they may receive preferential status under 
certain conditions, possibly explaining some of the variation between countries.  
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4. Research Questions and Plan of the PhD 
 
4.1. Gaps in the Literature and Hypotheses 
 
It is widely recognized that a coverage recommendation issued for the same drug and 
indication by several HTA bodies may differ, for many reasons as stated earlier.  Eight 
studies identified the extent of these differences and possible reasons for having issued 
different HTA recommendations (Table 3-1) (Clement et al., 2009; Kanavos et al., 
2010b; Lexchin et al., 2008; Morgan et al., 2006; Nicod, 2010; Pomedli, 2010; Shah et 
al., 2013; Van den Aardweg, 2010).  No attempt, however, has been made to scrutinize 
these variations and query why they occur in a systematic manner.  More specifically, 
the extent to which variations in coverage recommendations across agencies are due to 
the different type of evidence considered and methods used, or the manner in which 
the evidence was interpreted (e.g. how uncertainty was dealt with) are not clear.  
 
In addition, there is a gap in the literature between what we know about these inter-
country differences, how they differ across settings, and how this information can be 
useful to generate a better understanding of, and increase transparency in HTA 
processes, as well as improve HTA methods, and further down the line, improve 
access the clinically cost-effective treatments.  
 
The key issue when determining whether a technology provides value for money is 
that many different approaches to appraise a technology exist and little is known about 
HTA body expectations in these “grey areas” (e.g. the appropriate methods to be used, 
the weight “other considerations” have in the final decision, or the value judgments 
that are made as part of the deliberative process).  
 
Based on the above and considering attempts at approximating HTA structures in 
Europe, e.g. through joint actions such as the EUNetHTA, it is necessary to better 
understand and identify: (a) the evidence and methods used in HTA appraisals; (b) 
whether the evidence and methods were deemed acceptable or not by the evaluators 
when uncertain or incomplete, e.g. scientific value judgments; (c) the reasons behind 
the final recommendation; (d) whether “unacceptable” cases could have been 
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avoidable; and (e) to what extent “other considerations” influenced the final decision, 
e.g. social value judgments. 
 
There is a need for more clarity and transparency about the appropriate methods to be 
used in the different contexts and the acceptability criteria for uncertain evidence.  This 
would also include how disease or treatment characteristics are taken into account in 
the HTA processes, their weight on the decisions and whether they are accounted for 
consistently across cases (Earnshaw et al., 2008).  This would ensure that the decisions 
being made are fair, robust and transparent, and that health care resources are being 
used efficiently and deliver the best outcomes for society. 
 
4.2. Hypotheses 
 
In this context, this thesis tests a number of hypotheses: 
 
 Given that there are differences in HTA recommendations across countries, these 
differences are important and where they occur, they have substantial 
consequences for patient access to health technologies;  
 
 These differences may be a consequence of: 
o context-specific considerations, such as different willingness-to-pay 
thresholds, costs or national priorities;  
o the methodological approach used, whereby different evidence may be 
appraised alongside different methodological approaches; 
o agency-specific risk preferences, which consists of those risks or types of 
uncertainty that are more of a concern for certain decision-makers 
compared to others, resulting in different levels in accepting uncertain 
evidence; 
o potential subjectivity in the interpretation of evidence in terms of what 
constitutes acceptable levels of uncertainty, accounting for additional 
evidence or not; 
o social value preferences, which consist of “other considerations” beyond 
clinical benefit and cost-effectiveness (e.g. disease severity), that are 
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relatively more valued by some decision-makers compared to others and 
therefore carry more weight in the decisions in the former than in the latter; 
 
 Value judgments are routinely made to inform decisions as part of the deliberative 
process of HTA, during which experts and key stakeholders are consulted and the 
evidence is discussed until a decision is taken.  These value judgments originate 
from the individual decision-makers based on their experience and expectation 
about the preferences of society, including patients. 
 
 Scientific and social value judgments that are routinely made to inform decisions 
are not used consistently within a setting across drugs, but should be.  These 
judgments are not used consistently, but because of their importance, they should 
be.  These are identifiable and could be accounted for more consistently. 
 
 Decision-makers are willing to accept a higher ICER or uncertain clinical benefit 
in the case of orphan drugs to treat rare diseases by accounting for other 
considerations beyond routine HTA outcomes. 
 
 Issues related to the rarity of conditions (e.g. trial design and conduct) are reflected 
in the HTA submissions in the quality and level of the evidence presented, and the 
concerns that arise from the assessors.  These issues are not dealt with consistently 
and depend on the judgment of the decision-making committee members.  
 
This thesis focused on HTA coverage decisions for branded prescription-only orphan 
medicinal products in four European countries: England and Wales, Sweden, Scotland 
and France1.  More information about the structure and processes of these four HTA 
bodies and the reasons for their selection are provided in Chapter 5.   
 
                                                 
 
1 HTA bodies issuing the HTA recommendations are the following: 
- In England : the National Institute for Health and Care Excellence (NICE) 
- In France : the Transparency Committee of the Haute Autorité de Santé (HAS) 
- In Scotland : the Scottish Medicines Consortium (SMC) 
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4.3. Research questions  
 
The above gaps in the literature identified emphasise the need to understand, in a more 
systematic manner, the reasons for differences in HTA recommendations across 
countries, which formed the main research question of this thesis, as follows: 
 
-Main research question- 
Why are there differences in HTA recommendations across countries for a same 
drug and indication pair? Is there consistency within and across countries? 
 
This question was addressed in five inter-connected steps, which correspond to the five 
publishable papers that constitute this thesis (Figure 4-1). 
 
Figure 4-1. Thesis structure 
 
Source: The author. 
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4.3.1. Paper 1 
  
The first paper (Chapter 6, Paper 1) further explores differences in HTA coverage 
recommendations.  In addition to measuring the magnitude of these differences and 
potential reasons, the reasons and implications to understanding these differences were 
also emphasised, further contributing to existing literature.  
 
What is more, it aimed to identify the scope and extent of differences across five 
countries (Australia, Canada, England, Scotland, Sweden), and query whether similar 
patterns across therapy areas are seen in these countries.  The countries included were 
not the same as those analysed throughout the remainder of the thesis; results are 
nevertheless considered to be consistent and generalizable with the trends seen in 
previous studies that examined the same countries (Clement et al., 2009; Lexchin et 
al., 2008; Morgan et al., 2006; Shah et al., 2013).  The research question was the 
following: 
 
-Sub-research question 1- 
What are the commonalities and differences in HTA recommendations made 
across five countries and three therapy areas? On this basis, are these differences 
meaningful? 
 
Objectives were two-fold: 1) to examine the commonalities and differences in the 
HTA recommendations issued by the study countries and across three therapy areas 
between 2007 and 2009, and 2) to identify possible reasons for differences through a 
number of case studies in order to understand whether it is worth further exploring.  A 
comparative analysis of HTA recommendations for 287 drug-indication pairs 
appraised was undertaken, as well as an in-depth analysis of two case studies.  
 
Results showed significant inter-country variability in the HTA recommendations, 
where 46% of the 122 drug-indication pairs appraised by at least two agencies received 
diverging recommendations across countries.  Agreement levels in the 
recommendations issued amongst pairs of countries measured using Cohen’s kappa 
scores were poor to moderate, confirming the trend seen in previous research.  The 
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contribution of this study compared to the existing evidence is the comparison 
undertaken across therapy area, where the relative proportions of positive and negative 
recommendations for each therapy area would be assumed to be similar across 
countries.  Results showed the contrary, where associations between HTA 
recommendations issued by each HTA body per therapy area (cancer, orphan, CNS) 
differed from the general pattern observed across the complete sample.  These results 
suggest that expectations from HTA bodies in terms of relative effectiveness differ 
depending on the drug and disease characteristics, although agency-specific guidelines 
are homogeneous for all treatments.  Findings from this first chapter provided the 
rationale for the remainder of the thesis, emphasising that these differences are 
important and matter, and should be further explored.  
 
4.3.2. Paper 2 
 
In order to analyse these decisions in a more systematic, comprehensive and 
comparative manner, a methodological framework was developed and piloted (Chapter 
7, Paper 2).  In this respect, the research question for this second component of this 
thesis was the following: 
 
-Sub-research question 2- 
How can we identify and compare in a systematic manner similarities and 
differences in HTA recommendations? Developing and testing a methodological 
framework.  
 
This framework was developed using a mixed methods research design that enabled to 
capture the depth and complexity of these decision processes, while making them 
comparable across countries and drugs, and quantitatively analysable.  The framework 
enabled to examine the different stages of the HTA process across the countries for 
each drug and indication included, in order to identify when causes of variations were 
a consequence of national considerations or of differences in the methods used, the 
interpretation of the evidence, or the influence of the “other considerations”.  This 
approach was used to derive this instrument-based model referred to as the 
methodological framework, which was used as a basis for the analyses in the 
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remainder of the PhD.  Care was given to detail each step of the process undertaken to 
develop this framework to allow its transferability to third parties.  
 
4.3.3. Paper 3 
 
Once piloted, this framework was applied to a larger sample of orphan drug-indication 
pairs (Chapter 8, Paper 3), in order to answer the following research question:  
 
-Sub-research question 3- 
Why are there differences in HTA recommendations for orphan drugs in four 
countries? Can we learn from these differences? 
 
Results showed differences at each step of the decision-making process.  The same 
pivotal trials were generally appraised, but with varying levels in reporting the clinical 
outcomes, partly explaining some of the differences.  Agency-specific risk and value 
preferences were also identified, where one agency was relatively more concerned 
about an issue, or valued to a greater extent a specific criteria compared to the other 
agencies, which also contributed to explaining varying HTA recommendations.  When 
comparing the issues raised (e.g. uncertainty) by each agency, only 14.5% (Nu = 124) 
were common across countries, the remainder having been raised by only one or a few 
agencies.  Quantifying these differences using kappa scores showed that agreement 
was poor to moderate in interpreting the same evidence or in dealing with the same 
concerns.  Differences were also seen in the extent to which stakeholders, or how 
considerations relating to disease and treatment characteristics, influenced the 
decisions.  This study has led to a better understanding of how value is assessed by 
different HTA bodies and the reasons for differences differentiating for whether they 
relate to the processes or methods adopted in each jurisdiction, or whether they reflect 
weaknesses in the HTA methodological approaches used. 
 
4.3.4. Paper 4 
 
The next step was to focus on one component of the drivers of decisions, the value 
judgments made, using a more qualitative in-depth analytical approach (Chapter 9, 
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Paper 4).  The aims were (1) to explore in more depth how broader aspects of a 
treatment’s value and the impact of the condition on the patient (referred to as “other 
considerations”), not captured by routine HTA methods, influence HTA processes; and 
on this basis, (2) to explore whether orphan drugs have a “special status”. 
 
-Sub-research question 4- 
How do scientific and social value judgments influence HTA decisions? And on 
this basis, do orphan drugs have a “special status”? 
 
Results identified in total 125 different “other considerations” or value judgments, 
which were grouped into 16 subcategories based on the information provided.  
Between 19% and 100% of these, depending on the agency, were put forward as one 
of the main reasons for the final decision.  A classification framework was developed 
defining and dividing these into scientific or social value judgments.  This was then 
used to identify needs for further research and areas where more consistency in their 
use across cases is needed.  On this basis, different issues were addressed around better 
defining the determinants of social value or how to improve the lack of accountability 
for reasonableness particularly in cases when it is not clear how the “other 
considerations” identified influenced the decisions.  It also provided a way forward to 
eliciting whether these orphan drugs deserve a special status by eliciting preferences 
around some of the social value judgments made which are more likely to pertain to 
orphan drugs compared to normal condition, rather than focusing on the opportunity 
cost of these.  Given the challenges in producing robust evidence for orphan drugs due 
to the small patient numbers and heterogeneity of the diseases, scientific and social 
value judgments are unavoidably part of the decision process.  Identifying and 
understanding the scientific and social value judgments made provides a way forward 
to improving their transparency and consistency across decisions. 
 
These last two chapters showcase the added value of applying this framework, which 
enables to understand in a simple and comparable manner these complex decision 
processes, and learn from cases when differences across countries were seen.  This 
contributed to filling some of the gaps identified in the literature, which included 1) the 
need to scrutinize these variations and query why they occur in a systematic manner; 
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2) the need for a more consistent and transparent approach in the manner HTA 
agencies interpret the “other considerations”; and 3) the need to increase transparency 
in what the appropriate methods are in the different contexts.   
 
4.3.5. Paper 5 
 
The last paper (Chapter 10, Paper 5) builds on the key findings from previous chapters 
to steer a number of open-ended interviews administered to HTA body representatives 
to obtain their insights about the results and their meaning when dealing with orphan 
drugs.  
 
-Sub-research question 5- 
How is the value of orphan drugs assessed across different settings and how do 
differences affect coverage decisions? 
 
Semi-structured interviews with HTA body representatives in the study countries were 
conducted.  An interview topic guide was developed based on findings from a 
systematic comparison of HTA decisions for ten orphan drugs.  The interview 
questions were divided into four general themes: (a) Evidentiary requirements; (2) 
Stakeholder involvement; (3) Other considerations; (4) Orphan drugs.  Each theme 
discussed a number of issues seen for orphan drugs and derived from cases when 
differences were seen across countries or when it was unclear how certain of the 
criteria identified influenced the decisions.  Qualitative thematic analysis was applied 
to the interview transcripts using the Framework Approach.  These interviews were a 
way forward to furthering the debate about a number of HTA methodological issues, 
while simultaneously raising awareness about the types of differences that are seen 
across countries, which may also be applicable within countries when more than one 
decision-making body exists.  Results show that although agreement was generally 
seen in the evidentiary requirements or preferences, there were subtle differences in 
the circumstances where uncertain evidence may be considered acceptable, possibly 
explaining differences in HTA recommendations. 
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5. Overall PhD Methods 
 
Given that this thesis is in the form of a publishable paper thesis, Chapters 6-10 
corresponding to the five empirical papers summarise the methods adopted in greater 
detail.  This section provides an overview of the methods used throughout the thesis. 
 
The first paper (Chapter 6) sets the scene as to why it is important to understand the 
reasons for differences across countries.  The study provided a secondary analysis of 
the HTA recommendations issued in five countries (England, Scotland, Sweden, 
Canada, Australia) between January 2009 and December 2012.  The selection of the 
study countries was based on whether they had long-established HTA agencies and 
processes, the availability of HTA reports with the HTA recommendations, the criteria 
used to produce the recommendations (clinical and/or cost-effectiveness), and a 
geographical spread encompassing agencies in Europe, Canada, and Australia.  
Materials for the study were either publicly available or were requested from the study 
agencies in direct communication.  A number of HTA bodies fulfil these criteria, of 
which five of the more well-established were selected.  Countries like France were 
excluded because the final HTA recommendation (SMR and ASMR) is not directly 
comparable with the recommendations compared across the study countries (e.g. list, 
restrict, reject).  Other countries such as Germany or the Netherlands were excluded 
because of language barriers and/or the availability of the data.  Data for 297 drug-
indication pairs were compiled into a database together with two other research 
assistants prior to the start of my PhD and with my MSc supervisor.  The data 
compiled included the generic names of all drugs appraised within that period, their 
indication and ICD code, the date and the HTA recommendation – for each of the five 
countries.  Before using the data collated for my first empirical chapter, I crosschecked 
most of the data compiled by my colleagues to ensure their exactitude.  This database 
was used for the comparative analysis of cross-country differences in HTA outcomes, 
as well as of differences in the acceptability of three therapy areas (orphan, cancer, and 
central nervous system treatments).  Descriptive statistics were conducted to 
understand the frequencies of types of HTA recommendations, per HTA body and per 
therapy area.  Agreement levels and associations between HTA recommendations, 
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therapy areas and countries were measured quantitatively through correspondence 
analysis and Cohen’s kappa scores.  The evidentiary requirements of each HTA body’s 
guidelines were compared, and contrasts were highlighted.  From the cancer, orphan 
and central nervous system drug-indication pairs receiving non-homogeneous 
recommendations identified, two were randomly selected and further analysed to better 
understand the rationale for decision-making.  The criteria accounted for in their 
selection was that they should have received non-homogeneous recommendations and 
were from different therapy areas. The selection was a convenience one.  Results show 
the magnitude and contradictory nature of agreement across countries, suggesting that 
differences matter and are worth further investigating, which was the overarching 
objective of the remainder of this PhD. 
 
The second paper (Chapter 7) aimed to set up and test a methodological framework, 
which was accepted for publication in a peer reviewed journal2, further tested to a 
greater sample of orphan drugs in the subsequent chapters (Chapters 8-10), where the 
validity of the framework was explored, as outlined in the next paragraphs.  The first 
paper (Chapter 6) was used as a basis to set up a first outline of this framework.  The 
aim of the framework is to allow for a systematic comparison of HTA-based 
recommendations as reflected in their HTA reports across drugs and countries.  An 
exploratory sequential mixed methods research design in the form of an instrumental-
based model was adopted.  A mixed methods design was considered appropriate in 
order to capture the depth and complexity of these HTA decision processes, and the 
breadth of decisions across cases (generalisation).  The exploratory sequential design 
was used because (a) of the direct interaction between the qualitative and quantitative 
strands, (b) priority was given to the qualitative strand given that the research question 
was more qualitative by nature, (c) the qualitative strand was conducted before the 
quantitative one (e.g. sequential), (d) the mixing of both strands was done during data 
collection and analysis, and (e) the approach was exploratory given that the variables 
of interest were unknown and that no taxonomy of criteria existed.  The qualitative 
strand was used to explain, illustrate quantitative findings, and quantitative findings 
were used to enhance the qualitative ones (Creswell et al. 2011c).  
                                                 
 
2 This chapter has been published in Health Policy (2016) 
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Purposeful sampling was used to select the study countries based on predefined criteria 
(Creswell & Plano Clark, 2011b), notably whether, (a) they had well-established HTA 
agencies and processes, (b) similar decision-making criteria (clinical and/or cost-
effectiveness) were used, (c) the different approaches used in HTA were represented 
(e.g. clinical benefit assessment versus clinical and cost effectiveness, health service 
versus societal approach), (d) the HTA reports were publicly available and included 
the rationales for the recommendations, and (e) they were based in Europe.  These 
criteria were meant to ensure that the decision processes were comparable for the 
analysis.  On this basis, England, Scotland, Sweden and France were included and 
constituted the study countries for the remainder of this thesis.  France was included in 
the remaining empirical chapters given that the comparison focused on what went on 
during the decision process, therefore on the assessment and appraisal of clinical 
benefit, rather than solely on the final decision.  Other countries, such as Germany or 
the Netherlands were excluded because of language barriers and/or availability of the 
data. 
 
The framework was developed in three phases.  First, case study analyses were piloted 
in order to identify the range of criteria accounted for and the structure of the decision-
processes, such that they were comparable across countries.  The two case studies used 
to develop the proposed methodological framework were selected from all European 
Medicines Agency approved drug-indication pairs - until December 2012 - that had an 
orphan designation and were appraised in the four study countries.  Drug-indication 
pairs were excluded if (a) they did not undergo the single technology assessment 
process at NICE, or the full submission process at SMC where the full HTA process 
was conducted and documented, and (b) they did not receive diverging coverage 
recommendations.  This resulted in a selection of an oncologic and non-oncologic 
drug, which are likely to be valued differently by HTA bodies given that they differ in 
terms of disease and treatment characteristics.  Second and on this basis, the decision-
making process was decomposed into a more comprehensible manner by looking at the 
evidence accounted for, its interpretation and how this influenced the final 
recommendation.  This structure of analysis was used to establish the coding manual 
and case study template (Figure 7-3 & Appendix B. Case Study), which form the basis 
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of the methodological framework, used for the thematic coding of each HTA report.  It 
also enabled for the coding to be homogeneous, systematic and flexible given the 
iterative process adopted.  Third, the qualitative data were quantitatively analysed in 
order to understand and measure the level of agreement at each stage of the decision-
process and reasons for differences, as well as identify agency-specific preferences 
across the sample (risk and value preferences).  Data sources consisted in the publicly 
available documents containing the specific HTA recommendation, which will be 
referred to as the “HTA report”.  Throughout the thesis, reference to analysing HTA 
processes refers to the HTA processes and the drivers of the HTA recommendations as 
they are reflected in the HTA reports.  Based on the assumption of transparency, the 
information reported in the HTA reports were considered to reflect the key reasons 
around the final HTA recommendation.   
 
The validity of this methodological framework in terms of its accuracy, absence of bias 
and ensuring the interpretation is traceable and justified was verified through various 
means.  First, through data triangulation with various sources of data, from HTA 
reports, input from HTA stakeholders and interviews with HTA bodies, where the 
interpretation of the results was presented and comments were collected.  Second, data 
analysis was undertaken by adopting a more in-depth approach with the case study 
analyses, while conducting thematic analysis across a greater sample.  The advantage 
of this mixed methods approach allowed for the qualitative findings to explain and 
illustrate quantitative ones, ensuring that the interpretation of the results was accurate. 
Third, an audit trail was recorded and included all the thoughts, queries, uncertainties, 
clarifications and progress of the researcher whilst conducting the research.  This 
allowed for documentation and traceability of all the steps conducted and reasons for 
having interpreted an outcome in one way of another. 
 
The focus of Chapter 7 (Paper 2) was to describe the approach used to develop and 
pilot this framework, in order for it to be transferable.  An iterative process was 
adopted to develop the framework, where the case study template, coding manual and 
quantitative data extraction matrixes were re-worked and re-adjusted several times 
before arriving at the current framework.  The framework has now been applied to 
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other countries and drugs, by other researchers showcasing its feasibility and 
reproducibility. 
 
Its application to analysing a sample of orphan drugs in several countries facilitated the 
identification of a taxonomy of criteria that may have contributed to the decision 
process, as well as of similarities and differences across countries (Chapter 8, Paper 3).  
Ten orphan drug-indication pairs in the four study countries were analysed following 
the framework.  Orphan drugs were selected because they are characterised by high 
and uncertain cost-effectiveness ratios due to the small patient numbers and 
heterogeneous nature of the conditions they treat (Drummond et al., 2007; Dupont et 
al., 2011; Kanavos et al., 2012; McCabe, Claxton, & Tsuchiya, 2005).  For each drug, 
a case study report was compiled regrouping all the information of interest.  This 
information was then coded directly on the case study reports using NVivo 10 (QSR 
International Pty Ltd., 2012).  The advantages of having these case studies were to 
ensure the comparability of the information being related and to facilitate the 
interpretation of the results (during the next stage).  The data was extracted through 
various thematic matrixes from NVivo 10 into Excel, which allowed to categorise the 
variables by types and frequencies, into two-way contingency tables.  Descriptive 
statistics were used to quantitatively analyse the data coded. 
 
Correspondence analysis was conducted to measure the associations between the 
variables of interest using the chi-squared statistic test of independence, facilitating the 
understanding of these complex relationships in a simple bi-dimensional representation 
(Dickenson, 2010; Bartholomew, Steele, Moustaki, Galbraith, 2008b).  
Correspondence analysis was considered appropriate for the purposes of this thesis as 
it applies to categorical data, unlike principle component analysis that applies to 
continuous data.  It is a descriptive technique used to explore the associations between 
variables in a contingency table, which are considered dependent if the null hypothesis 
of independence is rejected.  The row and column profiles also allow us to explore the 
relative positions of the rows and columns to each other, and get a better understanding 
of the structure of the data.  
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It does so by looking at the proportions for each coordinate in the corresponding rows 
and columns (row/column profiles), and the overall proportion for each row or column 
(row/column mass or average row/column profile).  Each row and column profile is 
compared to the average row profile to determine the amount of scatter or variation, 
also referred to as inertia.  In the biplot, those points with the largest coordinates 
(profile masses) explain a larger amount of the inertia in that dimension.  Those points 
close to each other have similar profiles and are characterised by a stronger relative 
association.  When interpreting the two-way correspondence analysis biplots (e.g. 
Figure 6-2, Figure 6-3, Figure 7-4, Figure 7-5, Figure 8-2, Figure 8-3), the coordinates 
show the extent to which they contribute to the inertia in that dimension.  The two-way 
biplot captures two dimensions: the dimension on the vertical axis that captures a 
percent of the inertia, and the dimension on the horizontal axis that captures another 
percent.  The points on the origin of the biplot do not contribute to any inertia, whereas 
those farthest from the centroid contribute to the most inertia.  By transposing all 
points perpendicularly onto the vertical axis, we can identify those points farthest from 
the origin.  The variables that sit the closest together have the strongest associations.  
Those points on the positive and those on the negative section of the axis represent the 
contrasting associations amongst variables.  Doing the same with the horizontal axis 
gives additional insights on the existing associations between the variables. 
 
Cohen’s kappa scores were used to check the robustness of the results obtained by the 
primary metric measuring the frequency of common interpretation.  These scores were 
used to measure agreement between two HTA bodies and their interpretation of the 
evidence, by comparing agreement observed to agreement expected by chance.  The 
scores are calculated by estimating the amount of agreement by which the observed 
agreement exceeds that of expected by chance alone, divided by the maximum that this 
difference could be.  Agreement may range from poor (kappa = 0) to perfect 
agreement (kappa = 1).  Negative values of kappa correspond to cases when agreement 
was less than expected by chance.  
 
These results from Chapter 8 contributed to raising awareness about how value 
assessments are conducted in different settings: by shedding light on the four most 
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common reasons for differences, generating a taxonomy of criteria influencing these 
decisions, and showing that differences are often the result of a combination of 
circumstances.  The implications for orphan drugs were also discussed.  
 
The depth of the analysis enabled to capture certain aspects of what goes on during the 
deliberative processes.  The fourth paper (Chapter 9) focused specifically on the 
scientific and social value judgments made during processes.  It also aimed to further 
the debate as to whether orphan drugs deserve special status.  A classification 
framework was developed based on what is known from the literature and was applied 
to categorise the “other considerations” identified.  The willingness-to-pay thresholds 
in each country were compared to the actual ICERs accounted for in the decision, in 
order to understand whether greater flexibility was given to high and uncertain ICERs.  
The variables categorised as “other considerations” previously coded through thematic 
analysis were then extracted and grouped into clusters depending on the information 
provided (e.g. synonyms or common themes).  These were then analysed to understand 
what type of value judgment they pertained to (e.g. scientific or social), whether it 
pertained to disease or treatment characteristics, and how it influenced the final HTA 
recommendation, including in accepting the high and uncertain ICERs previously 
earmarked.  
 
The classification framework was used to identify needs for further research and to 
improve consistency in their use across cases.  This was then used to address different 
issues around identifying and better defining the determinants of social value or how to 
improve the lack of accountability for reasonableness.  It also provided a way forward 
to eliciting whether these orphan drugs deserve a special status by eliciting preferences 
around some of the social value judgments made which are more likely to pertain to 
orphan compared with nonorphan drugs, rather than focusing on the opportunity cost 
of these.  
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Figure 5-1. Triangulation of data and analysis 
 
 
 
Source: The author. 
 
The final paper (Chapter 10) consisted in conducting a number of semi-structured 
face-to-face interviews with HTA body representatives.  The objectives were to ensure 
that the interpretation of the researcher when analysing the decisions throughout the 
PhD was accurate, particularly in cases when differences across countries were one of 
the explanatory factors for different HTA outcomes across countries, and 
simultaneously get further insights on the drivers of these decisions in each agency.  
HTA body representatives from each study country were identified by partners of a 
European research consortium Advance-HTA. All interviewees accepted the 
invitation.  One interview per agency was conducted in order to capture discussions 
and reach common agreement amongst interviewees.  The interviewees included four 
men and four women, and occupied senior roles in their organisations, e.g. Head of the 
Technology Appraisal Programme, Head Economist or Pharmacist, Chair of the 
Appraisal Committee.  An interview topic guide was developed.  It included open-
ended questions derived from actual scenarios that arose in the context of our cross-
national comparison of 10 orphan drugs in Chapter 8.  The questions were open-ended, 
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which allowed some flexibility in the discussions such that the interviewees were free 
to offer additional insights and interviewers could ask spontaneous questions.  The 
topic guide received several rounds of comments from the co-authors of that chapter to 
ensure that the questions were meaningful.  Prior to the interview, it was circulated to 
interviewees.  One interview per agency was conducted, which included one to three 
interviewees and lasted between 1-3.5 hours.  Interviews were recorded and 
transcribed and sent to the interviewees for comment and validation.  Following the 
interviews, the topics or issues that emerged as relevant or different across countries 
were compiled and analysed together with a summary of the views of the interviewer, 
circulated amongst co-authors and accounted for during the analysis.  Qualitative 
thematic data analysis was undertaken using the Framework Approach (Gale NK, 
Heath G, Cameron E, et al. 2013).  Subthemes within each general theme were 
identified and inductively coded, and a matrix was created to facilitate comparison of 
each subtheme across the four HTA bodies.  The key findings from each of these 
subthemes were summarised in tables that incorporated illustrative quotes.  A list of 
follow-up questions was developed to complement the interviews where information 
was unclear or incomplete.  These additional questions were sent to each interviewee 
along with the summary of findings for their particular HTA body for confirmation.  
Results focus on the contrasts across countries identified within each theme.  These 
interviews were a way forward to furthering the debate about a number of HTA 
methodological issues, while simultaneously raising awareness about the types of 
differences that are seen across countries, which may also be applicable within 
countries when more than one decision-making body exists.  
 
Triangulation of data collection was applied throughout this thesis (Figure 5-1).  Data 
collection consisted in the database compiled of HTA recommendations issued by the 
study countries between 2007 and 2009, case study analyses and coding of HTA 
reports through thematic analysis, and interviews of competent HTA authorities.  
Findings derived from the methodological framework and from the interviews were 
integrated in the final step and are summarised in Paper 5 (Chapter 10).  A more 
detailed description of methods can be found in each paper (Chapters 6-10). 
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6. Commonalities and Differences in HTA Outcomes: A Comparative 
Analysis of Five Countries and Implications for Coverage 
Decisions3 
 
6.1. Abstract 
 
This paper aimed to identify diverging HTA recommendations across five countries, 
understand the rationale for decision-making in specific therapeutic categories, and 
suggest ways forward to minimize these inter-country differences.  A comparative 
analysis of HTA recommendations for 287 drug-indication pairs appraised by five 
countries (England, Scotland, Sweden, Canada, and Australia) between 2007 and 2009 
was undertaken, including an in-depth analysis of two case studies.  Agreement levels 
were measured using kappa scores. Associations were explored through 
correspondence analysis.  Results show that significant inter-country variability in the 
HTA recommendations exists: 46% of the drug-indication pairs studied received 
diverging recommendations across countries.  The level of agreement between 
agencies was poor to moderate.  Associations between HTA recommendations issued 
by each HTA body per therapy area (cancer, orphan, CNS) differed from the general 
pattern observed across the complete sample.  Expectations from HTA bodies in terms 
of relative effectiveness differ depending on the drug’s and disease’s characteristics, 
although agency-specific guidelines are homogeneous for all treatments.  
Distinguishing and accounting for the specifics underpinning individual conditions and 
their characteristics in HTA processes may constitute a way forward to improved HTA 
methods, while increasing transparency in the  expectations that HTA bodies have in 
terms of relative effectiveness of the drug depending on these characteristics. 
 
6.2. Introduction and Background 
 
Pharmaceutical costs account for an ever increasing proportion of health care costs 
(Kristensen, Makela, Neikter, Rehnqvist, Haheim, Morland, Milne, Nielson, & Busse, 
                                                 
 
3 A version of this chapter was published in Health Policy (Nicod E, Kanavos P, 2012) 
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2009), and it is anticipated that they will only continue to grow in significance with the 
increasing need for and cost of developing new treatments (Bach, 2009; Congressional 
Budget Office, 2006).  A general consensus at national level exists on the need to 
control these costs and use resources more efficiently in order to ensure system 
sustainability.  At the same time, the provision of equitable, effective and high quality 
care remains very challenging in many OECD countries because of both supply and 
demand-side constraints (e.g. ageing, increased patient expectations) (United Nations 
Population Fund, 2011; Wanless, 2002), as well as stringent budget constraints.  
Efforts have been converging towards controlling the level of expenditures through a 
number of regulatory mechanisms for an affordable, efficient and sustainable health 
care system (Scherer, 2000).  
 
A key operational contribution of health technology assessment (HTA) in informing 
decision-making is how to obtain value for money.  HTA relies on evidence-based 
medicine (EBM) to determine the relative effectiveness of a new technology compared 
to current (best) practice (Drummond et al., 2008), as well as the technology’s cost-
effectiveness (Eddy, 2009).  This mechanism enables a detailed identification of 
treatments that are cost-effective or provide additional (clinical) benefit compared to 
existing standard of care, in principle enabling rational decisions for resource 
allocation (Claxton, Briggs, Buxton, Culyer, McCabe, Walker, & Sculpher, 2008). 
 
Considering that HTA processes are based on internationally recognized methods, it 
can be assumed that the same drug-indication pair based on the same evidence and 
relying on –broadly– the same assessment techniques and processes would obtain a 
similar or comparable recommendation across countries.  However, significant 
disparities have been observed to date in the recommendations made by HTA agencies 
(Cairns, 2006; Clement et al., 2009; Drummond, 2009; Kanavos et al., 2010b; 
Kristensen & Gerhardus, 2010; Morgan et al., 2006; Nicod, 2010; Pomedli, 2010; 
Richards, 2010; Sorenson, 2009; Sorenson, Drummond, & Bhuiyan Khan, 2013; 
Sorenson et al., 2008; Van den Aardweg, 2010).  These may be due, among others, to 
the quality and type of evidence submitted (Clement et al., 2009; Sorenson et al., 2008; 
Velasco-Garrido et al., 2005), the appraisal processes (Clement et al., 2009; Sorenson, 
2009; Sorenson et al., 2008; Velasco-Garrido et al., 2005), country-specific 
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considerations (e.g. willingness to pay thresholds) (Clement et al., 2009; Drummond, 
2009; Kanavos et al., 2010b; Pomedli, 2010; Sorenson et al., 2008; Van den Aardweg, 
2010), or societal preferences (Clement et al., 2009; Sorenson, 2009; Sorenson et al., 
2008).  Yet, the identification of the key factors driving these diverging decisions is 
relatively under-studied. 
 
The implication of diverging HTA recommendations is that a particular treatment may 
be covered in one jurisdiction but not in another, based on individual country 
combinations of scientific and social value judgments.  While these decisions may be 
justifiable from a policy perspective as they are based on well-established processes, 
from a patient or societal perspective, having differential access to a particular 
treatment across –often neighbouring- countries may be difficult to comprehend, 
particularly in the context of divergent decisions being made by countries with similar 
levels of income and comparable levels of health care spending.  Addressing such 
disparities across countries has become both a concern and a priority internationally 
and a number of initiatives exist in this direction (DG Research and Innovation. 
European Commission, 2011; Hailey, 2009; HTAI, 2011; Kristensen et al., 2010; 
Kristensen et al., 2009).  A better understanding of the critical factors that drive 
decisions is an essential component in attempts to determine whether and how HTA 
processes across countries can be approximated. 
 
By pooling together all HTA recommendations across five HTA agencies and as many 
countries over the 2007-2009 period, the objective of this paper is threefold: first, to 
provide a post-hoc analysis of those cases where divergences in recommendations 
have been observed; second, to identify why such differences exist and analyse the 
critical factors leading to coverage decisions or rejections; and third, to analyse how 
these recommendations differ across HTA agencies with emphasis on cancer, orphan 
and central nervous system (CNS) treatments. 
 
The following section outlines the methods used for this analysis, followed by a 
presentation of the results subdivided into three parts: first, the overall results across all 
drug-indication pairs included in the study are presented; second, the specific 
outcomes across three broad therapy areas are studied (cancer, orphan and CNS 
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treatments); finally, two case studies illustrate some of the possible differences in HTA 
processes and outcomes by further investigating the appraisal process.  A discussion 
section subsequently identifies the policy implications.  The last section draws the 
main conclusions.  
 
6.3. Materials and Methods 
 
The study provides a secondary analysis of HTA processes and recommendations in 
five countries: England (National Institute for Health and Clinical Excellence – NICE), 
Canada (Common Drug Review – CDR, and Committee to Evaluate Drugs for 
oncology products appraised [since March 2007] - CED), Australia (Pharmaceutical 
Benefits Advisory Committee - PBAC), Sweden (Dental and Pharmaceutical Benefits 
Board - TLV), Scotland (Scottish Medicines Consortium - SMC) over a three-year 
period (January 2007-December 2009).  The selection of the study countries was based 
on whether or not they had long-established HTA agencies and processes, the criteria 
used to produce recommendation (clinical and/or cost-effectiveness), and a 
geographical spread encompassing agencies in Europe, Canada, and Australia.  
Materials for the study were either publicly available or were requested from the study 
agencies in direct communication.  
 
HTA recommendations over the study period were collected and compiled into a 
central database, together with their corresponding appraisal reports.  
Recommendations have been extracted from the appraisal reports issued by each 
agency.  Unique drug-indication pairs have been recorded, according to their 
international non-proprietary name, ICD10 WHO classification of indications (ICD10, 
2007), and HTA recommendation.  Only Single Technology Appraisal (STA) has been 
included in the case of England.  The focus of the study is limited to the HTA 
recommendation issued by the referent agency and not the final coverage decision.  
HTA recommendations provide a good indication about the level of access to 
medicines, since the decisions made are generally consistent with the 
recommendations issued by the HTA bodies (McMahon et al., 2006; Wonder et al., 
2006).  
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Recommendations were classified into three categories, namely: a) “list” (L), where 
the technology has been accepted as applied for; b) “list with criteria” (LWC), where 
the technology has been accepted with restrictions (e.g. by limiting the label 
indication); and c) “do no list” (DNL), where the application has been rejected based 
on a negative HTA appraisal.  In Canada, drugs that received a “list in a similar 
manner as drugs in the same class” were given a “L/LWC” rating for comparability 
purposes.  
 
Based on the above classification, cross-country comparisons were made to identify 
the differences and commonalities in HTA recommendations (homogeneous across the 
board, or mix of positive and negative), the number of technologies appraised, in 
general, and by therapeutic area.  Compounds from three therapy areas (cancer, orphan 
and CNS treatments) were subsequently extracted.  Reasons for their selection include 
the treatment and disease characteristics that define these three therapy areas.  These 
are very similar for cancer and rare diseases, which often represent severe and 
disabling diseases and where there is a high unmet medical need.  Although these two 
therapy areas are very similar, evidence shows that different levels of acceptance rates 
in their coverage decisions apply (Dupont et al., 2011).  This also links to the on-going 
debate as to whether orphan drugs deserve special status because of the small number 
of patients affected (Drummond et al., 2007).  CNS diseases differ from the latter, 
whereby treatments are often symptomatic and numerous alternatives are available 
(e.g. schizophrenia) (World Health Organisation, 2012); nevertheless, a strong need for 
additional treatments remains because of patient compliance issues (Huskamp, 2006).  
As such, these three therapy areas provide a good basis for comparison through their 
diversity in disease and treatment characteristics and acceptance rates for 
reimbursement.  The three therapy areas were defined as follows: a) orphan indications 
based on the EMA classification (N=26) (European Medicines Agency); b) cancer 
indications include all neoplasms classified under the ICD10 class C excluding orphan 
indications (N=51) (ICD10, 2007); c) CNS treatments include all treatments from 
ICD10 classes F (Mental and behavioural disorders), G (nervous system), and R 
(symptoms, signs and abnormal clinical and laboratory findings) (N=56) (ICD10, 
2007). 
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The level of agreement across agencies was measured using kappa score indicators 
(Cohen, 1960).  Correspondence analyses were performed to describe the associations 
between the HTA recommendations and the HTA body issuing the recommendation 
(Bartholomew et al., 2008b).  Comparisons of the associations across the three therapy 
areas were performed to determine whether coverage recommendations for specific 
therapy areas were likely to differ from the general pattern identified previously.  In 
addition, drug-indication pairs receiving non-homogeneous recommendations were 
identified, two of which were randomly selected and further analysed to better 
understand the rationale for decision-making.  The focus of these two case studies was 
on comparing the type of evidence submitted for HTA appraisal across countries, 
including the type of clinical trials, efficacy and safety endpoints, economic 
evaluation, the level of stakeholder involvement, and how all these factors were 
perceived by decision-making operating at national context.  
 
6.4. Results  
 
HTA agency-specific guidelines do not adopt the same perspective or approach in the 
way they appraise a technology across all study countries.  Table 6-1 summarizes the 
clinical and economic requirements for submission that are stated in agency guidelines 
(CDR, 2006, 2008a; NICE, 2008; PBAC, 2008; SMC, 2011b; TLV, 2003, 2012).  
While most agencies consider only direct costs and consequences of an intervention, 
TLV adopts a societal perspective including both direct and indirect costs and 
consequences (TLV, 2003).   
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Table 6-1. Clinical and economic agency-specific requirements/preferences  
  CDR/CED 
Canada 
NICE 
England 
PBAC 
Australia 
TLV 
Sweden 
SMC 
Scotland 
C
LI
N
IC
A
L 
EV
ID
EN
C
E RCT – H2H            
RCT – indirect        *   
RCT – placebo         
RCT – non-blinded       
Non-RCT – experimental and observational   **      
Systematic reviews        *   
EC
O
N
O
M
IC
 M
O
D
EL
 Cost-utility   Qol         
Cost-effectiveness  ***       *** 
Cost-minimisation  Eq   Eq  Eq  Eq 
Cost-benefit  Sec   Sec  *** 
 **** 
 
Cost-consequence  *** 
 **** 
  *****   
 Perspective Publicly-funded 
health care 
system 
NHS and PSS PBS  Societal  NHS and social 
work 
Source: (Nicod & Kanavos, 2012), based on individual agency guidelines. 
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 Preferred type of evidence;  
 Accepted; 
*systematic review of indirect comparisons, if no direct comparative evidence available; 
** if limitations with RCT and to supplement information from RCTs when they are available; 
*** if cost-utility analysis inappropriate; 
**** if cost-effectiveness analysis inappropriate; 
***** if disaggregation of outcomes would be helpful; 
 Qol: when there are differences in Health-Related Quality of Life; 
 Eq: when equivalence demonstrated; 
 Sec: as secondary analysis; 
 
Legend: RCT: randomized controlled trial; H2H: direct or head-to-head comparison; RCT-indirect: indirect comparison with a placebo-
controlled trial; RCT-placebo: placebo-randomized controlled trial; Non-RCT: non randomized controlled trial; CDR/CED: Common Drug 
Review/Committee to Evaluate Drugs; NICE: National Institute for Health and Clinical Excellence; PBAC: Pharmaceutical Benefits Advisory 
Committee; TLV: Dental and Pharmaceutical Benefits Board; SMC: Scottish Medicines Consortium; NS: not stated; NHS: National Health 
Services; PSS: Personal Social Services. 
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Looking at the type of evidence required in a submission, PBAC has a clear preference 
for head-to-head RCT (if available) and indirect comparisons (PBAC, 2008), where a 
submission relying exclusively on direct comparisons of a treatment to placebo will 
most likely be considered as being weak.  In contrast, placebo comparisons are listed 
as acceptable evidence for CDR, NICE and SMC, although in the case of NICE 
indirect comparisons are routinely used (CDR, 2008a; NICE, 2008; SMC, 2011b).  A 
similar picture emerges for the use of economic models; NICE typically accepts cost-
utility models, whereas CDR accepts cost-utility, cost-effectiveness, cost-
minimisation, and cost-consequence analysis depending on the outcome measure 
(CDR, 2008a).  At this level already, the evidence considered across the board is most 
likely to vary, potentially resulting in diverging HTA recommendations.  
 
6.4.1. Coverage decisions and differential access 
 
Between January 2007 and December 2009, 287 unique drug-indication pairs were 
appraised by at least one of the five agencies and received either a positive, restricted 
or negative coverage recommendation, 226 of which were appraised by at least 2 
agencies.  The former (287 drug-indication pairs appraised by at least one HTA 
agency) were used to study the general trends of the drugs appraised, whereas the latter 
(226 drug-indication pairs appraised by at least 2 HTA agencies) were used for 
comparative purposes. 
 
When comparing HTA outcomes across agencies, results show that only 54.0% (122 
out of 226) of the study drug-indication pairs appraised by at least 2 HTA agencies 
were homogeneously appraised (either all list and list with restrictions, or all do not 
list), the remaining having received a mix of positive and negative recommendations.  
In 46.0% of cases (104 out of 226), compounds may be available in one or some of the 
study countries, but not available in others.  This is further emphasized through the 
level of agreement across agencies measured by the kappa scores (Cohen, 1960) 
(Table 6-2).  Poor agreement exists between all agencies (-0.023 < kappa score < 
0.178), except for NICE and TLV, where moderate agreement can be seen (kappa 
score = 0.228).  Considering that the study countries are very similar in terms of GDP 
levels (average GDP per capita in 2009 = US$ 40,870 (SD US$ 4,317) (IMF, 2010)), it 
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is most likely that the reasons for different recommendations can be attributed to value 
judgments and preferences at national level, consequently it is important to determine 
what shapes these. 
 
Table 6-2. Level of agreement in HTA outcomes across agencies, measured by 
kappa scores 
 CDR/CED 
Canada 
NICE 
England 
PBAC 
Australia 
TLV 
Sweden 
SMC 
Scotland 
CDR - 0.038 0.165 -0.001 0.062 
NICE  - 0.178 0.228 0.105 
PBAC   - -0.023 0.132 
TLV    - 0.066 
SMC     - 
Source: (Nicod et al., 2012). 
 
Legend: CDR/CED: Common Drug Review/Committee to Evaluate Drugs; NICE: National 
Institute for Health and Clinical Excellence; PBAC: Pharmaceutical Benefits Advisory 
Committee; TLV: Dental and Pharmaceutical Benefits Board; SMC: Scottish Medicines 
Consortium 
 
Focusing on the 287 drug-indication pairs appraised by at least one HTA agency, 
Table 6-3 illustrates the number of compounds appraised by each agency, and the 
proportion of drugs accepted, restricted, or not recommended for reimbursement.  
Substantial differences exist in the number of drugs appraised by each agency; for 
example, 111 drugs were appraised in Sweden compared to 211 in Australia.  One way 
of explaining these variations across agencies is through country differences in terms 
of what drugs are required to undergo an HTA appraisal in each country.  Indeed, all 
drugs in Canada and Australia, and all newly licensed indications in Scotland can 
undergo an HTA process (ISPOR, 2012; PBAC, 2008; SMC, 2011b).  In contrast, the 
lower number of appraisals in Sweden can be explained partly by the fact that only 
outpatient drugs are appraised by TLV, compared to the other agencies that examine 
both inpatient and outpatient drugs (ISPOR, 2012; Sorenson et al., 2008).   
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Table 6-3. Total number of appraisals per country, and the proportion of drugs accepted, restricted, or not recommended for 
reimbursement 
  
CDR 
Canada 
NICE 
England & Wales 
PBAC 
Australia 
TLV 
Sweden 
SMC 
Scotland 
Total # appraisals 129 110 211 111 193 
List/L  
(+/- 95% CI) 
3.1%  
(0.1%; 6.1%) 
19.1% 
(11.7%; 26.4%) 
21.8% 
(16.2%; 27.4%) 
71.2% 
(62.7%; 79.6%) 
28.0% 
(21.6%; 34.3%) 
List with restrictions/LWC  
(+/- 95% CI) 
47.3% 
(38.7%; 55.9%) 
63.6% 
(54.6%; 72.6%) 
53.1% 
(46.3%; 59.8%) 
23.4% 
(15.5%; 31.3%) 
40.4% 
(33.5%; 47.3%) 
Do not list/DNL 
(+/- 95% CI) 
49.6% 
(41.0%; 58.2%) 
17.3% 
(10.2%; 24.3%) 
25.1% 
(19.3%; 31.0%) 
5.4% 
(1.2%; 9.6%) 
31.6% 
(25.0%; 38.2%) 
Source: (Nicod et al., 2012). 
 
Legend: CDR/CED: Common Drug Review/Committee to Evaluate Drugs; NICE: National Institute for Health and Clinical Excellence; PBAC: 
Pharmaceutical Benefits Advisory Committee; TLV: Dental and Pharmaceutical Benefits Board; SMC: Scottish Medicines Consortium; CI: 
95% confidence intervals for proportions. 
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In Canada, 49.6% (64 out of 129) of compounds have received a negative 
recommendation, whereas this is the case in only 5.4% (6 out of 111) of cases in 
Sweden.  Few or no indication restrictions have been issued in Sweden (23.4% of 111 
respectively) compared to Australia or England, where more recommendations with 
restrictions were issued than either outright positive recommendations or rejections 
(53.1% of 211 and 63.6% of 110 respectively).  
 
A similar exercise focusing on therapeutic areas also suggests significant disparities in 
the cumulative number of drugs appraised per therapy area across the 5 agencies 
(Figure 6-1).  A considerably higher number of drug-indication pairs from ICD 10 
class C00-D48 (23.7%, 68 out of 287 compounds) representing anti-neoplastic 
treatments, have been appraised by all agencies, followed by class M00-M99 
(musculoskeletal system and connective tissue and endocrine disorders) representing 
11.5% of the total, and E00-E99 (nutritional and metabolic diseases) with 10.8% of the 
total.  TLV has the lowest proportion of neoplasm drug-indication pairs appraised 
(18.0%, 20 out of 111) since it only appraises outpatient drugs, whereas many drugs in 
this category are used in inpatient settings.  
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Figure 6-1. Cumulative number of drugs per ICD10 class appraised across the study agencies,  
differentiating cancer, orphan and CNS drugs. 
 
Source: (Nicod et al., 2012). 
 
This figure represents the number of drugs within each ICD10 class that have been included in the study, and appraised by at least one of the 
study agencies. Cancer, orphan and CNS treatments have been differentiated. 
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Legend: ICD Categories  
Neoplasms C00-D48 
Musculoskeletal system and connective tissue M00-M99 
Endocrine, nutritional and metabolic diseases E00-E90 
Nervous system G00-G99 
Circulatory system I00-I99 
Infectious and parasitic diseases A00-B99 
Mental and behavioural disorders F00-F99 
Skin and subcutaneous tissue L00-L99 
Respiratory system J00-J99 
Symptoms, signs and abnormal clinical and laboratory findings R00-R99 
Blood-related D50-D89 
Digestive system K00-K93 
Genitourinary system N00-N99 
Eye and adnexa H00-H59 
Ear and mastoid process H60-H95 
Pregnancy, childbirth and the puerperium O00-O99 
Congenital malformations, deformations and chromosomal abnormalities Q00-Q99 
Certain conditions originating in the perinatal period P00-P96 
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6.4.2. Orphan, cancer and CNS treatments and HTA 
 
Narrowing down the study sample to three broad categories of products, those with an 
orphan status, cancer drugs and CNS treatments, similar results to the complete sample 
were obtained.  There were no marked differences in the proportion of drugs appraised 
by category submitted in each country, except for NICE and TLV where a small 
variance is seen in each.  Cancer drugs represent the highest proportion of appraised 
compounds amongst the three categories, on average 51.1%, ranging between 40.1% 
(29 out of 71) in Sweden and 67.1% (45 out of 67) in England of all compounds.  
NICE has the highest proportion of cancer drug appraisals most likely because it 
appraises drugs with the highest need for guidance, which are likely to have significant 
impact on NHS resources (Dranitsaris, Truter, Lubbe, Amir, & Evans, 2011), whereas 
TLV currently does not appraise inpatient drugs that are very often cancer therapies 
(but may be likely to do so in the future).  
 
The HTA recommendations made in each of the three categories suggest that there are 
substantial disparities in the recommendations made across categories and agencies.  In 
Sweden, all orphan drugs have been recommended with or without restrictions (100% 
of n=13), whereas in Scotland approximately 65% (15 out of 23) of orphan drugs 
appraised received a negative recommendation.  Focusing more specifically on the 
common 13 compounds appraised both in Sweden and Scotland, only 8% (one out of 
13) received a uniform assessment, 46% (6 out of 13) received diverging assessment 
(L or LWC in Sweden versus DNL in Scotland), and 46% (6 out of 13) were listed in 
Sweden and listed with restrictions in Scotland.  This demonstrates that there are 
differences in the key drivers when assessing an orphan drug in these two countries 
and their acceptability or not of high cost-effectiveness ratios.  Because of the nature 
of rare diseases (e.g. small patient population often associated with severe disability), 
it is more difficult to collect sufficient data to demonstrate efficacy and safety in very 
small patient populations, and as such, orphan drugs are often more prone to 
significant uncertainty in cost-effectiveness.  A number of studies focus specifically on 
orphan drug characteristics and emphasize their clinical uncertainty and high cost-
effectiveness (Drummond et al., 2007; Dupont et al., 2011; Simoens, 2011; Vegter et 
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al., 2010), making HTA processes more difficult and subject to interpretation in each 
setting.  
 
With regards to CNS drugs, 71% (22 out of 31) were rejected in Canada, whereas 
fewer negative recommendations took place elsewhere (34.1% in Scotland [14 out of 
41], 0% in Sweden [out of 29], 19.5% in Australia [8 out of 41], and 15.4% in England 
[2 out of 13]).  This demonstrates that CDR is possibly less inclined to provide a 
positive recommendation on drugs with marginal benefits (me-too drugs) than other 
agencies.  
 
Associations between the HTA agencies and their recommendations are summarised in 
Figure 6-2; further stratified in the three therapy areas in Figure 6-3.  In the first case, 
the Null Hypothesis of independence from the correspondence analysis was rejected 
(χ2=163.92; p<0.000), demonstrating that an association exists between the 
recommendations issued and the HTA body.  These associations are described in the 
correspondence analysis biplot, where TLV is relatively more likely to issue a positive 
recommendation (“L”) than the other study agencies; similarly, PBAC and NICE are 
relatively more likely to issue a positive recommendation with restriction (“LWC”), 
and CDR a negative recommendation (“DNL”) compared to the other study agencies.  
 
In the second case, the Null Hypothesis of independence was rejected (χ2=187.5; 
p<0.000), demonstrating that associations between the HTA recommendation issued 
and the HTA body making the recommendation exist.  The correspondence analysis 
biplot (Figure 6-3) suggests that, on aggregate, TLV is relatively more likely to issue a 
positive recommendation for all therapy areas than the other bodies; NICE is also 
relatively more likely to issue a positive recommendation for CNS treatments; PBAC 
is relatively more likely to issue a positive recommendation with restrictions for all 
therapy areas; and CDR and SMC are more relatively more likely to reject orphan 
indications.   
89 
 
 
Figure 6-2. Correspondence analysis biplot representing associations between all HTA recommendations and the HTA body issuing the 
recommendation 
 
Figure 6-2 summarizes the associations that exist between the HTA 
agencies and their recommendations issued.  The Null Hypothesis of 
independence was rejected (χ2=163.92; p<0.000), demonstrating 
that associations exist.  The correspondence analysis biplot 
illustrates these associations on two dimensions. Dimension 1 
explains most of the inertia (82.1%), and dimension 2 the remaining 
17.9%.  Results suggest TLV is relatively more likely to issue a 
positive recommendation than the other bodies, NICE and PBAC 
are relatively more likely to issue a positive recommendation with 
restrictions, and CDR is relatively more likely to negatively 
recommend when compared to the other bodies. 
Source: (Nicod et al., 2012). 
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Figure 6-3. Correspondence analysis biplot representing associations between all HTA recommendations and across three the therapy 
areas 
 
Source: (Nicod et al., 2012). 
 
 
 
Figure 6-3 represents the associations between the recommendations 
issued in three therapy areas (cancer, orphan and central nervous 
system indications), and the HTA body issuing the recommendation.  
The Null Hypothesis of independence was rejected (χ2=187.50; 
p<0.000), demonstrating that associations exist.  The 
correspondence analysis biplot illustrates these associations on two 
dimensions.  Dimension 1 explains most of the inertia (76.8%), and 
dimension 2 the remaining 23.2%.  Results suggest TLV is 
relatively more likely to issue a positive recommendation for all 
therapy areas than the other bodies; NICE is relatively more likely 
to issue a positive recommendation for central nervous system 
treatments.  PBAC is relatively more likely to issue a positive 
recommendation with restrictions for all therapy areas; and CDR 
and SMC are relatively more likely to reject orphan indications  
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Legend: L: list; LWC: list with criteria; DNL: do not list; CDR: Common Drug Review/Committee to Evaluate Drugs; NICE: National Institute 
for Health and Clinical Excellence; PBAC: Pharmaceutical Benefits Advisory Committee; TLV: Dental and Pharmaceutical Benefits Board; SMC: 
Scottish Medicines Consortium; c: cancer treatment; o: orphan treatment; n: central nervous system treatment. 
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NICE is generally relatively more likely to issue restrictions, but is relatively more 
likely to recommend CNS treatments.  Similarly, CDR is relatively more likely to 
reject CNS treatments and reject or restrict orphan and cancer indications; in contrast, 
the SMC is relatively more likely to reject orphan indications and restrict or reject 
cancer and CNS treatments.  The above suggests that HTA bodies may have different 
stance vis-à-vis incremental versus higher levels of innovation.  
 
Further insights about the nature of decisions can be obtained by examining in greater 
detail two cases of drug-indication pairs that have received variable recommendations.  
The results obtained by agency and the rationale are summarised in Table 6-4. 
 
The first case relates to Paliperidone (Invega©) for the treatment of schizophrenia.  It 
has been appraised by all HTA agencies except NICE and has received a mix of 
positive and negative recommendations (CDR, 2008b; PBAC, 2007; SMC, 2008; 
TLV, 2008).  Although submissions to HTA agencies were made during the same 
period (2007-2008), different clinical trials were presented.  SMC and CDR based their 
assessments mainly on placebo comparisons, whereas PBAC and TLV on indirect 
comparisons with quetiapine/olanzapine and risperidone respectively.  For SMC and 
CDR, the lack of comparative data with other anti-psychotics was raised as an issue 
and one of the main reasons for rejection.  
 
A further issue that was important in agencies’ deliberations related to the drug’s 
safety profile.  All trials considered, both placebo and indirect comparisons, had a 6-
week duration.  For CDR and SMC, this duration was considered insufficient to 
demonstrate the drug’s positive toxicity profile.  This issue was also raised by PBAC, 
because the 6-week period characterises only the acute phase of the disease, but did 
not seem to negatively impact the final decision, suggesting that the data provided 
were sufficient to demonstrate the drug's safety profile. 
 
The economic assessments presented included a cost-minimisation analysis to all 
except for SMC, which considered a cost-utility analysis.  For the latter, although the 
cost/QALY estimate was within acceptable range (lower than £30,000/QALY), the 
drug received a negative recommendation because of the uncertainty in the drug’s 
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clinical benefit.  The other three cost-minimisation analyses did not present the same 
comparators, or results (Table 6-4).  In Sweden and Australia, the cost comparisons 
with risperidone and olanzapine, respectively, were deemed acceptable.  In Australia, a 
flat pricing structure was also proposed and a risk sharing agreement was 
recommended.  In contrast, in Canada, paliperidone had a substantially higher price 
than generic risperidone, mainly because the generic version was used, which led to an 
unacceptable outcome.  Because of the lack of direct comparative data presented in the 
submission, this price difference was deemed not justifiable.  
 
In the case of Cetuximab (Erbitux©), indicated for the treatment of metastatic 
colorectal cancer (mCRC), the drug was appraised by three of the study agencies, 
positively by NICE and negatively by PBAC and SMC (NICE, 2009b; PBAC, 2010; 
SMC, 2009).  No assessments were found for TLV or CDR (Table 6-4).  In this 
context, different clinical trials were considered by the agencies.  NICE and SMC 
considered the same two placebo-controlled trials, whereas PBAC examined indirect 
comparisons of the same placebo-controlled trials with bevacizumab as comparator.  
 
Resistance to treatment by patients with mutations of the KRAS gene was 
demonstrated after the start of the two placebo-controlled trials.  Therefore, post-hoc 
analyses were performed on patients with wild-type KRAS gene and the drug’s 
indication was narrowed down to this patient population; results from this analysis 
were considered in all assessments, including indirect comparisons.  Efficacy was 
based on the primary endpoints of the two trials, notably "progression-free survival" 
and "response rate", which were statistically significant in the placebo controlled trials 
but not in the indirect comparisons.  Due to the nature of the sample considered from 
the post-hoc analysis (retrospective nature, patient representativeness, and sample 
size), the primary endpoints were deemed uncertain.  This was one of the main causes 
of query and negative evaluation in Scotland and Australia.  In England, where clinical 
experts were solicited and confirmed that these results were “biologically plausible 
given the current understanding of the pathology of metastatic colorectal cancer”, 
cetuximab received a positive recommendation (NICE, 2009b). 
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Table 6-4. HTA recommendation and criteria in the evaluation of paliperidone and cetuximab by the different HTA agencies 
  PALIPERIDONE CETUXIMAB 
  CDR/CED 
Canada 
PBAC 
Australia 
TLV 
Sweden 
SMC 
Scotland 
NICE 
England 
PBAC 
Australia 
SMC 
Scotland 
 Date of appraisal 05.2008 11.2007 09.2008 03.2008 08.2009 03.2010 03.2009 
 Recommendation DNL L L DNL L DNL DNL 
C
LI
N
IC
A
L 
EV
ID
EN
C
E 
Clinical trials* Syst-R 
P-RCT, IND 
IND 
9 trials 
IND P-RCT 
IND 
P-RCT 
(post hoc) 
IND P-RCT 
(post hoc) 
Clinical comparators Placebo 
Quetiapine 
Quetiapine 
Olanzapine 
Risperidone Placebo 
Quetiapine 
Placebo Bevacizumab Placebo 
Relative efficacy *   *  X* * 
Relative safety *   *  X*  
EC
O
N
O
M
IC
 
M
O
D
EL
 
Economic model CMA CMA CMA CUA CUA CMA, CEA CUA 
Economic 
comparator 
Generic 
risperidone 
Paliperidone 
Olanzapine 
Risperidone Olanzapine 
Quetiapine 
Chemo Chemo 
 
Chemo 
Cost-effective? *   Aripiprazole  X X 
RAS/PAS    X    
* Uncertain  
Source: (Nicod et al., 2012). 
 
Legend: P-RCT: placebo randomized controlled trial; IND: indirect comparison; NA: not applicable; CMA: cost-minimisation analysis; CUA: cost-utility 
analysis; Syst-R: systematic review; Chemo: chemotherapy; PAS: patient access scheme; RAS: risk sharing agreement; CDR/CED: Common Drug 
Review/Committee to Evaluate Drugs; NICE: National Institute for Health and Clinical Excellence; PBAC: Pharmaceutical Benefits Advisory Committee; 
TLV: Dental and Pharmaceutical Benefits Board; SMC: Scottish Medicines Consortium. 
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Based on results from the placebo comparisons, the drug's toxicity profile compared to 
placebo was deemed similar to the Summary for Product Characteristics (SPC) and 
acceptable.  For PBAC however, the nature of the indirect comparison with 
bevacizumab made it difficult to generate robust data about safety, though this had 
limited impact on the final assessment.  
 
In England and Scotland, cost-utility analyses were submitted.  The cost/QALY of 
cetuximab compared to chemotherapy was lower in England than in Scotland, because 
NICE used a provisional lower price.  In Scotland, where cetuximab received a 
negative recommendation, the model was deemed not robust enough because the 
cost/QALY estimate was above the £30,000 national threshold (ranging between 
£28,000 and £38,000), together with the uncertainties in the clinical claim.  In 
England, clinical uncertainty was addressed by expert input and an additional model 
integrating a Patient Access Scheme with an acceptable cost/QALY estimate (< 
£30,000), based on which a positive recommendation was given.  In Australia, based 
on the clinical claim that cetuximab was not different from bevacizumab, a cost-
minimisation analysis was submitted and the drug's cost-effectiveness was rejected 
mainly because of uncertainty surrounding the clinical claim that the drug is not 
different from its comparator.  
 
6.5. Discussion and Policy Implications  
 
This study confirms that significant disparities in coverage recommendations exist 
across the entire range of new pharmaceutical technologies appraised between January 
2007 and December 2009.  It also demonstrates that these differences are significant in 
numbers: forty-six per cent of diverging recommendations across countries and mainly 
a poor level of agreement across countries as indicated by the kappa scores, implying 
that access to these medicines could vary considerably in individual countries.  This 
may also reflect that HTA processes are influenced by different priorities in individual 
settings, different perception of benefit and value, and use different tools of addressing 
uncertainty within their HTA appraisal process.  It also reveals different preferences 
based on settings and the indication under consideration.  
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The comparisons of the two correspondence analyses exploring the associations 
between the HTA recommendations for all drugs across the three therapy areas 
(cancer, orphan and CNS treatments) and the HTA body issuing the recommendation 
has provided significant insights into some of the key factors driving the appraisal 
process.  SMC, for example, seems to be less likely to approve drugs with high and 
uncertain clinical cost-effectiveness than other agencies.  The latter may put more 
emphasis on other considerations such as the severity of the condition or the need for 
treatment alternatives; this is well illustrated in the case of orphan drugs, characterized 
by high and uncertain cost-effectiveness, which in the majority of cases have been 
rejected in Scotland but are all listed in Sweden.  Several studies have identified 
factors driving access to orphan drugs in different countries, where cost-effectiveness 
in some countries was complemented by other considerations such as disease severity, 
or the availability of other treatment alternatives (Denis et al., 2010a; Drummond et 
al., 2007; Dupont et al., 2011; Simoens, 2011; Vegter et al., 2010).  The analysis has 
also demonstrated that there are different perspectives in the assessment of me-too 
drugs.  For CNS treatments, CDR appears to put more emphasis on the relative 
effectiveness of a new treatment and does not appear to encourage marginal benefits, 
whereas other agencies seem less strict to be placing greater emphasis on other aspects 
such as patient characteristics or preferences.  As such, patient preferences and 
characteristics seem to weigh more heavily in certain disease areas than others, as also 
highlighted in the case of psychotropic drugs (Huskamp, 2006). 
 
The design of HTA submissions, including the evidence submitted, appears likely to 
be tailored by the manufacturers to match agency-specific preferences and 
requirements.  This can be resource-intensive and complex for manufacturers, while at 
the same time it may provide a window of opportunity to game the system.  The 
complexity of HTAs may itself lead to expectations from agencies being far from 
clear, and may lead to initial rejections and subsequent re-submissions.  This is likely 
to be time and resource consuming for both the manufacturer and HTA body.  Greater 
transparency, communication and collaboration at earlier stages of the processes could 
minimize such outcomes, also resulting in a potentially improved access to a treatment 
following an appraisal. 
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The case of paliperidone is a good example of different evidence submitted driven by 
agency-specific requirements.  In this case, the manufacturer intended to demonstrate 
the drug’s effectiveness based on placebo-comparisons in Canada and Scotland, and on 
indirect comparisons in Australia and Sweden, mainly because of the type of evidence 
required by each agency.  The drug’s relative effectiveness compared to placebo was 
deemed insufficient and as a result paliperidone was rejected in Canada and Scotland.  
Cetuximab also had a similar outlook, where all agencies except PBAC were presented 
with placebo-controlled trials.  This was mainly because PBAC has a clear preference 
for comparative evidence (head-to-head or indirect comparisons).  In the case of 
PBAC, the nature of the comparison was questionable and uncertain and as a result the 
drug's relative effectiveness was not demonstrated.  
 
In a number of cases, the interpretation of the evidence could lead to contradictory 
recommendations.  For instance, the 6-week trial duration was considered to provide 
limited data on paliperidone’s toxicity profile and was one of the main reasons for a 
negative recommendation in Canada and Scotland, whereas this was neither a 
necessary nor a sufficient reason for a negative recommendation in Australia and 
Sweden.  This was also illustrated for cetuximab that was rejected by all (PBAC and 
SMC) because of clinical uncertainty, except for NICE that addressed this through 
expert opinion.  This case highlights the importance of the ability and willingness of 
different agencies to leverage the different types of evidence available.  It further 
demonstrates that uncertain outcomes can be addressed in part if no explicit hierarchies 
in evidence exist and if the opinion of relevant stakeholders is accounted for (Pearson 
et al., 2005; Rawlins, 2008).  
 
Differences also exist in the agency-specific requirements regarding economic models 
and choice of comparator(s), which can partly explain diverging recommendations.  
The case of paliperidone is an example where the drug was rejected in Canada because 
of the significantly higher price compared to the price of a generic comparator as 
shown in the cost-minimisation analysis.  This was mainly because the cheapest 
available alternative should explicitly be included in the Canadian model (CDR, 2006), 
whereas this is not an explicit requirement elsewhere.  
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Finally, the possibility to set up risk-sharing agreements may also impact the final 
HTA recommendation.  In the case of paliperidone, a risk sharing agreement was 
proposed in the submission to PBAC; similarly, in the case of cetuximab, a PAS was 
included in the economic model and as a result, the drug was deemed cost-effective by 
NICE.  Had these not been suggested, it is likely that both drugs could have received a 
negative recommendation.  
 
6.6. Conclusion 
 
This study emphasizes the substantial level of disparity in the HTA recommendations 
issued for pharmaceuticals across five countries, implying that HTA methods may be 
influenced by different priorities in individual settings, different preferences based on 
individual settings and therapeutic area, levels of hierarchies in evidence, perceptions 
of value, tools used to address uncertainty, and the ability and willingness or not to 
consider and implement risk sharing agreements.  Adapting HTA submission 
requirements the specifics underpinning individual condition and their characteristics 
to disease areas, by being more explicit about expectations in terms of whether a 
manufacturer should demonstrate the drug’s relative effectiveness compared to 
placebo or to other comparators may avoid unnecessary rejections and resubmissions.  
This could also be improved through greater communication about what expectations 
HTA agencies may have at early stages.  A better understanding of agency-specific 
expectations could also improve the knowledge on why HTA agencies issue different 
recommendations for a same drug-indication pair, based on which solutions to 
harmonize guidelines across borders may be proposed.  Further research is needed in 
this direction, in order to better understand and quantify how the evidence submitted 
may impact the assessment within different therapeutic areas.  Ultimately, improved 
HTA processes may lead to better access and use of health care resources, resulting in 
better health to the population. 
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7. Developing an Evidence-based Methodological Framework to 
Systematically Compare HTA Coverage Decisions across 
Countries: A Mixed Methods Study4 
 
7.1. Abstract 
 
Health Technology Assessment (HTA) often results in different coverage 
recommendations across countries for a same drug despite similar methodological 
approaches.  This paper develops and pilots a methodological framework that 
systematically identifies the reasons for these differences using an exploratory 
sequential mixed methods research design.  The study countries were England, 
Scotland, Sweden and France.  The methodological framework was built around three 
stages of the HTA process: (a) evidence, (b) its interpretation, and (c) its influence on 
the final recommendation; and was applied to two orphan drugs.  The criteria 
accounted for at each stage were qualitatively analysed through thematic analysis.  
Piloting the framework for two drugs, 8 trials, 43 clinical endpoints and 7 economic 
models were coded 155 times.  Eighteen different uncertainties about this evidence 
were coded 28 times, 56% of which pertained to evidence commonly appraised and 
44% to evidence considered by only some agencies.  The poor agreement in 
interpreting this evidence (ĸ=0.183) was partly explained by stakeholder input (ns=48 
times) or by the agency-specific risk (nu=28 uncertainties) and value preferences 
(noc=62 “other considerations”), derived through correspondence analysis.  Accounting 
for variability at each stage of the process can be achieved by codifying its existence 
and quantifying its impact through the application of this framework.  The 
transferability of this framework to other disease areas, drugs and countries is ensured 
by its iterative and flexible nature, and detailed description. 
 
 
                                                 
 
4 A version of this chapter has been accepted for publication in Health Policy (Nicod & Kanavos, 2015) 
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7.2. Introduction 
 
Health technology assessment (HTA) is widely used to provide recommendations on 
whether health care systems should reimburse a particular drug or health technology.  
These recommendations rely on information on the comparative effectiveness of 
different treatment alternatives in a particular clinical setting and aim to ensure that the 
health technologies covered provide value for money (or are cost-effective) (Luce, 
Drummond, Jonsson, Neumann, Schwartz, Siebert, & Sullivan, 2010), ultimately, 
improving access to medicines.  In reality, differences in HTA coverage 
recommendations across countries are seen when appraising the same drug using 
similar methodological approaches and the same body of clinical evidence.  These 
differences are inevitable due to the complexity of the HTA processes and the context 
within which they operate, given that each country sets its own objectives for 
conducting HTA reflecting its values, preferences and constraints (Banta, 2003; Busse 
et al., 2002; Schwarzer et al., 2009).  
 
Better understanding the application of HTA in different settings together with the 
reasons for these differences through cross-country learning and sharing of expertise is 
high on European and supra-national agendas, and may contribute to identify ways to 
minimize these differences (European Commission, 2011, 2014) or understand how 
innovation was rewarded by HTA (Bouvy & Vogler, 2013; Pharmaceutical Forum, 
2013).  This is all the more important given the recent appreciation of HTA as a means 
towards universal health care (World Health Organisation, 2014) and the commitment 
of European Member States in implementing cross-border HTA collaboration through 
the EUnetHTA Joint Action 2 and to further pilot this collaboration in Joint Action 3.  
 
Nine studies (Clement et al., 2009; Kanavos et al., 2010b; Lexchin et al., 2008; 
Morgan et al., 2006; Nicod, 2010; Nicod et al., 2012; Pomedli, 2010; Shah et al., 2013; 
Van den Aardweg, 2010) compared HTA coverage recommendations for drugs in 
more than one country and identified important variations.  Three of these quantified 
these differences (Clement et al., 2009; Lexchin et al., 2008; Nicod et al., 2012), where 
agreement in HTA recommendations ranged from poor to moderate.  The countries 
compared included Canada, Australia, England, Scotland, France, New Zealand, and 
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other European countries.  One study concluded that the most common reasons for 
differing recommendations related to the HTA process and context (Clement et al., 
2009).  Another study highlighted cross-country variations for seventeen of the most 
expensive drugs, but the extent of and reasons for these differences were not explored 
(Morgan et al., 2006).  A more recent study compared HTA decisions in oncology 
concluding that negative recommendations were largely driven by the high relative 
costs in comparison to the marginal benefits (Shah et al., 2013).  Possible reasons for 
diverging recommendations included differences in interpreting the clinical endpoints 
or in levels of patient input, or issues around appropriate comparators (Shah et al., 
2013).  Further research on understanding these differences showed that preferences 
varied according to the therapy area being appraised (Nicod et al., 2012)5.  The authors 
highlighted the need for greater transparency around expectations in terms of what 
constitutes evidence of sufficient quality, how uncertainties are addressed, to what 
extent disease and treatment characteristics influence the assessment, and whether 
these vary depending on the therapy area being appraised (Nicod et al., 2012).  
 
These studies have in common the qualitative approach adopted (retrospective 
descriptive or cohort analyses) to identify these cross-country variations, highlighting 
possible reasons for these through single case study analyses.  None, however, have 
attempted to scrutinize these variations and query why they occur in a systematic 
manner.  This is likely due to decision-making processes being complex with many 
factors being accounted for, which may also be inter-related and thus challenging to 
compare.  Comparing these decision processes systematically could contribute to a 
better understanding of a more comprehensive range of factors accounted for and 
determine the extent to which they explain differences in coverage recommendations.  
This could be done by distinguishing between factors relating to context-specific 
considerations from those that relate to the complexities of HTA processes or the 
nature and quality of the evidence base of the technologies submitted.  Doing so would 
require a methodological approach that decomposes HTA processes in such way that 
they can be compared across settings and would enable the identification of the key 
drivers contributing to decision-making in a systematic way.  While this approach may 
                                                 
 
5 A version of this publication relates to Chapter 6. 
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not necessarily eliminate the variation observed in the criteria used to arrive at 
decisions, reducing it considerably would also be beneficial. 
 
The aim of this study is to develop and pilot such a methodological framework that 
allows for a comprehensive and systematic identification and comparison of the key 
factors that influence coverage decisions at different stages of the HTA process.  A 
better understanding of these value assessment processes may help to address some of 
the methodological challenges in conducting HTA and, potentially, minimize cross-
country differences when these are a consequence of the review or interpretation of the 
evidence. 
 
The framework proposed in this study is informed by evidence from drugs with a 
European Medicines Agency (EMA) orphan designation (EMA, 2013) and which have 
undergone an HTA in a variety of settings in Europe.  Orphan drugs are often 
characterized by significant inequalities in access (Le Cam, 2010) and are not always 
cost-effective (Dupont et al., 2011).  In this context, a broader range of factors are 
likely to be accounted for during the HTA process, which are to be captured by the 
proposed framework.  
 
7.3. Methods 
 
7.3.1. Study design 
A sequential exploratory mixed methods research approach was used to develop and 
pilot the methodological framework in the form of an instrument development design 
(Creswell & Plano Clark, 2011c).   Both the depth and breadth of the HTA decision 
process were captured within the qualitative (stages I and II) and quantitative strands 
(stage III) (Creswell, 2003; Creswell et al., 2011c), where findings from the former 
were built on designing and interpreting the latter aiming at their generalization.  A 
key characteristic of mixed methods design is the “iterative and cyclic approach used 
in the research” (Teddlie & Tashakkori, 2010), where an inductive logic was used in 
the qualitative strand in exploring and identifying the decision-making criteria, and a 
deductive position was used to test the hypothesis made by means of this framework in 
order to draw inferences from the findings in the qualitative strand (Bryman, 2004).  
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Priority was given to outline specifically the steps achieved in designing and piloting 
this methodological framework, while showcasing how the data collected can be 
analysed quantitatively without drawing any conclusions due to the small sample size.   
 
Figure 7-1 illustrates the stages of this mixed methods study aiming to “simplify the 
complex interrelationships among elements inherent in HTA processes” (Teddlie et al., 
2010), by distinguishing between the different methods and data sources used to 
address the research questions and their integration in the final stage (Merten, 2011).  
Within the qualitative strand, stage I consisted in understanding whether the HTA 
decision-making process was comparable, and, if so, how; this was achieved through 
two in-depth case study analyses.  The aim of stage II was to determine the similarities 
and differences in the HTA decision processes for the same drug across a number of 
countries.  For this purpose, qualitative thematic analysis was undertaken, where all 
criteria identified during the HTA process were coded such that they were comparable 
across case study drugs and countries.  Within the quantitative strand (stage III), codes 
were quantitatively analysed in order to understand HTA agency-specific risk and 
value preferences, as well as agreement levels across countries. 
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Figure 7-1. Visual model of the mixed methods research design used 
 
Source: (Nicod & Kanavos, 2015) 
 
Figure 7-1 illustrates the stages of this mixed methods study aiming to simplify the 
complex interrelationships by distinguishing between the different methods and data 
sources used to address the research questions and their integration in the final stage. 
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7.3.2. Sampling 
 
Purposeful sampling was used to select the study countries based on predefined criteria 
(Creswell & Plano Clark, 2011b), notably whether, (a) they had well-established HTA 
agencies and processes, (b) similar decision-making criteria (clinical and/or cost-
effectiveness) were used, (c) all the different approaches adopted in HTA were 
represented (e.g. clinical benefit assessment vs clinical and cost effectiveness, health 
service vs. societal approach), and (d) the HTA reports were publicly available.  On 
this basis, England, Scotland, Sweden and France were included and are referred to as 
the “study countries”.  Appendix A summarises some of the key operating features of 
HTA in these countries. 
 
The subject matter of the analysis was orphan drugs based on EMA orphan designation 
(EMA, 2013).  Their coverage decisions are often characterized by controversy due to 
high degrees of uncertainty about cost and outcome (Kanavos et al., 2012).  Drug and 
indication pairs were the unit of analysis.  The two case studies used to develop the 
proposed methodological framework were selected from all EMA approved drug-
indication pairs - until December 2012 - that had an orphan designation and were 
appraised in the four study countries.  Drug-indication pairs were excluded if (a) they 
did not undergo the single technology assessment process at NICE, or the full 
submission process at SMC where the full HTA process was conducted and 
documented, and (b) they did not receive diverging coverage recommendations.  
Coverage recommendations were either to list, restrict or reject the drug under review, 
or in the case of France, to issue a ranking of clinical benefit (Service Medical Rendu, 
SMR) defining the coverage decision and rate, or one of improvement in clinical 
benefit (Amelioration de Service Medical Rendu, ASMR) providing a basis for the 
price fixing regime applicable, ranging from major to insufficient.  For example, a 
medicine receiving an ASMR V is considered not to provide any additional benefit and 
is covered only if its price is inferior or equal to the other treatments.  
 
Two drug-indication pairs remained that formed the basis for analysis: eltrombopag 
(REVOLADE©) for the treatment idiopathic thrombocytopenic purpura (ITP) and 
everolimus (AFINITOR©) as a second line treatment for advanced renal-cell 
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carcinoma (RCC) after failure of alternative therapies.  These technologies have 
evidential characteristics that are broadly similar to other oncology and non-oncology 
products and are likely to be valued differently by HTA bodies given that they differ in 
terms of disease and treatment characteristics.  
 
7.3.3. Data sources and data analysis 
 
Stage I of the qualitative strand, involved an analysis of two drug-indication pairs in 
order to obtain an in-depth understanding of the decision-making processes, the 
evidence that informs these and determine whether they are comparable across 
countries.  Previous research aiming at better understanding the HTA decision-making 
process in each study country was used to outline the structure of the process (Nicod et 
al., 2012).  The case study analyses were used as “an intensive study of a single unit 
for the purpose of defining a larger class of similar units” (Gerring, 2007), where the 
decision-making processes for each drug were deconstructed in such way that the 
criteria identified were comparable across countries.  The structure was derived by 
decomposing the process into three components: (a) the clinical and cost-effectiveness 
evidence appraised; (b) the interpretation of this evidence in terms of whether it was 
deemed uncertain, the “other considerations” and stakeholder input accounted for; and 
(c) the impact of the evidence and its interpretation on the final HTA recommendation.  
Within each of these components, all of the related criteria recorded in the HTA were 
extracted into the case study template and coded.  Data sources comprised HTA 
recommendation reports and other relevant material published in the study countries 
and accessed by the authors.  Although these materials adopt similar structures and 
outline the rationale for the decision, their purposes may differ (e.g. legal document 
and memo in Sweden, summary of advice to the NHS in Scotland).  
 
The end-product of stage I was the development of the methodological framework, 
composed of the case study template and the coding manual used to inform the second 
stage of the research.  The case study template provides a structure for the information 
to be extracted and analysed.  It includes tables regrouping all the data identified and 
extracted for each of the components of the decision-process.  Each line item 
represents one criteria and whether it was accounted for by the individual HTA bodies.  
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It also includes identifiers to ensure cross-country comparability.  These are, for 
example, the number of trial participants to ensure that the trial being coded was the 
same in the other countries.  This facilitated the understanding and comparison of 
whether the criteria identified was accounted for in the different countries, and how; as 
showcased in our results.  The coding manual consists of an exhaustive list of all of the 
criteria identified and included in the case study templates, which were coded.  These 
codes were organized into hierarchical levels clustered into common themes according 
to the information provided, and are referred to as first-order, second-order (clustering 
first-order themes) and third-order (clustering second-order themes) themes.  
 
In stage II of the qualitative strand, the objective was to pilot the methodological 
framework developed in the previous stage by comparing the HTA recommendations 
and the evidence used for this purpose across countries in order to understand the 
reasons for differences for a same drug and indication pair.  This was done in a 
systematic manner involving thematic analysis in order to identify and study patterns 
in the data that describe the decision-making process (Bryman, 2004).  Bottom-up 
coding was undertaken (e.g. adopting an inductive approach, from specific to general) 
(Onwuegbuzie & Combs, 2010), where codes were created while examining the data 
to summarize and categorize the criteria and variables included in the decision-making 
process and identified during the case study analyses.  The unit of coding, which is the 
section of text coded that represents one criteria, was clearly defined for each theme 
(e.g. first-order, second-order, or third order theme) and was illustrated with examples, 
for consistency across codes to avoid confusion or duplication in the results (Boyatzis, 
1998).  Double-coding was performed to capture additional information such as those 
cases where differences across countries were seen, how these were dealt with, and 
whether this influenced the final decision.  For example, each uncertainty was double-
coded with: a) those agencies that raised the same concern, b) whether the uncertainty 
was addressed and by what means (e.g. stakeholder input), and c) whether it was one 
of the main reasons for the final outcome.  Similar double-coding was performed for 
the “other considerations” identified. 
 
Coding and clustering of codes were performed by the lead author.  Intra-coding 
reliability was tested to minimize coding bias.  Reliability of the clustering was tested 
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by an academic colleague, who re-categorised each individual code into one of these.  
Where differences were observed, adjustments were made.  An iterative approach was 
adopted throughout the coding process to ensure that the identified criteria captured the 
numerous dimensions of the decision-making process.  At the end of the coding 
period, all the information coded was reviewed to ensure that the codes reflect what 
was meant to be coded (within case-comparison) across all codes (cross-case 
comparison).  Primary data collection took place by means of the HTA reports 
summarizing the recommendations and soliciting input from HTA experts and HTA 
body representatives to obtain additional insights about the decisions and ensure that 
the criteria were coded accurately.  The analysis was performed using QSR 
International’s NVivo10 (QSR International Pty Ltd, 2012). 
 
In stage III, codes were quantitatively analysed both vertically and horizontally 
through descriptive exploratory analyses (Onwuegbuzie et al., 2010) to study their 
interrelationships.  Thematic-matrixes summarizing the codes per medicine and 
country were exported from NVivo10 into Excel and transformed into nominal 
variables.  The statistical software STATA13 was used for the analysis (StataCorp, 
2013).  The vertical dimension provided findings about agency-specific risk and value 
preferences.  “Risk” was derived from the concerns of the HTA bodies pertaining to 
uncertainty, and “value” from the “other considerations” relating to the disease and 
treatment characteristics accounted for. Preferences were explored through 
correspondence analysis, where the associations between the variables (HTA bodies 
versus uncertainty or “other considerations”) were measured and illustrated in 
correspondence analysis biplots (Bartholomew, Steele, Moustaki, & Galbraith, 2008a; 
Dickenson, 2010). The horizontal dimension provided a measure of agreement 
between the HTA bodies in interpreting the same evidence using Cohen’s kappa scores 
(Cohen, 1960), allowing for a more robust  evaluation of qualitative findings by 
comparing observed frequency of agreement with the probability of agreement 
occurring by chance.  
 
7.3.4. Study limitations 
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Whereas the objective of this study is to develop and pilot a framework, which would 
then be applicable to a wider sample of medicines because of its iterative nature, it is 
not without limitations.  One limitation is whether specific aspects of the decision-
making process, particularly the context within which a decision was made, were 
captured; these contextual considerations, however, were not within the scope of this 
study.  A second limitation relates to the purpose and level of detail provided in the 
HTA reports, which varies by country.  This is unlikely to have affected the results 
given that the key determinants, defined as the main reasons for the final 
recommendations, were included in all the reports and provide a good overview of the 
decision criteria; data triangulation ensured sufficient detail was captured in each case, 
and comprised the HTA reports, other material and case studies, input from HTA 
experts (e.g. Advance-HTA consortium, conferences), and interviews with HTA 
bodies where findings were presented and feedback collected.  A third limitation is that 
the framework relies on two case studies.  However, these were selected to proxy 
decision frameworks in orphan oncology and non-oncology treatments because the 
ways of valuing these may differ.  The two cases are very different in terms of both 
disease and treatment characteristics, and therefore are considered to appropriately 
cover different dimensions of decision processes.  Finally, the transferability of this 
framework to other countries and therapy areas is limited to those cases where similar 
decision-making criteria are accounted for, from HTA entities that are arm’s length, 
responsible for issuing coverage recommendations, and have a transparent process 
where sufficient detail about the appraisal process and reasons for the final decision 
are recorded in their decision reports. 
 
7.4. Results 
 
Results are divided into the qualitative (stages I&II) and the quantitative strands (stage 
III).  The first and second sections outline the information collected and coded 
following the case study template, showcasing how the proposed structure was used to 
set up and pilot the methodological framework.  The third section showcases how the 
data collected can be quantitatively analysed, where the case studies were used as 
illustrative examples and results are by no means generalizable due to the small sample 
size.  
   110 
 
 
 
7.4.1. Qualitative strand: Developing the methodological framework  
 
Within the HTA process, the manufacturer is responsible to provide evidence about the 
relative clinical (and cost) -effectiveness of its drug by submitting an HTA application.  
This evidence is then appraised by the HTA bodies and used as a basis for the 
recommendation.  Three key stages in this process were identified and used as the 
basis for the methodological framework: a) the evidence, which consists of all the 
clinical, safety and cost-effectiveness evidence presented (e.g. clinical trials, clinical 
endpoints, safety, economic model, comparator, comparative effectiveness), b) the 
interpretation of this evidence, which includes when the evidence was uncertain or 
incomplete, the “other considerations” accounted for, and the influence from 
stakeholder input, and c) the final HTA recommendation, focusing on how the 
previous two stages influenced the recommendation formulation (e.g. HTA 
recommendations are either to list, restrict or reject the drug for reimbursement for the 
respective indication) (Figure 7-2).  
 
Within each of these stages, the criteria that were accounted for during the appraisal 
process were identified and subsequently coded.  This was used to establish the case 
study template and coding manual, both tools forming the methodological framework.  
The case study gathers all the information accounted for and appraised in a comparable 
format in one document (Appendix B. Case Study ).  All the information included in 
the case studies was then coded in the HTA report, where each new code was included 
into the coding manual (Figure 7-3).  For example, if a phase III RCT was identified, 
the text providing information about this trial would then be coded once as “phase III” 
(first-order theme), and would represent the cluster “trial type” (second-order theme), 
within the cluster “clinical trial” (third-order theme), and so forth.  This facilitated the 
coding and avoided any misinterpretations or missing of information.  The next section 
exemplifies how this was done. 
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Figure 7-2. Methodological framework for the systematic comparison of HTA processes 
 
Source: (Nicod et al., 2015a). 
 
Figure 7-2 illustrates the three key stages identified and used as a basis for the methodological framework, together with the outcomes from 
quantitatively analysing the data collected both vertically (e.g. agency-specific preferences) and horizontally (e.g. when differences at each 
stage of the process explained differences in HTA recommendations across countries). 
   112 
 
 
7.4.2. Qualitative strand: Testing the methodological framework  
 
Eltrombopag (REVOLADE®) and everolimus (AFINITOR®) received diverging 
recommendations for the treatment of ITP and RCC respectively.  Eltrombopag was 
rejected in England, restricted to patients with severe symptomatic ITP or a high risk 
of bleeding in Scotland, and listed in Sweden until its re-assessment in 2 years’ time.  
In France, it was valued as having an important medical benefit and providing an 
important improvement in medical benefit (ASMR II).  Everolimus was rejected in 
England and Scotland, listed as applied for in Sweden, and was considered to provide 
an important medical benefit in France with a low added benefit (ASMR IV).  
 
Clinical and cost effectiveness evidence  
 
The same phase III primary trials were considered by all agencies for the two study 
drugs.  For eltrombopag, a number of additional clinical trials were considered, one of 
which was an indirect comparison of eltrombopag with romiplostim, which was 
appraised by NICE, SMC and TLV, but not by HAS.  For everolimus, subgroup 
analyses by prognostic categories (favourable, intermediate or poor) of the primary 
trial were also considered by SMC and HAS, whereas NICE additionally conducted a 
meta-analysis of 28 studies (Table 7-1). 
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Table 7-1. Clinical trials and their endpoints considered for eltrombopag and everolimus (non-exhaustive list) 
ELTROMBOPAG England 
NICE 
Scotland 
SMC 
Sweden 
TLV 
France 
HAS 
 
RAISE   Phase III, 6-month, placebo-controlled (N=197) 
Platelet response      
Rescue treatment      
Bleeding (WHO1-4)      
Bleeding (WHO2-4)     Clinically significant bleeding 
Bleeding (WHO3-4) x    Gross (grade 3) and debilitating (grade 4) blood 
loss 
Main reduction in bleeding  x    Seen in grade WHO2 
HRQOL (SF36)  4 
x 6 
 4   Significant over 4 domains, and not over 6 
KUTER  Indirect comparison with RAISE 
Platelet response  NR NR NR  
Platelet response x    Splenectomised patients 
Platelet response x    Non-splenectomised patients 
EVEROLIMUS      
RECORD-1  Phase III, placebo-controlled (N=416) 
Progression-free survival      
Overall survival x x x x Blinded phase 
HRQOL R* x*  x** *EORTC, FKSI-DRS, **QLQ-C30 
Objective response  x  x  
Progression-free survival (subgroup)     Per risk stratification group 
Source: (Nicod et al., 2015a). 
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Legend: √: Statistically significant; x: Non-statistically significant; R: reported; NR: not reported;; EORTC: European Organisation for Research 
and Treatment of Cancer; FKSI-DRS: Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms; QLQ-
C30: Quality of Life Questionnaire and the Symptoms Associated with the Disease. 
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A variety of ways to report the clinical endpoints and safety results from the same 
trials were seen (Table 7-1).  For instance, in the case of eltrombopag, WHO 3-4 
bleeding events were recorded only by NICE and quality of life relied on the number 
of domains reported, where it was significant over four (as reported by SMC), but not 
over six domains (as reported by NICE).  Results from indirect comparisons were 
statistically significant across the whole population, but not significant for the 
subgroups of patients (as reported only by NICE).  A similar scenario was seen for 
everolimus, where quality of life was not reported by TLV and neither was the 
objective response rate or progression-free survival in the subgroup analysis by NICE 
or TLV.  Adverse events were reported by all agencies except TLV, but this can be 
explained by the difference in purpose of the TLV reports, which are of legal nature.  
Generally, the most common and clinically significant adverse events, and treatment 
discontinuation rates were reported homogeneously.  Additionally, HAS usually 
provided more detail around the percentage of patients affected and deaths (even if not 
associated with the treatment).  
 
Three different categories of clinical evidence were identified (as third-order themes): 
(a) the clinical trials, comprising eight trials (three of which were considered as 
primary evidence) and five subgroup analyses with their respective comparators coded 
51 times across countries; (b) 43 different clinical endpoints (e.g. primary, secondary, 
health-related quality of life) coded 68 times, and (c) the assessment of safety, 
recorded in a variety of ways and coded 22 times.  This resulted in a total of 141 codes 
each representing an individual criterion defined as first-order themes, grouped into a 
number of second-order themes.  For example, each trial was coded according to the 
type of trial (e.g. phase III, phase II and so forth), the type of comparator (e.g. placebo, 
standard care) and whether it was a primary trial.  Trial is a third-order theme, defined 
by the trial type, comparator and whether it was primary evidence (second-order 
themes), each of these further defined in detail with the first-order theme (e.g. type of 
trials are defined by whether they are phase III, phase II, etc.).   
 
Economic models were appraised by all HTA agencies except HAS.  For eltrombopag, 
different economic models were considered.  The NICE submission included three 
models: a) the “watch and rescue model” comparing conventional care to eltrombopag 
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for splenectomised (£104,100/QALY) and non-splenectomised patients 
(£116,800/QALY), b) the “long-term continuous model” that included a sequence of 
treatments with eltrombopag, and c) a cost-effectiveness model comparing 
eltrombopag to romiplostim.  The watch and rescue model was considered the most 
appropriate (reflecting clinical practice), and the other two were rejected on the basis 
that they do not represent clinical practice (romiplostim was at the time of this 
assessment under review at NICE) or were not valid, respectively.  In contrast, SMC 
considered a cost-utility model where eltrombopag was found to dominate romiplostim 
in splenectomised (savings £12,641 and 0.039 QALY gain) and non-splenectomised 
patients (savings £2,094 and 0.028 QALY gain), and TLV a cost-minimization 
analysis with the same comparator based on a non-inferiority claim.  For everolimus, 
cost-utility models were considered by all with best supportive care as comparator.  
This resulted in a cost per QALY of £49,000 and £51,700 for NICE depending on the 
approach used, £61,330 for SMC, and was not specified in TLV’s HTA report. 
 
Two categories defined the cost-effectiveness evidence (third-order theme): the 
economic model (second-order theme), coded 7 times (first-order theme), and the 
comparator included in the model (second-order theme), also coded at 7 occasions 
(first order theme).  This resulted in a total of 14 codes (first-order themes), clustered 
into two groups (second-order themes).  The coding manual summarizes the full list of 
criteria identified as well as the groups they were clustered in (e.g. second-order and 
third-order themes) (Figure 7-3).  A similar approach was used for the component on 
the interpretation of the evidence, discussed in the next section.  
 
Interpretation of the evidence 
 
A total cumulative number of 18 (clinical) uncertainties were raised by the agencies 
for both case studies (10 for eltrombopag and 8 for everolimus) and coded 28 times 
(e.g. some may have been raised by more than one agency).  Some of these were based 
on evidence commonly appraised by all (56% of 18 uncertainties), while others on 
evidence included in only some of the appraisal reports (44% of 18 uncertainties).  
Additionally, some of these uncertainties were also put forward as one of the main 
reasons for the final recommendation (44% of 18 uncertainties).  
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Table 7-2 illustrates the different phases in interpreting the clinical evidence, 
structured in a way that it facilitates the understanding of events in the study countries.  
The first column reports the evidence (e.g. evidence, considered by) that was 
interpreted, and whether it came from the primary trial.  This enables us to highlight 
cases when the interpretation of the evidence was based on evidence also considered in 
the other countries.  The second column (e.g. interpretation, raised by) reports whether 
the assessors highlighted a concern or uncertainty about this evidence, and whether 
this issue was deemed acceptable or not (e.g. addressed or not).  It also highlights 
whether the HTA bodies raised the same uncertainty and whether it was dealt with in 
the same manner.  The last column (e.g. outcome, main reason for recommendation) 
reports whether this issue was also one of the main reasons put forward for the final 
recommendation, and how this compared in the other countries (e.g. was it dealt with 
in the same manner? was it also put forward in the other countries?).   
 
This allowed to understand how these issues were dealt with across settings.  For 
example, in the case of eltrombopag, the lack of direct comparative data was generally 
a concern for all and one of the main reasons for the final recommendation for TLV 
and HAS.  The duration of the primary trial was deemed too short to capture the full 
effects of the treatment for NICE, SMC, and HAS.  It was not specifically raised by 
TLV, but may indirectly be reflected in the conditional nature of the decision with its 
planned reassessment after 2 years.  The primary trial’s small sample size was a 
concern for TLV, but considered acceptable given the treatment’s orphan status.  
Although eltrombopag demonstrated improved outcomes in platelet response and need 
for rescue medication, NICE was concerned by the fact that this improvement was not 
significant in the low incidence of the most severe bleeding events (WHO grades 3 and 
4); this issue was not raised nor recorded by the other agencies either because this 
endpoint was not specifically appraised or was not identified as being relevant to the 
decision.  Quality of life data were presented in the submissions to NICE and SMC, 
but no mention is found in the TLV and HAS reports.  This was a concern for HAS, 
who acknowledged that quality of life is severely affected by the condition, and that 
there is a need for additional evidence around this.  
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Table 7-2. Differences and similarities in the interpretation of the clinical evidence and main reasons for recommendation 
  
Evidence 
considered by 
Interpretation 
uncertainty raised by 
Outcome 
main reason 
evidence considered 
*evidence considered 
within the pivotal trial 
positive 
influence 
(addressed) 
x negative 
influence 
(not 
addressed) 
positive 
influence 
(addressed) 
x negative 
influence 
(not addressed) 
  
Clinical uncertainties 
N
IC
E 
SM
C
 
TL
V
 
H
A
S 
N
IC
E 
SM
C
 
TL
V
 
H
A
S 
N
IC
E 
SM
C
 
TL
V
 
H
A
S 
El
tro
m
bo
pa
g 
Lack of comparator  * * * * x x x x 
  
x x 
Short duration of trial  * * * * x x 
 
x x 
  
  
Sample size  * * * *         
Trial population, indication under review * * * * x 
   
x 
   
Trial population, generalizability * * * *  x 
      
Trial population, low platelet count patients 
instead of those with severe risk of bleeding 
* * * *         
Significant bleeding events (WHO3-4) * 
   
x 
   
x 
   
Quality of life estimate        x    x 
Liver function monitoring 
 
 
   
x 
      
Uncertain nature of the indirect comparison    
 
x x 
      
Ev
er
ol
im
us
 Bias in overall survival (cross-overs) * * * *        x 
Weak overall and partial response  
 
* 
 
* 
 
x 
      
Lack of comparative safety evidence     
 
x 
      
Trial population, co-morbidities excluded * * * * 
 
x 
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Trial population, generalizability * * * *  
       
Risk of pneumonitis, immunosuppression      
       
Quality of life   
 
 
   
x 
    
Risk stratification method (subgroup analysis) 
 
   
 
x 
      
Source: (Nicod et al., 2015a). 
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In the case of everolimus, the trial was terminated early given the stopping rule around 
superior efficacy after which patients were given the opportunity to switch from 
placebo to treatment.  Results were biased due to this high number of cross-overs (81% 
of patients).  Nevertheless, for NICE, overall survival was deemed plausible based on 
clinical expertise and results from a meta-analysis.  SMC and TLV also agreed that 
one specific tool to derive overall survival into more accurate estimates was 
appropriate.  In contrast for HAS, no benefit was demonstrated in overall survival.  
 
A similar analysis about the interpretation of the economic models is possible in order 
to understand the types of concerns raised by each HTA body, how these are 
comparable and dealt with.  For eltrombopag, different economic models associated 
with different outcomes were appraised in the three countries considering clinical cost-
effectiveness.  The comparators differed: NICE considered both conventional care and 
eltrombopag within different treatment sequences, while SMC and TLV both 
considered romiplostim.  For both NICE and SMC, the trial’s secondary endpoint 
“bleeding events” was included as the main effectiveness endpoint; this was not 
specified in the report from TLV.  The assumption that differences between treatment 
arms occur because of bleeding events was a concern for NICE and SMC.  However, 
in the latter case, sensitivity analysis showed no differences with romiplostim and a 
substantially low threshold value for it not to be cost-effective.  For everolimus, the 
interpretation of varying clinical evidence was not associated with differing outcomes, 
but the different methods used to extrapolate the effects yielded different conclusions.  
These, together with different willingness to pay thresholds, are likely to have led to 
different HTA recommendations.  
 
A number of “other considerations” were identified in the HTA reports and coded 62 
times.  These are summarized into the case study template categorized within their 
second-order themes (Table 7-3).  They were divided between considerations around 
the treatment and its characteristics, such as the type of benefit provided from the 
treatment or its innovativeness, and those around the disease and its severity, unmet 
need, or the nature of the condition.  These may have been put forward as part of the 
reasoning for the final recommendation and/or may have been raised by different 
stakeholders (e.g. patients, clinicians).  For instance, the oral administration benefit of 
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eltrombopag was one of the main reasons for the final decision by SMC and TLV.  
Similarly, patients and clinicians stated that adverse events are tolerable and 
manageable, and that patients are willing to cope with them in order to get treatment.  
Another example is the life-threatening nature of the condition that was put forward by 
patients and clinicians in the NICE appraisal for everolimus and was also one of the 
criteria for recognising the drug as an end-of-life treatment.  In total, 41 “other 
considerations” were identified for the two case studies (first-order themes), and 
clustered into nine categories according to the information provided (second-order 
themes) (Table 7-3). 
 
Stakeholder input was seen 46 times in total across the two case studies in the NICE 
HTA reports and twice in the SMC reports; no stakeholder input was identified in the 
TLV and HAS reports.  In the NICE assessments, patient input was identified in 30% 
of cases (14 out of 46), providing mainly information on “other considerations” (e.g. 
impact of symptoms from the disease on daily activities, anxiety from the symptoms 
affecting quality of life, etc.); and clinical input was identified in 70% of cases (32 out 
of 46), providing mainly information on “other considerations” (e.g. on limited 
treatment options when current alternatives fail, issues around the use of treatment 
alternatives in clinical practice) and commenting on some of the clinical and economic 
uncertainties raised (e.g. about generalizability of results, issues around clinical 
practice).  For SMC, clinical experts provided input about “other considerations” (e.g. 
clinical practice) and commented on uncertainty (e.g. generalisability).  
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Table 7-3. “Other considerations” identified in the HTA reports 
      Eltrombopag Everolimus 
  Subcategory Illustrative quotations/code 
England 
NICE 
Scotland 
SMC 
Sweden 
TLV 
France 
HAS 
England 
NICE 
Scotland 
SMC 
Sweden 
TLV 
France 
HAS 
TR
EA
TM
EN
T 
 
 
Type of benefit Curative, life-extending      EoL    Innovativeness Innovative, new class of drugs  C   Main   C, P    
Adverse effects 
Similar across treatment arms         
Manageable, tolerated, 
transient, reversible      P    
Administration Oral administration   Main  Main      
D
IS
EA
SE
  
Unmet need 
Unmet need, no or few 
treatment alternatives, need for 
options 
C  Main  Main   C, P    
Nature of the 
condition 
Disease severity, serious 
condition    Main     Main  
Life-threatening  C, P   Main  
 C, P, 
EoL    
Short life-expectancy      EoL    Impact on quality of life, 
functional capacity, impact on 
daily activities 
 C, P  Main      
Social stigma, limiting of life-
style choices, ability to work, 
travel or undertake leisure 
activities 
 C, P        
Rare disease Orphan status, small population   Main  Main      
    123 
 
Clinical 
practice 
No routine standard pathway, 
complex clinical practice, 
tailored to the patient 
 C  C       
Comparator unlicensed for 
indication, and associated with 
important adverse events and 
anxiety  
 C, P        
No long term evidence and 
unknown dosage of 
comparator  
 C        
Late diagnosis (advanced 
disease)          
Preference for licensed over 
unlicensed  C        
National 
priority Plan Maladies Rares (2004)         
Source: (Nicod et al., 2015a).  
 
Legend: Main: considered one of the main reason for the final recommendation; : considered during the assessment; C: put forward by 
clinicians; P: put forward by patients; EoL: eligible as “end-of-life treatment” for NICE. 
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Figure 7-3. Coding Manual 
VERTICAL DIMENSION 
 
 
THIRD-
ORDER 
THEME
SECOND-
ORDER 
THEME
FIRST-ORDER 
THEME
DEFINITION UNIT OF 
ANALYSIS
Phase III
Phase II
Extension trial
Open-label trial
Indirect comparisons
Subgroup analysis
Trial primary Primary or pivotal 
trial
Refers to the pivotal trial or primary source of 
evidenc used as main evidence.
Code pivotal or 
primary trial together 
with trial type and 
comparator.
Placebo Refers to cases when the treatment is compared to 
placebo (no treatment).
Treatment Refers to cases when the treatment is compared to 
another treatment alternative.
Standard care
Refers to cases when the treatment is compared to 
standard care, which could be, for example, a 
surgical intervention or palliative care.
Standard care-
placebo
Refers to cases when comparison is made between 
standard care (= placebo) and standard care + 
treatment. Standard care could be, for example, 
chemotherapy.
None No comparators (e.g. open-label or observational 
studies)
Primary endpoint
Secondary endpoint
Health-related quality 
of life 
Clinical endpoint 
(type not specified)
Common adverse 
events
Refers to cases when the most common or frequent 
events are mentioned.
Severe adverse 
events
Refers to the more severe adverse events or those 
that are greater or equal to grade 3 events.
Discontinuation Refers to cases when discontinuations are reported.
Deaths
Refers to cases when deaths were recoreded, 
regardless whether they were linked to the 
treatment under investigation or not.
Percent of patients 
with adverse events
Refers to when the proportion of cases of patients 
with adverse events was reported.
Cost-utility analysis
Cost-effectiveness 
analysis
Cost-minimisation 
analysis
Placebo
Refers to cases when the economic model 
compares the treatment to treatment with placebo.
Treatment
Refers to cases when the economic model 
compares the treatment with another treatment 
alternative.
Standard care
Refers to cases when the economic model 
compares the treatment with standard care (e.g. 
chemotherapy, palliative care).
Sequence
Refers to models that include a sequence of 
treatments including the treatment under 
assessment.
Paragraph, sentence 
or part of the 
sentence with mention 
of the type of trial and 
comparator. 
Code each 
comparator only 
once. 
When the type of clinical endpoint is specified, 
code with specified effect type. If this is not 
specified, code under "not specified".
Paragraph, sentence 
or part of the 
sentence with mention 
of the type of trial and 
comparator. 
Refers to the type of trial included in the 
assessment, regardless whether or not results 
(outcomes from the clinical endpoints) were 
provided. 
C
LI
N
IC
A
L 
EN
D
PO
IN
TS
Paragraph, sentence 
or part of sentence 
with mention of the 
outcome of the effect. 
Also code if endpoint 
is mentioned but 
EC
O
N
O
M
IC
 M
O
D
EL
S Paragraph, sentence 
or part of a sentence 
with mention of the 
economic model and 
comparator. 
Code each model 
only once.
Refers to the type of economic model included in 
the assessment.
Economic 
comparator
Economic 
model
Paragraph, sentence 
or part of sentence 
with mention of the 
safety assessment. 
Code each type of 
safety event reported 
only once.
Effect type
Trial type
Comparator 
type
EV
ID
EN
C
E
C
LI
N
IC
A
L 
TR
IA
LS
SA
FE
TY
Safety type
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THIRD-
ORDER 
THEME
SECOND-
ORDER 
THEME
FIRST-ORDER 
THEME
DEFINITION UNIT OF 
ANALYSIS
Clinical benefit
Uncertain statistical significance or magnitude of the 
benefit lack of information with regards to a specific 
endpoint.
Evidence and study design
Potential bias from the design and conduct of the trials: 
uncertain nature of indirect comparisons,  assumptions 
around the trial design or randomisation.
Trial population
Generalizability of  trial results to local clinical practice, 
representation of the trial population to the indication 
being appraised.
Comparator Lack of comparative evidence, choice of comparator.
Sample size Trial not sufficiently powered due to sample size.
Trial duration Trial period  too short to capture the drug’s long term 
benefit or reflect clinical practice .
HRQoL Absence of any quality of life data in the submission.
Administration or 
provision
Issues around the additional requirements from receiving 
a treatment (e.g. monitoring).
Clinical benefit Little or no benefit actually seen.
Clinical practice Treatment sequences included are not representative of 
clinical practice.
Population
Trial population  not representative of the population in 
clinical practice, differences in trial population between 
treatment and controls.
Trial duration Trial considered not long enough to capture the full effect 
of the treatment.
Safety Lack of safety data for comparator treatments.
Clinical assumption Uncertain assumptions about recurrence rates or the 
clinical benefit of the control arm.
Sensitivity analysis
Sensitivity analyses testing how changing the parameters 
influence the incremental cost-effectiveness ratio.
Nature of the 
disease on the 
patient and its 
surrounding
Negative effects of the 
disease on quality of life 
or  ability to go to work, 
disease severity
Refers to the nature of the disease and its impact on the 
patient and his or her surroundings' quality of lives (e.g. 
ability to go to work, anxiety from the disease, social 
stigma).
Unmet need
Unmet need for treatment 
alternatives, few or no 
alternatives exist
Refers to cases when the unmet need for new treatments 
was emphasised, through the fact that little or no 
alternatives exist or that there is a need for additional 
treatments.
Rarity Rarity, orphan status Refers to cases when the rarity of the disease, the orphan 
status of the drug were put forward.
Issues with 
current 
treatment 
alternatives
Complex treatment 
pathways, no consensus 
on best practices
Refers to issues set forth around the current treatment 
pathway, such as the fact that little consensus on best 
practices, or that treatment pathways are complex.
National 
priority
National priority Refers to cases when the disease area under assessment 
is recognised as a national priority.
Type of 
treatment 
benefit
Curative
Refers to the type of treatment benefit (e.g. curative, 
symptomatic, etc.).
Innovativeness
Innovative nature of 
treatment
Refers to the innovative nature of the treatment, such as 
the new mechanism of action, or that is is considered a 
new class of drugs.
Indirect 
benefit from 
the treatment
Ability to go back to 
work from the treatment
Refers to any information provided around the indirect 
benefits from the treatment, such as being able to go 
back to work, improving functional capacities.
Tolerance of 
adverse events 
from the 
treatment
Adverse effects
Refers to any information provided around how adverse 
events from the treatment are tolerated (e.g. non life-
threatening,similar across treatment arms).
Clinical expertise
Patient expertise
Carer input
Consultees
Code section of 
information provided 
by stakeholder 
together with 
uncertainties or other 
considerationsST
A
K
E
H
O
L
D
E
R
 
IN
PU
T
Stakeholder 
input
Refers to information (uncertainties or other 
considerations) provided by on of the  stakeholders.
O
T
H
E
R
 C
O
N
SI
D
E
R
A
T
IO
N
S 
- D
ise
as
e 
ch
ar
ac
te
ri
st
ic
s
O
T
H
E
R
 C
O
N
SI
D
E
R
A
T
IO
N
S 
- 
T
re
at
m
en
t c
ha
ra
ct
er
ist
ic
s
Paragraph, sentence 
or part of a sentence 
with mention of  the 
the other 
considerations. 
Code once each 
other consideration 
once.
IN
T
E
R
PR
E
T
A
T
IO
N
 O
F 
T
H
E
 E
V
ID
E
N
C
E
Paragraph, sentence 
or part of a sentence 
with mention of the 
clinical uncertainty. 
Code each 
uncertainty only once.
Clinical 
uncertainties
E
C
O
N
O
M
IC
 M
O
D
E
L
 U
N
C
E
R
T
A
IN
T
IE
S
Economic 
model 
uncertainties
Paragraph, sentence 
or part of a sentence 
with mention of  the 
uncertainty raised 
around the economic 
Paragraph, sentence 
or part of a sentence 
with mention of  the 
uncertainty raised 
around the economic 
model.
Code once each 
model.
C
L
IN
IC
A
L
 U
N
C
E
R
T
A
IN
T
IE
S
Clinical 
uncertainties
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HORIZONTAL DIMENSION 
 
 
Source: (Nicod et al., 2015a). 
THIRD-
ORDER 
THEME
SECOND-
ORDER 
THEME
FIRST-ORDER 
THEME
DEFINITION UNIT OF 
ANALYSIS
Considered by all The clinical evidence related to the 
uncertainty was included in all the 
Not included by NICE
The clinical evidence related to the 
uncertainty was not included in the NICE 
submission.
Not included by SMC
The clinical evidence related to the 
uncertainty was not included in the SMC 
submission.
Not included by TLV
The clinical evidence related to the 
uncertainty was not included in the TLV 
submission.
Not included by HAS
The clinical evidence related to the 
uncertainty was not included in the HAS 
submission.
Uncertainty raised by all The uncertainty was raised by all
Uncertainty not raised by 
NICE
The uncertainty was not raised by NICE.
Uncertainty not raised by 
SMC
The uncertainty was not raised by SMC.
Uncertainty not raised by 
TLV
The uncertainty was not raised by TLV.
Uncertainty not raised by 
HAS
The uncertainty was not raised by HAS.
Positive impact
The consideration of the evidence, 
uncertainties, or other considerations had a 
positive impact on the final assessment
Negative impact
The consideration of the evidence, 
uncertainties, or other considerations had a 
negative impact on the final assessment
No impact
The consideration of the evidence, 
uncertainties, or other considerations had no 
impact on the final assessment
Main positive
Main restrict
Main negative
M
A
IN
 
R
E
A
SO
N
S Same unit of analysis 
as, and to be coded 
with: "uncertainties" 
and "other 
considerations".
Main reason for 
recommendation
Main reason explicitely put forward in the 
HTA report for the final HTA outcome.
Clinical 
evidence
IN
FL
U
E
N
C
E
 
Same unit of analysis 
as, and to be coded 
with "uncertainties" 
and "other 
considerations".
Influence on 
assessment
Different 
interpretation
C
O
M
PA
R
IS
O
N
Same unit of analysis 
as, and to be coded 
with "uncertainties".
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7.4.3. Quantitative strand (Stage III): outcomes from the methodological framework  
 
Applying the methodological framework showed the variety of ways seen in reporting 
and interpreting the same clinical evidence.  It also highlighted cases when the same 
clinical evidence was interpreted differently and cases where different evidence was 
accounted for and interpreted differently (Table 7-2).  These, in addition to the main 
reasons put forward by the agencies for the final recommendation, are defined as the 
criteria driving these recommendations.  This section showcases the outcomes of 
applying the methodological framework by quantitatively analysing the data collected.  
 
Clinical evidence and its interpretation 
 
Poor agreement in the interpretation of the same evidence was seen (ĸ = 0.183, 95% CI 
[0.015;0.35]) (Altman, 1991).  These differences may relate to a subjective 
(unexplained) component of the decision or to different risk or value preferences.  This 
is illustrated, for example, in the assessment of the short trial duration for eltrombopag.  
 
The correspondence analysis biplot in Figure 7-4 illustrates the relative risk 
preferences of agencies when appraising the same evidence.  Although the chi-squared 
probability of independence is non-significant given the small sample size (χ2=22.49; 
p=0.550), results nevertheless provide an indication of the relationships among these 
variables as well as the type of analysis that this framework allows for on a greater 
sample.  On dimension 1 (vertical axis), representing 51.1% of the inertia (or 
variation), HAS is relatively more likely to raise concerns around quality of life 
compared to the other agencies.  In dimension 2 (horizontal axis), representing 34% of 
the inertia, TLV is relatively more likely to raise concerns around sample size, and 
SMC around the administration mode of the treatment and trial design compared to the 
others.  In total, 85% of the inertia is captured across these two dimensions, which 
provides a good basis for exploring and understanding the associations seen in the 
data.  
 
Similarly, value preferences were derived from the “other considerations” identified 
through correspondence analysis and revealed a significant association in terms of the 
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relative value preferences for these two drugs (χ2=30.97; p=0.029) (Figure 7-5).  In 
dimension 1 (vertical axis), capturing 57.5% of the inertia, NICE is relatively more 
likely to account for considerations around clinical practice and adverse effects from 
the treatment compared to the other agencies, whereas HAS and TLV are more likely 
to account for considerations around the nature of the disease.  In dimension 2 
(horizontal axis explaining 24.9% of the inertia), SMC and to a lesser extent TLV, are 
relatively more likely to account for the treatment’s innovativeness compared to the 
other agencies, and HAS the treatment’s clinical benefit.  These findings relate to the 
two case studies and would only be generalizable if conducted on a greater sample of 
drugs.   
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Figure 7-4. Correspondence analysis biplots representing associations between the HTA body and the types of clinical uncertainties  
 
Source: (Nicod et al., 2015a). 
 
 
Despite the associations being non-significant given the small 
sample size (χ2=22.49; p=0.550), results provide an indication of 
the relationships among these variables.  Fifty-one percent of the 
inertia or variation between these variables is captured in dimension 
1 (biplot vertical axis).  The strongest association is seen with HAS, 
who is relatively more likely to raise concerns around quality of life 
compared to the other agencies.  In dimension 2, which represents 
34% of the inertia (or variation), TLV is relatively more likely to 
raise concerns around sample size, and SMC around the 
administration mode of the treatment and trial design compared to 
the others.  
 
Legend: HRQol: issues with health-related quality of life benefit; 
Size: issues with sample size; Administration: issues with the 
administration and provision of the treatment; Design: issues with 
the trial design and conduct; Duration: trial duration too short; 
Benefit; uncertain treatment benefit; Population: issues with 
population generalizability; Comparator: issues with comparator 
used; Safety: uncertain safety profile of treatment.  
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Figure 7-5. Correspondence analysis biplots representing associations between the HTA body and the “other considerations”  
 
Source: (Nicod et al., 2015a). 
 
Correspondence analysis revealed a significant association in terms 
of the relative value preferences for these two drugs (χ2=30.97; 
p=0.029).  Dimension 1 captures 57.5% of the inertia, where NICE 
is relatively more likely to consider considerations around clinical 
practice and adverse effects from the treatment compared to the 
other agencies, whereas HAS and TLV are more likely to account 
for considerations around the nature of the disease.  In dimension 2 
(explaining 24.9% of the inertia), SMC and to a lesser extent TLV, 
are relatively more likely to account for the treatment’s 
innovativeness compared to the other agencies, and HAS the 
treatment’s clinical benefit.  
 
Legend: Benefit: clinical benefit and type of benefit of the 
treatment; Nature: disease nature affecting the patient; Innovation: 
innovative nature of the treatment; AE: adverse events manageable 
or non-significant; Practice: complex pathway, no best practices; 
Need: unmet need; Rare: rarity, orphan status. 
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Criteria driving the decisions 
 
The criteria driving the HTA decisions were defined as: (a) the main reasons for the 
recommendation identified at each stage of the process (Table 7-2 & Table 7-3), (b) 
whether and how these were influenced by agency-specific risk and value preferences, 
and (c) whether they were influenced by decision-makers’ judgments about their 
interpretations of the evidence presented (measured by agreement levels), which 
resulted into the following decisions.   
 
Eltrombopag was rejected by NICE mainly because of the high uncertainty that 
increased the ICER to a level greater than what is considered cost-effective.  For SMC, 
although the clinical evidence was weak, eltrombopag was significantly more effective 
than placebo in platelet response and considered cost-effective, as greater uncertainty 
in the economic analysis was accepted because it offers additional treatment options, is 
an orphan drug, and is administered orally.  For TLV, eltrombopag was considered 
cost-effective because of its similar effect at a lower cost compared to romiplostim, 
which had already been considered as cost-effective by the TLV.  The orphan status, 
severity of the condition, and impact on the patient’s quality of life were also put 
forward.  TLV requested that a follow-up on the assessment of effectiveness take place 
in October 2013.  For HAS, while the trial duration was limited and comparative data 
were lacking, eltrombopag was considered similar to romiplostim until further 
evidence is provided (risk assessment plan). 
 
Because of the early termination of the trial, the estimated clinical benefit of 
everolimus was considered biased.  In England, overall survival was considered 
superior to three months and the treatment was eligible as “end-of-life treatment”.  
Nevertheless, sensitivity analysis showed only a very low probability of the drug being 
cost-effective and was rejected.  For SMC, the price was considered too high in 
comparison with the positive benefits provided.  In Sweden, the high cost per QALY 
was acceptable given the disease’s severity.  In France, despite being a serious and 
life-threatening condition, the evidence presented was not sufficient to demonstrate 
any improvement in survival or quality of life relative to alternatives. 
 
   132 
 
 
7.5. Discussion and Policy Implications  
 
7.5.1. Summary of key results 
 
This empirical study fitted a mixed methods research design to a research question 
requiring both an in-depth understanding of the HTA decision-making process and a 
systematic approach to comparing cases in order to gain a broader understanding of the 
HTA outcome.  The case study analyses highlighted the complexity of these decisions 
and identified a structure facilitating the understanding and comparability of these 
processes.  This was used to derive and pilot the methodological framework, which 
divided the decision-making process into three stages within which a set of criteria 
were identified and coded.  This enabled to identify the criteria driving decision 
processes and explaining cross-country differences. 
 
7.5.2. How do our findings fit with existing evidence? 
 
Comparing our results with existing studies that looked at the criteria influencing HTA 
decisions in at least one of the study countries (corresponding to the vertical dimension 
of this study), two studies were identified and their findings are consistent with ours.  
The literature review of quantitative studies conducted by Fischer aimed to identify the 
existing empirical evidence on coverage decisions for a range of health technologies 
(Fischer, 2012).  Despite not being directly comparable with our study given it 
included all types of technologies, it is of interest to ensure that the components of 
HTA included in our study are comprehensive.  Carroll et al. conducted a thematic 
analysis of the assessments made by the Evidence Review Group at NICE to identify 
the strengths and weaknesses in the submissions (Carroll, Kaltenthaler, FitzGerald, 
Boland, & Dickson, 2011).  Even though it is again not directly comparable to our 
study, it remains of interest since it is accounted for by NICE and corresponds to the 
“interpretation of the evidence” stage in our study; these are summarized in the HTA 
reports and correspond to the second-order themes within our study.  Findings from 
these two studies validate our classification of the decision-making criteria and 
confirm that our results are appropriate and comprehensive.  Focusing on the 
horizontal dimension included in our framework, only few comparative studies of 
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HTA decisions exist, as previously reported in the introduction section.  None, 
however, have compared the decision-making processes in a systematic and 
comprehensive manner. 
 
7.5.3. The methodological framework 
 
The added-value of this study is that by deconstructing HTA recommendations and 
developing a taxonomy of criteria that may have contributed to the decision-making 
process, it enables an enhanced understanding of HTA decision-making (Creswell & 
Tashakkori, 2007).  Without a mixed methods study design, we would not have been 
able to capture the depth and complexity of these decision-making processes, both 
within and across countries.  The novelty of this methodological framework lies, first, 
in the systematic approach adopted in analysing the data, and, second, in the inclusion 
of a horizontal dimension to capture additional aspects of the HTA decisions.  The 
coding and categorization of HTA documents enabled a systematic identification of 
the decision-making criteria in a homogeneous and comparable manner across 
countries and drugs.  Further, the horizontal dimension also captured, through double-
coding, the influence (“positive” or “negative”) of each criterion on the final decision 
(“main reason for recommendation”), and whether it was provided through stakeholder 
input.  Finally, this study exemplifies how this type of design can be implemented to 
fit a specific research question and disseminated in a clear and transparent manner.  It 
also highlights the inter-disciplinary potential of applying such designs to novel areas, 
such as HTA. 
 
7.5.4. Policy implications  
 
Based on its application to two cases, results show that a significant number of 
additional criteria and considerations may be used to inform decisions, which may 
override pre-existing rules, such as an ICER threshold.  This was a consequence of the 
heterogeneity seen in the evidence and its interpretation or of additional criteria or 
input, which may have influenced the decision.  This may be due, in part, to the orphan 
nature of these drugs, where accounting for “other considerations” may overcome 
some of the uncertainty characterising the evidence generated from small patient 
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populations.  It may also be interpreted either as a need to examine in greater depth the 
available evidence on specific drug-indication pairs rather than stick to a yes-no 
decision based on otherwise inflexible rules, or as a recognition of the imperfect nature 
of the HTA process to account for detailed information that may matter when making a 
decision at the margin, or a combination of both.  Results from applying this 
framework also allow us to raise awareness on the reasons for cross-country 
differences.  Where differences were a consequence of the review, the interpretation of 
the evidence and dealing with uncertainty, it may contribute to finding solutions to 
minimising these differences.  When applied across a greater sample of drugs, therapy 
areas and countries, the application of this framework may be beneficial in a variety of 
ways: to identify decision-making criteria that can feed into other types of models (e.g. 
multiple criteria decision analysis (MCDA)), to identify agency-specific preferences, 
to understand the type of stakeholder input meaningful to provide, or to ensure 
consistency in the “other considerations” accounted for (e.g. accountability for 
reasonableness). 
 
7.6. Conclusion 
 
Improving the level of access to medicines is a priority at both European and supra-
national levels (Bouvy et al., 2013; Pharmaceutical Forum, 2013).  This study 
highlighted the variations seen in the HTA outcomes across countries and the potential 
reasons for these differences.  These differences may be legitimate and reflect context-
specific considerations, or may be a consequence of limitations in the application of 
HTA methodological approaches.  Implications would be enormous in seeking to 
obtain value for money.  There is an urgent need to better understand the reasons for 
these variations and improve the quality of the assessments when they are a 
consequence of the approaches used.    In this study, we have proposed, developed and 
piloted a methodological framework aiming to account for (part of) the unexplained 
heterogeneity seen in HTA recommendations across settings.  The framework is 
detailed and provides insights into decision-making practices in the case studies 
concerned.  The framework’s external validity is being enhanced and applied to a 
larger sample of drugs, therapy areas and countries. 
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8. Why do HTA Coverage Recommendations for Orphan Drugs 
Differ? Applying a Mixed Methods Framework in Four European 
Countries6 
 
8.1. Abstract 
 
Health technology assessment (HTA) coverage recommendations differ across 
countries for the same medicine.  Unlike previous studies, this study identifies and 
explains these differences in a systematic manner.  HTA recommendations for ten 
orphan drugs appraised in England (NICE), Scotland (SMC), Sweden (TLV) and 
France (HAS) (N=35) were compared using an existing methodological framework to 
identify the criteria driving recommendations and highlight cross-country differences.  
A sequential mixed methods design was used comprising two stages: (1) qualitative in-
depth analysis of the decision-making processes; and (2) quantitative identification of 
agency-specific risk and value preferences through correspondence analysis, and 
agreement levels across countries through Cohen’s kappa scores.  Results showed that 
six of the ten study drugs received diverging HTA recommendations.  This was 
attributed either to contextual considerations (e.g. NICE end-of-life criteria, SMC 
modifiers, disease severity for TLV) or to cross-country heterogeneity in: (1) the 
evidence appraised (50% of six drugs with diverging recommendations), (2) the 
uncertainties raised when appraising the same evidence (33% of 6 drugs), (3) dealing 
with the same uncertainty (66% of 6 drugs), or (4) the ability to impose patient access 
schemes or future re-assessments.  Moderate to no agreement across countries was 
seen in dealing with uncertainty, which was influenced by agency-specific preferences 
in terms of stakeholder input or considerations relating to treatment characteristics.  
This research contributes to better understanding how different HTA bodies assess 
value.  As highlighted by the framework used, a more systematic approach is needed in 
order to look at the predictors of the drivers of coverage decisions in settings using 
HTA.  
                                                 
 
6 A version of this chapter is published in the European Journal of Health Economics (Nicod E, 2016) 
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8.2. Introduction 
 
National competent authorities tasked with making judgments about coverage of new 
medical technologies are faced with competing needs and goals in containing costs, 
rewarding innovation while providing safe, effective and quality care to their citizens 
in a context of a rising prevalence of chronic conditions (European Commission, 
2012).  Health Technology Assessment (HTA) is commonly used to support such 
resource-allocation decisions based on the best available evidence of comparative costs 
and benefits, therefore ensuring that resources are used efficiently (Banta, 2003; Luce 
et al., 2010).  
 
Providing equal access to affordable medicines across countries is high on the political 
agenda in many OECD countries including those in the European Union (European 
Commission, 2013b).  In reality, this is far from being achieved even in countries with 
similar or comparable policies, rules or priorities.  In countries using HTA to inform 
resource allocation decisions, poor to moderate agreement in HTA coverage 
recommendations across countries is often reported for the same medicine (Clement et 
al., 2009; Lexchin et al., 2008; Nicod et al., 2015a).  These divergences may partly 
relate to legitimate contextual differences such as the objectives adopted, where it 
might be a pharmacoepidemiological study in one country and a systematic review of 
all aspects of using a technology in another (Banta, 2003).  Equally, there may be 
different willingness-to-pay thresholds affecting the extent to which an HTA outcome 
is acceptable (Pearson et al., 2005; Webb, 2009).  Differences may also be due to 
controversies over the HTA process itself, including questions around the most 
appropriate methodological approach to undertaking HTA (Brousselle & Lessard, 
2011; Drummond, de Pouvourville, Jones, Haig, Saba, & Cawston, 2014a), the 
application of HTA in each setting, whether the measures used fully capture the effects 
and costs from taking the treatment (Brazier, 2008; Dolan et al., 2005; Sculpher, 
2008), what levels of evidence are acceptable (Gauvin, Abelson, Giacomini, Eyles, & 
Lavis, 2010; Rawlins, 2008), how to deal with uncertainty (Claxton, 2008), or to what 
extent “other considerations”, e.g. disease and treatment characteristics, were 
consistent across decisions (Earnshaw et al., 2008).  This, in turn, emphasizes the need 
to explore these areas of debate in greater depth in order to understand their 
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importance across settings and provide recommendations for methodological 
improvements in the conduct or interpretation of HTA and, by extension, evidence-
based policymaking in health. 
 
This problem, together with its implications, has been identified and possible 
explanations examined (Clement et al., 2009; Kanavos et al., 2010b; Lexchin et al., 
2008; Morgan et al., 2006; Nicod, 2010; Nicod et al., 2012; Pomedli, 2010; Shah et al., 
2013; Van den Aardweg, 2010).  These nine studies compared the HTA coverage 
recommendations made across a sample of drugs and countries and highlighted the 
extent of these differences.  Their research designs were in the form of retrospective 
descriptive or cohort analyses, and countries compared included Canada, Australia, 
England, Scotland, France and New Zealand.  The reasons for cross-national 
differences were also explored, but with varying levels of thoroughness.  Morgan and 
colleagues focus on the transparency and rigour of the processes rather than on case-
specific reasons for diverging recommendations (Morgan et al., 2006).  The three other 
studies investigate the reasons for these differences (Clement et al., 2010; Lexchin & 
Mintzes, 2008; Shah et al., 2013), but relied on a few cases or potential reasons.  First, 
they did not outline the key determinants or structure of the decision-making explored, 
where the reasons set forth may not constitute the full picture.  Second, issues relating 
to the clinical and pharmacoeconomic assessments, also referred to as clinical and 
economic uncertainty, were identified.  However, the level of detail provided in their 
assessments did not differentiate for the type of uncertainty (e.g. trial duration or 
magnitude of the benefit), how these were dealt with across countries (e.g. acceptable 
by some and not by others?), and what the factors influencing these processes were.  
Third, the methodological approaches used were not sufficiently detailed for these 
approaches to be transferable.  One exception may be the paper from Lexchin and 
colleagues that describes how the variables were categorised (Lexchin & Mintzes, 
2008), which was accounted for when setting up the coding scheme in this thesis.  
Given that these decision processes are complex and understanding what happened for 
one same drug in different countries may be challenging, a more systematic, 
structured, and comprehensive approach to identifying and comparing differences 
would be required.  Additionally, understanding how similar scenarios were dealt with 
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across settings may also constitute a way forward to identify limitations in applying 
HTA and learn from how these were dealt with across settings (Nicod et al., 2015a). 
 
Through the application of an existing methodological framework (Nicod et al., 
2015a), the purpose of this study is two-fold: (a) to systematically identify and 
compare the drivers of HTA recommendations for a sample of orphan drugs across 
four countries; and (b) to identify the reasons for the different HTA recommendations 
issued across countries at different stages of the HTA process.  The subject matter of 
the analysis was orphan drugs, given they are often not cost-effective due to the small 
patient numbers, heterogeneous nature of the conditions they treat, and their often high 
prices (Drummond et al., 2007; Dupont et al., 2011; Kanavos et al., 2012; McCabe, 
Claxton, & Tsuchiya, 2005).  Different studies nevertheless demonstrate that orphan 
drugs receive the same or a higher level of acceptance compared to other drugs treating 
more common disease areas (Simoens, 2011; Stolk et al., 2009).  Special attention was 
given to understanding the level of uncertainty in the evidence presented characterising 
orphan drugs, how it was dealt with, and how disease and drug-specific characteristics 
were accounted for in different settings. 
 
8.3. Methods 
 
8.3.1. Sampling of study countries and drug-indication pairs 
 
The study countries, England, Scotland, Sweden and France, were selected based on: 
(1) their well-established HTA agencies and processes, (2) the variety in HTA 
approaches used, notably clinical (e.g. France) and/or cost-effectiveness (e.g. England, 
Scotland, Sweden) as decision-making criteria, (3) the different types of HTA body 
(e.g. advisory in England and Scotland, regulatory in France and Sweden), (4) the 
different perspectives to HTA adopted (e.g. health service perspective in England, 
Scotland and France, and societal in Sweden), (5) the public availability of HTA 
reports, recommendations and other material, and (6) their European location.  
 
In order to arrive at a common sample amongst HTA bodies, NICE was used as a 
benchmark.  All drug-indication pairs with an orphan designation from the European 
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Medicines Agency (European Medicines Agency, 2012) and appraised by NICE in 
England through the Single Technology Appraisal process until December 2012 were 
included and recorded by their indication, generic name, and HTA recommendation 
(e.g. to list, restrict or reject a drug for coverage).  269 technology appraisal reports 
were published until December 2012 by NICE, 23 of which related to orphan drugs 
with an EMA designation.  Excluded were: those that underwent the Multiple 
Technology Appraisal process or were terminated at the time of data collection at 
NICE (9/23), and those that were appraised by fewer than three study of the four 
countries (4/23).  Additionally, when a compound underwent the abbreviated 
procedure at the SMC, it was not included given that the rationale for the decision, of 
interest for this study, was not made available.  This resulted in a selection of ten 
unique orphan drug-indication pairs and a total of 35 country and drug-indication pairs 
(Table 8-1).  Only five were included by TLV in Sweden, which appraised mainly 
outpatient drugs at the time of the study, while many of the study drugs were inpatient 
(Faulkner, Matuszewski, & Niziol, 2009).  
 
Special considerations in appraising orphan drugs in each country were identified.  
These included the recognition of rare diseases as a national priority in France 
enshrined in legislation (Ministere des Affaires Sociales et de Sante, 2004), and the 
SMC modifiers (e.g. life-threatening, life-expectancy and health-related quality of life 
(HRQol) improvement, curative treatment, unmet need) in Scotland (SMC, 2012).  By 
contrast in England and Sweden, orphan drugs follow the same HTA process as drugs 
for more common conditions. 
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Table 8-1. List of drug-indication pairs included in the study 
Generic 
name/Brand 
name 
Indication ICD 
10 
code1 
NICE 
England 
SMC 
Scotland 
TLV 
Sweden 
HAS 
France2 
Eltrombopag 
REVOLADE 
Chronic 
idiopathic 
thrombocytop
enic purpura 
D2 DNL 
TA205 
Oct 2010 
LWC 
625/10 
July 
2010 
LWC 
3731/201
0 May 
2011 
SMR 
important 
ASMR II 
June 
2010 
Romiplostim 
NPLATE 
Chronic 
idiopathic 
thrombocytop
enic purpura 
D2 LWC 
TA221 
Apr 2011 
LWC 
553/09 
May 
2009 
LWC 
833/2010 
Oct 2010 
SMR 
important 
ASMR II 
June 
2009 
Everolimus 
AFINITOR 
Renal cell 
carcinoma 
(2nd line, 
advanced) 
C DNL 
TA219 
Apr 2011 
DNL 
595/10 
Mar 
2010 
L 
853/2010 
Sep 2010 
SMR 
important 
ASMR 
IV 
Jan 2010 
Lenalidomide 
REVLIMID 
Multiple 
myeloma  
(3rd line) 
C LWC 
TA171 
Jun 2009 
LWC 
441/08 
Apr 2010 
L 
410/2010 
Jul 2010 
SMR 
important 
ASMR 
III 
Oct 2007 
Mifamurtide 
MEPACT 
Osteosarcoma C LWC 
TA235 
Oct 2011 
L 
837/13 
Jan 2013 
LWC 
2312/201
2 
Jan 2013 
SMR 
insufficie
nt 
DNL 
Nov 2010 
Azacitidine 
VIDAZA 
Myelodysplas
tic syndrome 
D1 LWC 
TA218 
Mar 
2011 
LWC 
589/09 
Aug 
2011 
NA SMR 
important 
ASMR II 
Apr 2009 
Imatinib 
GLIVEC 
Gastro 
intestinal 
stromal 
tumour 
(adjuvant, 
after surgery) 
C DNL 
TA196 
Aug 
2010 
LWC 
584/09 
Aug 
2010 
NA SMR 
important 
ASMR 
III 
Sep 2009 
Mannitol dry 
BRONCHITO
L 
Cystic 
fibrosis  
E LWC 
TA266 
Nov 
2012 
DNL 
837/13 
Jan 2013 
NA SMR 
weak 
ASMR V 
Sep 2012 
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Ofatumumab 
ARZERRA 
Chronic 
lymphocytic 
leukemia 
C DNL 
TA202 
Oct 2010 
DNL 
626/10 
Jul 2010 
NA SMR 
moderate 
ASMR V 
Oct 2010 
Trabectedin 
YONDELIS 
Soft tissue 
sarcoma 
C LWC 
TA185 
Feb 2010 
DNL 
452/08 
Jun 2011 
NA SMR 
important 
ASMR V 
Apr 2008 
Source: (Nicod, 2016a). 
 
1 WHO ICD10 code classifications: C & D1: Neoplasms, D2: Diseases of the blood 
and blood-forming organs and certain disorders involving the immune mechanism, E: 
Endocrine, nutritional and metabolic diseases. 
2 The ASMR (Amélioration du Service Médical Rendu) ranks drugs according to their 
relative improvement in clinical benefit in five levels, from a major innovation (level I) 
to no relative improvement (level V).  The SMR (Service Médical Rendu) ranks the 
drug according to the drug’s clinical benefit in five levels, from major to none. 
 
Legend: NICE: National Institute for Health and Care Excellence (NICE); SMC: 
Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; 
HAS: Haute Autorité de Santé; L: list; LWC: list with restrictions; DNL: do not list; 
NA: not applicable. 
 
 
   142 
 
 
8.3.2. Study design and methodological framework 
 
The methodological framework applied (Nicod et al., 2015a)allowed for the systematic 
comparison of HTA decision processes across countries and drugs.  The approach used 
was an exploratory sequential mixed methods design (Creswell & Plano Clark, 2011a), 
where the qualitative strand took priority and preceded the quantitative strand.  The 
framework consisted in a coding manual and case study template (Chapter 7).  This 
allowed to break down the decision process into sub-components, which can be 
analysed and compared across countries (Figure 7-2): (a) the evidence appraised (e.g. 
trial type, clinical and safety endpoints, comparators, economic models), (b) the 
interpretation of this evidence (e.g. nature of uncertainty, how it was dealt with, and 
the influence of stakeholder input and “other considerations”), and (c) their influence 
on the final recommendation (Nicod et al., 2015a).  Uncertain evidence was defined as 
evidence considered not fully capturing the effects of a treatment in the intended 
population by the assessors (NICE, 2009a).  “Other considerations” were defined as 
the non-quantifiable or non-quantified considerations relating to treatment or disease 
characteristics not captured by routine methods of HTA (e.g. QALY).  
 
8.3.3. Data analysis 
 
This multi-level research design allowed for an in-depth analysis of the criteria driving 
these decision-making processes (qualitative strand), and of their role in shaping these 
decision processes in each country and whether they explained cross-national 
differences (quantitative strand).  This research did not aim to generalise findings, but 
was interested in exploring and elucidating the reasons behind the HTA decisions, 
which is mainly qualitative by nature.  The quantitative strand aimed to complement 
and enhance the interpretation of the qualitative findings, and to produce more 
structured data to be used for subsequent analyses. 
 
Qualitative strand 
 
Data sources comprised publicly available HTA reports, other official documents that 
include information on the appraisal process and reasons for the final HTA 
recommendation (e.g. memos in Sweden), and comments from competent authorities.  
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Although their aims differ (e.g. “advice” in Scotland versus “decision” in Sweden), the 
HTA reports were assumed to reflect the determinants driving the recommendations 
given that countries are required to be transparent in their decision processes 
(European Commission, 1989).  Results were also regularly presented to HTA experts 
(e.g. Advance-HTA consortium) at various occasions, where feedback was collected. 
This contributed to ensuring that the interpretation of the decisions made by the 
researcher was accurate. 
 
At each step of the process, all the relevant information driving the decisions was 
extracted and coded.  First, the information from individual HTA reports was compiled 
into case study forms together with identifiable data (e.g. trial sample size) to ensure 
that the information collected was comprehensive and comparable across countries.  
Second, on this basis, thematic analysis was undertaken to code the HTA reports using 
the software NVivo 10 (QSR International Pty Ltd, 2012).  Coding was flexible and 
iterative with new codes being created for all newly identified criteria and included in 
the coding manual with their definition and coding rule, ensuring that the multiple 
dimensions of the decision-making process were captured.  The HTA reports already 
coded were re-examined with these new codes and adjustments were made if 
necessary.  Intra-coding reliability was tested for consistency of coding, as well as 
content validity for the representativeness and homogeneity of the information coded 
within codes (Creswell et al., 2011a).  Third, the data collected were exported into 
excel for analysis using different coding matrix queries.  
 
Quantitative strand 
 
The qualitative data collected were transformed into quantitative categorical nominal 
variables by exporting the data to Stata 13 (StataCorp, 2013).  Thematic matrixes and 
descriptive statistics were used to categorise the variables by types and frequencies of 
(a) evidence, (b) uncertainty, (c) “other considerations”, and (d) stakeholder input.  
The data also provided information about their influence on the final recommendation 
and how all these compared across countries. 
 
Quantitative data analysis consisted in identifying and measuring agency-specific 
preferences and cross-country agreement levels.  Risk preferences were derived from 
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the types of uncertainty, and value preferences from the “other considerations” 
identified in the HTA reports.  Correspondence analysis was used to measure agency-
specific risk and value preferences (Friendly, 1991; Hoffman & Franke, 1986), 
highlighting when one type of uncertainty or “other consideration” was relatively more 
commonly raised by one HTA body compared to another.  It allowed for the 
measurement of associations between these variables using the chi-squared statistic 
test of independence, facilitating the understanding of these complex relationships in a 
simple bi-dimensional graphical representation (e.g. correspondence analysis biplot) 
(Bartholomew et al., 2008b).  This technique was chosen as it applies to categorical 
data unlike principal component analysis that applies to continuous data (Bartholomew 
et al., 2008b).  For comparability purposes, TLV was not included in this first part of 
the analysis given that it relies on only five cases, but in a secondary analysis relying 
on the five drugs commonly appraised by all. 
 
Descriptive statistics were used to measure the frequency of agreement across 
countries in their interpretation of the evidence.  Cohen’s kappa scores of cross-
country agreement levels were measured to check the robustness of the results 
obtained by the primary metric (Cohen, 1960).  Kappa coefficients were used to 
quantify agreement adjusted for chance across HTA agencies about how the same 
evidence was interpreted, and was done so in a comparable manner given it focused on 
each individual concern (uncertainty) raised that was common across settings.  Two 
categories of agreement were measured: (a) the type of issues raised by each agency 
about the same evidence, and (b) how the same issues raised by at least two agencies 
were dealt with across settings.  This allowed to compare agreement observed to 
agreement expected by chance, ranging from poor (κ = 0) to perfect agreement (κ =1), 
and where negative values of κ correspond to cases when agreement was less than 
expected by chance (Altman, 1991).   
 
Finally, the analysis also aimed to identify those issues or considerations that relate to 
the rarity of these conditions, and understand and compare the different approaches to 
dealing with them across settings. 
 
8.4. Results 
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Six of the ten study drugs received diverging recommendations, where they were 
positively recommended or restricted in some countries and rejected in others (Table 
8-1).  Out of the four remaining cases with homogeneous recommendations, 
romiplostim and lenalidomide were restricted in their indications in some countries 
and not in others, ofatumumab was rejected by NICE and SMC and received the 
lowest ASMR V rating with a moderate SMR rating (30% reimbursement rate).  In 
only one case (azacitidine) were the recommendations issued really similar.  Different 
trends were also seen, where, for example, mifamurtide received a positive 
recommendation from NICE and SMC, but was considered insufficient and rejected by 
HAS.  This rarely occurs in France as most drugs considered not to provide any 
additional benefit would receive an ASMR V rating.  Another contrast was seen for 
eltrombopag, considered important by HAS with a substantially high ASMR rating 
(II), whereas it was rejected by NICE.  These examples illustrate the magnitude and 
contradictory nature of these cross-country differences, suggesting that they are 
important and have significant implications for patients in terms of access, and for 
society in terms of using healthcare resources efficiently.  In order to understand why 
they occur, the decision-making process was scrutinized and compared across 
countries for these ten drugs on the basis of the structure provided in the 
methodological framework.  
 
8.4.1. Evidence  
 
The same primary trials were considered, which were predominantly phase III RCTs, 
one of which was considered only by TLV within an indirect comparison (e.g. 
lenalidomide with bortezomib), and phase II trials for the two remaining drugs 
following early marketing authorisation (e.g. trabectedin and ofatumumab).  These 
primary trials had relatively small sample sizes (e.g. less than 300 participants in 60% 
of trials) and decisions often relied on results from subgroup analyses (e.g. 50% of 
cases).  Comparators were mainly standard care with the exception of two cases 
comparing different doses of the treatment under investigation (e.g. mannitol dry, 
trabectedin) and one case with no comparator (e.g. single-arm study for ofatumumab).  
For 80% of the study drugs, the primary endpoints were surrogate and predominantly 
validated with the exception of “time-to-progression” for soft tissue sarcoma and 
“platelet response” for idiopathic thrombocytopenic purpura.  In two cases, NICE’s 
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main outcome of interest was “overall survival” despite it not being the trial’s primary 
endpoint (e.g. imatinib, ofatumumab).   
 
The inclusion of the remaining non-primary non-phase III trials had very little 
influence on the assessment.  Outcomes from these trials were generally not reported, 
and when reported, the type of data provided was around safety (e.g. romiplostim, 
ofatumumab, eltrombopag), dosage research (e.g. eltrombopag) and historical controls 
(e.g. trabectedin). 
 
Focusing on the economic evidence, similar cost-utility models were considered by 
NICE, SMC, and TLV except for eltrombopag, for which a cost-minimisation analysis 
was considered by TLV.  Additionally, the comparators used by NICE and SMC for 
eltrombopag were different:  NICE considered conventional care, while SMC and TLV 
considered romiplostim.  No cost-effectiveness models were included in the HAS 
reviews, as cost-effectiveness was not a requirement for first time approvals at the time 
of the study.  
 
Different evidence was included by some agencies and not by others.  When 
comparing the trials considered by NICE to those considered by SMC, TLV and HAS, 
one out of 19 trials, four out of 15, and six out of 23 respectively were not included in 
the NICE appraisals.  These included a database used to estimate HRQol data for 
trabectedin for SMC; two open-label trials (eltrombopag) and two registries 
(romiplostim) for TLV; and four phase II open-label trials (azacitidine, eltrombopag), 
one post-marketing surveillance survey (study extension for eltrombopag), and one 
indirect comparison (trabectedin) for HAS. HRQol data was not specifically reported 
in 5 out of 10 cases, and in four other cases, it was not reported homogeneously across 
the board.  
 
These differences in the evidence appraised were associated with differing HTA 
outcomes in five cases (Table 8-2): (a) the inclusion of registry data for trabectedin by 
NICE as historical controls; (b) different primary endpoints for mifamurtide (“overall 
survival” for NICE and “progression-free survival” for SMC, TLV and HAS); (c) the 
secondary endpoint “severe bleeding events” for eltrombopag only reported by NICE; 
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(d) the lack of HRQol data in the assessment of eltrombopag for HAS; and (e) 
different economic models for eltrombopag. 
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Table 8-2. Cases when differences at each step of the HTA process explain differences in HTA recommendations (Nicod, 2016a). 
 
Eltrombopag Imatinib Mannitol dry Mifamurtide Trabectedin
Thrombocytopenic purpura Gastro intestinal stromal 
tumours (adjuvant, 
unresectable and/or 
metastatic)
Cystic fibrosis Osteosarcoma Soft tissue sarcoma
Positively 
appraised (list or 
restricted)
SMC, TLV, HAS (ASMR II) SMC, HAS (ASMR III) NICE, HAS (ASMR V) NICE, SMC, TLV NICE, HAS (ASMR V)
Rejected NICE NICE SMC HAS SMC
Ev
id
en
ce
Differences in the 
level of evidence 
reported 
X Severe bleeding events 
(WHO grade 3-4) (NICE)
X Lack of qol data (HAS)
Qol data included for NICE, 
SMC, and TLV 
X CUA-standard care (NICE)
✔ CUA-romiplostim (SMC)
✔ CMA-romiplostim (TLV)
✔ Progression-free survival 
= primary endpoint (SMC, 
TLV, HAS)
X Overal survival = primary 
endpoint (NICE)
✔ Use of registry data as 
historical controls (NICE)
Different 
interpretation of 
the same evidence 
appraised
Short trial duration
X NICE, SMC
Not raised by HAS
No reduction in hospital 
days and use of antibiotics
X HAS
Not raised by SMC, NICE
Qol not improved
X HAS
✔ NICE
Not raised by SMC
Different 
interpretation of a 
same uncertainty
Short trial duration
X NICE (experts), SMC, TLV
✔ HAS (same as comparator)
Overall survival not 
significantly improved
X NICE
✔ SMC (orphan)
✔ HAS (on-going trial)
Risk of bronchospasms
X HAS
✔ NICE (expert opinion)
Not raised by SMC
Risk of interaction 
between treatments
X HAS (other study)
✔ NICE, SMC (expert 
opinion), TLV (longer term 
data)
Lack of comparative evidence 
(phase II non-comparative 
pivotal trial)
X HAS
✔ NICE (rarity, early marketing 
autorisation, historical controls)
✔ SMC (rarity, investigational 
nature of the treatment)
Legend: NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium; TLV: Pharmaceutical Benefits Baord; HAS: Haute Autorite de Sante
Drug and indication pair
HTA 
recommendation
In
te
rp
re
ta
tio
n 
of
 th
e 
ev
id
en
ce
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8.4.2. Interpretation of the evidence 
 
In total, uncertainty was identified 124 times (Nu) in the HTA reports and grouped into 
ten categories depending on the type of concern raised.  Similarly, 125 individual 
“other considerations” (Noc) were identified and grouped into 16 categories (Figure 
8-1).  
 
Although the null hypothesis of independence was rejected (χ2=18.80; p=0.4040), 
correspondence analysis gives an indication about the existing relationships amongst 
the variables analysed, providing insights about the agencies’ risk preferences for these 
ten drugs (Figure 8-2).  NICE was relatively more concerned about population 
generalizability compared to HAS, which was more concerned about issues related to 
the treatment’s administration and provision.  In contrast, SMC was relatively more 
concerned about population generalizability and the treatment’s benefit, and HAS 
about safety and issues the design of the evidence presented.  Conducting the same 
analysis across the five study drugs appraised by all agencies, a non-significant 
association between variables was seen likely due to the small sample size (χ2=27.95; 
p=0.3451).  Nevertheless, similar results were seen with additionally NICE being 
relatively more likely concerned about sample size, HAS with the duration of the 
study, and TLV about the treatment’s administration and provision. 
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Figure 8-1. Number of drugs where clinical uncertainties and “other considerations” were identified. 
 
Source: (Nicod, 2016a). 
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This Figure illustrates the number of cases where clinical uncertainties and “other considerations” were identified influencing the decision 
process in each country.  In total 124 clinical uncertainties were identified across the 35 country drug-indication pairs grouped into 10 
categories, and 125 “other considerations” grouped into 16 categories.  The latter 16 categories were further distinguished between those that 
relate to living with the disease in question, from those to taking the treatment.  The representation of each group was ordered such that the more 
frequently identified clinical uncertainty, disease-related “other considerations” or treatment-related “other considerations” are represented at the 
top of the graph. 
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Figure 8-2. Correspondence analysis biplot illustrating relative associations between the HTA bodies and the issues (clinical 
uncertainty) raised. 
 
Source: (Nicod, 2016a). 
 
This figure represents the correspondence analysis biplot 
illustrating the relative associations between the HTA bodies and 
the clinical uncertainties raised by each HTA body.  Although the 
null hypothesis of independence was rejected (χ2=18.80; 
p=0.4040), it provides an indication about specific risk 
preferences.  On the horizontal axis (67.5% of the variation), 
NICE is more likely concerned about population generalizability 
and conformity to clinical practice than HAS and SMC, who are 
more concerned about issues related to the treatment’s 
administration and provision, and the duration of the trial.  On the 
vertical axis (32.5% of the variation), SMC was more likely 
concerned about population generalizability and the treatment’s 
benefit, and HAS about quality of life improvement and trial 
design. 
 
Legend: Qol: quality of life; safety: safety assessment; design: trial design; comparator: comparator; duration: duration of the trial; administration: 
administration and provision of the treatment; benefit: benefit of the treatment; size: sample size; population: population generalizability; practice: clinical 
practice. 
 
   153 
 
 
 
Figure 8-3. Correspondence analysis biplot illustrating the relative associations between the HTA bodies and disease (left) and 
treatment characteristics (right). 
 
Source: (Nicod, 2016a). 
 
 
   154 
 
 
 
The figure to the left represents the statistically significant relative associations between the HTA bodies and disease characteristics (χ2=40.05; 
p=0.0008).  On the horizontal axis (72.1% of the variation), NICE was more likely to account for existing treatment alternatives, clinical 
practice, and the impact of the disease on the patient’s surrounding, whereas SMC and HAS for rarity and unmet need.  On the vertical axis 
(27.9% of the variation), HAS was more likely to value the nature of the disease, and SMC the rarity of the condition.   
 
The figure to the right illustrates the significant relative associations between the HTA bodies and treatment characteristics (χ2=29.46; 
p=0.0011).  On the horizontal axis (93.5% of the variation), NICE was relatively more likely to value the treatment’s safety and challenges in 
conducting RCTs, and HAS the drug’s clinical benefit compared to other agencies.  On the vertical axis, relationships were relatively less 
meaningful given that only 6.5% of the variation was captured. 
 
Legend: rare: rarity, small sample size, orphan drug; unmet: unmet need; nature: nature of the condition and its impact on the patient; pathway: 
complex pathway, no best practice; alternative: issues around current alternatives; cost: cost burden of current treatment alternatives; 
nature_surr: disease nature affecting the patient’s surrounding; mgt_comp: issues around the management of treatment alternatives; benefit: 
clinical benefit and type of benefit; indirect: indirect benefits from the treatment; innovation: innovative nature of the treatment; AEs: adverse 
events from the treatment manageable or non-significant; RCT: challenges in conducting RCTs; indications: additional indications of treatment. 
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Focusing on preferences relating to disease characteristics, the relative associations 
with NICE, HAS and SMC were significant across the 10 study drugs (χ2=40.05; 
p=0.0008) (Figure 8-3).  NICE was relatively more likely to account for existing 
treatment alternatives and clinical practice, as well as the impact of the disease on the 
patient’s surrounding, whereas SMC and HAS were more likely to value rarity and 
unmet need.  HAS was relatively more likely to value the nature of the disease, while 
SMC the rarity of the condition.  Conducting the same analysis across the five drugs 
appraised by all agencies, associations were statistically significant (χ2=47.37; 
p=0.0008).  Preferences for NICE, SMC and HAS were similar, where TLV was 
relatively more likely to value the nature of the condition (e.g. disease severity). 
 
Correspondence analysis examining relative value preferences around treatment 
characteristics and NICE, SMC and HAS for the 10 study drugs showed a significant 
association between these variables (χ2=29.46; p=0.0011) (Figure 8-3).  NICE was 
relatively more likely to value the treatment’s safety and challenges in conducting 
RCTs, and HAS the drug’s clinical benefit compared to the other agencies.  
Conducting the same analysis across the four drugs appraised by all four agencies, 
similar conclusions were reached (χ2=21.05; p=0.0496).  Additionally, TLV was 
relatively more likely to value the innovativeness of the treatment compared to the 
other agencies. 
 
These risk and value preferences identified across the ten study drugs may have 
influenced these processes and contributed to explaining cross-country differences.  
Examining each of the concerns more in depth, only 14.5% of the uncertainties 
identified (18 of the Nu=124) were commonly raised by all agencies, the remainder 
having been raised by only one or some of the agencies.  This was further highlighted 
in the poor to less than expected by chance agreement measured between agencies in 
the clinical uncertainties raised about the same evidence (κ range -0.30 to 0.08) (Table 
8-3).   
 
In four cases, this poor level of agreement in interpreting the same evidence related to 
one of the main reasons for the final decision (Table 8-2).  For imatinib, the primary 
trial length was deemed too short by NICE and SMC; this was not highlighted by 
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HAS.  Additionally, the secondary endpoint “overall survival”, considered as main 
parameter of interest by NICE, was not significantly improved negatively influencing 
the decision (e.g. imatinib was rejected by NICE).  For mannitol dry, the lack of 
improvement in hospital days and antibiotic use reduction was a concern for HAS, but 
not for NICE or SMC.  Further, the lack of improvement in HRQol negatively 
influenced HAS’s decision (e.g. ASMR V).  This concern was also raised by NICE, 
who acknowledged that the current measures used do not fully capture the effect of the 
disease and treatment; this was not highlighted by SMC. 
 
Agreement between two agencies was reached if a concern was considered addressed 
or not by both, and disagreement if addressed by one and not the other.  There was 
agreement for 13 and disagreement for five of the 18 concerns commonly raised.  
When comparing agreement across each pair of countries, it varied ranging between 
moderate to lower than expected by chance depending on the agencies (κ range -0.50 
to 1.0) (Table 8-3).    
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Table 8-3. Agreement between HTA bodies in the uncertainty raised about the 
same evidence (raised versus not raised); and when the same uncertainty was 
raised, agreement about how it was dealt with (addressed versus not addressed). 
Kappa scores 
[95% confidence intervals] 
Standard error (SE) 
Number of observations (n) 
Level of agreement in the uncertainties raised  
(raised versus not raised) 
Level of agreement in 
interpreting the same 
uncertainties  
(addressed versus not 
addressed) 
 
NICE SMC TLV HAS 
NICE 1 
-0.06 
[-0.235-0.124] 
SE=0.091 
n=117 
-0.15 
[-0.434-0.143] 
SE=0.147 
n=44 
0.01 
[-0.172-0.183] 
SE=0.090 
n=110 
SMC 
0.51 
[0.203-0.814] 
SE=0.156 
n=29 
1 
-0.30 
[-0.588--
0.018] 
SE=0.145 
n=43 
0.08 
[-0.108-0.261] 
SE=0.094 
n=110 
TLV 
1.00 
[1.00-1.00] 
SE=0.00 
n=7 
0.72 
[0.232-1.00] 
SE=0.249 
n=7 
1 
-0.07 
[-0.324-0.180] 
SE=0.128 
n=44 
HAS 
-0.08 
[-0.227-0.067] 
SE=0.075 
n=24 
0.18 
[-0.272-0.630] 
SE=0.230 
n=22 
-0.50 
[-1.00-0.235] 
SE=0.375 
n=4 
1 
Source: (Nicod, 2016a). 
 
Cohen’s kappa scores (κ) rank agreement levels from poor (κ = 0) to perfect agreement 
(κ =1) and where minus values of κ correspond to cases when agreement was less than 
expected by chance. 
 
Legend: NICE: National Institute for Health and Care Excellence (NICE); SMC: 
Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; 
HAS: Haute Autorité de Santé. 
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Between 5% and 51% of these clinical uncertainties (Nu=124), depending on the 
country, were addressed through various means (51% of nunice=68 uncertainties for 
NICE; 12% of nusmc=60 for SMC; 47% of nutlv=21 for TLV; and 5% of nuhas=44 for 
HAS).  First, stakeholder input was used to confirm the plausibility of a (uncertain) 
clinical claim.  Second, the uncertainties were raised but nevertheless considered 
acceptable by the Appraisal Committee.  Third, greater uncertainty was accepted given 
the rarity of the condition or accounting for non-primary evidence.  
 
In three cases, differences in the interpretation of evidence were also one of the main 
reasons for the final recommendation (Table 8-2).  Two of these were based on expert 
opinion: the risk of bronchospasms was deemed minimal by NICE clinical experts for 
mannitol dry, and the risk of interactions with other treatments was deemed minimal 
by clinical experts from NICE and SMC for mifamurtide.  In one case (trabectedin), 
the lack of comparative data for the primary phase II trial was a concern for all but was 
addressed differently.  It was deemed acceptable given the rarity of the condition and 
investigational nature of the treatment by NICE and SMC; additionally NICE 
accounted for registry data as historical controls; in contrast, it was not deemed 
acceptable by HAS. 
 
A number of other considerations were also put forward by the agencies as one of the 
reasons for the final recommendation, and associated with differing final outcomes.  In 
a number of cases, greater flexibility was granted to the ICER on the basis of the 
following considerations: (a) SMC modifiers relating to orphan drugs at SMC (5 out of 
10 drugs), (b) national priority for rare diseases by HAS (all 10 study drugs), (c) NICE 
end-of-life supplementary advice (4 out of 10 drugs) (NICE, 2009c), (d) patient access 
schemes at NICE (7 out of 10 drugs) and SMC (3 out of 10 drugs), or (e) disease 
severity at TLV (all five study drugs).  In particular, four drugs fulfilled the NICE end-
of-life criteria, where three were considered cost-effective with an ICER lower than 
£50,000/QALY (lenalidomide, azacitidine, trabectedin), and one not cost-effective 
with an ICER greater than £50,000/QALY (everolimus).  Similarly, the high ICERs 
were accepted by SMC for lenalidomide and azacitidine given the SMC modifiers, and 
by TLV for lenalidomide given the severity of the disease.  
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8.4.3. Reasons for different HTA recommendations 
 
Through the application of this methodological framework, differences at each stage of 
the HTA process were identified partly explaining differences in HTA 
recommendations (Table 8-2).   
 
First, heterogeneity was seen in the evidence accounted for (e.g. parameter of interest, 
economic model and comparator, non-primary evidence) partly explaining the 
different HTA outcomes in 50% of the six cases with diverging recommendations (e.g. 
eltrombopag, mifamurtide, trabectedin).  A further contrast was seen in the main 
parameters of interest considered for eltrombopag and romiplostim despite treating the 
same condition, which were bleeding events (SMC, NICE) and platelet response, 
respectively. 
 
Second, the diverging interpretation of the same evidence (e.g. trial duration, HRQol 
improvement, reduction in resource use) partly explained differences in HTA 
outcomes for 33% of the six cases (e.g. imatinib, mannitol dry).   
 
Third, the different ways identified in dealing with the same uncertainty (e.g. trial 
duration, clinical benefit, safety, comparative data) also contributed to partly 
explaining differences in HTA outcomes for 66% of the six cases (e.g. imatinib, 
mannitol dry, mifamurtide, trabectedin).   
 
Some of the differences in interpretation were likely to be a consequence of the 
agency-specific risk or value preferences identified, as well as the willingness to 
account for stakeholder input.  For example, correspondence analysis identified for 
HAS a relative risk preference about issues relating the treatment’s administration and 
provision.  This was seen for mannitol dry, where HAS was the only one concerned 
about the lack of reduction in hospital days and antibiotic use from taking the 
treatment.  Similarly, value preferences around the rarity of the condition and the 
innovativeness of the drug were identified for SMC.  This was reflected for 
trabectedin, where the lack of comparative evidence was deemed acceptable by SMC 
given the rarity of the condition and investigational nature of the treatment.  Finally, 
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accounting for stakeholder input also explained some of these differences as seen for 
mannitol dry (NICE) and mifamurtide (NICE, SMC).  
 
Fourth, there were factors that contributed to modulating the ICER or uncertainty to an 
acceptable level, further explaining differences.  These included: disease severity for 
TLV, end-of-life criteria for NICE, the ability to implement Patient Access Schemes or 
lower discounting rates, imposing a restriction, or by imposing future re-assessments.  
For example, a higher ICER was accepted for everolimus by TLV because of its 
severity, but was considered too high by NICE and SMC and rejected.  In the case of 
lenalidomide, uncertainty was addressed by imposing a restriction to third line 
treatment (SMC, NICE), or a re-assessment in a near future once more evidence is 
collected (TLV).  Another modulating factor was the ability to implement a lower 
discounting rate on costs and effects captured in the model, as was seen for 
mifamurtide by NICE and SMC, whereas the high ICER was acceptable for TLV 
given the severity of the condition, and was rejected by HAS for the reasons discussed 
in the next paragraph. 
 
A final contrast was seen when assessing cost-effectiveness versus clinical benefit, 
resulting in opposite conclusions.  Indeed, a number of compounds rejected by NICE 
or SMC received: (a) an important SMR rating (translating into a 65% to 100% 
coverage rate): eltrombopag, everolimus or imatinib; and (b) a high ASMR rating (I-III 
associated with a more favourable pricing scheme): eltrombopag, imatinib.  In these 
cases, the negative recommendations issued by NICE and SMC were mainly because 
of the high ICER, which also relied on the parameter of interest included in the model 
(e.g. bleeding events, overall survival).  There were also drugs that were positively 
appraised by NICE or SMC and received very low SMR ratings (moderate (30%) and 
weak (15% coverage)) and an ASMR V, or were considered insufficient and rejected 
for coverage: mannitol dry, ofatumumab, mifamurtide.  This was because of the lack 
of comparative data as a result of the early marketing authorisation granted 
(ofatumumab) and early scientific advice received (mannitol dry), or the highly 
uncertain evidence presented (mifamurtide).  Mannitol dry and mifamurtide also had in 
common that they were the only two drugs that were not part of the temporary 
authorisation scheme (ATU) in France, which may be considered a modulating factor 
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to accepting greater uncertainty when data is being continuously being collected, 
although results from our limited sample size are insufficient to affirm this. 
 
8.5. Discussion  
 
In summary, this study applied an existing methodological framework to 
systematically identify and compare HTA decision processes in different settings.  
Results show that despite its aims in being “transparent, unbiased, robust and 
systematic” (European Commission, 2015a), there is important heterogeneity in the 
evidence appraised, its interpretation and the extent to which this influenced the final 
recommendation during the HTA processes.  HTA remains a flexible instrument that is 
subject to the decision-maker’s interpretation about uncertainty and social values, as 
part of the deliberative process of HTA and in support of existing tools to assess 
uncertainty (e.g. sensitivity analyses, elicited social values).   This study shows that 
nevertheless, the interpretation may vary based on the decision-maker’s own 
interpretation, observed agency-specific risk and value preferences, or the ability to 
modulate the ICER or estimate of clinical benefit to an acceptable level, possibly 
explaining some of the variation in HTA recommendations across countries.  These 
differences may relate to contextual differences or to controversies over the HTA 
process itself.  Identifying and raising awareness around these at each stage of the 
process is a way forward towards furthering the debate on HTA and its application.    
Three areas are discussed here, the methodological challenges of HTA, context-
specific considerations in these processes, and issues related to the rarity of these 
conditions and how they are being dealt with.  The limitations in this study are then 
described. 
 
These findings are also relevant for collaborative initiatives such as the EU-level HTA 
assessments piloted within EUnetHTA, as they contribute to understanding areas 
where disagreements may arise and clarifying possible solutions to deal with them 
based on past experiences.  An illustrative example was seen for trabectedin and the 
circumstances under which the use of historical controls was accepted.  The 
retrospective identification of the criteria driving previous decisions, applied in this 
study, is also recognised as one approach to criteria elicitation for MCDA purposes 
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when used for priority setting, according to the ISPOR MCDA Emerging Good 
Practices Task Force.  The criteria elicited by the EVIDEM (Evidence and Value: 
Impact on Decision Making), also for the purpose of MCDA in priority setting, are 
very similar to those identified in this study, which can contribute to the definition 
and/or validation of these sub-criteria.  For example, unmet needs were categorised as 
unmet need in efficacy, in safety, in patient-reported outcomes, and patient demand 
(EVIDEM, 2015).  Findings from this study identified the different ways HTA bodies 
refer to unmet need, such as the importance of having new treatment options, the lack 
of (satisfactory) treatment alternatives, alternative treatments not being routinely 
available, the need to improve therapeutic management, and so forth.  The distinction 
about the existence of alternatives, whether they are satisfactory, and the need for 
improved care despite current practices should be accounted for when referring to 
unmet need.  Results can further contribute to defining the attributes of the criteria 
being accounted for by EVIDEM or other criteria elicitation processes (e.g. MCDA, 
Discreet Choice Experiments), such as disease severity, type of benefit, effectiveness, 
safety and HRQol, cost and cost-effectiveness, and so forth. 
 
8.5.1. HTA methodological challenges 
 
RCT weaknesses are well known and include limitations around safety and 
generalisability to heterogeneous populations or clinical practice, as well as the cost to 
conduct these (Rawlins, 2008).  These limitations are compatible with our findings 
where, for example, generalisability to clinical practice was often a concern for NICE 
(e.g. azacitidine, eltrombopag, everolimus, mifamurtide) and SMC (e.g. eltrombopag, 
lenalidomide and romiplostim).  Other issues relating to the heterogeneity of the trial 
population comprised the: (a) non-inclusion of certain patient groups (e.g. SMC for 
azacitidine) or subgroup heterogeneity (e.g. NICE, SMC and HAS for mannitol dry), 
(b) trial population non-representative of the indication under review (e.g. NICE for 
eltrombopag), or (c) imbalances in the characteristics or responses across the different 
subgroups (e.g. SMC for azacitidine and NICE for imatinib). 
 
Given that preference for RCTs was seen in the primary trials appraised, the above 
concerns emphasise the need to recognise complementary forms of robust and valid 
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evidence (Rawlins, 2008).  Apart from a few cases (e.g. expert opinion to confirm 
generalizability), this was not seen in practice given the limited role of non-phase III 
evidence observed in this study.  The uptake of such forms of evidence is still modest 
and likely due to the lack of expertise around dealing with a variety of types of 
observational evidence including those based on real world data such as electronic 
patient records, (Berger, Martin, Husereau, Worley, Allen, Yang, Quon, Mullins, 
Kahler, & Crown, 2014) or patient-reported outcomes (McClimans & Browne, 2011).  
Their role, however, is to be stressed given their potential use for policymaking in, for 
example, the value-based system or process for Highly Specialised Medicines at 
NICE, the Patient and Clinician Engagement (PACE) programme at SMC, the use of 
managed entry agreements (Ferrario & Kanavos, 2013), and, more recently, the 
introduction of a pilot study on adaptive licensing at EMA level (Eichler, Oye, Baird, 
Abadie, Brown, Drum, Ferguson, Garner, Honig, Hukkelhoven, Limn, Lim, Lumpkin, 
Neil, O'Rourke, Pezalla, Shoda, Seyfert-Margolis, Sigal, Sobotka, Tan, Unger, & 
Hirsch, 2012; European Medicines Agency, 2014).  With these new developments, the 
environment is shifting towards increasingly relying on expert opinion, observational 
studies and real world data (Doward, Gnanasakthy, & Baker, 2010), which could 
provide insights about treatment effectiveness, the burden of illness, the nature of a 
condition, or the indirect health care costs and benefits from taking the treatment.  
 
There is also a need for a more formalised and consistent recognition of this type of 
evidence, which could be achieved by generating criteria for their acceptability based 
on past decisions such as the specific circumstances (e.g. early marketing 
authorisation) or quality standards (e.g. reliability, validity) required.  For example, 
findings for ofatumumab and trabectedin suggest that comparative evidence is a 
crucial component for HTA when measuring clinical benefit (particularly for HAS) 
and that, under certain circumstances, historical control data could be acceptable as a 
proxy.   
 
Progression-free survival is increasingly being used as the primary endpoint within 
trials, instead of overall survival (Booth & Eisenhauer, 2012).  There is continued 
disagreement as to whether progression-free survival is the appropriate measure to 
capture a meaningful improvement for patients, and only very few disease areas have 
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been able to prove the surrogacy of progression-free survival to overall survival. 
(Booth & Eisenhauer, 2012).  This disagreement was reflected in our results, where 
progression-free survival was accepted as the main parameter of interest by some and 
not by others, who only accept overall survival, further explaining differences (e.g. 
imatinib and mifamurtide).  Similar scenarios were seen for other clinical endpoints, 
where the parameter of interest for two different drugs treating the same condition in 
the same country differed (romiplostim, eltrombopag). 
 
8.5.2. Context-specific considerations  
 
Context-specific considerations throughout the HTA process are legitimate and reflect 
different willingness-to-pay thresholds, cost and modelling considerations, 
perspectives adopted in the assessments (e.g. societal perspective), or agency-specific 
risk and value preferences.  Results highlight those cases when these influenced the 
appraisal processes explaining differences in recommendations. 
 
The economic models considered were somewhat comparable with one exception 
(eltrombopag).  Nevertheless, they resulted in different outcomes in four cases: 
everolimus, imatinib, trabectedin, and mannitol dry.  This was a consequence of 
different modulating factors rendering the high ICER acceptable.  These included: (a) 
disease severity for TLV, (b) SMC modifiers, (c) the ability to implement patient 
access schemes, (c) NICE end-of-life criteria, (d) the restriction to a subgroup 
population for which the drug is more cost-effective, or (e) the ability to impose a 
future re-assessment rendering uncertainty more acceptable.  The first three reflect 
different willingness-to-pay thresholds and special considerations for orphan drugs, 
while the latter cases suggests the ability to go beyond the ICER in order to identify 
circumstances or subgroups for which the treatment is cost-effective, or accept greater 
uncertainty for a limited period of time until more evidence is generated.  
 
The ability to implement patient access schemes is another way to improving the cost-
effectiveness by improving some of the uncertainty (Towse, 2010), and providing 
earlier access to these treatments (Russo, Mennini, Siviero, & Rasi, 2010).  However, 
their effects on innovation and expected returns are still unclear (Ferrario et al., 2013), 
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and a number of issues around their implementation have been already noted (Boggild, 
Palace, Barton, Ben-Shlomo, Bregenzer, Dobson, & Gray, 2009).   
 
In terms of the societal perspective adopted by TLV, there was no clear differentiation 
in the results around risk and value preferences, or in the type of evidence appraised 
that reflected societal preferences.  Societal risk and value preferences include, for 
example, the ability to contribute to society after taking the treatment or the impact of 
the disease on the patient’s family and surrounding.  As an example, these were 
accounted for by NICE for mifamurtide, but not explicitly by TLV. 
 
8.5.3. Issues related to the rarity of the conditions 
 
The nature of the evidence presented, e.g. small trials, phase II primary trials, lack of 
comparative data, subgroups, surrogate endpoints, is similar to what is commonly seen 
for orphan drugs, characterised by more uncertainty because of the issues in generating 
high quality evidence due to their rarity (Bell & Tudur Smith, 2014; Kesselheim et al., 
2011).  This was clearly reflected in the number of issues highlighted by the HTA 
bodies that relate to rarity and the orphan status (e.g. small sample size, insufficient 
statistical power).  In some cases, these were considered acceptable because of the 
condition’s rarity or the recognised difficulties in recruiting sufficient patient numbers 
in trials (e.g. TLV for eltrombopag, NICE for mifamurtide and romiplostim).  In 
contrast, the concerns relating to population subgroups often remained inconclusive 
because of their lack of statistical power or retrospective nature (e.g. azacitidine or 
mannitol dry).  When comparing the prevalence rates used by SMC in their budget 
impact analysis and the HTA recommendations issued, two observations arise. The 
three drugs treating less than 20 patients per year (ofatumumab, mifamurtide, 
trabectedin) had generally poorer outcomes: they all received the poorest ASMR (V) 
rating, and were more likely to be rejected by the other agencies (ofatumumab by all, 
trabectedin by SMC).  This was a consequence of the lower quality of the evidence 
from small sample sizes or the lack of comparative data.  In the “more prevalent” rare 
conditions analysed (between 200-300 patients per year in Scotland), similar issues 
were encountered but to a lesser extent were these linked to the small sample size 
(eltrombopag, mannitol dry).  These experiences could be a good starting point to 
   166 
 
 
 
generate the circumstances under which small sample sizes or other issues specific to 
rare diseases may be acceptable due to the rarity of the condition, also ensuring these 
are accounted for consistently across cases. 
 
Rare diseases are often characterised by greater unmet need, and therefore few or no 
treatment alternatives are often available.  It also entails that little is known about the 
natural progression of these conditions and what the appropriate comparators should 
be, as illustrated in our sample where 30% of cases did not include any comparative 
data and the remainder mainly relied on comparisons with standard care.  This had a 
negative influence in France because of the lack of comparative data, given that the 
ASMR assessments rely on the treatment’s additional clinical benefit.   
The high number of validated or non-validated surrogate endpoints identified in this 
study (80% of cases) is again representative of orphan drug characteristics and were 
dealt with discordantly raising questions about the selection of the appropriate 
endpoints and whether they reflect what brings value to the patient.  This was 
illustrated when dealing with progression-free-survival and overall survival, where 
NICE always seems to prefer the latter and the others tend to account for the trial’s 
primary endpoint.  Another subtlety was seen for eltrombopag and romiplostim, which 
treat the same condition and where the main parameter of interest differed (e.g. 
bleeding events and platelet count).   
 
The limited number of cases that included evidence about HRQol improvement also 
raises the question as to whether the measures used were sufficient to capture the full 
effects of the treatment to the intended population.  These are important considerations 
for rare diseases, given that the issues around validated surrogate endpoints (Miyamoto 
& Kakkis, 2011) and availability of HRQol data (Price, Klaassen, Bolton-Maggs, 
Grainger, Curtis, Wakefield, Dufort, Riedlinger, Soltner, Blanchette, & Young, 2009) 
are more likely to be a concern in these cases, further emphasising the need to account 
for other levels of evidence.   
 
Finally, given that orphan drugs are characterised by greater uncertainty, there were 
instances (TLV and HAS) where greater uncertainty was accepted because of 
continuous generation of evidence and planned re-assessments.  Given that orphan 
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drugs are characterised by greater uncertainty due to the small patient populations they 
treat, it is all the more important to ensure that coverage decisions do not only rely on 
one assessment at one time point, but that the proper incentives are implemented for 
continuous data collection and assessment. 
 
The above experiences could be a good starting point to generate the circumstances 
under which small sample sizes or other issues specific to rare diseases may be 
acceptable due to the rarity of the condition, also ensuring these are accounted for 
consistently across cases.  
 
8.5.4. Limitations and need for further research 
 
This research is not without its limitations.  
 
First, the data was mainly collected from secondary sources.  It would have been 
preferable to have full information about the submissions (e.g. manufacturer 
submission), but this was not possible in the current scheme.  The information 
obtained by applying the methodological framework was unavoidably limited by the 
level of detail provided in the HTA reports and whether the framework captures all 
aspects of the decision-making process (Nicod et al., 2015a).  The information 
published was assumed to be transparent and reflect the main determinants driving the 
decisions (Transparency Directive).  The analysis of these published documents were 
considered to provide sufficient detail and explain how decisions were reached.  
Validation of the findings was enhanced through a triangulation of the data collected 
with semi-structured interviews of HTA body representatives.  The objective of the 
interview was to validate the findings that arose from the interpretation of the 
researcher and obtain additional insights about the different approaches to valuing 
orphan drugs, which may have not been captured by even the most complete 
documentation.   
 
Third, sampling issues arising from differences among the four agencies in the way 
they select topics for their assessments.  Despite these differences, a suitable sample 
was identified.   
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Fourth, this research focused specifically on orphan drugs, which undergo the same 
HTA process as drugs for more common conditions.  Some of the findings may also be 
applicable to these more common conditions.  One component of the analysis did 
focus on identifying those challenges that are specific, but not necessarily always 
unique to, dealing with these rarer conditions and draw key lessons from these.     
 
A final limitation is the relatively small sample size, which does not allow for 
multivariate regression analysis.  However, this research resulted in meaningful 
outputs derived from a more in-depth and qualitative component showing that 
differences across countries do matter.  A more structured understanding of the 
possible explanations for differences were derived from the findings, allowing for 
subsequent more quantitative analyses to focus on certain aspects of the decision-
making process across a greater sample.  Further research could look at the drivers of 
these differences across a larger sample of drugs and therapy areas using multivariate 
regression analysis for a greater generalisation of the results, by extending it to other 
types of drugs to assess how different agencies assess different drug and disease 
characteristics.  In order to maintain the depth and breadth of the analysis building on 
the methodological framework used in this study, it is highly recommended to begin 
by prioritising the qualitative strand to ensure that the depth of the processes are 
captured and comparable across settings. 
 
8.6. Conclusions and policy implications 
 
This research contributes to better understanding what matters in decision-making 
beyond the assessment of cost-effectiveness and clinical benefit, and explains the 
reasons for differences across countries.  The added value is the approach used, in the 
application of an existing methodological framework enabling to identify and compare 
in a systematic and comprehensive manner these decision processes across settings.   
 
The results of this study have implications for policy.  First, they confirm the high 
level of uncertainty characterising orphan drugs from the types of concerns raised by 
the HTA bodies (e.g. small trials, short trial duration, issues with the trial design and 
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conduct, lack of comparative data, phase II primary trials, surrogate endpoints, 
subgroup data).   Substantial differences in dealing with these were also observed, as 
emphasised by the poor level of agreement measured across countries when dealing 
with uncertainty, which in turn contributed to explaining differences in the HTA 
recommendations issued across countries.  These consisted in the different levels of 
evidence accounted for and the different interpretations of this evidence, including 
how these were influenced by agency-specific risk and value preferences.  There were 
also modulating factors that enabled to address uncertainty or modulate the ICER to an 
acceptable level, as well as differences depending on whether the assessment relied on 
cost-effectiveness or clinical benefit.  Policymakers should be aware of this more 
comprehensive range of factors accounted for the decisions, as well as the different 
expressions of rarity in practice and the different ways to deal with the issues specific 
to -but not limited to- orphan drugs.   
 
Second, given the limitations identified from dealing with –predominantly- 
experimental evidence (RCTs) and evidence from these rarer conditions, this study 
suggests that HTA processes may be insufficient.  This was illustrated by the lack of 
clear pattern observed around how countries dealt with the issues identified.  The 
reasons explaining differences were identified at each stage of the decision-making 
process, with contrasting trends within and across countries.  Therefore, not only is 
more consistency and clarity needed within countries in the means used to address 
uncertainty or accept a greater ICER (e.g. “other considerations”, stakeholder input), 
but there is a need for new mechanisms to deal with uncertain evidence and high 
ICERs, often characterising these orphan drugs.   
 
An important limitation of HTA, particularly with orphan drugs, is that the process 
often relies on the assessment of evidence at one particular time point (often shortly 
after marketing authorisation).  This was quite clearly illustrated in this study, and 
given the difficulties to generate robust evidence and obtain significant point estimates 
with small patient populations, it is all the more important to introduce novel 
approaches to assessing these.  This could be through a system of continuous data 
generation and assessment to reduce uncertainty over time, which requires proper 
incentives at European level at early stages to implement high quality registries and 
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processes that include re-assessments over time.  This is already in place in some 
countries such as Sweden or France (under the ATU scheme), which has contributed to 
dealing with uncertainty in some of the cases evaluated without imposing additional 
conditions or restrictions.   
 
A last implication is the misalignment observed between marketing authorisation and 
HTA, particularly in those three cases that received either early marketing 
authorisation or early scientific advice (about the trial design), which received 
generally poor acceptance rates due to the lack of comparative data or highly uncertain 
nature of the evidence produced.  This further emphasises the need for a better 
alignment in the incentives in place as well as innovative approaches to continuously 
assessing these treatments. 
 
The implications of this research are all the more important given the shift towards 
more niche markets and personalised medicine, where more and more of the 
treatments undergoing regulatory and coverage processes are characterised by some of 
the important issues discussed in this paper.  This research is also topical and in line 
with the recognised need to better understand pricing and reimbursement systems 
through cross-country learning and sharing of experiences (Kaplan, Wirtz, Mantel-
Teeuwisse, Stolk, Duthey, & Laing, 2013).  It is also useful for European-level 
initiatives, such as the pilot for a common European HTA (EUnetHTA) as it helps 
better understand how different countries are dealing with value assessments and what 
the causes for variation are, including areas where HTA methods may be improved.  It 
is a valid tool for policymakers and contributes to ensuring that resources are used 
efficiently, ultimately improving access to medicines. 
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9. How do Scientific and Social Value Judgments Influence HTA 
recommendations in England, France, Scotland, and Sweden?7 
 
9.1. Abstract 
This chapter explores how broader aspects of a treatment’s value and the impact of the 
condition on patients not captured by routine HTA methods using clinical and 
economic evidence, defined as “other considerations”, influence these HTA processes 
in different settings.  Countries included were England, Scotland, Sweden, and France, 
and data sources were the publicly available reports on HTA recommendations.  Ten 
drugs with EMA orphan designation for a specified indication and all appraised in 
England were selected.  Qualitative thematic analysis was used to systematically 
identify and code all “other considerations” considered based on an existing 
methodological framework, which also coded how it influenced the decision and how 
it was provided.  These pertained to the scientific assessment or to societal preferences, 
which were quantified or elicited, or non-quantified or non-elicited, respectively.  On 
this basis, a classification framework was developed and used throughout the study.  In 
total, 125 different “other considerations” were identified and grouped into 16 
subcategories based on the information provided.  Between 18% and 100% of these, 
depending on the agency, were put forward as one of the main reasons for the final 
decision potentially contributing to accepting a higher ICER or uncertain clinical 
benefit.  Some of these were non-quantified or non-elicited and pertained to the 
assessor’s judgment of the treatment’s value (e.g. oral administration benefit, unmet 
need, innovativeness).  Results were used to create a taxonomy of criteria accounted 
for as scientific or social value judgments that can be used in future cases to ensure 
their consistent use.  Results also contributed to better defining the determinants of 
social value and to improving the lack of accountability for reasonableness.  
Identifying and understanding the scientific and social value judgments made provides 
a way forward to improving their transparency and consistency across decisions. 
                                                 
 
7 A version of this chapter is under peer review with International Journal for Technology Assessment in 
Health Care (submitted June 2015) 
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9.2. Introduction 
 
Health care decision-makers are responsible for resource allocation decisions with the 
primary objective to maximise health or social welfare in the whole population 
(Brouwer, Culyer, van Exel, & Rutten, 2008; Hurley, 2000), alongside other ambitions 
such as rewarding innovation.  HTA helps make such decisions about whether to 
reimburse a new treatment by providing guidance on the efficient use of resources, 
ultimately, optimising access to patients.  It relies on systematic approaches to 
appraising evidence about the value of using this treatment in terms of benefits (and 
costs) in real world settings, while including considerations of social, ethical and legal 
aspects to inform coverage for this technology (Luce et al., 2010).  When both clinical 
and economic evidence are considered, the HTA outcome is most often the ICER that 
provides information about the cost per unit of effect from taking this new treatment 
compared to existing standards of care in real world settings.  It provides “value for 
money” if the ICER is worth the investment and ranges within the payer’s maximum 
WTP.  
 
Routine HTA methods that rely on clinical (and economic) evidence may not 
adequately capture all the important considerations of a treatment’s value and the 
impact of the condition on patients in real world settings (O'Donnell, Pham, Pashos, 
Miller, & Smith, 2009).  This is partly because HTA is undertaken at the time of the 
treatment’s launch onto the market when evidence is often incomplete or uncertain 
since real world evidence is generally not available.  HTA bodies also tend to prefer 
experimental evidence collected within controlled environments (e.g. RCTs) (Rawlins, 
2008), in spite of their limitations in capturing real world settings (Black, 1996).  In 
such cases, scientific judgments about the reliability, generalisability and 
meaningfulness of this evidence in the clinical context are made (Rawlins, 2014; 
Rawlins & Culyer, 2004).  Elicited societal preferences, referring to cases when 
society agrees to forego health in order to treat specific populations (e.g. preference to 
treating children), are also captured by routine HTA approaches (e.g. disease severity 
in Sweden, EQ-5D preference weights).  Preference granted during the appraisal 
process may nevertheless have been granted despite it not having been previously 
elicited by the general population; these relate to the social value judgments made by 
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the assessors (Rawlins, 2014; Rawlins et al., 2004).  These judgments are usually made 
as part of the deliberative process of HTA, during which experts and key stakeholders 
are consulted and the evidence is discussed until a decision is taken (Garau, Shah, 
Towse, Wang, Drummond, & Mason, 2009b).  The main criticisms of this process is 
the lack of accountability for reasonableness given that there is not always a clear 
process to account for the inclusion of these other forms of evidence in the assessment 
process, as well as the lack of consistency in accounting for these “other 
considerations” (Daniels & Sabin, 2008; Earnshaw et al., 2008; Garau et al., 2009b; 
Schwappach, 2002). 
 
Drugs used to treat rare conditions with an orphan designation are often characterised 
by high and uncertain ICERs, and likely not cost-effective according to standard WTP 
thresholds (Denis et al., 2010a; Drummond et al., 2007; McCabe et al., 2005).  This is 
a consequence of the difficulties in producing robust evidence due to the small patient 
populations and the heterogeneity of these conditions, as well as their high prices  
(Clarke, 2006; Drummond & Towse, 2014b; Dupont et al., 2011; Simoens, 2011).  In 
such cases, these reimbursement decisions rely on whether society is willing to forego 
health to the whole population in order to treat fewer patients with a rare condition 
(Drummond et al., 2014b). 
 
Little evidence in support of a societal preference for rare conditions exists, and the 
few studies that attempted to elucidate this suggest the contrary when patients with 
more common diseases are deprived of treatment in order to treat fewer patients with a 
rare condition (Desser, Gyrd-Hansen, Olsen, Grepperud, & Kristiansen, 2010; McCabe 
et al., 2010; NICE Citizens Council Report, 2004; SMC, 2011a).  In such cases, these 
decisions partly rely on the decision-makers’ willingness to accept high and uncertain 
ICERs based on additional factors that influence their judgment of (scientific and 
social) value, such as, for example, disease severity, the treatment’s orphan status, or 
to what extent uncertain evidence is acceptable (Dupont et al., 2011; Kanavos et al., 
2012; Nicod, 2015; Simoens et al., 2011).  They also rely on the flexibility of these 
processes in, for example, their ability to implement managed entry agreements or the 
availability of separate funding programs for certain conditions (e.g. Scottish fund for 
ultra-orphan drugs, Cancer Drug Fund in England).  It is somewhat different in France, 
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where a procedure has been set up to expedite access to drugs for rare diseases, as a 
means to support development and dissemination of treatment for populations 
suffering from rare conditions.   
 
The purpose of this study goes beyond the assessment of clinical and economic 
evidence into other areas that help explain value.  We explore how broader aspects of a 
treatment’s value and the impact of the condition on patients, not captured by routine 
HTA methods, influence these HTA processes in different settings.  Particular focus 
was given to those cases with high ICERs or poor SMRs, in view of understanding 
which “other considerations” contributed to accepting higher ICERs or greater 
uncertainty.  The subject of analysis was a sample of orphan drugs in four countries 
(England, Scotland, Sweden, and France), due to the likelihood of greater uncertainty 
in the evidence generated.  We then examined whether the social value judgments 
revealed pertain to orphan drugs furthering the debate as to whether they have a 
preferential status.  
 
9.3. Methods 
 
9.3.1. Study sample 
 
The methodological approach to HTA is built around pre-specified criteria, such as 
whether clinical and/or cost-effectiveness are considered and the context within they 
operate insofar as what is being captured (e.g. health service or societal perspective).  
On this basis, purposive sampling was used to select the study countries with the aim 
of having a good representation of different types of decision-making characteristics, 
in terms of: (a) the criteria used in the appraisal process; (b) the perspective adopted; 
and (c) any existing elicited preferences (Table 9-1).  The HTA agencies included 
were: NICE in England, SMC in Scotland, TLV in Sweden, and the Transparency 
Committee of HAS in France. The three former focus their assessment on the 
treatment’s clinical cost-effectiveness (NICE, 2008; Rawlins, Barnett, & Stevens, 
2010; SMC, 2013b; TLV, 2013).  HAS assesses the drug’s medical benefit to inform 
whether it should be covered and at what rate (Service Medical Rendu (SMR)), and the 
relative improvement in medical benefit to inform the pricing negotiation 
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(Amelioration du Service Medical Rendu (ASMR)), ranking treatments in five levels.  
Both the drug’s medical effectiveness (risk-benefit ratio) and its interest in terms of 
public health (ISP) are accounted for in the SMR assessment.  No economic modelling 
was done by HAS at the time of the sampled drugs’ appraisals.  For cost 
considerations, NICE and SMC agencies adopt a health service perspective and TLV a 
societal perspective.  
 
Ten drug and indication pairs, given that the HTA appraisal process focuses on one 
drug for one specific indication, were selected based on (a) whether they received an 
orphan drug designation by the European Medicines Agency, (b) were appraised by 
NICE through the Single Technology Appraisal process until December 2012, and (c) 
by at least two other of the study countries (Table 9-2).  
 
9.3.2. Data collection and analysis 
 
This empirical study applied an existing methodological framework enabling the 
systematic identification and comparison of the criteria driving HTA decisions for the 
same drugs in different countries through a mixed methods research design comprising 
three key elements: the evidence appraised, its interpretation and its influence on the 
final recommendation (Nicod et al., 2015a).  The focus of this chapter is on the results 
from one of the components about the interpretation of the evidence.  Specifically, the 
analysis focused on exploring the elements beyond cost-effectiveness, cost, 
effectiveness and safety that were raised by the HTA agencies and whether these 
played a role on the decision-making.  
 
Thematic analysis was conducted to identify and code all the “other considerations” 
accounted for during the appraisal process and recorded in the study drugs’ appraisal 
report(s). Bottom-up coding was performed, where codes were inductively created 
while examining the data to summarise what was put forward and categorise this data 
depending on the type of information provided (Onwuegbuzie et al., 2010).  The 
section of text coded included all the text referring to the “other consideration”.  For 
example, if the assessors pointed out that very few treatment alternatives exist, this 
whole section of text would be coded as “few treatment alternatives”.  Codes were 
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then categorised into subcategories depending on the type of information provided, and 
recorded in a coding manual.  These were considered as part of two clusters, those 
relating to living with the disease (disease characteristics) and those to taking the 
treatment (treatment characteristics).  For example, “few treatment alternatives” were 
clustered under “unmet need” and considered as a disease characteristic.  Coding was 
iterative and flexible to ensure transferability of codes to other drugs and countries, 
and additional codes were created with newly identified “other considerations”.  
Coding was conducted by the PhD candidate.  Reliability and validity of the coding 
was tested by an academic colleague, who re-categorised each individual code into one 
of these.  Where differences were observed, adjustments were made.  Feedback from 
external experts were also received, this included the HTA bodies concerned, who 
have been presented most of this work, from HTA experts that are part of the 
Advance-HTA consortium, and from colleagues at different conferences.   
 
Coding was performed vertically and horizontally.  In the former, all “other 
considerations” were coded in a systematic manner as prescribed in the coding manual.  
The latter was implemented by double coding all “other considerations” to capture 
whether it was put forward as one of the main reasons for the decision, where the 
information came from (e.g. experts), and whether it was accounted for in the other 
countries.  The data collected qualitatively was then quantitatively analysed to 
determine: (a) the type and frequency of “other considerations” accounted for; (b) 
cases when these were one of the main reasons for the decisions; (c) how they were 
provided (e.g. expert opinion); and (d) how they compared across agencies.  The 
qualitative statistical software NVivo 10 was used for the data collection and 
analysis,(19) and Excel for further data analysis.  Data sources consisted in the HTA 
reports publicly available from each HTA body, complemented with a review of the 
literature and input from key stakeholders, e.g. HTA bodies and HTA experts from the 
Advance-HTA consortium. 
 
Each sub-category of “other considerations” were further explored to determine 
whether they are more likely to pertain to orphan drug and rare disease characteristics.  
Orphan drug and rare disease characteristics were identified from reviewing the 
literature. 
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9.4. Results 
 
9.4.1. Value judgment classification framework  
 
When the evidence appraised is uncertain or incomplete, scientific value judgments are 
made about the acceptability of this evidence.  This includes about the uncertainty (e.g. 
reliability, generalisability, meaningfulness), the assumptions made (e.g. economic 
modelling) or about certain non-quantified considerations around disease and 
treatment characteristics.  Societal preferences are also accounted for by HTA 
approaches.  These pertain to giving preference to certain (non-quantifiable) aspects of 
living with a disease or taking a treatment, which are translated into prioritising certain 
groups of patients over others (Table 9-1) (Rawlins, 2014).  These can be either 
elicited or not (Rawlins et al., 2004).  The former are typically elicited by a group of 
representative citizens.  In England, this formal process is conducted through NICE’s 
Citizens Council (NICE Citizens Council, 2014).  In Scotland, a societal preference for 
orphan drugs exists by means of the “SMC modifiers”, which were defined by the 
SMC, input from clinical experts and Patient Interest Groups (SMC, 2011a, 2011c).  In 
France, rare diseases are recognised as a national priority under the 2004 Law 
(Ministere des Affaires Sociales et de Sante, 2004).  In Sweden, preference is given to 
the more severe conditions, for which a higher ICER is accepted.  They define disease 
severity “on the basis of the relevant, initial condition and risk of permanent injury, 
ultimately death without treatment…. All the positive effects the medicine has on 
people’s health and quality of life are accounted for” (TLV, 2012).  Non-elicited 
preferences originate from the individual appraisal committee member’s value 
judgment based on their experience or on what they believe society would prefer, and 
are usually made as part of the deliberative processes of HTA.  These are referred to as 
social value judgments, judgments made about societal preferences.  Within the scope 
of this study, these scientific and social value judgments are defined as “other 
considerations” (Table 9-1).  
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Table 9-1. Classification framework of scientific and social value judgments  
HTA Body Scientific assessment Social or societal preferences 
HTA criteria & 
perspective 
-quantified- 
Scientific value judgments 
-non-quantified- 
Preferential status 
 
-elicited- 
Orphan drug 
preferential status  
-elicited- 
Social value judgments 
 
-non-elicited- 
England 
National 
Institute for 
Health and Care 
Excellence -  
NICE 
ICER 
 
NHS & PSS 
perspective 
As part of the deliberative 
process, judgment about the 
acceptability of uncertain or 
incomplete evidence, 
including about the 
assumptions made (e.g. 
economic modelling), or 
about certain non-quantified 
considerations around 
treatment and disease 
characteristics. 
 
Examples: health-related 
quality of life, administration 
benefits, uncertain resource 
use, clinical pathways, 
discount rate, disease 
severity 
End-of-life 
supplementary advice: 
life-threatening, small 
patient numbers, life-
extending  
  As part of the deliberative 
process, giving preference to 
certain non-quantifiable 
considerations around treatment 
and disease characteristics when 
these have not been elicited 
from a representative population 
of citizens. Preference 
originates from the individual 
judgments of the appraisal 
committee based on their 
experience or on what they 
believe society would prefer or 
on conclusions of citizen's 
councils / juries.  
 
Examples: orphan status, unmet 
need, treatment innovativeness,  
disease severity 
Scotland 
Scottish 
Medicines 
Consortium -  
SMC 
ICER 
 
NHS & PSS 
perspective 
  SMC modifiers: life- 
threatening, life-
extending, quality of life 
improvement, curative 
intent,  unmet need 
Sweden 
Dental and 
Pharmaceutical 
Benefits Board - 
TLV 
Human value, 
need and 
solidarity, ICER 
 
Societal 
perspective 
Disease severity & 
unmet need 
  
France 
Haute Autorité 
de Santé - HAS 
SMR & ASMR   Public Health Act 2004, 
recognising rare diseases 
as a national priority 
Source: (Nicod & Kanavos, 2016b) 
Legend: ICER: clinical cost-effectiveness; NHS: National Health Service; PSS: Personal Social Services; SMR: Clinical Benefit; ASMR: 
Relative Improvement in Clinical Benefit 
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9.4.2. Study drugs and HTA recommendations 
 
In countries that use the ICER, the WTP threshold is the amount above which a drug is 
not cost-effective unless certain pre-specified characteristics are fulfilled or the 
assessors are willing to accept this high ICER.  No precise WTP threshold exists in 
England, but the ICER is considered within a maximum allowable range of £20,000 to 
£30,000 per QALY depending on the certainty of the evidence and whether quality of 
life and the treatment’s innovativeness were appropriately captured, and £30,000 per 
QALY if a strong case is made (e.g. end-of-life treatment (NICE, 2009c), 
disadvantaged populations and children (Rawlins et al., 2010)) (NICE, 2008).  
Although no WTP threshold exists, SMC guidance notes that NICE’s threshold may 
influence the assessment (SMC, 2011b).  TLV does not have a fixed threshold but 
based on previous decisions, the average ICER accepted between 2002 and 2007 was 
EUR 36,000 per QALY and the highest granted was EUR 90,000 per QALY (Persson, 
2012).  In France, no threshold exists though a two-stage process is used where 
coverage relies on the clinical benefit (SMR) and the price negotiation uses the 
(relative) improvement in clinical benefit (ASMR). 
 
The study included ten drugs for specific indications (Table 9-2).  Five were not 
appraised by TLV because they were inpatient drugs and at the time of the study, TLV 
only appraised outpatient drugs.  Based on the indicative cost-effectiveness thresholds, 
a number of drugs with an ICER greater than the acceptable range received a positive 
recommendation: mannitol dry, azacitidine, lenalidomide, mifamurtide, and 
trabectedin for NICE; azacitidine, lenalidomide, mifamurtide, and imatinib for SMC; 
everolimus, mifamurtide and romiplostim for TLV.  In some instances, the ICERs for 
these products were improved by application of a Patient Access Scheme that provided 
a confidential discounted drug price.  In France, where coverage is disconnected from 
the ICER and no threshold exists, only one case was rejected for reimbursement 
(mifamurtide), three drugs received an ASMR V where no additional benefit was 
recognised (ofatumumab, mannitol dry, trabectedin), and the remainder were 
considered to provide additional benefits.  
 
 
180 
 
Table 9-2. ICER & coverage decision 
 
Source: (Nicod & Kanavos, 2016b) 
Legend: The grey-shaded cells are for when the HTA recommendations are in line 
with the known willingness to pay for an ICER, or in France, have been granted an 
ASMR V or a rejection. The non-shaded cells are for those HTA recommendations 
that were positive despite an ICER greater than the expected willingness to pay 
threshold.     
Drug 
Indication
ICER Decision ICER Decision ICER* Decision SMR ASMR
Eltrombopag
Chronic thrombocytopenic 
purpura
✗ £104,000-
£116,000/QALY 
(standard care)
Reject ✔CUA dominant 
compared to 
romiplostim
(SMC modifiers)
Restrict
(Subgroup severe 
ITP and high risk of 
bleeding)
✔CMA dominant 
compared to 
romiplostim
(severity)
Restrict
(Re-
assessment, 
and for hospital 
)
Important II
Ofatumumab
Chronic lymphocytic 
leukemia
✗ £50,300 - 
£81,500/QALY, 
depending on subgroup
(PAS)
Reject ✗£108,815/QALY Reject Moderate V
Mannitol dry
Cystic fibrosis
✗£50-£80,000/QALY 
rhDNase
★< £30,000/QALY no 
rhDNase
Restrict
(Subgroup with no 
rhDNase, rapid decline 
of lung function, 
intolerant to osmotic 
agents)
★£20,736/QALY no 
rhDNase
Reject Weak V
Everolimus
Renal cell carcinoma 
(2nd line, advanced)
✗£51,700/QALY
(EoL, PAS)
Reject ✗£61,330/QALY Reject ★Cost/QALY high but 
justified given the 
severity of the disease
(severity)
List Important IV
Azacitidine
Myelodysplastic syndrome
✗£47,200/QALY
(best case scenario)
(EoL, PAS)
List ✗£51,275/QALY
(SMC modifiers, PAS)
List Important II
Lenalidomide
Multiple myeloma 
(2nd, 3rd line)
✗two or more prior 
therapies: 
£41,300-43,800/QALY
(chemo alone)
(EoL, PAS)
Restrict
(Subgroup 3rd line)
✗£34,286-
£41,381/QALY
(chemo alone)
(SMC modifiers)
Restrict
(Subgroup 3rd line)
✔SEK290,000/QALY 
(bortezomib)
= EUR 32,000/QALY
(severity) 
List Important III
Mifamurtide
Osteosarcoma
✗£36,000/QALY
(1.5% discount, PAS)
List ✗£48,579/QALY
(1.5% discount, PAS)
List ★-✗SEK 700,000-
900,000/QALY
= EUR 77-99,000/QALY 
(severity, 3% discount)
List Insufficient DNL
Trabectedin
Soft tissue sarcoma
✗£34,500/QALY
(EoL, PAS)
List ★£36,841/QALY
(PAS)
Reject Important V
Imatinib
Gastro-intestinal stromal 
tumours (GIST)
(adj. unresectable and/or 
metastatic)
★£21-£23,000/QALY 
(significant and 
moderate risk of 
recurrence)
Reject ★£20,655/QALY 
(SMC modifiers)
Restrict
(Subgroup of 
patients with high 
risk of recurrence 
following complete 
resection)
Important III
Romiplostim
Chronic thrombocytopenic 
purpura
✔High risk of bleeding
< £20,000/QALY 
slenectomised 
= £30,000/QALY non-
splenectomised
(PAS)
Restrict
(Subgroup with high 
risk of bleeding, risk 
management plan)
✔High risk of 
bleeding:
£15,220/QALY 
splenectomised 
£16,673/QALY non-
splenectomised
 (standard care)
(SMC modifiers)
Restrict
(Subgroup with high 
risk of bleeding, 2nd 
line or when 
surgery is 
contraindicated)
★SEK 400-
600,000/QALY
= EUR 44-66,000/QALY
Restrict
(Re-assessment 
& risk 
management 
plan)
Important II
✔
★
✗
HAS
France
SMC
Scotland
TLV
Sweden
NICE
England
Acceptable ICER: 
- within 20,000/QALY for NICE. 
- SMC: no threshold, but accounts for NICE threshold
- TLV: no threshold, but based on previous decisions average of drugs approved is Eur 36,000/QALY
Acceptable ICER accounting for other factors:
- NICE: £20-£30,000/QALY
- SMC: no threshold, but accounts for NICE threshold
- TLV: no threshold, but based on previous decisions average of drugs approved is Eur 36,000/QALY, up to Eur 90,000/QALY
High ICER, likely not acceptable except if exceptional circumstances:
- NICE: > £30,000/QALY (e.g. end-of-life treatment)
- SMC: no maximum threshold, but accounts for NICE threshold
- TLV: no maximum threshold, but based on previous decisions ICER greater than EUR 90,000/QALY
*1 SEK = 0.110202 EUR
Legend: PAS: Patient Access Scheme; EoL: End-of-Life treatment; severity: disease severity considered high; QALY: quality-adjusted life years; ICER: incremental 
cost-effectiveness ratio; NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits 
Board; HAS: Haute Autorite de Sante.
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9.4.3. “Other considerations”: an overview 
 
In total, 125 individual “other considerations” were coded and grouped into 10 
categories (Figure 8-1).  94 of these 125 codes were included by NICE and used 173 
times across all 10 cases (e.g. one “other consideration” may have been coded for more 
than one drug), followed by 24 codes used 67 times by HAS, 23 codes used 50 times 
by SMC, and 33 codes used 56 times included by TLV.  The most common disease 
characteristics raised by all agencies were about the nature of the disease and its rarity, 
and the treatment’s unmet need.  The most common treatment characteristics included 
the type of treatment benefit (e.g. curative), the treatment’s innovative nature (e.g. new 
class of drugs), its indirect benefit (e.g. such as the ability to go back to work from the 
treatment) and the non-significance of adverse events. 
 
9.4.4. “Other considerations” as pivotal factors in the decision processes 
 
A proportion of these 125 “other considerations” were also put forward by the HTA 
bodies as one of the main reasons for their decisions and identified through the double 
coding process.  These represent 18% of the “other considerations” put forward by 
NICE (32 of 173), 24% by SMC (12 of 50), 34% by TLV (19 of 56), and 100% by 
HAS (67 of 67) (Table 9-3).  For the purpose of HAS, these “other considerations” 
were mainly discussed in the conclusions of the Transparency Committee when 
assessing the ISP and consequently have all been considered as having been put 
forward together with the main reasons for the final recommendation. 
 
A proportion of these (e.g. cases with a superscript in Table 9-3) pertained to those 
preferences elicited by each HTA body (Table 9-1), where higher ICERs or uncertain 
evidence may be accepted.  Four drugs were eligible under the NICE end-of-life 
supplementary advice, three of which were considered cost-effective with an ICER 
ranging between £34,000-£47,000/QALY (lenalidomide, azacitidine, trabectedin), and 
the fourth (everolimus) not cost-effective with £51,700/QALY.  Weaknesses in the 
economic model were deemed acceptable because of the SMC modifiers in four cases 
(eltrombopag, imatinib, azacitidine, lenalidomide).  For HAS, all study drugs were 
recognised as targeting patients with rare diseases, and assessed within the framework 
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of one or more ministerial plans.  In Sweden, the severity of the condition was put 
forward by TLV for all five cases and resulted in accepting higher ICERs.  
 
Cases without a superscript in Table 9-3 represent the additional (non-quantified or 
non-elicited) “other considerations” put forward as one of the main reasons for the 
decision, which relate to the scientific and social value judgments made.  For NICE, 
these included the treatment’s unmet need for lenalidomide, mifamurtide and mannitol 
dry, its innovativeness for azacitidine and mifamurtide, and the severity of the disease 
for mannitol dry.  Additionally, the impact on families’ and friends’ quality of lives, 
the rarity of the disease, and the ability to contribute to society, and live an active and 
fulfilling life were also put forward for mifamurtide.  For SMC, these included the 
benefit from oral administration, the orphan status and unmet need for eltrombopag; 
the potential reduction in resource use for romiplostim; and the life-extending nature of 
the treatment for mannitol dry and azacitidine.  Similarly, TLV also valued certain 
treatment characteristics, such as the benefit from oral administration (e.g. 
eltrombopag), the treatment’s novel mechanism of action (e.g. eltrombopag, 
romiplostim), the impact of the disease on quality of life and daily activities (e.g. 
eltrombopag, romiplostim, lenalidomide), or the treatment’s orphan status (e.g. 
eltrombopag).  Unmet need was also recognised (e.g. eltrombopag, romiplostim), and 
in one case, TLV acknowledged the changing environment in clinical practice (e.g. 
lenalidomide).  For HAS, both disease and treatment characteristics were put forward 
during the assessments for all drugs, namely around the nature of the disease and its 
effect on the patient, the need for treatment alternatives, as well as the type of direct or 
indirect benefit from taking the treatment.  In France, orphan drugs are presumed to be 
innovative and thus subject to fast-track HTA consideration.  In the assessment, the 
innovativeness of a drug is recognized for those drugs with ASMR I-III. 
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Table 9-3. “Other considerations” as pivotal factors in the decision (Nicod & Kanavos, 2016b) 
 
El
tr
om
bo
pa
g
Ro
m
ip
lo
st
im
Ev
er
ol
im
us
Le
na
lid
om
id
e
Az
ac
iti
di
ne
Im
at
in
ib
M
an
ni
to
l d
ry
M
ifa
m
ur
tid
e
Of
at
um
um
ab
Tr
ab
ec
te
di
n
Scientific value 
judgment
-non-quantified-
Social value 
judgment
-non-elicited-
National priority
- Rare disease plan
- Cancer plan
- Plan for improving qol in patients with chronic diseases
- Public Health Law 2004
- Falls in the scope of the fight against cancer
HASrare
HASrare
HASrare
HASrare
HASrare
HASrare HAS
rare
HASrare
HASrare HAS
rare
HASrare
HASrare
HASrare
HASrare
HASrare
HASrare
Issues around current treatment alternatives
- changing treatment pathways TLV ★
Disease nature affecting the patient
-Short life expectancy
- Disease severity
- Disease with a poor prognosis
- Serious condition
- Life threatening
- Incurable
- Requires life long treatment
- Affects quality of life
- Affects daily activities and functional capacity
HAS, TLVseverity
TLV
HAS
TLV, HAS
TLV
TLVseverity
HAS
TLV
HAS, TLV
HAS, TLV
NICEend
TLVseverity
HAS
HAS
NICEend, HAS
TLVseverity
HAS
TLV
NICEend, HAS
HAS
HAS
NICE
HAS
HAS
HAS
HAS
HAS, TLVseverity
HAS HAS
NICEend
HAS
HAS
★  
★  
★
★
★
★
★
★
★
Disease nature affecting the patient's surrounding
- Impact on quality of life of family and friends NICE ★
Rarity, orphan status, small patient population
- Small patient population
- Minor public health burden because of rarity 
- Orphan status
TLV
HAS
SMC
HAS
NICEend NICEend
SMCmodifiers
NICEend
SMCmodifiers
HAS
SMCmodifiers
HAS
NICE
HAS
NICEend
HAS
★
Unmet need 
- Importance of new treatment options
- Few developments in last years
- No (satisfactory) alternatives exist
- Alternatives exist
- Need to improve therapeutic management
- Few therapeutic options
- New treatment would offer new options
- Alternative treatments not routinely available 
TLV
HAS
SMC
HAS
TLV
HAS
HAS
NICE
HAS
NICE
NICE
HAS
NICE
HAS
HAS
HAS
HAS
 ★
Type of treatment benefit
- Curative
- Palliative
- Preventive
- Symptomatic
- Salvage treatment
- Life-extending
- Benefit extended over a long period
HAS HAS, SMCmodifiers HAS
NICEend
HAS
NICEend
HAS
NICEend,SMCmodifiers
HAS
SMCmodifiers
HAS 
SMC
NICEdiscount, HAS
SMCmodifiers
NICE
HAS
HAS
HAS
NICEend
★
Innovative nature of the treatment
- Important advance
- Novel mechanism of action
- Significant innovation for a rare disease
- New class of drugs
- Potential valuable new therapy
- Oral administration advantage
HAS
TLV
TLV, SMC, HAS
TLV
NICE
NICE
NICE
NICE
★
Indirect benefits from taking the treatment
- Ability to lead an active and fulfulling life
- Ability to contribute to society
- Significant impact on morbidity
- Significant impact on mortality
- Significant impact on quality of life
- Resource use reduction HAS, SMC HAS
HAS
HAS
HAS
HAS
NICE
NICE
★
★
★
★
★
★
Legend: end: NICE End-of-life supplementary advice; severity:severe disease; modifiers: SMC modifiers; NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits 
Board; HAS: Haute Autorite de Sante
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9.4.5. Stakeholder input 
 
No mention of stakeholder input was found for TLV given that this is done informally 
and generally not documented, which is reflected in the results.  In contrast, formal 
channels exist to collect stakeholder input during the technology appraisal processes 
through the Public Involvement Programme (PIP) at NICE, the Patient and Public 
Involvement Group (PAPIG) at SMC, and the procedures for rapporteurs at HAS 
(HAS, 2015; NICE, 2004; SMC, 2013a).  The CT meeting minutes at HAS note how 
many outside experts provided input but not the content of their advice. 
 
“Other considerations” were provided by stakeholders in 116 out of 173 “other 
considerations” identified in the NICE appraisals.  41% of these (n = 116) were 
provided by clinical experts, 21% by patient experts, and 35% by both clinical experts 
and patient representatives.  Clinical experts provided information about the nature of 
the disease affecting the patient (27%), issues around current treatment alternatives 
(13%), the treatment’s unmet need (11%) and innovativeness (10%), and the non-
significance of adverse events (10%).  Patient representatives provided information 
about the nature of the disease affecting the patient (33%), the non-significance of 
adverse events (14%), the indirect benefits from taking the treatment (12%) and the 
patient’s unmet need (11%).  In Scotland, all drugs received a Patient Interest Group 
submission except for trabectedin and imatinib.  The detail of these submissions was 
not accessible.  Additionally in two cases, clinical input was recorded in the HTA 
reports, where they commented that treatment pathways depend on symptoms 
(e.g.eltrombopag) and existing treatments are unlicensed (e.g romiplostim).  
 
9.4.6. Orphan drugs and special status  
 
Table 9-4 represents the subcategories of “other considerations” identified in the 
sampled drugs (rows) and whether they pertain to certain characteristics specific, but 
not limited to, rare disease and orphan drugs (columns).  Unmet need is more likely to 
characterise, but is not limited to, rare diseases given the scarcity of relevant 
knowledge and expertise and the fact that often no effective cure exist.  This is due to 
issues around the diagnosis of some of these rare diseases, the complex and unknown 
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nature of these conditions, together with the lack of coordination amongst centres of 
expertise at EU- and international-levels, and the lack of knowledge around best 
practices (Commission of the European Communities, 2008; EPIRARE, 2013; 
EUCERD, 2013; Rare Best-Practices, 2013).  Further, given that orphan drugs often do 
not have any effective cure, hence the reason for implementing incentives at marketing 
authorisation level, treatments for rare diseases are more likely to be innovative.  On 
this basis, the “other considerations” that were put forward as one of the main reasons 
for the final decision identified previously, therefore influencing the final decision, 
may favour orphan drugs compared to drugs to treat normal conditions.  This was seen, 
for example, with “unmet need” for lenalidomide, mifamurtide and mannitol dry by 
NICE, and for eltrombopag, romiplostim by SMC. 
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Table 9-4. Special status of orphan drugs 
 
Source: (Nicod & Kanavos, 2016b) 
Special 
status?
Subcategories of "other considerations"
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Nature of the disease affecting the patient 
eg disease severity, impact on quality of life and daily 
activities
★ ✔ ✔ ✔ ✔ ✔ ✔
Nature of the disease affecting the patients' surrounding
eg impact of the disease on the families' quality of lives, 
anxiety, limiting life choices
★ ✔
Rarity, orphan status, small patient numbers ✔ ✔
Unmet need
eg no or few treatment alternatives exist, treatment pathway 
unclear
★ ✔ ✔
Type of treatment benefit
eg curative, life extending
★ ✔ ✔ ✔
Innovative nature of the treatment
eg new mechanisms of action
★ ✔ ✔
Indirect benefit from the treatment
eg quality of life improvement, ability to live normal lives, 
improved symptoms, administration benefit
★ ✔ ✔ ✔ ✔ ✔
Disease or treatment characteristic specific to rare diseases and orphan drugs
✔ Characteristic specific to rare diseases and orphan drugs
★ Characteristics likely specific to rare diseases and orphan drugs
187 
 
 
9.5. Discussion 
 
This study identified the value judgments made for a sample of ten orphan drugs in 
four countries in order to understand how they influenced the assessment process, 
particularly in those cases with a high ICER or, in the case of France, a high ASMR (I-
III), which allows the manufacturer to set the price (consistent with other European 
markets).  The study also identified those cases when these “other considerations” 
were provided by different stakeholders, by type of information provided, as well as 
those cases when the “other considerations” pertain more to orphan drug compared to 
more normal conditions.  Implications from these findings are discussed in this 
section, and focus on five topical areas: (a) the added-value of a classification 
framework, (b) how results compare with existing literature, (c) the determinants of 
social values, (d) accountability for reasonableness, and (e) orphan drugs and special 
status.   
 
Based on what we know about value judgments (Rawlins, 2014; Rawlins et al., 2004), 
one of the significant contributions of this study is the proposed classification 
framework of these (Table 1).  Its application enabled to identify and differentiate the 
scientific and social value judgments made (Table 3), where implications are two-fold.  
First, it constitutes a way forward to highlighting needs for further research (when 
evidence is incomplete or preferences are non-elicited).  Second, if they continue not 
to be elicited or quantified, retrospectively identifying these to prospectively create a 
taxonomy of criteria may facilitate their being used more consistently when similar 
scenarios are encountered in the future.  For example, NICE emphasised the impact of 
osteosarcoma on families’ and friends’ lives when assessing mifamurtide, or SMC and 
TLV recognised the “oral administration benefit” when assessing eltrombopag.  These 
are non-quantified or non-elicited criteria for which preference could be given in future 
cases by their inclusion in the taxonomy of criteria to be accounted for.  This is all the 
more important when considering the extent to which these considerations are different 
across countries and likely also across decision-making bodies within one HTA 
agency.  These differences are either a consequence of agency-specific value 
preferences (Nicod, 2016a), or of committee-specific preferences reflecting the 
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composition of the decision panel and their individual judgments driven by their 
experiences, and it is therefore important to improve the consistency in their use. 
 
The different “other considerations” identified and their classification into sub-
categories and clusters are in line with findings from the literature on (social) value 
judgments.  Schwappach (2002) divides the determinants of social value into those 
factors relating to patient characteristics and those to the treatment (Schwappach, 
2002).  Our study clustered these determinants in a similar manner into two clusters 
(e.g. treatment or disease characteristics), and takes one step further by applying this 
same classification to both social and scientific value judgments.  Second, a number of 
individual social values were identified in the literature.  One study in England used 
qualitative techniques to define these, where respondents agreed to favour need, 
preventive care, quality of life, health improvement and life expectancy, in addition to 
not favouring certain populations according to age or socio-economic status (Baker, 
Bateman, Donaldson, Jones-Lee, Lancsar, Loomes, Mason, Odejar, Prades, Robinson, 
Ryan, Shackley, Smith, Sugden, Wildman, & Team, 2010).  Generally there is 
agreement about what these social values are, but the determinants of social value 
remain broadly defined and no exhaustive list of these exists.  When comparing these 
results to the topics defined within the ethical, organisation and social domains of the 
EUnetHTA Core Model (EUnetHTA, 2013), commonalities and differences are seen.  
The topics included in the ethical domain relate to the societal preferences (elicited 
social values), those in the social domain relate to treatment characteristics, and those 
in the organisational domain to the financial impact or organisational impacts of using 
the treatment.  The Core Model domains do not necessarily capture those aspects put 
forward about the patient experience in living with the disease, but rather focuses on 
those aspects that change when taking a treatment.  In contrast, results presented in this 
chapter do not capture all of the domains highlighted in the Core Model, likely because 
these had not been put forward in these particular cases analysed.  Nevertheless, this 
study contributes to understanding how those topics included in the Core Model may 
be expressed in practice. 
 
Given that the determinants of social value are only broadly outlined, this study 
contributes to better defining these.  For example, “need” or “unmet need” is a 
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determinant of social value.  It is accounted for in the weighing of disease severity by 
TLV, as one of the SMC modifiers, and discussed by a NICE Citizen Council meeting.  
Nevertheless, no clear definition of unmet need exists.  Our results captured the variety 
of ways of expressing “unmet need” (Table 8-3), which can be used to define it.  
Another example is disease severity, for which no single definition exists.  It is 
characterised by a number of determinants, which include the impact on quality of life 
and mobility, or considerations of life expectancy (Dolan & Shaw, 2004; Garau et al., 
2009b).  Severity is included into HTA either through a weighing of the QALY (or of 
other measures of HTA) or as part of the deliberative process (Garau et al., 2009b).  
The latter would apply to our study countries since no specific weighing for severity 
was seen, including in Sweden where it is explicitly accounted for despite the 
definition of disease severity being broad (as noted earlier).  Our results identified the 
various forms of expressing severity, which can be used to better define severity for 
future cases.  For TLV, these included: the life-threatening nature of the disease, the 
negative impact on daily activities including functional capacity and on quality of life, 
and the short life expectancy from having the disease.  In France, where no ICER or 
threshold exist, informal methods are used to incorporate societal and political values 
into the assessments.  This is explicit in the evaluation of the public health value 
(intérêt de santé publique) of drugs as part of the coverage evaluation (SMR), 
however, whether these determinants of (social) value are accounted consistently 
across cases is another question, which could be partly addressed by applying the 
taxonomy of criteria. 
 
For a resource allocation decision to be accountable for reasonableness, the process 
should be transparent and public, based on reasons that are relevant, decisions should 
be revisable when new evidence is available, and the process should allow for these 
conditions to be enforced (Daniels, 2000; Daniels et al., 2008).  This usually takes 
place during the deliberative process of HTA, during which the Committee discusses 
the evidence and accounts for stakeholder opinion until a decision is made.  The 
decision and reasons for the decision should then be documented in the HTA report, 
most often publicly available, as is the case with our study countries.  In terms of 
stakeholder input, a clear process exists at NICE and SMC where they are given the 
opportunity to voice their concerns or opinions.  Our analysis confirmed that this is 
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well-reported for NICE (given the high number of “other considerations” provided by 
different experts), but is not as detailed in SMC’s summary of advice, probably 
because it is a less detailed report.  HAS has specific procedures governing outside 
experts (rapporteurs) who provide advice and input in the evaluation process.  For 
TLV, no official procedures exist, although some of the key stakeholders are 
represented within the Appraisal Committees (e.g. clinical experts).  Generally, the 
type of input from these stakeholders could be better documented or transparent.  
Some argue that it is not sufficient to have a formal procedure to account for 
stakeholder input and value judgments, but that it should also be clear how these have 
influenced the decision, which is often lacking (Garau et al., 2009b).  Our results 
further confirm this in the number of “other considerations” (from stakeholders or not) 
identified, where it is not entirely clear how these factors contributed to the decisions 
particularly in those cases where these were (non-elicited or non-quantified) value 
judgments.  The taxonomy of criteria developed together with the type of input from 
different stakeholders may help understand the criteria that are relevant to decision-
making and their sources that go beyond routine methods of assessing clinical benefit 
and ICERs.  
 
Little agreement exists on whether patients with rare diseases requiring orphan drug 
treatments deserve a preferential status (Desser et al., 2010; McCabe et al., 2010; 
NICE Citizens Council Report, 2004).  Nevertheless, governments recognise the 
difficulties in appraising these treatments and the fact that they should be treated 
differently.  In France, patients with orphan diseases have a preferential status, but 
their needs go much beyond drugs.  Only recently, NICE and SMC have implemented 
new procedures for end-of-life and ultra-orphan drugs.  The treatment’s additional 
benefit and other elements not captured by the ICER (e.g. unmet need, disease 
severity, added value the patient and surrounding) are now accounted for by SMC, 
together with patient and clinical engagement.  These other elements correspond to the 
“other considerations” identified in this study.  Similar questions are arising in 
Sweden, where a consultation on how to appraise orphan drugs has recently been 
issued.  Further, in NICE’s recent consultation on value-based pricing, they attempted 
to find novel approaches to capturing burden of illness and other issues.  They 
concluded that approaches to adjusting the QALY were insufficient, and therefore it is 
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essential to identify the criteria that are important in decision-making and that go 
beyond the ICER.  This study provides an alternative to the issue of preferential status 
by accounting for the non-elicited or non-quantified “other considerations” that 
influenced previous decisions, and query whether it would be worth eliciting 
preferences for these.  This could then feed into novel approaches in assessing orphan 
drugs. 
 
9.6. Conclusions 
 
This study systematically identified the scientific and social value judgments made in 
four countries for a sample of orphan drugs, and explored how they influenced the 
deliberative process of HTA.  The proposed classification framework of these value 
judgments was used to identify needs for further research and to improve consistency 
in their use across drugs within one agency.  This was then used to address different 
issues around identifying and better defining the determinants of social value or how to 
improve the lack of accountability for reasonableness particularly in cases when it was 
not clear how the “other considerations” identified influenced the decisions.  It also 
provided a way forward to eliciting whether these orphan drugs deserve a special 
status by eliciting preferences around some of the social value judgments made which 
are more likely to pertain to orphan drugs compared to normal condition, rather than 
focusing on the opportunity cost of these.  Given the challenges in producing robust 
evidence for orphan drugs due to the small patient numbers and heterogeneity of the 
diseases, scientific and social value judgments are unavoidably part of the decision 
processes for these drugs.  Identifying the scientific and social value judgments 
through the application of this framework enables us to create a taxonomy of criteria 
that were relevant in these decision-making processes and which go beyond route 
methods for HTA.  
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10. Dealing with Uncertainty and Accounting for Social Value 
Judgments in Value Assessments for Orphan Drugs: Qualitative 
Evidence from Four European Countries8 
 
 
10.1. Abstract  
 
We compared the value assessment of orphan drugs in four European countries and 
explored differences in reimbursement decisions.  Semi-structured interviews with 
HTA body representatives in England, Scotland, Sweden, and France were conducted.  
An interview topic guide was developed based on findings from a systematic 
comparison of HTA decisions for ten orphan drugs.  Qualitative thematic data analysis 
was applied to the interview transcripts using the Framework Approach.  Eight HTA 
body representatives were interviewed between March and June 2015.  Evidentiary 
requirements and approaches to dealing with uncertainty were discussed around: trial 
design, population and duration, comparators, relevant endpoints and economic 
modelling.  HTA bodies agreed that decisions regarding orphan drugs are made in a 
context of greater uncertainty.  The threshold of acceptable uncertainty varied by 
country and was generally not related to the risk of not marketing the drugs.  The 
acceptability of surrogate endpoints was not consistent across countries nor were the 
validation requirements.  Different mechanisms were used to modulate the ICER in 
cases of uncertainty (e.g. Patient Access Schemes).   Some countries require higher 
evidentiary standards for greater clinical claims, which may be more challenging for 
orphan diseases.  The most common social value judgments identified related to 
innovation, disease severity and unmet need.  Trivial differences were seen in the way 
these concepts were defined and accounted for across countries.  Although agreement 
was seen in evidentiary requirements or preferences, there were subtle differences in 
the circumstances where uncertain evidence may be considered acceptable, possibly 
explaining differences in HTA recommendations.  
                                                 
 
8 A version of this chapter is soon to be submitted for publication to Value in Health (Nicod E, Berg 
Brigham K, Durand-Zaleski I, Kanavos P, 2015) 
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10.2. Introduction 
 
HTA aims to ensure that technologies offered are safe, efficacious and provide value 
for money (Hurley, 2000).  Value may be perceived within the context of efficiency by 
reimbursing only the most efficient technologies within an allowable budget; however, 
this does not necessarily account for what truly matters to society and to those being 
treated (Caro, 2009).  Value may also reflect specific attributes, such as innovation, 
with direct implications for patients in terms of improved prognosis or quality of life, 
and indirect ones for society through increased productivity, other societal 
contributions, possibly also benefiting patients in other disease areas through 
knowledge spill-overs.  HTA is best viewed as an umbrella concept in a multi-
disciplinary field that aims to capture the value of a new technology through a range of 
facets relating to different stakeholder perspectives and attributes of interest.  
 
For a given drug, two bodies may reach opposite conclusions despite appraising the 
same evidence and using similar measurement outcomes (Nicod et al., 2012).  These 
processes may rely on different attributes of value or on different approaches to 
dealing with often imperfect evidence.  The acceptability of uncertain clinical benefit 
and cost-effectiveness therefore depends on the tools used to address uncertainty and 
on the judgment of the decision-makers with consideration of additional qualitative 
criteria (e.g. stakeholder input, disease or treatment characteristics) (Nicod et al., 
2015a).  The internal regulations of HTA bodies explain the frameworks under which 
they operate, and the opinions or recommendations regarding specific health 
technologies generally provide documentation of the evidence considered and the 
bases for the decision.  However, subtleties may not be captured even in the most 
complete documentation.   
 
This is particularly the case with respect to orphan drugs, because it may be impossible 
to apply the generally-applicable rules in defining the appropriate evidence for small 
populations facing very serious chronic or life-limiting diseases.  Producing high 
quality evidence has proven to be challenging because of the small patient numbers, 
heterogeneous nature of these conditions, and lack of scientific expertise (Vickers, 
2013).  This has implications for clinical trial design (e.g. appropriate endpoints, trial 
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duration or clinical pathways) and conduct (e.g. recruitment from scarce patient 
numbers and specialists) (Vickers, 2013).  Two studies compared trials for orphan and 
nonorphan conditions and found that orphan drugs were generally characterised by 
lower quality evidence (Bell et al., 2014; Kesselheim et al., 2011).  These challenges, 
in addition to their high prices, result in orphan drugs generally not being cost-
effective (Drummond et al., 2007).  Orphan drugs often undergo the same HTA 
processes as for more prevalent conditions.  Ongoing debate is whether we (society) 
are willing to pay more for these rarer conditions.  This was not supported by a number 
of surveys that aimed to elicit this question and found the contrary when resources are 
taken from more prevalent conditions (Drummond et al., 2014b).  A better 
understanding is therefore needed about how HTA bodies value orphan drugs and deal 
with issues related to rarity, and further the debate on whether they deserve a special 
status or their processes should be differentiated. 
 
In a previous study, the decisions of four HTA bodies for 10 orphan drug-indication 
pairs were analysed based on the opinions and in light of each entity’s internal 
regulations (Nicod, 2016a).  While the same clinical trial evidence was considered by 
each HTA body, their analyses and conclusions were not uniform, where a substantial 
number of drugs (60%) received diverging recommendations (Table 10-1).  On this 
basis, this study aimed to develop a broader perspective about how value is assessed 
for orphan drugs in four European countries and how differences affect reimbursement 
decisions based upon interviews of representatives of the HTA bodies.  
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Table 10-1. Drugs included in previous study and overview of key characteristics 
seen in the trial submission 
 
HTA recommendations NICE SMC TLV HAS 
ICER or ASMR (pricing scheme) and SMR 
(coverage rate) in France 
England, N 
10 
Scotland, N 
10 
Sweden, 
N 5 
France, N 
10 
Eltrombopag Reject Restrict 
(high risk of 
bleeding) 
List II (EU) 
Chronic idiopathic thrombocytopenic purpura >£100k  Dominant Dominant  important 
(65%) 
Romiplostim Restrict  
(high risk of 
bleeding) 
Restrict 
(high risk of 
bleeding) 
List II (EU) 
Chronic idiopathic thrombocytopenic purpura £30k 
splenectomised, 
<£20k non-
splenectomised 
£15k 
splenectomised, 
£17k non-
splenectomised 
Sek4-
600k 
important 
(65%) 
Everolimus Reject Reject List IV 
Renal cell carcinoma (2nd line, advanced) £52k  £61 High important 
(100%) 
Lenalidomide Restrict  
(3rd line) 
Restrict  
(3rd line) 
List III (EU) 
Multiple myeloma (2nd, 3rd line) >WTP 2nd line 
<£44k 3rd line 
£34-41k 3rd 
line 
Sek290k important 
(65%)* 
Mifamurtide List List List Reject 
Osteosarcoma £36k £48k Sek7-
900k 
insufficient 
(0%) 
Azacitidine List List NA II (EU) 
Myelodysplastic syndrome £47k £51   important 
(65%)* 
Imatinib Reject Restrict  
(high risk of 
recurrence after 
resection) 
NA III (EU) 
GIST (adjuvant, after surgery) £21-23k £21k   important 
(100%) 
Mannitol dry Restrict 
(no rhDNase) 
Reject NA V 
Cystic fibrosis £50-80k 
rhDNase 
<£30k no 
rhDNase 
£20k no 
rhDNase 
  weak 
(15%) 
Ofatumumab Reject Reject NA V 
Chronic lymphocytic leukemia £50-80k £108k   moderate 
(30%)* 
Trabectedin List Reject NA V 
Soft tissue sarcoma £34k £36k   important 
(65%)* 
Evidence appraised          
Primary trials (#) 13 13 6 13 
Design         
Phase III (% trials) 85% 85% 100% 85% 
196 
 
 
Phase II (% trials) 15% 15% 0% 15% 
Study population         
Less than 300 patients (% trials) 62% 62% 50% 62% 
Subgroup data (% drugs) 40% 40% 20% 40% 
Comparators         
Alternative treatment (% trials) 0% 0% 17% 0% 
Standard care (% trials) 92% 92% 83% 92% 
None (% trials) 8% 8% 0% 8% 
Relevant endpoint         
Clinical endpoint (% drugs) 20% 10% 0% 10% 
Surrogate endpoint (% drugs) 80% 90% 100% 90% 
Health-related quality of life         
Included (% drugs) 50% 50% 40% 20% 
Not explicitly reported (% drugs) 50% 50% 60% 80% 
Economic models         
Cost-utility models (% drugs) 100% 100% 80% NA 
Cost-minimisation models (% drugs) 0 0 40% NA 
Source: The author, based on (Nicod, 2016a). 
 
Legend: N: # of drugs; * Coverage rate not specified in report; EU: European price levels and 
price negotiation. 
 
NOTES: Two economic models recorded in TLV's report for lenalidomide.  
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10.3. Methods 
 
10.3.1. Study sampling and data collection 
 
Purposeful sampling was used to select the study countries, each of which undertake 
assessments using well-established processes and criteria, have publicly available 
recommendation reports and represent a cross-selection in terms of HTA approach and 
perspective.  The selected study countries were England (National Institute for Health 
and Care Excellence, NICE), Scotland (Scottish Medicines Consortium, SMC), 
Sweden (Dental and Pharmaceutical Benefits Board, TLV) and France (Haute Autorité 
de Santé, HAS).  Each HTA body also accounts for elicited societal values, which 
allows greater flexibility in the face of high and uncertain ICERs or outcomes.  
 
We conducted semi-interviews with HTA body representatives identified by partners 
of a European research consortium (Advance-HTA) in each of the study countries.  An 
interview topic guide was developed by the lead author and reviewed by all co-authors 
(Appendix C).  It included open-ended questions derived from actual questions that 
arose in the context of our cross-national comparison of 10 orphan drug-indication 
pairs, including how certain identified criteria were considered and influenced the 
opinions.  The interview questions were divided into four general themes: (a) General 
evidentiary requirements for orphan drugs, to better understand what scientific 
evidence is required and to what extent it is different for orphan drugs compared to 
other drugs; (b) Dealing with uncertainty, to understand whether more flexibility is 
given to accepting certain types of uncertainty when other types of evidence are 
presented or because of the rarity of the treatments under review; (c) Social value 
judgments, to understand the type of value judgments made by the assessors and how 
these are accounted for during the processes; (d) Stakeholder involvement, to 
understand who else other than the manufacturer and the HTA body members have 
input in the assessments.  The structure and responses to the questions in the interview 
topic guide are shown in Table 10-2.  The interview guide was developed in such a 
way as to ensure consistency of focus while providing flexibility in the discussions, so 
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that interviewees were free to offer additional insights and interviewers could ask 
spontaneous questions.   
 
An invitation to participate in a face-to-face or telephone interview was sent to each of 
the identified interviewees by email along with the interview topic guide.  Interviewees 
were ensured anonymity, and their responses remained confidential pending their 
confirmation and approval of the content.  The study protocol underwent the LSE 
Research Ethics procedure and received exemption.  Interviews were recorded and 
transcribed by the lead author and sent to the interviewees for comment and validation.  
Following the interviews, the topics or issues that emerged as relevant or different 
across countries were compiled and analysed by the authors together with a summary 
of the views of interviewer(s), circulated amongst co-authors and accounted for during 
the analysis.   
 
10.3.2. Data Analysis 
 
Qualitative thematic data analysis was undertaken using the Framework Approach 
(Gale, Heath, Cameron, Rashid, & Redwood, 2013).  After familiarisation with the 
topics discussed, a number of subthemes within each general theme were identified 
and inductively coded.  These included, for example, “preferred type of trial” or 
“comparator”, “appropriate endpoint”, etc.  An interview matrix was created in Excel 
to facilitate comparison of each subtheme across the four HTA bodies.  The key 
findings from each of these subthemes were summarised in tables and incorporated 
illustrative quotes from the interviewees.  The findings were discussed by all co-
authors, and a list of follow-up questions for the four HTA bodies was developed to 
complement the interviews where information was unclear or incomplete.  These 
questions were sent to each of the interviewees along with the summary findings for 
their particular HTA body for response and confirmation.  
 
Results focus on the contrasts across countries identified within each theme. Themes 
were reorganised as follows: (a) clinical evidence and uncertainty, (b) comparators, (c) 
treatment outcomes and safety, and (d) additional qualitative criteria.  Results about 
stakeholder input were excluded, as no additional information was provided compared 
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to the previous chapters.  Each theme protrays the agencies’ perspectives about the 
clinical evidence appraised and whether this evidence for orphan drugs is characterised 
by even greater uncertainty compared to more prevalent conditions.  This evidence-
based used for HTA is imperfect or incomplete, therefore uncertain, as it relies on 
estimated values from experimental or observational studies (Rawlins, 2014; Rawlins 
2014, Claxton, 2008).  Decision-makers make scientific value judgments about the 
extent to which this uncertain evidence is acceptable.  This includes judgments about 
whether the evidence presented fully and accurately captures the effect of the 
intervention, whether it is generalizable to the local context of the decision, whether 
quality of life changes are accurately captured, or whether it is appropriate to impose 
restrictions to population subgroups (Rawlins 2014).  I aimed to shed light on the 
different perspectives adopted when making these judgments about uncertainty 
regarding the themes discussed, where cross-country differences had already been 
identified. 
 
10.4. Results  
 
Eight representatives from each of the four HTA bodies agreed to participate in the 
interviews between March and June 2015.  Interviewees occupied senior positions in 
their agencies (e.g. Head of the Technology Appraisal Programme, Head Economist or 
Pharmacist, Chair of the Appraisal Committee).  Interviews were conducted face-to-
face and, in one case, by telephone, lasting between one to three and a half hours.  This 
section summarises the most relevant and contrasting findings (Table 10-2). 
 
10.4.1. Clinical evidence and uncertainty  
 
Trial design 
 
No formal requirements around minimum levels of evidence are imposed, though 
phase III comparative trials are often preferred.  This was illustrated in the primary 
trials considered, which were predominantly phase III trials (with relatively small 
patient numbers), with the exception of two phase II trials that received early 
marketing authorisation (e.g. trabectedin and ofatumumab) (Nicod, 2016a).  HAS also 
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requires all existing and available data at the time of the HTA submission.  An 
important distinction was seen in their expectations about the quality of the evidence 
submitted when examined within the context of the clinical claim.  TLV has higher 
scientific and methodological demands for superior efficacy with a price premium, and 
greater uncertainty is accepted for non-inferior efficacy (and low price) or for treating 
untreatable diseases as long as the treatment is safe.  Similarly, the highest ASMR 
rating should demonstrate in a good way the treatment’s benefit on survival.  HAS also 
judges whether the evidence presented is of sufficient quality by accounting for the 
situation of the disease in terms of prevalence and number of recruitable patients.  
 
The type of information generated from non-primary non-phase III trials was about 
safety, dosage research and historical controls (Nicod, 2016a).  A contrast was seen in 
the acceptance of historical controls for trabectedin only by NICE due the non-
comparative nature of the phase II trial presented.  Although rarely used, the agencies 
agreed that historical controls are acceptable when no other data is available (NICE), 
when it is the best data available (SMC, TLV), to collect data on disease progression 
when no alternative treatments exist (HAS), or when the disease is rare or other special 
circumstances are seen (SMC).  Historical control data is considered generally of poor 
quality, which would explain its limited use and in our example and the fact that it was 
only considered by NICE for trabectedin.  All agencies recognised that no established 
treatment alternatives exist and were presented historical control data.  It was not 
accepted by SMC and HAS because of the statistical methods used in analysing the 
data, whereas it was accepted by NICE because of the investigational nature of the 
treatment.  The interviewees recognised the usefulness of registry data to obtain 
historical controls, and information about disease progression for economic modelling 
purposes (NICE), or to obtain longer term data (particularly for rare conditions, which 
are often chronic and rely on short-term data) about efficacy and safety (HAS).  Their 
limited use is explained by the unknown nature of the type of data useful in the future 
(NICE) or the missing data where comparisons become inappropriate (HAS), as 
illustrated in our example.   
 
Trial length 
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In our previous study, the HTA bodies were often concerned about the trial duration 
being too short (eltrombopag, imatinib, mannitol dry, romiplostim) or the uncertain 
optimal treatment duration (imatinib).  When questioning the agencies about how the 
appropriate trial length is assessed, different approaches were described accounting for 
the summary of product characteristics (SMC), the durability of response (TLV, 
SMC), the assessment by the EMA (TLV), or the natural prognosis of the disease 
(TLV, HAS) (Table 10-2).  Given the often chronic nature of these rarer conditions, 
issues around the short trial length may be more common, as recognised by SMC and 
TLV who are willing to accept greater uncertainty for orphan drugs, but not for NICE 
who does not make any differentiation for orphan drugs.  This was illustrated for 
mannitol dry to treat cystic fibrosis, a chronic condition, where the length of the two 
trials assessed were considered too short by HAS and SMC given that the treatment is 
to be taken over a prolonged period of time, but not by NICE nor TLV, possibly 
because they were the pivotal trials considered for marketing authorisation.  In the 
previous section, HAS recognised the usefulness of registry data particularly for the 
rarer and often chronic conditions.  This may explain the negative decision for 
mannitol dry, which was not made available under the temporary authorisation scheme 
(ATU) and for which no longer-term data was being collected.  
 
Study population 
 
Four out of the ten drugs analysed relied on subgroup data (Nicod, 2016a) (Table 
10-1).  When asking the interviewees about how they deal with subgroup data, 
different perspectives were given.  Pre-specified subgroup data is generally preferred, 
but acceptable under certain circumstances (Table 10-2).  This was illustrated for 
mannitol dry, where HAS was concerned that the trial population (including children 
and adults) was not representative of the indication for marketing authorisation 
(adults).  This was due to the data presented in the HTA assessments, which included 
both adults and children and were presented either together (SMC, HAS) or only for 
adults (NICE).  Additionally, extrapolating treatment effects from subgroup data to a 
wider population would also not be accepted by HAS.  For the others, preference 
would be given to the subgroup driving the results (most cost-effective subgroup).  
This was seen for eltrombopag restricted by NICE and SMC to patients with a severe 
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risk of bleeding, given that the need for rescue medication was the main driver of costs 
and cost-effectiveness, and for which the ICER across the whole population was not 
cost-effective.  This was also highlighted by TLV, who rather than impose a 
restriction, requested a re-assessment in the future to assess its cost-effectiveness in 
practice.  
 
Comparators 
 
The comparators included in the primary trials for the ten orphan drugs analysed were 
placebo or standard care, except for three cases without comparators due to early 
marketing authorisation (ofatumumab) or comparing different doses of the treatment 
under investigation (trabectedin, mannitol dry) (Nicod, 2016a).  The scoping process to 
identify the appropriate comparator differs across countries, where it takes place before 
the appraisal process at NICE and during the appraisal process for the others.  Subtle 
differences were seen across countries in the selection criteria of the appropriate 
comparator (Table 10-2), where the judgment about its appropriateness usually relies 
on clinical expertise and local clinical guidance.  For NICE and TLV, one of the most 
frequent issues encountered relate to the comparator, whereas this is more seldom seen 
for SMC and HAS.  This contrast was not reflected in the systematic comparison, 
where the lack of comparative data was an issue in five cases with varying levels of 
concern and approaches in their dealings.  For example, the lack of comparative data 
with another treatment for romiplostim, which relied on standard care, was either 
acceptable due to the rare and heterogeneous nature of the disease (NICE) and the 
numerous (unlicensed) treatments used in practice (SMC), or not, due to missing 
transposability into clinical practice (HAS).  A similar scenario was encountered for 
trabectedin.  These illustrate common scenarios encountered for rare diseases (e.g. no 
comparator, unlicensed options, unknown clinical pathway, no comparative data, 
unknown optimal dosage), where the validation of the appropriate comparator may be 
more challenging due to fewer experts with sufficient knowledge in these disease 
areas, as highlighted by SMC.   
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Treatment outcomes 
 
The relevant clinical endpoint used to assess a treatment’s clinical benefit varies 
depending on the agencies, circumstances, and economic models used (Table 10-2).  
NICE only accepts the QALY, whereas it is required by SMC and TLV when cost-
utility models are appropriate.  If non-inferiority between two treatments is 
demonstrated, then cost-minimisation models are preferred (SMC, TLV).  For HAS, 
the choice depends on the situation of the disease (e.g. short term consequences) and 
aim of the drug (e.g. symptoms for a symptomatic treatment).  
 
Orphan drugs often rely on surrogate endpoints (Joppi, Bertele', & Garattini, 2013), as 
illustrated in 8 of the 10 study drugs analysed that were predominantly validated 
except for two cases (Nicod, 2016a).  Surrogate endpoints are defined as “biomarkers 
intended to substitute a clinical endpoint”(Biomarkers Definitions Working Group, 
2001), which is the definitive or clinically meaningful endpoint to the patient, such as 
overall survival.  The acceptability of surrogate endpoints by the interviewees 
depended on their validation, against a hard or soft endpoint, with the exception of 
HAS for the latter.  A non-validated endpoint would probably not be accounted for by 
NICE, whereas it may be acceptable under certain circumstances for the others (Table 
10-2).  Greater acceptance of surrogate endpoints for orphan drugs would not be 
accepted NICE or TLV, and accepted if no other option is available (HAS) or if the 
drug fulfils the SMC modifiers (e.g. life-extending treatment, life-threatening 
condition), where greater uncertainty including around surrogate endpoints is accepted.   
 
Progression-free survival is one of the most commonly encountered surrogate 
endpoint.  Different levels of acceptability were seen:  NICE always prefers overall 
survival to progression-free survival, even if it is the trial’s secondary endpoint (e.g. 
mifamurtide and imatinib).  Progression-free survival is accepted by SMC when there 
is an established link with life extension or HRQol, or when the main benefits of the 
treatment are improved HRQol rather than life extension.  TLV also prefers overall 
survival, but understands it is often not available and relies on progression-free 
survival considered potentially closer to patients’ needs: at the point of conversion 
between two survival curves, the area between the curves are likely to reflect a benefit 
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to patients.  In HAS’s approach focusing on short-term risks, progression-free survival 
would not replace overall survival in a situation where the patient would die shortly 
unless it were a validated surrogate of overall survival. 
 
The main contrast seen for HRQol data was in its considerations as a hard (NICE, 
TLV, SMC) or soft endpoint (HAS).  Despite the weight of HRQol not being explicit, 
HAS highlighted issues when this data was not provided or no improvement was 
demonstrated (e.g. eltrombopag, everolimus, mannitol dry, trabectedin).  Subtle 
differences were seen in the preferred types and sources of HRQol data (Table 10-2).  
In our study, HRQol data was not commonly reported (50% of cases), nor was it 
reported homogeneously when reported.  Issues relating to HRQol were raised for nine 
out of the ten study drugs and related to the lack of HRQol data (all), the lack of 
HRQol data collected from the pivotal trial (NICE), the lack of improvement in HRQol 
(HAS), or the limitations in the HRQol data presented (SMC, NICE) (Nicod, 2016a).  
These issues influenced the decision either negatively or were dealt with in different 
manners, via other types of HRQol data or through clinical expertise.  Challenges in 
collecting HRQol data may be seen, particularly for the rarer conditions (TLV), but are 
not considered necessarily specific to orphan drugs (SMC). 
 
Safety 
 
Safety is not, per se, part of the assessment for NICE, SMC and TLV given it has 
already been assessed for marketing authorisation.  It is considered if it impacts on 
QALY gains or whether it is adequately captured by utility, survival and cost estimates 
(SMC, NICE).  It is somewhat different for HAS, which assesses safety in the same 
way as efficacy.  There were also situations where agencies agreed that safety can 
modulate the assessment of efficacy (e.g. if efficacy is the same and safety is worse), 
including in the context of the consequence of not giving a treatment (TLV).  In 
practice, this would translate into ensuring that comparative safety data is available 
between the treatments being compared or whether one alternative shows greater 
events than the other, and whether this produces extra costs.  As seen in our examples, 
the safety issues highlighted related to specific risks (e.g. hearing loss) in six cases 
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(NICE, HAS) or to the uncertain nature of the evidence (e.g. lack of long-term or 
comparative safety data) in five cases (NICE, SMC and HAS) (Nicod, 2016a).   
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Table 10-2. Summary of interview findings about clinical evidence and uncertainty, including illustrative quotations 
      NICE SMC TLV HAS Illustrative quotations/comments 
Tr
ia
l d
es
ig
n 
Requirements 
None      No formal requirements 
All available evidence        HAS: "HAS requires all the clinical trial data available at the time of the assessment" 
Pr
ef
er
en
ce
s 
Best or highest available 
evidence       
HAS: "HAS has a preference for demonstrative data, which means data that 
are the highest level of evidence (e.g. phase III comparative well-designed 
and conducted trial)" 
Phase III comparative trials       
NICE: "The Committee feels more comfortable about making decisions on 
clinical effectiveness based on phase III trials, but it is very rare to actually 
have phase III trials with the correct comparator" 
Requirements similar for all 
drugs       SMC: "each case is viewed upon its own merits" 
Higher methodological 
requirements for 
superior/higher efficacy claim  
  
    
TLV: "If their price is really low (and clinical claim is non-inferiority), than 
any uncertainty is ok as long as patients don’t die (which has already been 
checked by the EMA)" 
HAS: a higher claim should demonstrate in a good way the effect of the 
treatment - "ASMR I is granted for drugs that have a demonstrated in a good 
way a substantial effect on survival"… The ASMR IV is for a demonstration 
that is not so perfect and with a quantity of effect which exists but is not very 
important" 
Lower methodological 
requirements when the 
consequence of the decision is 
severe 
  
      TLV: "Greater uncertainty accepted if the consequence of the decision is severe" 
Quality of the evidence is 
assessed according to the 
situation of the disease 
(prevalence and number of 
recruitable patients)  
     
HAS: "accounts for the real situation of the disease, considering the 
prevalence and number of patients that are recruitable in trials, as often seen 
for orphan drugs" 
 
co nt
r
ol
s, 
ac
c
ep
t
ab
i   When no other data available        NICE: "Historical controls are rarely seen mainly in cases when no other data 
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is available" 
When it is the best evidence 
available         
When no other treatments are 
available and to obtain data 
on disease progression 
       
HAS: "HAS is very much in favour for prospective appropriate data 
collection on natural history of a disease that can serve as a comparison when 
another comparison is not possible" 
When the disease is rare or 
other special circumstances 
are seen  
   
SMC: "the acceptability of registry data by the Committee would depend on 
many factors already discussed (e.g. rarity, etc.)…" 
R
eg
is
try
 d
at
a,
  
us
e 
Historical controls       
Natural progression of the 
disease (e.g. to obtain long-
term data) 
      NICE: "lifelong modelling of the disease and therefore need long term data about disease progression, which will never come from any trial" 
Treatment efficacy and safety        
HAS: "at the first assessment for reimbursement, in general only short term 
data is available and orphan disease are in majority chronic diseases so they 
also rely on registries to have longer term data on efficacy first, and safety 
second" 
Tr
ia
l l
en
gt
h 
A
cc
ep
ta
bi
lit
y 
cr
ite
ria
 
Natural progression of the 
disease  
  
   
NICE: "the Committee always welcomes data on natural history of the 
disease to validate any extrapolation curves." 
HAS: " If the duration is too short compared to the natural course of the 
disease then it will be criticised" 
Likely durability of treatment 
response     
NICE: "The Committee always welcomes data on the parameter, or seeks 
sensitivity analyses with different assumptions if no data is available."SMC: 
"… the likely durability of treatment response (may be informed by other 
sources)"HAS: “…sufficiently long to generate solid evidence about the type 
of benefit to the patient”TLV: "The trial length needs to cover the time spam 
up to the point where we can see that both treatments converge" 
Corresponds to the EMA 
assessment      
TLV: “This is done by the EMA and TLV trusts that the right 
recommendations were given.” 
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SPC advice for treatment 
duration      
NICE: "NICE would be bound by the treatment duration specified in the SPC, 
unless a stopping rule is proposed by the company and supported by the 
clinical community." 
SMC: " It will relate to consideration of factors such as the duration of the 
trial relative to what the SPC advises in terms of treatment duration" 
Greater flexibility accepted 
for orphan drugs     
NICE: "we do not differentiate orphan drugs" 
SMC: "Trial duration isn’t something that is specifically teased out as an 
issue but may be something that is noted as a general weakness of the 
evidence base (particularly if very short in relation to a very long term 
economic model). To the extent that we offer greater flexibility in dealing 
with the general limitations with orphan drugs, issues with limitations in trial 
duration would be afforded similar flexibility." 
TLV: "greater uncertainty regarding the clinical effect is accepted" 
St
ud
y 
po
pu
la
tio
n 
Su
bg
ro
up
 d
at
a,
 a
cc
ep
ta
bi
lit
y 
cr
ite
ria
 
Pre-specified     
HAS: "The Transparency Committee will not be confident in the results if the 
subgroup was posthoc, and have a clear preference for pre-planned or pre-
specified subgroups"…"has to be pre-specified in the protocol of the trial" 
Posthoc       
NICE: "sometimes the population in the licence is from a posthoc group, in 
which case NICE needs to consider it. Otherwise, these are very rarely 
included, only if there is a strong biological plausibility of a strong cost-
effectiveness argument for including it." 
TLV: "Subgroups must have been pre specified before using them, it is an 
absolute rule" 
SMC: "consideration would be given to whether the subgroup was pre-
specified or post-hoc and also the relative size of the subgroup and the 
potential significance of any results." 
Relative size of the 
subgroup       
NICE: "ideally, small subgroups are not considered, but that depends on what 
population the licence covers." 
If it is the only available 
evidence for a very severe 
rare condition, non-
specified data could be 
acceptable 
        
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Significance of results 
(credibility, relevance, and 
practicalities) 
      
NICE: "often not possible with subgroups" 
SMC: "From a clinical point of view, important considerations are whether 
the subgroup has clinical credibility, relevance, and practicality (where it can 
be easily identified as a group of patients in Scottish practice)" 
If the subgroup is driving 
the clinical trial results, the 
indication should be 
restricted to this group 
     
NICE: ".... the drug needs to be cost-effective in the subgroup and not in the 
overall group. Only then is recommending the drug for a subgroup only 
appropriate."SMC: "This may particularly be the case for a medicine that 
looks to have poorer cost-effectiveness for the whole group as we may try to 
find ways that can maximise the chance of  the medicine being accepted at 
least for some patients. "TLV: "if the whole study is driven by a subgroup, 
then very important to treat this subgroup and to exclude the study as a whole 
because of evidence demands could be very counter-productive." 
Limited to the marketing 
authorisation and trial 
indication 
         
C
om
pa
ra
to
r 
Sc
op
in
g 
pr
oc
es
s 
By HTA agencies before the 
HTA process (literature 
review, expert opinion) 
         
Based on MAH's submission 
during the HTA process 
(clinical experts queried about 
choice of comparator) 
     
SMC: "Within the critical appraisal process, SMC will go to a bank of 
clinical experts with a set of generic questions about the medicine, which tend 
to elicit responses about comparators, treatments used in current practice, 
what would be displaced with the new treatment, etc." 
TLV: "Experts are the most important source of information. As well as 
guidelines from the Swedish Medical Products Agency about the treatment 
recommendations for different conditions. The choice of comparator needs to 
be very specific to Swedish circumstances. Therefore literature reviews does 
not play." 
Se
le
ct
io
n Existing treatment/standard of 
care to be replaced/routine 
practice 
     
NICE Guide to Methods of Technology Appraisal 
TLV: "Criteria for relevant comparator: most cost-effective, treatment most 
likely to be replaced (e.g. if the patient doesn’t get this new drug, what it 
he/she getting instead)" 
SMC: SMC Guidance to Manufacturers for Completion of New Product 
Assessment Form 
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Therapeutic technology used 
at the same stage of the 
therapeutic strategy    
 HAS: "therapeutic technologies that you can use at the same stage of the therapeutic strategy" 
Most cost-effective          
Tr
ea
tm
en
t o
ut
co
m
es
 
R
el
ev
an
t c
lin
ic
al
 e
nd
po
in
t, 
cr
ite
ria
 
Overall survival, utility, 
QALY     
  NICE only accepts QALYs, and TLV has a clear preference for QALYs 
(except when the clinical claim is non-inferior efficacy) 
TLV: “Take home message: TLV is big on QALYs” 
The endpoint in the MAH 
submission is critically 
appraised (not identified by 
Committee) 
  
   
  
SMC: "SMC does not identify the endpoint. The company presents the 
endpoint and SMC judges whether it is appropriate or not. This would take 
place as part of the deliberative process"…  
Unmet need based on expert 
opinion  
  
   
  SMC: “It depends on a range of things such as what was presented in the 
dossier by the manufacturer, need and unmet need fed from experts.” 
Endpoint used for the 
economic model (e.g. survival 
+ quality of life for cost-
utility analysis) 
  
   
  
SMC: "A long-term model would require important information on overall / 
long term survival, which is not always possible other than with extrapolation 
from short term trials." 
Should reflect the aim of the 
treatment 
    
   HAS: "if the treatment is symptomatic, they will consider the symptoms…" 
Should reflect the short term 
consequence of the disease        
HAS: "If the disease is leading patients to die shortly, survival should be 
chosen." 
Su
rr
og
at
e 
en
dp
oi
nt
s, 
ac
ce
pt
ab
ili
ty
 c
rit
er
ia
 Validated for life 
expectancy (=hard 
endpoint) 
    
NICE: "If they are not validated against the outcome of interest (qol or life 
expectancy), they are probably not going to be taken into account" 
HAS: "If surrogate is validated as predictive for the change of a more hard 
endpoint, then it will be accepted" 
Validated for HRQol (=soft 
or subjective endpoint)      
SMC: "acceptability is greater where the committee can see that there is an 
established link between the surrogate outcome measure and the final 
outcome of interest" 
Clinically relevant        TLV: "Surrogate endpoints must be clinically relevant. How do they relate to qol and life expectancy" 
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Certainty of the validation       NICE: "they will look at the certainty or uncertainty of that validation" 
Non-validated      
NICE: " They have to be validated" 
TLV: "If not validated, a surrogate may have to be accepted if it is an 
important new treatment (and depending on the consequences)" 
HAS: "If it is not validated, they would not accept surrogates" 
Surrogates for orphan 
drugs more acceptable     
NICE: "we don't differentiate orphan drugs" 
SMC: "the committee does have more latitude to accept greater uncertainty 
(through the modifier) and this can lead to a greater acceptance of a surrogate 
outcome" 
TLV: "Surrogates are not necessarily more accepted for orphan drugs" 
HAS: "if there is no other possibility, intermediate endpoints are accepted." 
Situation of the disease      
HAS: "HAS adapt their assessment to the situation. If a disease that has 25-30 
patients and the trial has included the same amount of patients in a world-
wide situation, they will accept a non-comparative study, with a surrogate 
endpoint, etc. They will consider whether they have tried to reach the highest 
level of evidence they could." 
O
ve
ra
ll 
an
d 
pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
, r
eq
ui
re
m
en
ts
 a
nd
 
pr
ef
er
en
ce
s 
Preference for OS     TLV: "TLV has a preference for OS, but it is hardly the case that that information is available" 
Even if OS is a secondary 
trial endpoint  
  
    NICE: "It doesn’t matter if it is a primary or secondary endpoint (like utility), NICE will always prefer OS" 
When QALYs depend on 
life extension 
  
     SMC: "OS is preferred where QALY gained depends on life extension" 
When patients may die 
shortly        
HAS: "PFS cannot replace survival in a situation where the patient would die 
shortly" 
Pr
og
re
ss
io
n-
fr
ee
 
su
rv
iv
al
,  
ac
ce
pt
ab
ili
ty
 
cr
ite
ria
 
PFS validated for OS       HAS: "There is some literature showing that in some kinds of cancer, PFS has shown to be a surrogate of OS and in those cases they would be accepted" 
PFS validated for HRQol          
PFS better predictor of 
(validated) HRQol than OS      
  SMC: "For some analyses, PFS is a reasonable outcome to use because it is 
likely that the main benefits of treatment will be in terms of quality of life 
rather than in any degree of life extension" 
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PFS may be a better 
predictor of patients' needs 
(If OS same for two 
alternatives, area between 
the curbs may be a value to 
patients) 
       TLV: " there might be cases when PFS is at least as interesting and as relevant to patients and clinicians as OS" 
H
ea
lth
-r
el
at
ed
 q
ua
lit
y 
of
 li
fe
, r
eq
ui
re
m
en
ts
 
an
d 
pr
ef
er
en
ce
s 
Required in submission        NICE: utility measures are needed for the cost-utility model (NICE requirement) 
Preferred if claim is superior 
efficacy (with a price 
premium), or if a cost-utility 
model used (hard endpoint) 
      
TLV: "We need to have some knowledge of qol. Or need to make an 
assumption. Rare are the cases when it not accounted for (e.g. CEA), apart 
from CMA" 
Preference for generic utility 
measures (e.g. EQ-5D)      
SMC: "SMC has a preference (rather than a requirement) for utility estimates 
from a validated generic utility instrument such as the EQ 5D" 
Collected within the clinical 
trial      
SMC: "Where utility assessment has taken part within the key clinical 
studies, we would have a preference for the company using this data in their 
economic analysis, unless there was a good reason to expect that the data 
were not appropriate" 
Secondary to assessment (soft 
endpoint)   
  
   HAS: HAS will first look at results on the hard endpoint, and second  will look at HRQol to see how the life is for the patient" 
N
on
-g
en
er
ic
 u
til
ity
 
m
ea
su
re
s, 
ac
ce
pt
ab
ili
ty
 
cr
ite
ria
 
Validated mapping techniques     
SMC: "SMC can accept other sources of utility values, for example, via use 
of validated mapping techniques or use of values from the literature or 
registries" 
TLV: "It is very important to have validated mapping techniques" 
Values from the literature or 
registries        
Values from other diseases 
areas *    *NICE: "only under exceptional circumstances" 
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Values from expert opinion * *   
*NICE: "only under exceptional circumstances" 
SMC: " The use of expert opinion as a source of utility values would likely be 
perceived as the most uncertain source of utility values, but has been used in 
some submissions for some health state valuations" 
TLV: "Expert opinion can be done for the QALY though the delfi panel (but 
not when clinical claim is superior efficacy)...It can be used to estimate 
QALY gains in terms of simplified administration, or parameters that are 
softer." 
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Not assessed per se given it 
has already been done for 
marketing authorisation 
      
Accounted for if it impact on 
QALY/utility gains        
Considered if adequately not 
captured in the utility values         
Assessed in the same way as 
efficacy data        
Life-threatening diseases, 
more likely to accept 
uncertain efficacy if the risk 
of adverse events is low 
     
NICE: "probably" 
TLV: "If the risk of severe adverse events from the treatment is low, and that 
patients can only get better even from taking the treatment, even if we don’t 
know for sure, TLV would allow them to take the chance by paying for this 
drug. This is also considering that EMA had already looked into safety." 
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10.4.2. Additional qualitative criteria considered 
 
In addition to appraising the evidence, additional qualitative criteria were considered 
that relate to treatment innovativeness, disease severity and unmet need (Nicod et al., 
2015b).  This section aimed to further the understanding of these determinants, 
summarised in Table 10-3. 
 
Treatment innovativeness 
 
NICE explicitly accounts for the innovative nature of the treatment and defines 
innovation if it renders a step change for patients rather than belongs to a new class of 
drugs or contains a new mechanism of action.  TLV and SMC do not have specific 
criteria for innovation as it is considered to be captured by gains to patients.  In France, 
the innovative nature would be captured by a higher ASMR rating (ASMR I, II, III) 
and a price set within European levels without price negotiations (CEPS).  If the 
innovativeness is recognised in the opinion issued and the drug is for hospital use, it 
would be covered by a special list on top of the hospital DRGs tariff.  Additionally and 
before the assessment by HAS, if a drug is considered innovative based on three pre-
defined criteria (e.g. new mode of action, good efficacy and correct tolerance, covers 
an unmet need), the MAH can submit a pre-file before the marketing authorisation in 
order to undergo the fast track procedure and submit an application at the same time as 
the EMA application.   
 
Disease severity 
 
A higher ICER (up to £30,000/QALY) is accepted by NICE for the more severe 
conditions, decided during the deliberative process.  Severity is defined by how a 
person’s quality of life is affected without the treatment, rather than how the treatment 
improved survival, which is considered to be captured in the model together with its 
baseline severity.  Generally, most of the cases appraised are terrible or severe. 
Severity is also explicitly accounted for by TLV, where higher severity is considered 
to correspond to a greater unmet medical need and higher ICER levels are accepted.  
No explicit weighing or definition of severity exists (work in progress).  In contrast, 
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severity is not explicitly accounted for, though it may be intrinsically, by the 
Committee members at SMC.  For HAS, severity is captured within the SMR ratings 
and comprises five pre-defined categories: severe, not so severe, affecting quality of 
life, life-threatening, etc.  These categories are not given explicit weights and their 
influence on the assessments has shown to be minimal according to unpublished 
evidence (e.g. severe disease in 50% of sufficient SMR, and severe disease in 50% of 
insufficient SMR).   
 
Unmet need 
 
For SMC, unmet need is assessed for each case by drawing on clinical expertise to 
understand current treatment options and how the new treatment option might fit in 
clinical practice.  ‘No treatment’ would likely have some priority over a situation 
where ‘few treatments’ were available, and unmet need would also be recognised in 
cases where few treatments with intolerable side effects are available.  Unmet need 
would be accounted for as part of the deliberative process through the application of a 
SMC decision modifier (“lack of available treatments of proven efficacy”) and are 
strictly applied when there is no treatment available of proven efficacy in that 
particular indication.  For TLV, unmet need is captured in the severity measure by 
focusing on the consequence of the decision without treatment.  For NICE, unmet need 
would be also captured in a similar manner as severity and the consequence of the 
decision.  It is considered in the context of the drug’s place in the therapeutic strategy 
and the medical/healthcare needs.  A real unmet need would be recognised when no 
treatment options are available.  For HAS, unmet need is considered within the context 
of assessment the place of the treatment in the therapeutic strategy, as part of the 
analysis on identifying the comparators.  This includes a description of how the disease 
is treated, where the new drug would fit, and whether other options at the same stage 
of treatment are available.  If no other options were available, it would be considered a 
great unmet need. 
 
Consistency across decisions  
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For NICE, consistency in accounting these other considerations is not a concern if the 
ICER is below £20,000, which is the case in many therapeutic areas with relatively 
cheap treatments that produce enormous benefits (e.g. cardiovascular).  For cancer 
however, it is more difficult and every case is different, where different Committees 
may apply the end-of-life criteria more or less generously.  SMC agreed that precedent 
can be an important factor for consideration and that manufacturers sometimes argue 
that similar circumstances apply to their medicine in question.  TLV also agree that 
accounting for severity consistently across cases is very complex and should be more 
distinct.  In France, evidence around the use of severity also suggests inconsistencies 
across cases. 
 
10.4.3.  Economic analysis and pricing considerations  
 
Our sample of orphan drugs were characterised with relatively high ICERs, most being 
above £20,000/QALY in England and Scotland, and similarly in Sweden.  This was 
mainly due not only to the high prices (considering all models were cost-utility except 
for the one appraised by TLV for eltrombopag), but also the uncertain evidence 
presented (Nicod, 2016a).  Each country has its own mechanisms allowing to modulate 
these ICERs to a more acceptable level, such as: Patient Access Schemes, lower 
discounting rates when treatment effects prolonged over a long period of time, 
additional considerations, stakeholder input (confirming the plausibility of an uncertain 
assumption).  These countries also elicited certain circumstances where greater 
uncertainty or higher ICERs are accepted.  These include the SMC disease modifiers 
for orphan drugs, disease severity in Sweden, or end-of-life considerations at NICE.  
Their application has helped to improve ICERs but nevertheless, important differences 
remain in the HTA recommendations issued across countries, explained by some of the 
trivial differences discussed in this paper. 
 
The situation is somewhat different in France, where the ASMR rating drives the 
pricing and the SMR the coverage decision.  Prices of drugs with an ASMR I-III are 
set according to European price levels and negotiated with the Pricing Committee 
(CEPS), whereas those with a lower ASMR should be lower than their comparators.  
The SMR also provides information about the coverage rate (15%, 35%, 65%), where 
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the difference (depending on the rate) is often covered by private health insurances.  
Additional consideration should be made as to whether the drug is under temporary 
authorisation (ATU), as seen for all of the study drugs with the exception of 
mifamurtide and mannitol dry, or if it is a hospital drug, in such case it may also be 
covered on top of hospital DRGs.  The lack of comparative data and uncertain nature 
of the evidence presented drove the low ASMR ratings (V) in three cases (mannitol 
dry, ofatumumab, trabectedin), and a rejection for mifamurtide.  This contrast 
compared to the other agencies is very important   to highlight, as the lack of 
comparative data was acceptable in certain cases, also thanks to the different 
mechanisms in place allowing to modulate and interpret (e.g. sensitivity analysis) the 
ICER.  The ATU may also be an important consideration as the two drugs (mannitol 
dry and mifamurtide) that did not have an ATU received the lowest SMR ratings, 
which has a significant impact on the level of coverage. 
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Table 10-3. Information provided about innovation, unmet need and severity 
  Innovation Unmet need Severity 
NICE Elicited = defined by 
whether the treatment 
benefits patients, 
determined during the 
deliberative process  
 
E.g. delaying 
chemotherapy, first oral 
treatment replacing 
intravenous 
administration. Counter-
examples: new class of 
drugs, new mechanism of 
action (without visible 
benefits to patients) 
Non-elicited = defined by the 
consequence of the decision, 
determined during the 
deliberative process where 
NICE is willing to accept a 
higher ICER (up to 
£30K/QALY) for the 
conditions with a high unmet 
need 
 
E.g. effect on quality of life of 
patients without treatment 
Non-elicited = defined 
by the consequence of 
the decision, 
determined as part of 
the deliberative 
process where NICE is 
willing to accept a 
higher ICER (up to 
£30K/QALY) for the 
more severe diseases 
 
E.g. effect on quality 
of life of patients 
without treatment 
SMC Non-elicited = intrinsic 
to the decision, likely 
captured differently.  
Anything providing 
benefits to patient, 
captured by the ICER or 
accounted for during the 
deliberative process 
 
E.g. a first in class could 
fulfil an unmet need, new 
mode of action or 
administration benefits, 
advantages in terms of 
service delivery, reduced 
severe adverse events, 
step-change in patient 
management 
Elicited (for orphan drugs 
through the modifiers) = "lack 
of available treatments of 
proven efficacy", determined 
as part of the deliberative 
process and from clinical 
experts 
 
E.g. "No treatment" would be 
prioritised over "few 
treatments". If there were "few 
treatments" with intolerable 
side effects, it would be 
considered an unmet need 
Non-elicited = no 
definition, may be 
accounted for 
intrinsically  during the 
deliberative process 
TLV Non-elicited = benefits to 
patients, captured by the 
ICER or as part of the 
deliberative process 
 
E.g. improved 
administration form 
benefits patients and 
reduced costs 
Elicited = defined by the consequence of the decision, 
determined as part of the deliberative process 
Disease severity and unmet need are considered to be 
related: the greater the severity, the greater the unmet 
need 
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HAS Elicited (captured within 
the ASMR) = a drug with 
an ASMR I, II or III 
would be considered as 
innovative. Prices would 
be set at European levels 
and would not be 
negotiated with the 
economic committee 
(CEPS). 
 
Elicited (captured within the 
SMR) = place in the 
therapeutic strategy: if no 
other options at the same stage 
of the disease, based on the 
analysis of comparators and 
the description of therapeutic 
strategy (how the disease is 
treated, where the drug would 
fit and what are the current 
existing alternatives). 
 
E.g. a real unmet medical need 
would be recognised when 
there are no other treatment 
options.  
Elicited (captured 
within the SMR) = 
Different categories of 
severity defined: 
severe, life-
threatening, short life 
expectancy, affects 
quality of life, not so 
severe.  
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10.5. Discussion 
 
10.5.1. Differences in the HTA process and application of HTA, implications for 
orphan drugs 
 
The HTA approach adopted, in terms of clinical benefit and cost-effectiveness, the 
subtle differences in the acceptability criteria of evidence and uncertainty outlined in 
the results, and the willingness to accept greater uncertainty in specific circumstances 
relating to rare diseases may have implications on the assessments.  These are 
discussed here, together with their implications when valuing orphan drugs.   
 
Despite the known limitations in generating robust evidence for orphan drugs (Vickers, 
2013), formal evidentiary requirements are similar for orphan and non-orphan drugs, 
with the exception of HAS that accounts for prevalence when examining the evidence.  
Higher evidentiary requirements are also seen for superior efficacy by TLV and high 
ASMR ratings by HAS.  This has implications for orphan drugs often characterised by 
a lack of treatment options (Kesselheim et al., 2011), whereby a new treatment would 
likely be a superior one.  Demonstrating survival benefits or the more clinically 
relevant benefits to patients usually require well-designed phase II trials or phase III 
trials (Korn, Freidlin, Abrams, & Halabi, 2012; Wieand, 2005), and treatment effects 
should be greater in smaller trials to attain statistical significance (Boudes, 2013).  
Innovative trial designs exist to deal with small patient trial populations (Gagne et al., 
2014), and  could be complemented with historical data from registries (Boudes, 
2013).  As shown in our study, the use of innovative trial designs and registry data is 
still limited, likely because their quality is often poor.  In line with the feedback 
received during the interviews, registries are often difficult to analyse and time 
consuming as it should capture what is historically known about the effectiveness of a 
product (Haffner, 1998).  Their usefulness, particularly for rarer conditions, is 
recognised in collecting information about the patient experience and natural history of 
the disease.  Collecting this evidence over time has shown to improve its quality and 
reliability (when collected from patients, particularly if they understand the added-
value of collecting this data) (Howie, Hirsch, Locklear, & Abernethy, 2014).  
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Evidentiary requirements for cost-effectiveness (NICE, SMC, TLV) differ from 
clinical benefit assessments (HAS).  In the former, the estimate of clinical benefit is 
tailored to fit the economic model to represent clinical practice in terms of the 
magnitude of effect (e.g. life extension and/or HRQol) over a period of time (e.g. life-
long), resulting in a single quantified measure (ICER).  Assumptions are required 
about these determinants.  In the latter scenario, clinical benefit is considered the hard 
endpoint, and quality of life and other qualitative criteria are accounted for as soft 
endpoints during the deliberative process.  The approach used had a number of 
implications, some of which are discussed in this section.  One important consideration 
is in the tools made available to deal with uncertainty when conducting an economic 
evaluation, where sensitivity analysis may help assess whether uncertain evidence is 
acceptable or not.  This is true for any parameter tested within the economic model, 
and may be more relevant for orphan drugs given their greater uncertainty.   
 
A distinction was seen in assessing the appropriate trial length, which is particularly 
relevant in the context of orphan drugs given they are often characterised by shorter 
clinical testing phases compared to nonorphan drugs (Kesselheim et al., 2011).  This 
may relate to challenges in defining the appropriate trial length particularly when the 
natural history of the disease is unknown (Vickers, 2013) or when the disease is 
chronic or has an early age of onset; as reflected in our findings.  The criteria in 
assessing the appropriate trial length were similar across countries and related to the 
natural course of the disease and likely duration of the treatment.  Further, TLV relies 
on the judgment made by marketing authorisation authorities.  Nevertheless, pivotal 
trials may not be sufficiently long to capture the benefits of a drug in clinical practice, 
particularly for life-long conditions (as shown for mannitol dry).  A further 
consideration relates to the temporary authorisation (ATU) applicable in France for 
severe or rare conditions, which may also contribute to a greater acceptance of 
uncertainty.  This could be illustrated by mannitol dry, which was not under an ATU at 
the time of the assessment, and for which one of the main issues highlighted by HAS 
was the uncertainty around its long term benefits (in addition to other issues).   
 
Another contrast was seen in the consideration of subgroup data, whether within or 
outside of an economic model.  There was agreement that if a particular subgroup 
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drives the cost-effectiveness results, the indication should be restricted to this 
subgroup.  Nevertheless, differences were seen in practice, where some impose 
restrictions and others future re-assessments, as was the case for romiplostim with 
NICE and SMC versus TLV respectively.  In contrast, this treatment received top 
ratings by HAS (important SMR, and ASMR II).  In addition to the preferences seen 
for pre-specified subgroups, it should also be the same as for marketing authorization 
or included in the trial for HAS.  Subgroup analyses in trials are included to identify 
whether certain patient groups are more likely to benefit from treatment, and are 
usually defined by their characteristics, such as age, sex, stage of disease, genomics 
characterized by biomarkers, etc.  Despite the increasing body of research around 
predictive biomarkers, very few of these are included in the licensing indication and 
likely do not reflect their use in practice (Malottki, Biswas, Deeks, Riley, Craddock, 
Johnson, & Billingham, 2014).  Therefore, the marketing authorization indication may 
not necessarily reflect clinical practice.  A review of 894 RCTs showed that half of 
these reported subgroup analyses, of which 46% were planned in the trial protocols 
and 10% of those matched those reported in the publication (Kasenda, Schandelmaier, 
Sun, von Elm, You, Blumle, Tomonaga, Saccilotto, Amstutz, Bengough, Meerpohl, 
Stegert, Olu, Tikkinen, Neumann, Carrasco-Labra, Faulhaber, Mulla, Mertz, Akl, 
Bassler, Busse, Ferreira-Gonzalez, Lamontagne, Nordmann, Gloy, Raatz, Moja, 
Rosenthal, Ebrahim, Vandvik, Johnston, Walter, Burnand, Schwenkglenks, Hemkens, 
Bucher, Guyatt, & Briel, 2014).  Another study showed that when the primary 
endpoint was not statistically significant across the whole patient population, subgroup 
analyses were most likely to be reported, particularly for industry-sponsored trials 
(Sun, Briel, Busse, You, Akl, Mejza, Bala, Bassler, Mertz, Diaz-Granados, Vandvik, 
Malaga, Srinathan, Dahm, Johnston, Alonso-Coello, Hassouneh, Truong, Dattani, 
Walter, Heels-Ansdell, Bhatnagar, Altman, & Guyatt, 2011).  Subgroup data is 
therefore to be assessed with caution, particularly given that this evidence is likely to 
be even more uncertain (with greater confidence intervals) when the trial population is 
small, as is commonly the case for orphan indications.  In such cases, considerations 
should be given as to whether the trial subgroup was pre-specified and matched what 
was planned in the trial protocol, and if discrepancies were to be seen, to impose a 
post-marketing follow-up to collect additional longer-term evidence and assess the 
effect of the treatment on a hard endpoint within clinical practice.   
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Issues relating to the quality or availability of comparative evidence is more common 
for orphan drugs, as they are more likely to rely on single arm and non-randomised 
studies (Kesselheim et al., 2011).  This was illustrated for three cases: mannitol dry, 
trabectedin, which compared different doses of treatment, and ofatumumab (phase II 
non-comparative trial).  This was translated into an ASMR V rating in France, given 
that it was not possible to assess the effect of the treatment compared to usual care.  In 
contrast, more flexibility was granted by NICE and SMC because of the 
investigational nature and rarity of the treatment, and existing unlicensed alternatives 
(trabectedin).  Such contrasts also illustrate consequences from misalignments between 
marketing authorisation and HTA processes.  In our sample, the comparators were a 
consequence of the early marketing authorisation granted for ofatumumab and 
trabectedin, and the early scientific advice for mannitol dry (Bilton, Robinson, Cooper, 
Gallagher, Kolbe, Fox, Jaques, Charlton, & Investigators, 2011).   
 
Surrogate endpoints are more common for orphan drugs compared to nonorphan drugs 
(Joppi et al., 2013; Kesselheim et al., 2011), further confirmed in our study (80% of 
drugs).  Additionally, different levels of acceptability of progression-free survival was 
seen, which may explain differences in the assessments in two cases (e.g. mifamurtide, 
imatinib).  There were subtle differences in the endpoints to use for the validation 
(hard versus soft endpoint), which may have implications for orphan drugs given also 
their often questionable clinical relevance (e.g. 6-minute walk or platelet response) 
(Joppi et al., 2009) or difficulties in establishing their validation (Boudes, 2013).  
Evidence suggests that surrogate endpoints tend to overestimate treatment effects, 
which can be minimized by quantifying their magnitude and certainty through their 
validation with the relevant patient outcomes (Ciani, Buyse, Garside, Pavey, Stein, 
Sterne, & Taylor, 2013).  As with subgroup data, ongoing data collection through 
registries or other sources may render these uncertain outcomes more acceptable 
pending longer-term data about the clinical endpoint (e.g. overall survival).   
 
A last significant contrast in the acceptability criteria for evidence was seen in the 
consideration of HRQol data as hard (captured in the economic models) or soft 
endpoint (HAS).  In the last case, it may be the case that a lack of improvement in 
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quality of life data may have greater implications than if captured in an economic 
model, as seen for everolimus and mannitol dry.  Further, for cost-utility modelling, 
generic utility data is generally preferred, despite not always being the most 
appropriate way to capture quality of life (Tordrup, Mossman, & Kanavos, 2014).  
This may have implications for rare diseases given they are often chronic, severe and 
disabling diseases, affecting quality of life and beyond, such as aspects of hopelessness 
linked to illness chronicity, or the search for normalcy in being part of a community 
and gaining social recognition (Caputo, 2014).   
 
In addition to the different preferences and levels of acceptability of uncertain 
evidence, qualitative criteria are also accounted for in these processes.  The most 
frequently identified being innovation, unmet need and severity, which have played an 
important role in modulating the decisions in accepting greater uncertainty or ICERs.  
Trivial differences were seen in the way these concepts are captured or defined.  
Despite common agreement about the definition of innovation (treatment benefits to 
patients), differences were seen in the way it is being accounted for: explicitly by 
NICE and HAS (through the ASMR), and captured within the ICER (or implicitly as a 
value judgment of the Committee members) by SMC and TLV.  Examples of cases 
when innovation was highlighted in the decisions include the oral administration 
benefit of eltrombopag highlighted by SMC and TLV, or the new principle of 
treatment of romiplostim highlighted by NICE and TLV.  Contrast was also seen in the 
definition of unmet need, defined in two different manners: by the consequence of the 
decision (NICE and TLV) or by the lack of available treatment options (SMC and 
HAS).  The first closely relates to the severity of the disease and how patients would 
be affected without the treatment, whereas the second accounts for alternative 
treatments (e.g. a new treatment with better adverse effects would cover an unmet 
need) without differentiating the degree of severity.  While severity is captured with 
unmet need for NICE and TLV, it has little or no weight for SMC and HAS given it is 
not explicitly accounted for by SMC and although categorized by HAS, unpublished 
evidence suggests that it does not have any influence on the assessment.  However, it 
may be reflected through the temporary authorisation (ATU) scheme, where greater 
uncertainty may be accepted for these drugs due to the ongoing collection of data 
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about efficacy or safety.  This contrast is suggested in our sample but no evidence 
exists to support this statement.  
 
This furthers the discussion about defining the social values which need preference 
elicitation, and how accountability for reasonableness and consistency in their use can 
be improved.  For innovation, this would pertain to those aspects of innovation not 
captured by the ICER or ASMR, which could include aspects around managing and 
living with a disease, and their importance for patients.  The main question around 
unmet need relates to whether it should capture severity and prioritise the most severe 
conditions or whether it is a way to ensure that patients have treatment options at each 
stage of the disease.  Prioritising the most severe conditions would put less weight on 
certain “less severe” or non-life-threatening problems from living with the disease or 
taking the treatment (e.g. pain, adverse effects, reduced mobility).   
 
10.5.2. Study limitations 
 
The structure of the qualitative research review guidelines (RATS) were followed in 
order to ensure the quality and clear dissemination of the research (Clarke, 2003).  
Despite this, the study is not without its limitations.  First, the interview questions were 
derived from the analysis of ten orphan drugs.  While this sample may be considered 
limited and not representative of all issues surrounding orphan drugs, a number of 
scenarios nevertheless repeated themselves suggesting that many common issues have 
been covered.  Additionally, the topics covered dealt with all different levels of 
evidence (primary, non-primary, outcomes, etc.) and a number of additional 
considerations, and on this basis, we assumed that the analysis was sufficiently 
comprehensive.  However, the sample did not include ultra-orphan drugs and the 
issues highlighted may in reality be even more uncertain than those analysed.  The 
main advantage of focusing the interview questions around scenarios that were 
encountered is that we were then able to compare the responses with how this was 
enforced in practice.  Second, different levels of detail may have been captured during 
the interviews due to their varying durations.  A second round of questions together 
with the tables summarising the interpretation of their interviews, were sent to the 
interviewees to ensure the comparability and reliability of the research.  Third, the 
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differentiation between how these findings apply to orphan and nonorphan drugs may 
at times appear unclear.  This was because orphan and nonorphan drugs undergo the 
same process.  We were nevertheless able to highlight some of the issues specific to 
orphan drugs and focus on these, and explore whether some aspects of the process 
could be differentiated for orphan drugs in order to overcome some of the specific 
limitations encountered in appraising these.  Finally, the interviewees in each agency 
were interviewed together.  This allowed to foster discussion amongst the respondents 
and capture richer discussions.  However, this approach did not allow to capture 
potential contrasting opinions across interviewees in one same agency, particularly 
considering that they were given the opportunity to prepare their answers in advance. 
 
10.6. Conclusions and Policy Implications 
 
HTA bodies agreed that decisions regarding orphan drugs are made in a context of 
greater uncertainty, as illustrated throughout the paper.  Despite the broadly similar 
agreement seen in the evidentiary requirements or preferences, subtle differences were 
identified with respect to the circumstances under which uncertain evidence may be 
considered acceptable.  These relate to differences in the expectations around the 
quality of the evidence dependent on the clinical claim, in the recognition of usefulness 
and acceptability of registry data (e.g. historical controls), in their criteria for 
acceptability of uncertain trial duration, subgroup data, comparative data, surrogate 
outcomes, HRQol data, or safety data, and the extent to which more flexibility is 
granted to uncertainty because of the rare nature of these conditions.  These, together 
with the varying approaches used for HTA (e.g. clinical benefit versus cost-
effectiveness) and the special considerations given to orphan drugs, may modulate the 
interpretation of the outcomes of HTA and explain differences in the HTA 
recommendations made across countries.  The former relate to the ability to implement 
patient access schemes, the NICE end-of-life criteria, disease severity at TLV, and 
implementing lower discounting rates when the benefits are sustained in the long run, 
or the way qualitative criteria are accounted for and weigh on the decisions.  The latter 
ones specific to orphan drugs relate to the SMC modifiers, and possibly also those 
orphan drugs that are made available through the temporary authorization scheme 
(ATU) in France, where the continuous collection of data may contribute towards a 
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greater acceptance of uncertainty.  These three categories of modulating factors may 
contribute towards accepting greater uncertainty or higher ICERs that what would 
normally be permitted, and explain the significant differences in the HTA 
recommendations made across the four countries.   
 
Better understanding these modulating factors is essential to improve HTA and decide 
whether these processes should be differentiated in particular circumstances and how.  
For example, continuous data collection and re-assessment is even more relevant for 
rare conditions given the substantial uncertainty characterizing their assessments at the 
time of HTA – as illustrated in this study (e.g. trial length, surrogate outcomes, 
subgroups).  Policy-makers should ensure that the correct incentives are implemented 
to collect this data at early stages of the drug development process.  The limitations 
around RCTs, in collecting comparative data and implications on the decisions were 
also highlighted in this study, which only reinforces the need to ensure that what is 
being measured for HTA is responsive to patient needs, preferences and values, 
through continuous involvement of patients throughout the whole drug development 
process.  Their input could help determine, for example, whether overall survival or 
progression-free survival respond better to patient needs in a particular disease setting.  
The fact that rare diseases often affect children may highlight the need to consider in a 
more explicit manner the circumstances when lower discount rates should be 
implemented to reflect the long term effects of treatments, based on existing evidence 
around their appropriate use (Severens, 2004).  This study contributed to showing the 
reasons why current systems, and the HTA methodological approaches being used, are 
not sufficiently suitable to tackle the issues that relate to rarity, as highlighted not only 
be the magnitude of and conflicting differences in the HTA recommendations made, 
but also be the contrasts seen in the various ways of dealing with these issues emerging 
from the rare nature of the diseases they treat.  This is all the more important in a 
changing pharmaceutical environment that is shifting towards more niche and targeted 
therapies ("the right patient with the right drug at the right dose at the right time"), 
where such issues will soon become a daily reality.   
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11. Conclusions 
 
11.1. The Contribution of this Thesis 
 
This section outlines the main contributions of this thesis grouped into three 
categories: methodological and empirical contributions, and how findings fit with 
existing research, which are discussed here.  
 
11.1.1. Methodological contribution 
 
This thesis used a mixed methods research design to address a specific empirical 
research question.  This type of study has never been done before in the area of HTA.  
It shows the inter-disciplinary potential of applying mixed methods research designs to 
novel areas in social sciences.   Specifically, an instrument-based model in the form of 
a methodological framework was developed and piloted (Chapter 7), which allowed 
for an enhanced understanding of complex decision processes in different HTA 
settings.  This was done using a sequential exploratory mixed methods design, which 
captured both the depth and breadth of these decisions.  It provided a structured 
understanding of the decision-making process, by breaking it down into three distinct 
steps, each comprising a specific type of criteria (evidence, its interpretation, and 
influence on the final decision).  This structured categorisation is also what allowed to 
conduct cross-country comparisons of the criteria that were accounted for in each 
setting (commonalities and differences across countries).  Each step undertaken to set 
up and test this framework was outlined in detail to ensure its transparency and also 
transferability to third parties, by means of a coding manual and case study template 
(Figure 7-3 and Appendix B). 
 
The novelty of this research is twofold: (1) its innovative design through the 
integration of both a vertical and horizontal component; and (2) the applicability of the 
methodological framework to other HTA settings and disease areas given its iterative 
and flexible nature.  The vertical component comprises coding each individual drug in 
a systematic, homogeneous and comprehensive manner (based on the existing and 
flexible coding manual) in order to quantitatively devise (through correspondence 
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analysis) agency-specific preferences in the type of evidence, concerns (e.g. risk 
preferences), and “other considerations” (e.g. value preferences) identified.  The 
horizontal component of applying the framework enables to capture how HTA 
processes compare across countries, whether the criteria had a positive or negative 
influence on the decision, where the criteria put forward came from (e.g. stakeholder 
input), and whether the criteria were one of the main reasons for the final 
recommendation.   
 
Therefore, the main methodological contribution of this research is the methodological 
framework developed, piloted and tested, which allows to systematically compare 
HTA decision processes across settings and drugs.  Through its application, it is 
possible to identify a more comprehensive range of criteria accounted for during the 
decision processes in a structured manner, including those that go beyond standard 
measures used for HTA (e.g. ICER).  It also allows for a comparison across countries 
of these criteria identified as influencing these processes.  
 
11.1.2. Empirical contributions  
 
Four main empirical contributions resulted from this thesis in addressing its 
overarching objective to understand why there are differences in HTA 
recommendations across countries for a same drug and indication, and whether there is 
consistency with countries, focusing on orphan drugs.  The empirical contributions 
follow the same structure as the sub-research questions addressed in this thesis and 
repeated again in the boxes below. 
 
Findings from this thesis first contributed to understanding the commonalities and 
differences in the HTA recommendations made across countries, and also across 
therapy areas.  
 
Question 1 
What are the commonalities and differences in HTA recommendations made 
across five countries and three therapy areas? On this basis, are these differences 
meaningful? 
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Variations in HTA recommendations across countries were already recognised at the 
time this thesis commenced.  These may be a consequence of context-specific 
considerations, such as WTP thresholds, available budgets, context-specific costs or 
national priorities.   A number of studies explored this matter, however, the extent of 
and reasons for differences were not thoroughly scrutinized.  This thesis further 
demonstrated the magnitude of these differences across a larger sample of 287 drug-
indication pairs and five countries, where as much as 46% of the 122 compounds 
appraised by at least two agencies received diverging recommendations across 
countries.  The extent of these differences suggests that other reasons may cause this 
divergence, such as differences in the methods adopted or in the interpretation of the 
same evidence.   
 
When comparing the acceptance rates across therapy areas, the assumption was made 
that the same trends would be observed across countries for the same drugs.  For 
example, if the cancer drugs included in the sample had a greater acceptance rate in 
one country compared to the other therapy areas, the same trend would be assumed in 
the other countries.  This was not seen in practice, where different countries were more 
likely to accept certain therapy areas compared to others, suggesting that expectations 
in terms of relative effectiveness differ depending on the drug and disease 
characteristics despite agency-specific guidelines being generally homogeneous for all 
drugs (Chapter 6).  Therefore, the first empirical contribution of this thesis was to 
demonstrate that these differences are meaningful because of their magnitude and the 
contradictory trends observed across countries, and that there is a need to query why 
they occur.  
 
This is all the more important in the current European and international context, where 
various initiatives aim to foster greater cooperation and incentivise cross-country 
learning and sharing of expertise.  This includes the EUnetHTA at European-level that 
aims to enhance HTA cooperation across countries towards a system of knowledge 
sharing and promotion of good practice and methods (European Commission, 2015a), 
or the willingness to minimise different levels of access to medicines across European 
Member States with the EU Cross Border Directive (Directive 2011/24/EU).   The 
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final conclusions and recommendations of the Pharmaceutical Forum also recognise 
the need to improve access to orphan medicines for all EU citizens, in line with their 
objectives to “offer equal access to medicines at an affordable overall cost” 
(Pharmaceutical Forum, 2013).  Consequently, understanding the reasons for 
differences can contribute towards these goals, and ultimately, improve and harmonise 
patient access to treatment across EU Member States. 
 
Given that these differences in the HTA recommendations issued across countries 
matter, the second research question in this thesis aimed to understand why countries 
issued different HTA recommendations.  The analysis focused on ten orphan drugs 
appraised in four countries (N=35). 
 
Question 2 
Why are there differences in HTA recommendations for orphan drugs in four 
countries? What can we learn from these differences? 
 
Through the application of the methodological framework, this sample of drugs and 
countries were systematically compared.  One of the first main observations from the 
results is that no clear and systematic reasons for differences across countries were 
identified.  Instead, differences were identified at each step of the decision-making 
process (as per the structure of the framework developed, e.g. evidence, its 
interpretation, influence on final recommendation) and were non-homogeneous within 
and across countries.  No clear pattern emerged.  Differences were seen in the main 
parameters considered of interest by the HTA bodies despite coming from the same 
primary trials.  When assessing the same evidence, heterogeneity in the concerns 
raised was observed (e.g. in what was considered uncertain by the agencies).  In 
certain cases, but not for all, these concerns were in line with those types of concerns 
more commonly raised by some agencies compared to others (e.g. agency-specific risk 
preferences, identified through correspondence analysis).  There were also instances 
where the same concerns were raised by more than one HTA body, but were dealt with 
in different ways.  Different means were used to address uncertainty in addition to 
existing standard tools (e.g. sensitivity analysis).  This was achieved, for example, 
through expert opinion or the assessor’s own judgments during the deliberative process 
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of HTA.  These value judgments are about the scientific evidence or about social 
values, and whether they are willing to pay more for drugs that fulfil certain 
characteristics.  Some of the social values identified were more likely to be made by 
some agencies compared to others (e.g. agency-specific value preferences, identified 
through correspondence analysis).  All these contributed to explaining some of the 
differences in the HTA recommendations made across countries. 
 
In summary, this thesis contributed to generating the ability to identify the various 
reasons explaining differences in the HTA recommendations, which includes also the 
identification of the softer endpoints (e.g. value judgments) and their influence on the 
final decision.  In addition to the ICER or magnitude of the clinical benefit, these 
decisions are also influenced by the type of evidence preferred, the different attitudes 
(agency-specific preferences) or means (e.g. sensitivity analysis, expert opinion, 
additional evidence) in accepting uncertainty, the availability of certain modulating 
factors that may help improve the ICER (e.g. PAS, SMC modifiers) or measure of 
clinical benefit (ATU), and finally, a subjective component that depends on the 
Committee’s judgment (e.g. value judgments).  All these reasons relate to how 
agencies are dealing with uncertainty, which always rely on the scientific and social 
value judgments of the assessor’s and depend on the level of ambiguity around what 
constitutes acceptable evidence or acceptable ways to deal with uncertainty, the 
processes or means available that may allow to modulate the ICER to an acceptable 
level or allow for a greater acceptance of uncertainty (future re-assessment). 
 
Shedding light on these cross-national differences also allows to query why they occur 
and what we can learn from them, particularly in those cases where they may reflect 
weaknesses in the HTA methodological approaches used.  For example, issues relating 
to the limitations of RCTs (generalisability, safety) are well-known, nonetheless, they 
are still considered the most robust and preferred type of evidence.  Given that the 
majority of primary trials were RCTs, these issues were unavoidably likely to be 
raised, as seen in the results.  This contributed to understanding how these issues were 
dealt with in the different settings.  For instance, generalizability to clinical practice 
was a frequent concern for NICE and SMC, and was most often addressed through 
clinical expertise in the former case, and had a negative influence on the assessments 
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in the latter.  Other issues included that (a) patients with certain characteristics were 
not included in the trial or around the heterogeneity of the subgroups appraised, (b) the 
trial population did not represent the indication under review, or (c) imbalances were 
seen in terms of the characteristics or responses across the different subgroups.  This 
highlights the potential value of accounting for other forms of evidence, such as expert 
opinion or observational data to complement RCT evidence. 
 
Raising awareness about these differences (and similarities) facilitates cross-country 
learning including sharing practices about how value is assessed in different settings.  
Better understanding these processes and how value is assessed in different settings 
can be useful for all stakeholders involved in the process: HTA bodies, manufacturers, 
patients, clinicians, payers, etc. 
 
One of the components contributing to addressing uncertainty and explaining 
differences across countries were the value judgments made and identified through the 
application of the framework developed.  This thesis contributed to furthering the 
understanding around what these value judgments look like in practice, how they can 
be categorised, and whether orphan drugs have special status (Chapter 9).  
 
Question 3 
How do scientific and social value judgments influence HTA decisions? And on 
this basis, do orphan drugs have a “special status”? 
 
An important contribution is the classification framework proposed about the value 
judgments made that distinguishes those judgments about the scientific evidence, 
usually quantified, from those about social values, usually elicited.  This is an 
important distinction as the former relates to the acceptability about uncertain or 
incomplete evidence and the latter relate to non-quantifiable aspects of living with a 
condition and taking a treatment.  Both of these occur during the deliberative process 
and rely on the decision-maker’s experience, on what they believe society would 
prefer, or on conclusions of citizen's councils or juries.  Based on this classification, it 
is possible to categorise these value judgments made and identified by applying the 
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framework, and differentiating those that were quantified or elicited from those that 
were not quantified or elicited, respectively.  
 
Their identification contributes towards assessing whether these value judgments are 
consistent across cases.  It also allows to better define the determinants of these social 
values based on how they were accounted for retrospectively (e.g. unmet need).  For 
those value judgments that were not elicited, it may provide a good basis to seek 
elicitation about societal preferences, particularly for the more commonly identified 
ones (e.g. unmet need, innovation, severity).  Their identification improves the lack of 
accountability for reasonableness particularly in cases when it is not clear how the 
“other considerations” identified influenced the decisions.  It also contributes to 
eliciting whether these orphan drugs deserve a special status by eliciting preferences 
around some of the social value judgments made which are more likely to pertain to 
orphan drugs compared to normal condition, rather than focusing on the opportunity 
cost of these.   
 
In the last empirical chapter of this thesis, insights from HTA body representatives 
were collected about the differences seen across countries or the challenges that HTA 
bodies were facing when appraising orphan drugs, with a particular focus on those 
relating to the rarity of the conditions.  Results focus on some of the contrasts and 
subtleties identified across countries and how these may have contributed towards 
explaining some of the cross-country differences observed.   
 
Question 4 
How is the value of orphan drugs assessed across different settings and how do 
differences affect coverage decisions? 
 
HTA bodies agreed that decisions regarding orphan drugs are made in a context of 
greater uncertainty.  The main contribution of this last part of the thesis was to 
understand the contrasting approaches in the application of HTA when appraising 
orphan drugs.  Despite the broadly similar agreement about evidentiary requirements 
or preferences, subtle differences were identified with respect to the circumstances 
under which uncertain evidence may be considered acceptable.  These relate to 
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differences in the expectations around the quality of the evidence dependent on the 
clinical claim, in the recognition of usefulness and acceptability of registry data (e.g. 
historical controls), in their criteria for acceptability of uncertain trial duration, 
subgroup data, comparative data, surrogate outcomes, HRQol data, or safety data, and 
the extent to which more flexibility is granted to uncertainty because of the rare nature 
of these conditions.  These, together with the varying approaches used for HTA (e.g. 
clinical benefit versus cost-effectiveness) and the special considerations given to 
orphan drugs, may modulate the interpretation of the outcomes of HTA and explain 
differences in the HTA recommendations made across countries.  The former relate to 
the ability to implement patient access schemes, the NICE end-of-life criteria, disease 
severity at TLV, and implementing lower discounting rates when the benefits are 
sustained in the long run, or the way qualitative criteria are accounted for and weigh on 
the decisions.  The latter specific to orphan drugs relate to the SMC modifiers, and 
possibly also those orphan drugs that are made available through the temporary 
authorization scheme (ATU) in France, where the continuous collection of data may 
contribute towards a greater acceptance of uncertainty.  Shedding light on the three 
main categories of modulating factors contributes to understanding means to accepting 
greater uncertainty or higher ICERs that what would normally be permitted, which in 
turn explain the significant differences in the HTA recommendations made across the 
four countries.   
 
11.1.3. How do findings fit with existing research? 
 
Since the beginning of this thesis and the review of the literature conducted to identify 
the gaps in the literature, a number comparative studies that include the study countries 
have been published (Drummond, de Pouvourville, Jones, Haig, Saba, & Cawston, 
2014a; Cerri et al., 2014; Maynou Pujolras & Cairns 2015).  
 
Drummond and colleagues (2014a) contrast the advantages and disadvantages of the 
two approaches to HTA used in England and France (cost-effectiveness and 
cost/QALY versus added benefit (ASMR)).  By comparing the assessments of QALY 
increases and ASMR ratings, they show that the two countries arrive at similar 
assessments of added clinical benefit, but arrive at different conclusions when NICE 
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accounts for costs and cost-effectiveness.  Findings from this thesis are complementary 
and provide more detail about what happened to explain these differences.  In terms of 
the contrasts seen between NICE’s decisions and HAS’s ASMR rating, two drugs 
(eltrombopag and imatinib) with a high ASMR (I-III) were considered cost-ineffective 
by NICE.  However, this was not only a consequence of the costs being accounted for, 
but also of the clinical endpoints considered relevant in the decision problem (which 
were not necessarily the primary trial endpoints for NICE), resulting in high ICERs.  
Findings from this thesis additionally highlighted three contrasting cases that received 
the lowest ASMR rating (V), but were positively received by NICE (mifamurtide, 
mannitol dry, trabectedin).  This was because of the lack of comparative evidence 
presented due to early marketing authorisations or early scientific advice received, 
where no added benefit was demonstrated.  Given the particular circumstances of these 
three drugs, NICE was more lenient in accepting uncertainty and positively received 
the drug.  The authors also observe that HAS’s ASMR assessment is less transparent 
than NICE’s process.  This is supported by findings from this thesis, where the criteria 
(considered as soft endpoints) and their weight on the ASMR decision was often 
unclear. 
 
The recent study by Cerri and colleagues (2015) compared the factors that contribute 
to explaining differences in coverage decisions in England, Scotland, the Netherlands 
and France.  When comparing the same drugs on a wide range of variables that may 
affect the decisions, only 30% of the variability across countries could be explained by 
the model possibly because of the range of factors that are highly specific to each 
agency.  Such factors could relate to what went on during the decision process and the 
combination of factors that rendered the decision positive or negative.  Such subtleties 
would not be captured when exploring the role of a set of pre-defined criteria, but 
would require more qualitative exploratory approaches, as was adopted in this thesis.  
The authors also found that the strength of the evidence had a significant role in the 
decisions, while some variables such as the number of observational studies did not 
show any effect.  This is congruent to results from this thesis highlighting the limited 
role of non-primary non-phase III trials.  A number of variables showed to have a 
significant impact on the decision (e.g. population size associated with a decreased 
probability of recommendation, indication).  These were not captured within this thesis 
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as they are characteristics of the disease and treatment and require a larger size and 
heterogeneous sample to be able to measure their effects.  
 
Another recent study by Maynou-Pujolras and Cairns (2015) explored the extent to 
which a number of variables contributed to explaining different HTA 
recommendations in ten European countries comparing 199 drugs.  These results have 
been integrated with results from this thesis in order to assess whether findings from 
these two qualitative and quantitative studies respectfully are congruent, 
complementary or discrepant.  The paper is soon to be submitted for peer review 
(Nicod, Maynou-Pujolras, Visintin, & Cairns, 2016).  Results show that the two 
approaches are often complementary, and capture different aspects of the decision-
making process.  For example, quantitatively, a cost-effective ICER was more likely to 
receive a positive recommendation, whereas this thesis showed that a cost-effective 
ICER likely to receive a positive recommendation is often a modulated one.  There 
were also a number of variables that were excluded from the quantitative analysis as 
not explaining sufficient variability in the model.  Many of these, however, were 
captured qualitatively in this thesis and their role in the decision was explained (e.g. 
influence of severity in Sweden).  There were also some contradictory findings across 
these two studies, where, for example, higher levels of stakeholder involvement were 
associated with a lower probability of recommendation.  This thesis showed the 
contrary, where stakeholder involvement often contributed to confirming or not the 
plausibility of a claim being made.   
 
These last three studies adopted quantitative techniques to analyse larger samples 
compared to the comparative studies previously discussed in Chapter 3 and the 
findings from this thesis.  Generally, the findings are in line with each other.  
However, there are certain aspects that can only be captured using one technique or 
another.  For example, the qualitative approach used in this thesis did not allow to 
analyse a large sample or assess the impact of certain disease or treatment 
characteristics on the final decision (e.g. orphan status, population size).  By contrast, 
it did allow to capture a more comprehensive range of criteria and the interaction 
amongst criteria in the decisions, many of which may not have been captured 
quantitatively.  This includes the subjective component of these decisions, which may 
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be highly specific to the agency and/or to the decision-maker.  This clearly emphasises 
the added value of adopting mixed methods approaches, where quantitative findings 
allow to enhance and build upon qualitative findings, and qualitative findings allow to 
explain, illustrate and foster the credibility of quantitative findings (Mertens, 2011).  
The limited amount of variability captured using quantitative approaches seen (Cerri et 
al., 2015) also emphasises the added value of adopting an exploratory approach, as was 
done in this thesis.  
 
There were also a number of studies that investigated the drivers of the HTA 
recommendations in one specific country (Devlin & Parkin, 2004; Dakin, Devlin, & 
Odeyemi, 2006; Cerri, Knapp, & Fernandez, 2014; Svensson, Nilsson, & Arnberg, 
2015; Dakin, Devlin, Feng, Rice, O’Neill, & Parkin, 2015). 
 
The first study by Devlin & Parker (2004) investigated whether NICE has a cost-
effectiveness threshold and other factors influence its decisions by conducting a binary 
choice analysis.  They assess the effect of six independent variables (e.g. ICER, 
uncertainty) on the HTA recommendation.  Results support the notion of a threshold, 
where the probability of rejection increases as the cost/QALY increases, with an 
additional effect of the burden of disease and uncertainty on these decisions.  They 
echo findings from this research by stating that decisions are based on imperfect and 
incomplete evidence and rely on the decision-makers’ judgments.  Similarly to the 
conclusions made for the comparative studies, the quantitative approach does not 
enable to capture the depth of what went on during these decisions, while the 
qualitative approach used within this thesis does not allow to interpret the relative 
contributions of each of the variables assessed.  
 
A more recent study conducting a similar analysis for NICE focusing on a wider range 
of variables also support that cost-effectiveness is the main driver of their 
recommendations (Dakin et al., 2015).  This concords with findings from this thesis, 
where all drugs above NICE’s cost-effectiveness threshold were rejected.  What this 
study adds is that the ICER is often a modulated one as already previously discussed.  
The other variable that may have influenced the decision is the type of disease, which 
was not captured in this thesis given the focus on orphan drugs and the small sample 
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size.  An earlier study by the same authors also found that patient submissions were 
more likely to increase the probability of endorsement for routine care rather than 
restricted use (Dakin et al., 2006).  This further supports findings on the influence of 
stakeholder involvement in these processes.  
 
The study by Cerri and colleagues (2014) examined the impact of evidence, process 
and context on NICE decisions by assessing the relative contribution of 32 variables 
using a multinomial logistic regression.  Four of their variables had a significant effect 
on the decisions (demonstration of superiority, ICER, number of pharmaceuticals 
appraised in the same HTA, and the appraisal year).  Only the first two variables were 
captured in this thesis, as the others would require a larger sample and those 
technologies undergoing the multiple technology assessment process (which was not 
the scope of this thesis).  Findings about the ICER concur with this thesis as previously 
discussed, whereas those about clinical superiority were not explicitly captured when 
assessing cross-country differences, as they may have been reflected in the ICER or 
ASMR rating.  This further supports the conclusions on the complementarity of using 
different approaches to obtain a better understanding of the drivers for decisions.  
 
Finally, the study by Svensson and colleagues (2015) analysed the impact of cost-
effectiveness and severity on HTA decisions in Sweden for 102 decisions.  Their 
findings elucidate the willingness to pay for a QALY and the fact that higher ICERs 
are accepted for the more severe conditions.  This echoes the findings from this thesis, 
where higher ICERs were generally accepted for the sample of orphan drugs analysed.  
The main question remains about the definition of severity, where it was categorised as 
severe or non-severe.  This thesis further contributed to better understanding the 
attributes of severity by coding how these were expressed during these decisions 
(Chapter 9).  
 
11.2. Policy Implications and Recommendations 
 
In the past decade, health expenditure has increased at a faster rate than national GDP 
(Figure 2-1), stressing the issue about its sustainability.  The European Commission 
has recognized this issue as one of the cornerstones in their strategy on “investing in 
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health”, where cost-efficiency is to be obtained through innovation and measuring 
health system performance (European Commission, 2013a).  “Ensuring efficiency and 
making the provision of health services more cost-effective and efficient is crucial if 
countries are to ensure universal access to and equity in health services and their 
adequate and sustainable financing” (Directorate-General for Economic and Financial 
Affairs, 2012; European Commission, 2013a).  Ensuring efficiency was also 
understood as a vital element for the sustainability of a health system’s performance 
during the 67th WHO World Health Assembly, which “urges” Member States “to 
consider establishing national systems of health intervention and technology 
assessment, encouraging the systematic utilization of independent health intervention 
and technology assessment in support of universal health coverage to inform policy 
decisions…” (Sixty-seventh World Health Assembly, 2014). 
 
Understanding the drivers of health expenditure is a way towards understanding where 
improvements are needed.  These include the ageing population, increasing costs of 
care and labour, growing demand, as well as inefficiencies in the organisation and 
payment of care (Sorenson et al., 2013).  In terms of the drivers for pharmaceutical 
expenditures, one systematic review identified these as increased drug quantities and 
the introduction of new and expensive drugs (Mousnad et al., 2014).  New drugs 
generally carry high prices, which are justified by the investments in research and 
development and the added benefit of the treatment.  A more recent study identified 
another potential cause for high drug prices in cancer that they referred to as the 
“market spiral pricing effects”, where prices of last year’s drugs are increased and 
prices of new drugs are set above the new market price (Light et al., 2013).  The 
authors further argue that research and development costs are over-estimated (by about 
10 times), that generally these drugs provide little or no added value, and that high 
prices are a consequence of monopolistic positions. 
 
The complexity of these market dynamics, as also highlighted in Chapter 2, make it all 
the more challenging for policymakers to make the right resource allocation decisions, 
when already their objectives are competing in ensuring access to safe, efficacious and 
quality care while containing costs and incentivising innovation.  Our systems should 
ensure that incentives for research and development target those drugs providing 
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additional benefits to patients and society, and outweigh their costs.  It is generally 
recognised that HTA is one way to achieve this.  However, we’ve seen that the 
successful implementation of HTA depends on various factors including the 
availability of evidence to demonstrate the value of these technologies (Sorenson et al., 
2013).  
 
This thesis contributed to better understanding the different ways in implementing 
HTA through cross-country comparisons and by elucidating the issues HTA bodies are 
facing during these assessments, including those that relate to dealing with rare 
conditions, and how they are dealing with them.  As emphasised in Chapter 3, these 
differences are often legitimate because of the complexity of these processes and 
context in which they operate (Banta, 2003).  A distinction should also be made 
between the assessment and appraisal phases of the processes, where it can be 
expected that the assessment is similar across countries while the appraisal differs 
according to context-specific considerations, which may frequently be accounted for 
ad hoc.  In this context, decisions are inevitably based on the decision-makers’ 
judgments about the evidence, influenced by their preferences and own knowledge and 
this will always be legitimate.  However, the magnitude, and contradictory nature of 
the differences seen in HTA recommendations made across countries further 
emphasise the need to understand the reasons for these and understand when these are 
a consequence of weaknesses or limitations in the application of HTA approaches, and 
whether they occur during the assessment or appraisal phase.  Policy implications and 
the recommendations from the findings of this thesis are discussed here.  
 
11.2.1. Policy implications 
 
The main contributions of this thesis discussed in the previous section can be 
summarised around three levels.  First, the framework developed enables to capture a 
more comprehensive range of criteria accounted for during these decision processes, 
systematically and in a comparable manner.  Second, it allows to raise awareness of 
those cases when the reasons for cross-country differences are a consequence of HTA 
methodological limitations and highlight areas for potential methodological 
improvements.  Finally, it also highlights the challenges HTA bodies are facing when 
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assessing orphan drugs and how they deal with these.  Better understanding the 
application of HTA in different settings has implications for policy, which are 
discussed here. 
 
The identification of a more comprehensive range of the criteria accounted for across 
all drugs, therapy areas, indications, and countries is useful in several ways.  
Identifying the type of criteria that contributed to decision-making at each stage of the 
process provided a more structured understanding of these decisions and improved 
their transparency.  This may help improve their accountability for reasonableness, 
which is obtained when it is transparent and public, based on reasons that are relevant, 
revisable when new evidence is available, and with a decision-making process that 
allows for these conditions to be enforced.  This was emphasised in the findings from 
Chapter 9 (Paper 4) suggesting that although the study countries were relatively 
transparent in reporting the rationale for their decisions, it was not always clear how 
the different criteria weighed on the decisions.  For example, it was not clear how 
disease severity was accounted by TLV apart from accepting greater ICERs.  The 
criteria identified also included the softer endpoints made as part of the deliberative 
process, referred to as the scientific and social value judgments (e.g. elicited/quantified 
or not), which had not been identified in such a systematic manner previously together 
with how they influenced the decisions.  This, together with the agency-specific 
preferences observed, are a way forward to improving the consistent use of these 
“other considerations” or preferences, while better defining their attributes based on 
previous applications.  This will also improve the understanding of the expectations 
HTA bodies have in the submissions, which will minimise unnecessary and resource-
consuming rejections and re-submissions. 
 
The identification of a more comprehensive set of criteria accounted for also has 
practical implications in other priority setting applications, such as MCDA or discreet 
choice experiment (DCE).  MCDA is a technique supporting decision-making 
allowing to account for explicit criteria without quantitative modelling (Thokala, 
Devlin, Marsh, Baltussen, Boysen, Kalo, Longrenn, Mussen, Peacock, Watkins, 
Ijzerman, 2016).  Different uses for MCDA exist together with different 
methodological approaches.  For example, DCE is one way to involve patients in these 
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decisions by eliciting their preferences.  This is done by asking them to choose 
between two different scenarios with different attributes and repeating the exercise 
changing the attributes to choose from.  With regression analyses techniques, it is 
possible to elicit their preferences for the different attributes (Thokala et al. 2016).  
Additionally, MCDA techniques enable to give explicit weights or categories to 
criteria in decisions through various means (e.g. stakeholder participation) (Angelis & 
Kanavos 2016).  The same authors also argue that it is a way to capture unexplained 
heterogeneity rather than wait until the appraisal phase to capture these. This is 
because standard cost-effectiveness approaches account for costs and effects during the 
assessment phase and additional criteria during the appraisal phase, whereas with 
MCDA, all these criteria can be accounted for in the assessment and appraised 
together.  One illustrative example is the way unmet needs were defined in the context 
of MCDA within the EVIDEM project, which accounted for the type of therapeutic 
benefit (e.g. efficacy, safety, etc.), but did not capture the different levels of needs (e.g. 
lack of satisfactory alternatives).  Findings and the application of the framework 
developed in this thesis may also be useful for EU-level collaboration initiatives, such 
as EUnetHTA, in highlighting the differences seen across countries that can then be 
discussed when facing similar scenarios in the future.  Findings may also contribute to 
recent initiatives, such as PACE in Scotland and the highly specialised technologies 
programmes at NICE, which account for additional criteria beyond the ICER in their 
decision-making processes, such as disease severity or unmet need.  Retrospectively 
identifying how these factors have emerged in practice and were accounted for may 
feed into better defining and accounting for them in future cases. 
 
Identifying the reasons for cross-country differences pertaining to the varying 
application of HTA enabled to further the debate about some of the limitations around 
current HTA methodological approaches.  Table 7-2 summarises the reasons for 
differences in HTA recommendations across countries at each step of the process in 
terms of the evidence appraised and its interpretation.  These differences were used to 
further the debate on some of the limitations around current HTA methodological 
approaches, namely: 
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• RCT limitations. This thesis showed that for the range of treatments studied 
RCTs continue to be the main source of evidence accounted for in these HTA 
decisions and that other forms of evidence had a limited effect.  RCT limitations are 
well-known and include issues around safety and generalizability to heterogeneous 
populations of clinical practice.  These issues were raised in the decision processes 
analysed and different ways in dealing with them were seen across countries.  In some 
instances, it had a negative influence on the decision, and in other instances, it was 
considered acceptable through various means, such as stakeholder input.  
 
• Use of non-phase III trials.  Results showed that there were only a few cases 
when non-phase III secondary evidence had any influence on the decision.  Outcomes 
from these trials were generally not reported, and when reported, the type of data 
provided was around safety, dosage research or historical controls.  The uptake of such 
forms of evidence is still modest and likely due to the lack of expertise around dealing 
with a variety of types of observational evidence including those based on real world 
data such as electronic patient records (Berger et al, 2014) or patient-reported 
outcomes (McClimans and Browne, 2011).  More clarity and research is needed 
around the quality standards for when such types of evidence can be deemed 
acceptable or not. 
 
• Differences in the evidence appraised.  Differences were seen in the level of 
evidence reported (different trials, different endpoints from the same trials or different 
levels of analysis).  In some instances, these differences were also one of the 
explanatory factors for diverging decisions.  These included registry data as historical 
controls for trabectedin (NICE), different primary endpoints for mifamurtide (overall 
survival for NICE and progression-free survival for SMC and HAS), the secondary 
endpoint “severe bleeding events” for eltrombopag only reported by NICE, the lack of 
quality of life data in the assessment of eltrombopag for HAS and TLV.  More clarity 
is needed on the expectations from HTA bodies on the reasons for including some of 
these endpoints, which were not included by others.  Specifically, more clarity is 
needed around how the endpoints of interest are selected and their level of importance. 
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• Differences in the uncertainties raised.  These refer to cases when one HTA 
body raised a concern about the evidence, which was not raised by the others.  This 
thesis showed that these are likely to be a consequence of agency-specific risk 
preferences or of the interpretation of the decision-making Committee, showcasing the 
subjectivity of these decisions that rely on the decision-maker’s own preferences and 
experience.  This is legitimate given the uncertain nature of evidence in general within 
which they operate.  Policymakers should be aware of these happenings and query the 
different methodological approaches to minimising or better dealing with uncertainty 
(e.g. real world evidence, patient input).  It is also important to continue to query and 
shed light about these preferences (as was done in Chapter 10) such as to improve 
transparency around the expectations from HTA bodies. 
 
• Dealing with the same uncertainties.  Agreement was generally low to less than 
expected by chance in dealing with the same uncertainty.  In other words, when one 
agency addressed an uncertainty by various means, there was moderate to less than 
zero chance that the same uncertainty was addressed by another agency.  A number of 
different ways were seen in dealing with these (Table 11-1).  Such cases could be a 
good starting point for policymakers to discuss alternative scenarios in view of 
establishing criteria for accepting greater uncertainty in future cases.  For example, in 
the case of trabectedin, due to the early marketing authorisation granted, the 
assessment relied on a phase II non-comparative study.  Under certain circumstances 
historical control data could be acceptable.   
 
Table 11-1. Dealing with uncertainty 
Type of uncertainty Criteria for acceptability Examples 
Non-significant 
improvement in clinical 
benefit (overall survival) 
Orphan status SMC for imatinib 
Expecting results from an 
on-going trial 
HAS for imatinib 
Risk of severe adverse event 
(risk of bronchospasm) 
Expert opinion NICE for mannitol dry 
Risk of interaction between 
treatments 
Expert opinion NICE for mifamurtide 
Lack of comparative Rarity, early market NICE for trabectedin 
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evidence (pivotal phase II 
trial) 
authorisation, use of 
historical controls 
Rarity, investigational 
nature of the treatment 
SMC for trabectedin 
 
• Value judgments. It is generally recognised that more transparency and 
consistency in the social value judgments made across cases are needed (Daniels, 
2000; Daniels and Sabin, 2008; Earnshaw and Lewis, 2008).  This can be achieved by 
categorising the types of value judgments made based on the classification framework 
developed, and on this basis, ensure that they are accounted for consistently across 
cases.  It also contributes to identifying those value judgments made where further 
elicitation of societal preferences are needed, and to better defining these based on 
previous decisions.  Better understanding the value judgments made can contribute to 
informing new initiatives such as the value-based pricing system or the highly 
specialised technology processes in England, or the ultra-orphan approach in Scotland, 
which account for additional criteria such as disease severity, unmet need, or the added 
value of the medicine for the patient, their carer or family (Brown, 2014).  
 
• Societal perspective at TLV.  None of the criteria identified pertained to 
adopting a societal perspective.  More clarity around how this is accounted for during 
the decision-making process is needed. 
 
Finally, the challenges HTA bodies are facing when assessing orphan drugs were also 
identified together with the different ways of dealing with these across countries.  This 
is a consequence of the particularities in assessing orphan drugs due to the small 
patient numbers involved, where they are hardly cost-effective (Drummond et al., 
2007).  Despite this fact, evidence suggests that orphan drugs are prone to receive a 
similar or greater level of acceptance for reimbursement than other more common 
conditions (Dupont et al., 2011; Simoens et al., 2011; Stolk et al., 2009).  The types of 
concerns raised that related to the rarity of these conditions were identified.  This 
included issues in recruiting sufficient patient numbers or cases when results relied on 
subgroup data.  The assessments also relied on (validated or non-validated) surrogate 
endpoints and frequently lacked quality of life data.  These scenarios can be considered 
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common for rare diseases given the scarcity of knowledge and expertise, and the 
difficulties in generating robust evidence.  The main question was to understand 
whether HTA bodies are accepting greater uncertainty in the evidence, higher ICER 
estimates, or are negatively assessing these drugs because of this.  In some cases, this 
uncertainty relating to orphan drugs (but not necessarily specific to), was considered 
acceptable because of the condition’s rarity or the recognised difficulties in recruiting 
sufficient patient numbers.  In contrast, certain concerns were more commonly 
negatively appraised.  This related to, for example, dealing with subgroup data (seen in 
50% of cases), where the concerns remained inconclusive because of their lack of 
statistical power or retrospective nature.  Another contrast was seen in the lack of 
comparative data, characterising 30% of the study drugs (likely due to the rare nature 
of these conditions where few or no alternatives exist, and therefore for ethical or early 
marketing authorisation, they did not include placebo comparisons).  Given that HAS 
relies on the added benefit of the drug, this evidence was insufficient to demonstrate 
any added benefit and therefore received the lowest ASMR ratings (V).  More 
flexibility was granted to this lack of comparative data in the other countries because 
of their rarity or investigational nature.  More consensus in HTA processes is needed 
in dealing with these specific and common issues related to rarity. 
 
In summary, the concerns raised often related to the well-known evidentiary issues 
seen in orphan drugs from the small patient populations, scarcity of existing 
knowledge about the disease, unmet need, or heterogeneity of these conditions.  
Different patterns were observed in dealing with these, where some accepted greater 
uncertainty for certain types of concerns (e.g. lack of statistical significance) under 
certain circumstances (e.g. post-marketing surveillance and planned future re-
assessment), others used various means to modulate the ICER to an acceptable level 
(e.g. PAS, restriction to the most cost-effective subgroup, NICE end-of-life criteria, 
SMC modifiers, TLV and disease severity), additional considerations may have been 
accounted for particularly in those cases where it was recognised that the measures of 
clinical benefit provided did not capture the full effects of living with the disease and 
taking the treatments, or finally, they may have simply a negative impact on the 
decisions (e.g. lack of comparative data in France).  Policymakers should be aware of 
these limitations and account for, in a more consistent way across cases, the different 
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approaches in dealing with these situations.  Identifying these special cases and how 
they were dealt with is a good starting point to generating a set of criteria when greater 
uncertainty may be accepted in future cases. 
 
11.2.2. Varying approaches to using HTA 
 
When examining the different uses of appraising the clinical and health economic 
evidence within HTA, different approaches across countries were identified despite 
being driven by the same fundamental objective of clinical benefit and/or cost-
effectiveness. Those countries with a formal (or informal) ICER threshold, such as 
NICE or SMC, would tend to be more instrumental, where anything above the 
threshold would not be considered cost-effective. For example, in the case of NICE, 
the starting point is always the ICER derived from the cost-utility analysis, its 
magnitude and certainty. If the most plausible ICER is reasonable (within the 
£20,000/QALY threshold), it would be considered cost-effective. However, if it were 
based on unreasonable assumptions, the drug would not be recommended or additional 
information would be requested (if possible and plausible).  If the ICER is greater than 
the acceptable threshold of £20,000/QALY, additional considerations would be 
accounted for to understand whether the ICER fully captured the effects of the disease 
and the treatment, or whether the treatment can be considered an end-of-life treatment, 
or whether the company accepts to decrease the price to make it cost-effective for that 
promised effectiveness. This takes place during the deliberative process, where the 
ICER would be used for enlightenment during the decision.  
 
In the case of TLV, which does not have a formal cost-effectiveness threshold, the 
starting points are the clinical claim made (e.g. superiority or non-inferiority) and the 
consequence of the decision (severity of the consequences if patients were not to 
receive the treatment, which would be greater for those with a higher unmet need).  
The ICER is therefore considered within this context, where higher evidentiary 
requirements are seen for higher clinical claims and price premiums, and where greater 
flexibility would be accepted for uncertain evidence for non-inferiority claims.  
Additionally, the greater the severity and unmet need, the more high ICERs would be 
acceptable.  
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In the case of HAS’s coverage decision, the consequence of the SMR and ASMR 
ratings is somewhat different than in the other study countries (where a drug with a 
negative HTA recommendation would not probably not be covered). Drugs that 
received the lowest SMR and ASMR ratings would be made available to patients, but 
with a lower level of coverage and at a price set equal to or below already existing 
alternatives. In February 2014, HAS has implemented the requirement for an economic 
evaluation to inform drug pricing negotiations for those drugs that received an ASMR 
I, II or III, and a significant impact on healthcare resources. The SMR and ASMR 
ratings drive the coverage rate and pricing scheme, while the economic evaluation 
enlightens the price negotiations in the pricing scheme applicable. 
 
It can be concluded that in the study countries, the use of clinical and cost-
effectiveness evidence can be considered as enlightening the decision process, rather 
than instrumental.  Their use differ across countries, depending on the criteria 
accounted for, the existence of a threshold, and the consequence of the HTA 
recommendation.  This may not be the case in other countries, where the HTA 
decisions are instrumental, and may be based solely on the ICER or on the HTA 
decisions in other countries.  This is partially the case, for example, in Bulgaria, where 
their recent regulation implemented in December 2015 on the conditions and 
procedures for conducting HTA states that the “HTA procedure shall be terminated in 
the cases when a negative HTA assessment for the evaluated medicinal product is 
available by a state institution of the UK, France or Germany” (Bulgarian Ministry of 
Health, Article 17 of their Regulation No. 9 of the 01.12. 2015 on the conditions and 
procedures for conducting health technology assessment). A negative recommendation 
in one of the referenced countries would be used as instrumental in issuing a negative 
decision in Bulgaria. 
 
11.2.3. Recommendations 
 
The recommendations that emerge from this research relate to (1) the added value of 
applying this framework (e.g. multiplicity of criteria, breakdown of the decision-
making process), (2) cross-country comparisons of the application of HTA across 
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settings and implications for HTA methodological approaches, (3) value judgments, 
and (4) dealing with rarity. 
 
 This research sheds light on the multiplicity of criteria accounted for throughout 
the decision processes.  
 
Beyond clinical benefit, ICER and elicited societal preferences, a number of 
additional criteria that influenced these decision processes have been identified, 
namely the influence from other sources of evidence (e.g. registry data) or 
stakeholder input, or the value judgments made (e.g. unmet need, severity, 
innovativeness).  These were generally accounted for to address uncertainty.  A 
first recommendation would be to ensure that these additional criteria are 
accounted for in a more consistent and explicit manner in future decisions.  
 
The use of additional criteria also highlights current limitations in appraising 
imperfect or incomplete evidence (e.g. from phase III trials considered the gold 
standard, but generating evidence from controlled environments), and the different 
approaches, beyond sensitivity analysis, to deal with these.  This often relates to 
uncertainty around the real world use of these treatments (e.g. population 
generalizability, clinical practice, trial length capturing treatment effects).  A 
recommendation is for these assessments to capture more comprehensively the use 
of these treatments in real world settings, and to do so, consider additional sources 
of evidence in a more systematic manner, such as stakeholder expertise or 
observations studies.  
 
Accounting for the criteria used beyond standard HTA methods and understanding 
their weight in the decisions can help decision-makers apply similar approaches 
when faced with similar scenarios in the future.  This will contribute to a more 
consistent use of these criteria and improved accountability for reasonableness.  
This can also feed into other research. 
 
The added value of this research is the breakdown of the decision-making process 
in an easily understandable and comparable manner by the structure given: the 
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evidence, its interpretation (including value judgments) and their influence on the 
final decision.  This allows to differentiate cases when differences are legitimate 
and a consequence of contextual factors (e.g. comparators reflecting clinical 
practice, elicited societal preferences, costs, willingness to pay levels), from cases 
that are a consequence of the evidence and review of the evidence (e.g. different 
evidence, issues raised, ways of dealing with the same issues, consideration of 
other forms of evidence beyond primary trials (non-primary trials, stakeholder 
input, “other considerations”).  The latter cases can be used to further the debate 
around the application of HTA, types of challenges being faced and how they are 
dealt with.  When focusing on conducting or comparing HTA across several 
countries, this structure of the decision-making process may be useful (e.g. 
EUNetHTA). 
 
The application of this framework can also be useful for different stakeholders 
aiming to understand how certain types of criteria influenced the process.  For 
example, patients can retrospectively identify all cases where patient input was 
provided, and understand the type of input provided and how this influenced the 
decision. 
 
 Identifying the reasons for cross-country differences and when these were a 
consequence of the application of HTA methods enabled to generate additional 
evidence about the application of HTA in different settings, the challenges faced 
and how they were dealt with.  A number of policy implications were highlighted 
in the previous section, based on which the following recommendations are made: 
 
A recommendation would be to encourage the use of other forms of evidence to 
overcome some of the well-known limitations relating to RCTs (e.g. reflecting 
clinical practice), which are considered the gold standard of evidence.  This relates 
to evidence about the use of the treatment in the real world (e.g. stakeholder input, 
observational studies) or that can help deal with uncertainty in addition to current 
methods (e.g. sensitivity analysis). 
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The parameters from the primary trials, which were in most cases RCTs, were 
mainly considered for the decisions.  The influence of other evidence (non-primary 
and non-RCTs) on the decisions was quasi inexistent.  More clarity and research is 
needed around the quality standards for these observational studies, and around 
cases when such types of evidence are considered acceptable and for what 
purposes.  More clarity is also needed around how the relevant endpoints are 
selected and the weight quality of life or safety may have in the decision process, 
particularly when the latter is considered as a soft endpoint. 
 
Better alignment of incentives across the drug development pipeline is needed 
when early marketing authorization is granted and the assessments rely on phase II 
trials, sometimes even non-comparative.  This could be through the ability to 
implement patient access schemes (e.g. coverage with evidence development) 
allowing to share the risk of reimbursing the treatment with the manufacturer. 
 
More clarity around the application of a societal perspective is needed (e.g. TLV), 
which can also feed into current developments at NICE or SMC pertaining to the 
special processes for ultra-orphan or highly specialized medicines. 
 
 This research identified the social value judgments across countries and drugs.  
 
Retrospectively identifying these can contribute towards better defining them for 
future cases.  For example, disease severity is a prioritization criteria for TLV but 
no definition of attributes for severity is provided.  Identifying the different ways 
that severity was recognized across cases can help defining this attribute.  The 
same can be done for unmet need, innovation, etc.  These are criteria that are often 
discussed and are of interest to account for explicitly in innovative models such as 
MCDA, or within the new value-based pricing system in England.  
 
Identifying these retrospectively and recording them could help improve their 
accountability for reasonableness in order to account for these in future cases. 
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 When dealing with orphan drugs, a number of issues relating to rarity and evidence 
generation were identified.  Policymakers should be aware of these limitations, 
how they were dealt with in order to generate a set of criteria when greater 
uncertainty may be accepted.  
 
Decision-makers should consider whether the best available evidence is of 
sufficient level considering prevalence and the number of recruitable conditions, 
and innovative trial designs (e.g. N of 1 trials) that may help dealing with small 
sample sizes. 
 
Decision-makers should understand the challenges around generating evidence and 
account for these during the appraisals, including how to deal with the following: 
subgroup analysis, surrogate outcomes, short trial duration, large confidence 
intervals due to small sample sizes, unknown treatment pathway. 
 
Given the higher level of uncertainty characterizing orphan drugs, a continuous 
collection of data about their use in real-world settings and future re-assessments 
may contribute towards addressing uncertainty over time.  This could be done with 
registries, post-marketing surveillance for efficacy and safety, PROs, and so forth.  
This further also emphasizes the need to empower patients at each stage of the drug 
development pipeline in order to produce evidence that responds to their needs and 
preferences, and measures what is most relevant.  This may also be a way to 
identify and account for the wider impacts of the disease on patients and their 
carers (e.g. particularly when diseases affect children, and the chronicity of these 
conditions). 
 
This thesis contributed to highlighting that the current system is not suitable enough to 
tackle these more rare conditions, as highlighted not only be the magnitude of and 
conflicting differences in the HTA recommendations made, but also be the contrasts 
seen at various levels in dealing with these particular cases.  This is all the more 
important in a changing pharmaceutical environment that is shifting towards more 
niche and targeted therapies ("the right patient with the right drug at the right dose at 
the right time"), where such issues will soon become a daily reality.  Policymakers 
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should be aware of this and work towards differentiating these processes for them to 
account for the particularities of orphan drugs, including agreeing on ways that will 
modulate the assessments towards greater acceptability of uncertainty (e.g. coverage 
with evidence development, continuous assessment and re-assessment).   
 
11.3. Limitations 
 
Each Chapter has outlined the limitations relating to the empirical work carried out, 
this section describes the overarching limitations throughout the thesis.   
 
Data sources 
 
The data sources used to understand the decision-making processes were the HTA 
reports issued by each agency summarising the decisions.  The reports also do report 
the same level of detail when comparing countries.  We assumed that these reports 
reflected the key determinants, defined as the main reasons for the final decisions, 
driving these decisions given that countries are required to be transparent about these 
(European Union, 1988).  Nevertheless, all aspects of the decision, such as the context 
within which the decisions were made, were likely not captured within these reports, 
nor during the interviews given that these decisions were made a few years back and 
certain specific issues discussed during the deliberative process of HTA are probably 
not recorded in their memories.  These contextual and other considerations, however, 
were not within the scope of this study but should be acknowledged as possibly having 
influenced these decisions.  One of the HTA bodies also mentioned that when a 
positive decision is made, there may also be less reason for report in detail everything 
that was accounted for.  This was indeed a limitation, even though the most relevant 
information for the purpose of this thesis were the main reasons for the final decision, 
which were usually reported in all decision reports. 
 
A further limitation relating to the data collected when applying the methodological 
framework came from secondary sources.  It would have been preferable to have full 
information about the submissions (e.g. manufacturer submission), but this was not 
feasible in the current scheme.  The objective of the interview was to validate the 
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findings that arose from the interpretation of the researcher and obtain additional 
insights about the different approaches to valuing orphan drugs, which may have not 
been captured by even the most complete documentation.     
 
Similarly, Chapter 9 explored and analysed the scientific and social value judgments 
made during the decision processes.  Given that this is generally accounted for during 
the deliberative processes, it would have been preferable to record these discussions by 
taking part of the Committee meetings and interview the Committee Members about 
their individual judgments.  However, these meetings are not open to the public and I 
relied on the assumption that the decision reports should be transparent and capture 
these judgments made. 
 
The interviews were driven by scenarios derived from findings of the previous 
chapters.  It would have been preferable to go through each case study in detail with 
the HTA bodies to ensure that the interpretation was correct and illustrate what 
happened in the other countries.  This was not possible because of the limited 
availabilities of the interviewees and the fact that they were not the decision-makers of 
the study drugs.  Therefore, the interviews focused on a number of scenarios identified, 
where contrasts were seen across countries. 
 
Sampling and sample size 
 
Another limitation relates to sampling issues arising from differences among the four 
agencies in the way they select topics for their assessments (e.g. highest need for 
guidance at NICE, outpatient drugs at TLV).  Despite these differences, a suitable 
sample has been identified.  The sample size analysed in Chapters 8 and 9 was 
relatively small consisting in ten orphan drugs.  It would have been ideally preferable 
to have a greater sample size to conduct multivariate or regression analyses.  However, 
given the depth of what was captured during these decisions, the focus of the analysis 
was to capture the nuance of the decision without being constrained to a limited 
number of pre-defined variables.  On this basis, the decision was made to prioritise the 
qualitative strand of this mixed methods research project.   
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The sample size for TLV remained smaller (5 compounds), but was nevertheless 
included in order to explore the Swedish context and understand how the societal 
perspective adopted in the assessments influenced the decisions compared to the other 
countries, which adopt a health service perspective. 
 
The study countries included in Chapters 7-10 (England, Scotland, Sweden and 
France) were a convenience sample with known and well-established HTA bodies that 
fulfil a set of pre-defined criteria that were considered relevant to ensure their 
comparability.  Other countries, e.g. Germany, the Netherlands, would have fulfilled 
the criteria but were not selected either because of language barriers or lack of 
available data, or because of a lack of capacity.  Including additional countries would 
have required more time and resources, and therefore, given the quantity of data 
collected with the current sample, I did not include any additional countries.  Further, 
once the methodological framework was tested for its feasibility, it was applied to 
additional drugs and countries by colleagues from the Advance-HTA project under my 
supervision.  The analysis is currently on-going. 
 
A final limitation relates to the relatively small sample size, which does not allow for 
multivariate analysis.  However, this research put greater focus on the qualitative 
component in order to get an in-depth understanding of the subtleties in each country, 
which would not have been possible if the analysis focused on more drugs.  Now that 
we have a better understanding of the reasons for differences and trivialities in each 
country, it would be meaningful to now look at the drivers of these differences across a 
larger sample of drugs and therapy areas using multivariate regression analysis, and 
can be extended to other types of drugs to assess how different agencies assess 
different drug and disease characteristics.  This is discussed in the next section. 
 
Data analysis and generalisability of results 
 
One of the main limitations of this thesis was around its external validity.  The results 
of this thesis are not generalizable to all orphan drugs, but to the sample analysed.  
Despite this, results provide a more structured and fuller understanding of the potential 
reasons for differences.  For results to be generalisable, the analysis should be 
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conducted over a larger sample of drugs.  However, in order to maintain the depth and 
breadth of the analysis building on the methodological framework used in this study, it 
was highly recommended to begin by prioritising the qualitative strand to ensure that 
the depth of the processes is captured and comparable across settings.  Further research 
could look at the drivers of these differences across a larger sample of drugs and 
therapy areas using multivariate regression analysis for a greater generalisation of the 
results, by extending it to other types of drugs to assess how different agencies assess 
different drug and disease characteristics.  
 
Further, given the prioritization of the qualitative strand and the fact that the 
quantitative analyses conducted were more of descriptive nature to help with the 
interpretation of the results, one of the limitations in line with the lack of 
generalizability of the results is that it was not possible to interpret the relative 
contribution of each criteria identified in the decision, given that no adjustments were 
made with the other criteria identified.  This would be possible to do over a larger 
sample of drugs by conducting a regression or multivariate analysis (Cerri et al., 2015). 
 
The transferability of the methodological framework developed to other countries and 
therapy areas is limited to those cases where similar decision-making criteria are 
accounted for, from HTA entities that are arm’s length, responsible for issuing 
coverage recommendations, and have a transparent process where sufficient detail 
about the appraisal process and reasons for the final decision are recorded in their 
decision reports. 
 
 
11.4. Future Research Agenda 
 
As more and more countries continue to implement HTA as drivers for drug coverage 
decisions and constantly aim to adapt and improve HTA methodologies, it is important 
to continue to learn from each other’s experiences.  Initiatives such as EUnetHTA are 
one way of doing this through collaborations, where the assessment of relative 
effectiveness are jointly conducted by several Member States on behalf of all 
participating Member States, on the basis of the common methodologies and 
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guidelines developed.  Results from this common assessment are then used by each 
agency to build the cost-effectiveness model and make the final decision at 
jurisdiction-level.  They also provide a platform where HTA bodies can exchange and 
learn from each other when questions or issues arise.  
 
This initiative is currently being piloted, and individual HTA bodies are still 
responsible to conduct the full assessments on their territory.  Differences are therefore 
inevitable, and it is even more important to understand the reasons for these given the 
important uptake of HTA in Europe and around the world.  This was the objective of 
this PhD.  Chapter 2 set the scene by emphasising the need to understand the reasons 
for differences across countries, partially reflecting HTA methodological weaknesses.  
Chapter 3 developed and tested a tool enabling to systematically compare these 
decision-making processes across countries and drugs in order to identify the reasons 
for different HTA outcomes.  Chapter 4 successfully applied this tool to a sample of 35 
orphan drug and indication pairs, and generated meaningful results, while Chapter 5 
concentrated on one of the components (“other considerations”) to further understand 
how they are accounted for during these processes.  Finally, HTA body representatives 
provided their input in Chapter 6 about the meaningfulness of these findings and the 
implications for HTA.  
 
These five Chapters focus on a number of issues related to orphan drugs both in-depth 
and across all study drugs.  Results helped better understand trends and preferences 
across the study drugs, while at the same time scrutinizing the implications of some of 
these findings, as done in Chapter 5 with the “other considerations”.  Greater depth and 
breadth to these results can be added by applying the framework to additional drugs, 
therapy areas and countries.  This is feasible given the flexible and iterative approach 
adopted when developing the framework, and is already being undertaken as part of 
the European project funding this thesis (Advance-HTA).  
 
Subsequent indications being analysed are cancer and central nervous system (CNS) 
treatments.  Reasons for selecting these three therapy areas are: cancer and orphan 
drugs are therapeutically more innovative and beneficial than CNS treatments, 
according to their ASMR ratings (Nicod et al., 2012).  Cancer and rare diseases have 
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similar characteristics (e.g. disease severity) also given that many rare diseases are rare 
cancers.  However, evidence suggests that different levels of acceptance rates for 
coverage decisions apply (Dupont et al., 2011).  These two samples will be interesting 
to compare and examine on what basis orphan drugs receive higher acceptance levels 
than cancer (and CNS) drugs.  CNS diseases have different characteristics than cancer 
and rare diseases, where a strong need for new treatment remains because of patient 
compliance or tolerance, despite many already existing.  These three therapy areas will 
provide an appropriate basis for comparing the manner in which different agencies 
appraise different therapy areas with a special focus on disease and treatment 
characteristics.  The analysis can further be broadened to additional therapies and 
countries.  Other interesting comparisons would be between orphan and ultra-orphan 
drugs, cancer orphan and non-orphan, orphan and non-orphan cancer, and so forth. 
 
This thesis provides a good basis on how to analyse the data and disseminate the 
findings in a meaningful manner.  Once a larger sample size is available, explanatory 
and confirmatory factor analysis will be conducted to quantitatively understand the 
factors most contributing to these decisions.  The latent variable will be the 
unobservable variable “decision-making”, and explanatory variables the different 
criteria identified through the methodological framework to the three therapy areas.  
Expected results are to measure the contributions of each of these criteria to the 
decision-making process through the factor loadings, including those that have a 
greater influence over others, and whether some of the criteria are associated.  The 
residual correlation matrix (observed minus fitter variables) will then allow to assess 
whether one variable or another does not contribute to explaining the latent variable, 
and as such will be excluded from the analysis.  The goodness of fit test will be 
conducted using a likelihood ratio test.  Finally, the analysis will also assess how the 
contributions of the variables to decision-making differ depending on the therapy area 
being appraised.  
 
The methodological framework can also be further developed and tailored for the 
needs of different stakeholders, such as HTA bodies, patient groups, clinical experts or 
manufacturers.  For example, HTA bodies may use it to better understand how other 
HTA bodies deal with uncertainties for a sample of drugs, using only a specific 
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component of the framework.  Patient or clinical experts could also retrospectively 
identify the type of information provided by experts and their influence on the 
decisions to tailor future inputs or advocate for a greater formalisation and consistency 
of their contributions.  Manufacturers could use this framework to better understand 
the expectations of HTA bodies in the different countries on the basis of previous 
assessments, which could help them tailor their submissions in the different countries. 
 
Another potential application of this framework is within the multiple MCDA models 
currently being developed (Angelis & Kanavos, 2014; Goetghebeur, Wagner, Khoury, 
Levitt, Erickson, & Rindress, 2012).  MCDA models are being developed and tested to 
complement HTA processes in their capacity to account for a broader range of criteria.  
Criteria are usually accounted for by a range of stakeholders and their preferences in 
terms of the different weights that should be allocated to the different criteria.  
Applying the framework to identifying, in a retrospective manner, the criteria 
accounted for in previous decisions can be useful to add on an additional dimension 
around consistency, in accounting for what has been done in previous cases. 
 
Building on another study that also investigated the reasons for cross-country 
differences in HTA recommendations using a quantitative approach (Maynou-Puljoras 
& Cairns, 2016), further research could be to explore the interface between their 
results and those from this thesis (more qualitative by nature).  This is currently on-
going. 
 
The findings also have implications for new programmes dealing with (ultra-)rare 
conditions.  A recent paper building on the results of this thesis is under review and 
aims to identify the challenges commonly encountered with orphan drugs, and how 
new programmes specifically for orphan and/or ultra-orphan drugs were established 
and whether they were done so to explicitly deal with the challenges highlighted in this 
thesis. On this basis, a conceptual framework summarising these challenges was 
developed and examined for each new HTA programme (Nicod, Annemans, Bucsics, 
Lee, Upadhyaya and Facey, 2016) 
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Findings may also be used for educational purposes to different stakeholders.  For 
example, HTA was recently introduced in Bulgaria and is influenced by HTA 
recommendations from other countries. Indeed, their legislation state that “HTA shall 
be terminated in the case when a negative HTA assessment for the evaluated medicinal 
product is available by a state institution of the UK, France or Germany (Bulgarian 
Ministry of Health, Article 17 of their Regulation No. 9 of the 01.12.2015 on the 
conditions and procedures for conducting health technology assessment).  Therefore, it 
is important for them to understand the processes in these different countries, the 
reasons for issuing different recommendations as well as the implications of these 
decisions. 
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Appendix A: Selected HTA Countries 
 
England & Wales: National Institute for Health and Care Excellence (NICE) 
 
The National Institute for Health and Clinical Excellence (NICE) was established in 
1999 to reduce regional variations in the drugs that are subsidized and acts as an arm’s 
length organization funded by the Department of Health (NICE).  NICE has a 
regulatory role in deciding on the reimbursement of medicines, and provides four types 
of guidance on the use of medicines: 1) technology appraisals, 2) clinical guidelines, 3) 
public health guidance, and 4) reports on interventional procedures (Drummond, 
2008).  Recommendations are therefore legally binding, and those receiving a negative 
decision are listed in a negative formulary.  Those drugs that do not undergo the NICE 
process, decisions about whether or not they are provided are taken at local level by 
the Clinical Commissioning Groups (CCGs), who are responsible for ensuring that the 
services provided by the NHS meet patient needs. 
 
In terms of pricing, free-pricing of branded products is applicable under the voluntary 
PPRS scheme, where profits are regulated by a fixed allowable return on capital 
invested (PPRS).  In terms of reimbursement decisions by NICE, two approaches exist 
to appraising pharmaceuticals.  During the multiple technology appraisal approach 
(MTA), evidence for a group of competing technologies treating a specific condition is 
appraised based on the manufacturer’s submission and evidence produced by the 
review team; the duration of the process is 52 weeks.  The single technology appraisal 
(STA) was established at a later stage to speed up the process, where only one drug is 
appraised based mainly on evidence submitted by the manufacturer; the process lasts 
about 39 weeks depending on the number of appeals (Drummond, 2008).  For 
comparability reasons, this thesis focuses solely on STA appraisals. 
 
Initiation of the HTA process is done through the topic selection phase.  Evidence is 
provided from several sources.  The manufacturer or sponsor provides the main 
evidence.  An independent expert committee (Technology Appraisal Committee 
(TAC)) represented by many stakeholders is commissioned by NICE to appraise the 
evidence and issue a report based on the technologies’ relative benefit and cost-
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effectiveness.  On this basis, NICE issues its guidance.  Stakeholders (manufacturers, 
patient groups) have the right to comment or appeal.  Once the guidance is finalized it 
is sent to the NHS and the PCTs have three months to adopt it (Drummond & 
Sorenson, 2009b).  Timelines for the STA process depend on the complexity of the 
cases, but generally are limited to 34 weeks. 
 
NICE Single Technology Appraisal Process 
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Source: Guide to the single technology appraisal process, NICE, October 2009 
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Scotland: Scottish Medicines Consortium (SMC)  
 
The Scottish Medicines Consortium (SMC) was established in 2001 in order to issue 
an advice for all of Scotland about the value of each new medicine and the patients 
who would most benefit from these.  The SMC is a consortium of NHSScotland’s 14 
Health Boards.  The SMC issues an advice to the Health Boards and their Area Drug 
and Therapeutics Committees on the use of all newly licensed drugs.  The Health 
Boards then recommend or not the use of these new drugs in their area, and it is up to 
the clinicians to decide whether or not to prescribe them (SMC, 2015a). 
 
SMC assessment process flow chart 
 
Source: (SMC, 2015b)  
 
For all newly licensed medicines, manufacturers are requested to provide an HTA 
application before the drug in question is marketed in Scotland, or within 3 months of 
marketing authorisation.  The independent committee of the SMC, the New Drug 
Committee (NDC), reviews this and issues a provisional advice on reimbursement.  
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During the SMC meeting, this advice, together with feedback from the manufacturer, 
is considered by the SMC.  Patient Interest Groups are also given the opportunity to 
provide their input, to ensure that the patient and carer perspective is accounted for 
during the review process.  The SMC issues a Detailed Advice Document (DAD), 
communicated to the NHS Boards and the pharmaceutical company making the 
submission.  The advice for reimbursement is either (a) accepted for use, (b) accepted 
for restricted use, or (c) not recommended for use.  Four weeks later, the advice is 
made public.  Timelines for the SMC Assessment process is approximately 18 weeks.   
The assessment relies on evidence about the drug’s relative clinical and cost 
effectiveness using a health service perspective (e.g. NHS Scotland and social work), 
in order to demonstrate that the drug provides value for money based on a robust 
clinical and economic case.  
 
Greater flexibility and uncertainty in the economic case is accepted in certain specific 
circumstances, where a greater uncertainty or higher cost per QALYs is accepted.  
This applies to orphan drugs as per the EMA definition of orphan designation.  SMC 
recognises that trial patient populations may be smaller and accepts greater uncertainty 
in the economic case in this respect.  Additional factors are also: life-threatening 
disease, substantial increase in life-expectancy or quality of life, reverses rather than 
stabilises the disease, or bridges the gap to a definitive therapy.  More detail is required 
for other parts of the submission, such as the relevance of surrogate markers and the 
theoretical basis for their selection.  Additionally, SMC requires that long term 
monitoring be implemented about the use of the drug (e.g. patient registries).  
 
A higher ICER is accepted when the economic case is robust & additional factors 
pertaining to orphan drugs are true: 
- Substantial improvement in life expectancy with sufficient quality of life (e.g. 
median gain of 3 months survival) 
- Substantial improvement in quality of life (with or without survival benefit) 
- Specific and extra benefit for a subgroup of patients 
- Absence of therapeutic options provided by the NHS 
- Possible bridging to another therapy (e.g. bone marrow transplantation) 
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- Licensed medicine as an alternative to an unlicensed product used in NHS 
Scottish clinical practice. 
- Additional other drug and disease characteristics highlighted by the 
manufacturer and by clinical or patient experts (e.g. PAPIG). 
 
Since October 2013, a new procedure has been implemented at SMC for end of life 
(for patients with less than 3 years life expectancy) and ultra-orphan drugs (for 
conditions affecting less than 1 in 50,000).  This does not apply to our study given than 
it does not apply to our study period.  
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Sweden: Dental and Pharmaceutical Benefits Board (TLV) 
 
The TLV is a regulatory body deciding on the pricing and reimbursement of drugs in 
Sweden.  During the study period, TLV appraised primarily outpatient drugs.  Three 
different processes exist: the new drug, the re-assessment, and hospital drug process. 
This study will focus solely on the new drug process.  It is up to the company to apply 
for reimbursement.  Drugs that haven’t been assessed by TLV are in general not 
reimbursed.  Reimbursement decisions are based on three principles: cost-
effectiveness, human value, and need and solidarity, adopting a holistic perspective 
where medical, humanitarian and socio-economic aspects are considered.  The 
company carries the burden of proof, and TLV’s decision is based on the 
manufacturers’ submission together other available evidence, and advice from 
scientific advisors and medical experts.  A memorandum is written with the decision 
and course of action.  Companies have a few weeks to comment, and if the decision is 
restrictive, companies also have an opportunity to discuss with the committee.  The 
final decision is then made, and a written decision is issued to the public; this is the 
report analysed in this research. 
 
TLV New Drug Appraisal process 
Source: personal communication with TLV 
Application from company 
Questions of clarification to the company 
Investigation by TLV 
• Contact with external experts (if needed) 
 
Memorandum to the company – with the suggested decision form the working 
group 
Memorandum to the deciding committee 
Company has the possibility of having a discussion with the committee if the 
decision is unfavorable for the company 
Decision by the committee 
Appeal (decided by the company) 
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France: Haute Autorité de Santé (HAS) 
 
The HAS is an advisory body to the Minister of Health in France, assessing a drug’s 
medical benefit using a health service perspective.  The Commission nationale 
d’évaluation des dispositifs médicaux et des technologies de santé (CNEDiMTS) is an 
independent scientific body within the HAS that appraises the evidence.  Two different 
processes exist: new drugs, and re-assessments; the first is the focus of this research.  
As of October 2013, economic evaluations are being conducted by HAS, but will not 
be included in this research given that the study drugs were appraised prior to this.  All 
drugs undergo the assessment at HAS, where manufacturers are invited to submit an 
HTA application; the CNEDiMTS will also review the literature and in some instances 
request input from stakeholder experts.  Focusing on the drugs that are approved for 
the first time, HAS focuses solely on the drug’s clinical effectiveness, and assesses its 
medical benefit (“Service Médical Rendu”) and relative improvement in medical 
benefit (“Amélioration du Service Médical Rendu”), ranking treatments from major to 
insufficient medical benefit and major innovations to no improvement through SMR 
and ASMR ratings respectively.  SMR ratings drive the general coverage rate (e.g. a 
major or important SMR with a high disease severity is covered at 65% of the cost, for 
the remainder of cases it is covered at 35%).  Patients with a rare disease are eligible 
for 100% coverage, regardless of the coverage for the drug.  ASMR will drive 
reimbursement decisions based on improvements in therapeutic benefit in relation to 
the current standard of care.  Assuming the SMR rating is positive, the ASMR 
assessment has been used to provide an appraisal of the drug’s perception by the 
decision maker relative to its comparator(s).  A technology receiving an ASMR V 
rating is classed as providing no additional therapeutic benefit and coverage occurs if 
the price of the technology is equal to, or lower than its comparator(s).  The process 
lasts 180 days. 
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HAS new drug assessment process 
 
Source: L’évaluation des  médicaments à la HAS, Powerpoint presentation by Dr  Francois Meyer, March 2011 
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Appendix B. Case Study example 
 
Indication & HTA recommendation 
Eltrombopag (Revolade©) received EMA marketing authorisation to treat chronic 
immune (idiopathic) thrombocytopenic purpura:  
- in splenectomised adults whose condition is refractory to other treatments 
(corticosteroids, immunoglobulins), or 
- as 2nd line treatment in non-splenectomised adults where surgery is 
contraindicated. 
 
It underwent the HTA process in the four study countries for this same indication and 
received diverging recommendations: rejected by NICE, restricted by SMC, TLV, and 
HAS (Table 1). 
 
Table B-1. HTA recommendations and restrictions 
HTA body NICE SMC TLV HAS 
Date of recommendation 10.2010 07.2010 05.2011 06.2010 
Recommendation Reject Restrict Restrict SMR important 
(65% 
reimbursed)* 
ASMR II  
Restrictions     
Patient population with severe 
ITP and high risk of bleeding 
     
Re-assessment (October 2013)      
Hospital use      
* Coverage is 100% under the ALD programme (Affectation de Longue Duree) 
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Evidence submitted 
 
Efficacy & Safety 
 
The primary phase III RCT trial, RAISE, was appraised by all alongside a number of 
additional secondary trials.  In the HTA report, NICE was the only agency to report 
results from subgroup analyses for two groups of patients: splenectomised (whose 
spleen has been removed) and non-splenectomised patients (whose spleen has not been 
removed).  The additional trials considered included: (1) a dosage research phase II 
trial (TRA100773A) considered by NICE and HAS; (2) a phase III trial 
(TRA100773B) considered by all (despite the trial name not being specified in SMC’s 
report, it was assumed to correspond based on the same trial design and outcomes); (3) 
a meta-analysis including three trials only considered by NICE (RAISE, 
TRA100773A, and TRA100773B); (4) an open-label (REPEAT) and an open 
extension (EXTEND) trial only considered by HAS; and  (5) an indirect comparison of 
eltrombopag (RAISE) with romiplostim (Kuter 2008) considered by NICE, SMC, TLV 
(Table B-2).  
 
Table B-3 summarises the clinical endpoints for each of the trials considered and 
included in the HTA reports. A variety of ways to report the clinical endpoints were 
seen. Some of the endpoints were not reported by all agencies, and in other cases the 
outcomes depended on the population or instrument used. For instance, WHO 3-4 
bleeding events, which correspond to the more severe events, were only reported by 
NICE. Quality of life relied on the number of domains reported, where it was 
significant over 4 and not over 6. Results from the indirect comparison were 
significant across the whole population, but non-significant when considering the 
subgroups of patients separately, and so forth (Table B-2). 
 
Table B-2. Clinical trials and endpoints  
 NICE SMC TLV HAS 
RAISE 
Phase III, N 197, 6 months, placebo-controlled 
Platelet response * *   
Rescue treatment     
Bleeding (WHO 1-4)     
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Bleeding (WHO 2-4) 
(= clinically significant bleeding) 
    
Bleeding (WHO 3-4)     
Concomitant medication 
(% reducing or stopping concomitant 
medication) 
    
HRQOL (SF36) 
(4) = 4 domains; (6) = 6 domains 
 (4) 
 (6) 
 (4) 
 
  
Response duration     
75% minimum response     
Improvement activities and concerns 
associated with Thrombocytopenia 
    
Main reduction in bleeding in group 
WHO 2 
    
Subgroup RAISE 
Splenectomised (1/3) 
Platelet count     
Rescue treatment      
Bleeding (WHO1-4)     
Bleeding (WHO2-4)     
Subgroup RAISE 
Non-splenectomised (2/3) 
Platelet count     
Rescue treatment      
Bleeding (WHO1-4)     
Bleeding (WHO2-4)     
TRA100773A 
Phase II, N 118, 6 weeks, placebo-controlled 
Platelet response     
TRA100773B 
Phase III, N 114, 6 weeks, placebo-controlled 
Platelet response     
Bleeding     
HRQOL     
REPEAT (TRA 108057) 
Open-label, N 66, 26 weeks 
Platelet response     
EXTEND (TRA 105325) 
Open extension, N 207, Average 91.5 days (range 2-523 days) 
Platelet response     
Secondary endpoints     
Indirect comparison 
RAISE-KUTER 2008 
Platelet response     
Platelet response, splenectomised     
Platelet response, non-splenectomised     
Legend. : statistically significant, : not statistically significant, : reported, : 
considered within a meta-analysis (combined result). 
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Safety 
 
The safety profile of eltrombopag was appraised based on a number of types of 
adverse events.  These were reported by all agencies, except TLV.  Table B-3 suggests 
that SMC and HAS conducted a more thorough toxicity assessment, according to the 
number of more severe adverse events reported.  Some of these risks were a major 
concern for HAS, whose HTA recommendation was conditional until reassessment of 
results from the risk management plan to be implemented by the manufacturer. 
 
Table B-3. Adverse events reported in the different countries  
 NICE SMC TLV HAS 
Type of adverse events (AE) reported 
Common AE     
Clinically significant or severe AE     
% of cases with AE     
Deaths     
Discontinuation     
Similar to SPC     
Reporting of specific more severe or significant events 
Liver dysfunction     
Cataracts     
Reticulin deposits in bone marrow     
Hepatobiliary laboratory abnormalities     
Thromboembolic events     
Risk of malignant haematological diseases     
Recurrence of thrombocytopenia on 
treatment cessation 
    
Risk of bone marrow fibrosis     
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Economic models 
 
A variety of economic models were submitted in the different study countries.  
Differences were seen in the comparators and types of economic models were used.  
Three cost-utility models were reported for NICE: a) the “watch and rescue model” 
that compared eltrombopag and “watch and rescue” to “watch and rescue” alone, b) 
the “long-term continuous model” that looked at eltrombopag as part of a long-term 
sequence of treatments, and c) a cost-effectiveness model comparing eltrombopag to 
romiplostim.  “Watch and rescue” treatment consists of immunosuppressive agents and 
if necessary rescue treatments for bleeding with anti-D or intravenous 
immunoglobulin.  In contrast, the SMC submission included a cost-utility model 
comparing eltrombopag with romiplostim, and TLV a cost-minimisation analysis with 
the same comparator. 
 
Interpretation of the evidence 
 
Clinical uncertainties 
 
A number of concerns about the clinical evidence were raised by the different agencies 
(Table B-4).  NICE and SMC were concerned about the trial duration (6 months for 
RAISE, and 6 weeks for the other trials), which were deemed too short to reflect 
clinical practice and long-term safety.  This was further confirmed by clinical experts 
at NICE.  This concern was also raised by HAS, but because the treatment was 
considered to partially address an important public health need, the benefit of 
eltrombopag was nevertheless considered similar to its comparator romiplostim despite 
the lacking of direct comparative data. 
 
TLV and NICE were also concerned about the lack of direct comparative data with 
romiplostim.  For SMC, the main issue was that the effect of eltrombopag as a 2nd line 
treatment is unknown given that only placebo comparisons were presented.  
 
NICE, SMC and TLV considered the indirect comparison of eltrombopag (RAISE) 
with romiplostim (Kuter 2008), but only NICE reported the detailed results in the HTA 
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report.  NICE and SMC raised a number of issues related to these.  The nature of this 
indirect comparison was deemed uncertain, which considered both alternatives to 
have similar effect.  Reasons for these uncertainties were due to the differences 
between the study populations and the specification of the clinical endpoint (overall 
response).  In the case of NICE, the manufacturer and ERG revised the comparison, 
which showed little impact on the initial results and was statistically significantly in 
favour of romiplostim.  The sensitivity analysis showed no differences between 
treatment groups.  For SMC, sensitivity analysis showed no difference in efficacy 
between both treatments; it also indicated that a mixed treatment comparison may have 
been more appropriate to account for trial differences.  
 
Although eltrombopag demonstrated improved outcomes in platelet response and need 
for rescue medication, NICE was concerned by the fact that this improvement was not 
significant in the more severely affected patient population (Bleeding events WHO3-
4); this was not raised by the other agencies, and what is more, this clinical endpoint 
was not recorded in their HTA report.  
 
HAS was concerned that the impact of eltrompobag on quality of life was not 
adequately documented, although it was considered to be severely affected by ITP.  
This was not raised by TLV, and was not a concern for NICE and SMC, given that 
quality of life data was included in the submission. 
 
Eltrombopag is indicated in “splenectomised adults whose condition is refractory to 
other treatments, and as 2nd line treatment in non-splenectomised adults where surgery 
is contraindicated”.  NICE however raised concerns that the trial population was not 
in line with the indication being assessed.  First, a 17% response rate in RAISE was 
seen in the comparator arm, together with a minority of patients received treatment 
with intravenous immunoglobulin, which goes against the assumption that these 
patients are refractory to other treatments; second, the study population included in the 
non-splenectomised group did not have any contraindications to splenectomy.  Further, 
NICE was concerned that RAISE included only patients with low platelet count 
where the risk of bleeding is variable, and not those with a persistent risk of bleeding.  
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Trial representativeness was raised by NICE and the SMC, where the trial population 
was deemed not to be representative of the UK and Scottish population respectively; 
clinical experts at NICE, however, confirmed the plausibility of this concern.  For the 
SMC, initiation of treatment with eltrombopag based on platelet count is not deemed to 
reflect clinical practice that would also consider symptoms and whether an invasive 
procedure is planned.  Finally, SMC was concerned that eltrombopag requires liver 
function monitoring. 
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Table B-4. Clinical uncertainties, and whether they relate to the same evidence and were put forward as one of the main reasons for the final 
recommendation. 
 
Evidence 
Considered by 
Interpretation 
Uncertainty raised by 
Outcome 
Main reason for 
recommendation 
 evidence considered 
*evidence considered 
within the primary trial 
 positive 
influence 
(addressed)  
 negative 
influence (not 
addressed) 
 positive 
influence 
(addressed)  
 negative 
influence 
(not addressed) 
Clinical uncertainties 
N
IC
E 
SM
C
 
TL
V
 
H
A
S 
N
IC
E 
SM
C
 
TL
V
 
H
A
S 
N
IC
E 
SM
C
 
TL
V
 
H
A
S 
Lack of comparator (RAISE) * * * *     
  
  
Short duration of trial (RAISE, 6 months) * * * *   
 
  
  
 
Sample size (RAISE) * * * * 
  
 
   
 
 
Trial population, indication under review not 
corresponding (for patients refractory to other 
treatments, contraindication to splenectomy) 
* * * *  
   
 
   
Trial population generalizability  * * * *   
      
Trial population, low platelet count patients 
instead of those with severe risk of bleeding 
* * * *  
       
Low benefit for populations in the lower * 
   
 
   
 
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incidence of the more severe bleeding events 
(WHO 3-4) 
Lack of quality of life data   
     
 
   
 
Liver function monitoring required 
 
 
   
 
      
Uncertain nature of the indirect comparison 
(different trial populations, overall response 
not pre-specified in RAISE) 
   
 
  
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Other considerations 
 
A number of “other considerations” were identified in the reports, some of which were 
also put forward as one of the main reasons for the final decision (Table 5).  Unmet 
need was highlighted by NICE for specific subgroups of the population for which no 
evidence was submitted, and by TLV and HAS who acknowledged that generally 
limited treatment options are available for this population.  HAS mentioned that the 
treatment is curative.  Clinical experts in England qualify eltrombopag as being 
innovative, with a new mechanism of action, together with romiplostim, but no 
evidence demonstrating distinctive benefits was presented and therefore this had no 
impact on the final outcome.  TLV recognised that eltrombopag was part of a new 
class of drugs, and SMC and TLV recognised its advantage from oral administration.  
The drug’s orphan status seems to provide favourable outcomes for the size of the 
trial population for TLV.  For SMC, the orphan status of eltrombopag resulted in 
accepting greater uncertainty in the evidence.  For HAS, the rarity of the condition 
signifies that the public health burden is small.  NICE, TLV and HAS have highlighted 
the important impact of the disease on quality of life to the patient.  NICE also 
accounted for the impact of the disease on patients’ daily activities, lifestyles, ability to 
work, travel and conduct leisure activities, social stigma, or the fact that the disease is 
life threatening.  For NICE although patients may have some anxiety to undergo 
surgery, clinical specialists indicate that surgery is today routinely performed with very 
few medical contraindications.  Similarly, TLV acknowledged the severe and life 
threatening condition, and the fact that patients’ functional capacities are affected from 
having the disease.  HAS also recognised the severe condition, and impact on daily 
activities. 
 
Clinical experts in England highlight the fact that no routine practice for ITP exists, 
and that treatment pathways depend on the patient’s characteristics.  SMC also 
recognised the complexity of these treatment pathways.  ITP is recognised as a 
national priority in France because it is an orphan drug (“Plan Maladies Rares, 2004).  
Finally, more flexibility was given to issues relating to the clinical evidence (lack of 
direct comparisons, short duration of trials) based on the fact that an important public 
health need was recognised in France (Table B-5).   
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Table B-5.  “Other considerations” identified across the study countries 
TREATMENT 
CHARACTERISTICS 
NICE SMC TLV HAS Quotations 
Type of therapeutic benefit      
• Curative    * HAS: “eltrombopag is a curative treatment” (translated) 
Innovativeness of treatment C    NICE: “Innovative treatment that mimics the action of 
the hormone thrombopoietin and stimulates platelet 
release from the bone marrow” 
• Novel mechanism of action     NICE: “with romiplostim, eltrombopag represents a new 
approach to therapy” 
• New class of drugs   *  TLV: “the drug belongs to a new class of drugs” 
(translated) 
• Oral administration benefit  * *  SMC: “benefit from oral administration” 
TLV: “eltrombopag is the only oral treatment available” 
(translated) 
Adverse effects      
• Adverse effects similar across 
treatment arms 
    NICE: “adverse events were similar between the 
eltrombopag and placebo groups in RAISE” 
DISEASE CHARACTERISTICS      
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Unmet need  C    NICE: “greatest unmet need for treatment for patients 
with a low platelet count and persistent risk of 
uncontrolled bleeding, and that a sequence of treatments, 
in which eltrombopag might have an appropriate place, 
would be used to control the persistent risk of bleeding” 
• No treatment alternatives exist   *  SMC: “Oral corticosteroids and intravenous 
immunoglobulin are recommended as first-line 
treatments but the recommendations for second-line 
therapy and treatment of refractory patients are less clear. 
In these patients treatment should be tailored to suit the 
individual.” 
TLV: “no satisfactory treatment options for patients with 
chronic refractory ITP exist (only romiplostim and 
eltrombopag).” (translated) 
• Few treatment alternatives exist   *  NICE: “limited treatment options when conventional 
treatments fail to reduce risk of bleeding” 
TLV: “treatment options are limited” (translated) 
HAS: “limited therapeutic options available” (translated) 
• Need for treatment options  *   SMC: “Eltrombopag will provide an additional treatment 
option” 
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Nature of the condition      
• Disease severity   *  TLV: “patients with severe disease may lead to severe 
haemorrhage” (translated) 
 
• Serious condition    * HAS: “ ITS is a serious condition” (translated) 
• Quality of life  C, P  * * NICE: “affects quality of life” 
HAS: “important impact on quality of life of patients 
that have a risk of bleeding” (translated) 
TLV: “quality of life affected” (translated) 
• Functional capacity affected   *  TLV: “functional capacity affected” (translated) 
• Impact on daily activities  C, P    NICE: “bleeding and bruising can have significant 
impact on patients’ daily activities ” 
HAS: “daily activities are limited from having the 
disease”  (translated) 
• Social stigma  C, P    NICE: “bruising can lead to social stigma” 
• Limiting of life-style choices  C, P    NICE: “bleeding can prevent or delay surgery and limit 
life style choices” 
• Anxiety from risk of bleeding     NICE: “anxiety about the risk of bleeding can also affect 
quality of life” 
• Ability to work, travel or leisure  C, P    NICE: “impact on person’s ability to travel and take part 
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activities in leisure activities” 
• Life threatening  C, P  *  NICE: “Spontaneous bleeding is an important but rare 
cause of premature death in people with ITP” 
TLV: “severe disease that may lead to death in the worst 
cases” (translated) 
Rare disease characteristics      
• Orphan  *   SMC: “weaknesses in the clinical evidence were deemed 
acceptable partly because of the treatment’s orphan 
status” 
 
• Rarity   * * TLV: “evidence is consistent and based on a relatively 
large number of patients given that ITP is rare” 
(translated) 
HAS: “minor public health burden because of the rarity 
of the condition” (translated) 
Clinical practice/management      
• No standard treatment pathway 
used in routine practice 
 C    NICE: “no single treatment pathway could be defined as 
routine practice” 
• Unlicensed comparator  C    NICE: “rituximab does not have a marketing 
authorisation for the treatment of chronic ITP” 
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• Complex and tailored to patient C  C   NICE: “the pathway for ITP would vary depending on 
the individual person’s circumstances” 
SMC: “the approach of treatment has become more 
conservative and its initiation is based on clinical 
symptoms and whether invasive surgery is planned, in 
addition to platelet count” 
• Adverse events of comparator 
treatments important 
 C, P    NICE: “current treatment options may be associated 
with adverse effects” 
• No long term evidence with 
comparative treatments 
 C    NICE: “no long term safety data are currently available 
for people treated with rituximab” 
• Correct dosage of treatment 
alternative unknown 
    NICE: “correct dosage of rituximab is unknown” 
• Preference for licensed over non-
licensed 
C    NICE: “preference to use licensed treatments before 
unlicensed options” 
• Anxiety related to treatment 
alternatives 
 P    NICE: “anxiety about the risk of contracting a hospital-
acquired infection and the increased risk of infection 
following spleen removal, which requires life-long 
treatment” 
National priority    * HAS:  “Plan Maladies Rares”  (translated) 
Legend: C: information provided from clinical experts; P: information provided from patient representatives; *: put forward as main reason for 
decision
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Economic model uncertainties 
 
A number of concerns relating to the economic modelling were raised, and are 
discussed here (Table B-6).  In the NICE submission, the first model (“watch and 
rescue model”) was rejected because of its high and uncertain cost-effectiveness.  
Concerns about the assumptions included: (1) the trial population not corresponding to 
the indication under review, (2) the assumption that differences in treatment arise 
because of bleeding events, (3) the assumption that the 26-week time horizon was 
similar in the future, and (4) the issues in the comparability of the evidence with 
romiplostim.  Further, sensitivity analysis showed that the model was mainly driven by 
costs and not by clinical benefit, and multivariate exploratory analysis showed that 
there was a high degree of uncertainty in the model results.  Consultation consultees 
suggested to consider the low budget impact of this drug, but the Committee responded 
that they do not account for this in their assessment.  The challenges in modelling 
because of unknown clinical practice were also argued, though based on STA 
guidelines, the Committee does not give more flexibility to this type of scenario.  The 
Committee did not account for the innovative nature of the treatment since no evidence 
demonstrating distinctive benefits was submitted. 
 
For the long-term continuous model, similar issues were raised: (1) the trial population 
not corresponding to the indication under review, (2) the treatment sequences used not 
likely to reflect clinical practice, (3) the fact that it is uncertain where the place of 
eltrombopag in this sequence should be, and (4) the uncertainties around the relative 
effectiveness with comparator treatments.  Further, there were large variations in the 
ICER with changes in the order of treatments with rituximab, and was driven by large 
variations in cost and little variations in health benefit.  Consequently, the model was 
considered not to be valid given the assumptions and the cost per QALY that was 
greater than the acceptable 100 thousand pounds per QALY.  
 
Finally, the model comparing eltrombopag to romiplostim was considered not to be 
relevant to the decision problem being considered, and as such rejected.  This was 
mainly because of a number of issues raised with the model and the fact that 
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romiplostim was under review with NICE and therefore not routinely used in clinical 
practice. 
 
In the model appraised by SMC (cost-utility model comparing eltrombopag with 
romiplostim), the nature of the indirect comparison led to uncertainties in the drug’s 
relative effectiveness.  Despite this, the treatment was considered cost-effective given 
the benefit from oral administration and its orphan status.  
 
TLV considered a cost-minimisation analysis comparing eltrombopag with 
romiplostim.  Eltrombopag was considered cost-effective, given that clinical benefits 
in both drugs were deemed comparable, and that the cost of treatment for eltrombopag 
was lower than romiplostim, which was already previously considered cost-effective 
for TLV. 
 
Table B-6. Economic models and final ICER considered for decision, clinical 
uncertainty 
 NICE SMC TLV 
Watch and rescue model 
(eltrombopag versus standard 
care)  
Cost-utility model 
Splenectomised: 
£104,100/QALY 
Non-splenectomised: 
£116,800/QALY 
  
Short duration of trial (RAISE) *   
Low benefit for populations in the 
lower incidence of the most severe 
bleeding events 
*   
Lack of adverse event data for 
comparator treatments 
   
Assumption made that differences 
between treatments arise because of 
bleeding events 
*   
Sensitivity analysis suggested that 
the model driven by costs and very 
small difference in effect 
*   
Exploratory multivariate analysis: 
high degree of uncertainty in the 
model results 
   
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Long-term continuous treatment 
model 
Cost-utility model 
Not reported 
  
Suitability of trial population for 
modelled population 
   
No survival benefit across treatment 
sequences 
   
Sequences presented do not reflect 
clinical practice, according to 
clinical specialists 
*   
Eltrombopag versus romiplostim Cost-utility model 
Not reported 
Cost-utility model 
Splenectomised: 
Savings £12,641 and 
0.039 QALY gain 
(dominant) 
Non-splenectomised: 
Savings £2,094 and 
0.028 QALY gain 
(dominant) 
Cost-
minimisation 
model 
Similar benefit 
to romiplostim 
at lower cost 
Eltrombopag was superior to 
romiplostim using this crude 
comparison of bleeding events, but 
there is no robust evidence to 
support this assumption as a formal 
indirect comparison based on this 
outcome was not conducted 
   
Choice of clinical endpoint: bleeds 
instead of primary endpoint platelet 
response 
   
Sensitivity analysis showed no 
difference with romiplostim 
   
The relative risk of bleeding events 
would have to fall substantially from 
the base case values before 
eltrombopag would no longer be 
considered cost-effective 
   
Budget impact No impact No impact  
Legend:  uncertainty not addressed; * uncertainty put forward as one of the main 
reasons for the final decision. 
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Final HTA recommendation 
 
The reasons for the HTA recommendations issued are summarised in Table B-7, and 
includes the overall conclusion about the treatment’s clinical effectiveness and main 
reasons for this, as well as the conclusion about the treatment’s cost-effectiveness and 
main reasons for this. 
 
 
Table B-7. Conclusions about clinical effectiveness and cost-effectiveness 
HTA body NICE SMC TLV HAS 
Recommendati
on 
DNL LWC L ASMR II - 
LWC 
Clinical 
effectiveness 
* * * * 
Main reasons 
for clinical 
effectiveness 
assessment 
Platelet 
response was 
better for 
eltrombopag 
than placebo, 
but results 
were deemed 
uncertain 
because of the 
long-term 
effect 
 
 
Although 
clinical 
evidence weak, 
significantly 
more effective 
than placebo in 
raising and 
maintaining 
platelet count – 
benefit from 
oral 
administration 
and orphan 
status. 
Indirect 
comparison 
shows that 
drugs are likely 
to have similar 
effects, though 
small patient 
population, it is 
acceptable 
because of 
orphan status. 
 
Follow-up on 
clinical 
effectiveness 
and 
uncertainties in 
October 2013. 
Limited trial 
duration and 
lack of 
comparative 
data. Benefit 
deemed similar 
to romiplostim 
until further 
evidence 
provided 
 
Risk 
assessment 
plan to monitor 
toxicity. 
Cost- * *  NA 
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effectiveness 
Main reasons 
for cost-
effectiveness 
assessment 
Watch and 
rescue model: 
uncertain 
effects = 
unacceptable 
cost/QALY > 
£100k 
 
Continuous 
model: trial 
population not 
generalizable 
to ITT 
population, 
treatment 
sequence not 
consistent with 
clinical 
practice 
 
Uncertainties 
in clinical 
evidence 
addressed as 
per above 
Similar benefit 
to romiplostim 
at lower price 
(comparator 
having been 
assessed as 
cost-effective). 
 
*: clinical effectiveness uncertain and not demonstrated 
: improved or positively assessed clinical effectiveness 
 
Notes: HAS issued an ASMR II rating because it is deemed similar to romiplostim in 
terms of the expected public health benefit, although this expected is considered to be 
weak because of lack of evidence.  
  
 
326 
Appendix C. Interview Topic Guide 
TOPIC GUIDE FOR INTERVIEWS 
Haute Autorité de Santé 
 
The objective of these interviews is to ask a number of open-ended questions around 
some of the findings from an on-going research project, which aimed: (a) to identify 
the criteria underlying the HTA opinions for a number of orphan drugs, and (b) to 
understand why, for a same drug and indication, different HTA bodies issued different 
opinions.  This is to ensure that the interpretation of the researcher when analysing the 
opinions was accurate, particularly in cases when differences across countries were 
one of the explanatory factors for different HTA outcomes, to correct any 
misinterpretations and to obtain further insights into the drivers of these opinions in 
each agency.  This research is being undertaken in the context of Advance_HTA, a 
project funded by the European Commission’s Research Framework Programme 
(FP7). http://www.advance-hta.eu  
 
Findings were derived from a mixed methods research project that enabled (1) the in-
depth analysis of the decision processes through case study analyses, and (2) the 
generalisation of findings across all case studies.  In the first stage, a case study 
template was set up and used for each drug-indication pair, from which the criteria 
driving the HTA opinions were identified and extracted from the HTA reports 
(publicly available on the agencies’ websites).  On the basis of this case study, 
thematic analysis was conducted to code the HTA reports according to a previously 
established coding manual listing the criteria driving these opinions.  This allowed for 
the comparison across cases, which helped us to better understand how different 
agencies conduct value assessments as well as the reasons for differences across 
countries.  The HTA bodies included are: the National Institute for Health and Clinical 
Excellence (NICE) in England, Scottish Medicines Consortium (SMC) in Scotland, 
Pharmaceutical and Dental Benefits Consortium (TLV) in Sweden, Haute Autorité de 
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Santé (HAS)9 in France.  Ten drug and indication pairs were included in the study 
(Appendix C-1).  
 
Interviews will take place face-to-face (or if no convenient dates are found by skype or 
by phone), and may last approximately one to two hours, depending on your 
availability.  Interviewees are competent HTA body representatives, which may 
include the Head of one of the Committees making the recommendations, a clinician 
Committee member, a pharmacist or health economist.  The interview topic guide 
consists of this document and will be used as a basis for the discussion.  Interviewees 
may send their responses in writing prior to the interview if desired.  The interview 
questions are divided into four general themes: (a) General evidentiary requirements 
for orphan drugs; (2) Other considerations; (3) Dealing with uncertainty; (4) 
Stakeholder involvement. Each theme discusses a number of related issues that were 
derived from cases when differences were seen across countries, or when it was 
unclear how certain of the identified criteria influenced the opinions. 
 
These interviews are a way forward to furthering the debate about a number of HTA 
methodological issues, while simultaneously raising awareness about the types of 
differences that are seen across countries, which may also be applicable within 
countries when more than one decision-making body exists. 
 
Thank you for your participation.  
 
                                                 
 
9 The analysis focuses on the Opinion issued by the Transparency Committee, and its 
conclusions about the assessment of actual benefit (“Service Médical Rendu (SMR)”), 
improvement in actual benefit (“Amélioration du Service Médical Rendu (ASMR)”), and final 
recommendations. 
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GENERAL EVIDENTIARY REQUIREMENTS 
This section seeks to understand what scientific evidence is required, and to what 
extent it is different for orphan drugs compared to other drugs.  
 
1. Primary evidence  
For 8 of the 10 study drugs (Appendix C-1), the primary evidence considered was 
phase III trials; for the remaining two study drugs, it was phase II trials (e.g. 
trabectedin and ofatumumab).  The latter cases were due to the early marketing 
authorisations granted by the EMA, and therefore the manufacturers were not required 
to conduct any RCTs.  Additionally for ofatumumab, results relied on an interim 
analysis of subgroup data (Table C-1).  
For trabectedin, the primary endpoint “time-to-progression” was significantly 
improved.  Similarly for ofatumumab, the primary endpoint “response rate” was also 
significantly improved. 
 
Table C-1. Phase II primary trials & recommendations 
Trabectedin 
Soft tissue sarcoma 
Ofatumumab 
Chronic lymphocytic leukaemia 
STS-201: phase II randomised trial (N 
270) testing trabectedin at different doses 
(cross overs permitted) 
Subgroup analysis of Hx-CD20-406 
including patients refractory to 
ludarabine and alemtuzumab (N 59) 
 
Hx-CD20-406: prospective, non-
randomised, non-comparative phase II 
trial (N 154) testing different groups of 
patients refractory to different therapies 
or non-refractory (3 arms). 
NICE SMC TLV HAS NICE SMC TLV HAS 
 
Restricted 
 
Rejected 
NA SMR 
Important 
ASMR V 
 
Rejected 
 
Rejected 
NA SMR 
moderate 
ASMRV  
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All HTA bodies were concerned about the trial designs, including the lack of 
comparative evidence, but this was perceived in different ways (Table C-2).  
Additionally, for ofatumumab, all HTA bodies deemed the nature of the subgroup data 
insufficient to demonstrate the drug’s clinical benefit (Table 2). 
 
Table C-2. How the lack of comparative data was perceived by the HTA bodies 
(✔ acceptable, or ✗ not acceptable) 
 NICE SMC HAS 
Tr
ab
ec
te
di
n 
✔ rarity of the condition 
✔ investigational nature  
✔ registry data as 
historical controls 
 
✔LWC (discount) 
✔ rarity of the condition 
✔ investigational nature  
 
 
 
✗ DNL 
✗ therapeutic 
contribution unknown 
given the lack of 
comparative evidence 
(ASMR V) 
 
✔ SMR important (no 
validated alternative 
drug)   
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O
fa
tu
m
um
ab
 
✗non-comparative 
study 
✗difficulties in 
conducting RCTs could 
have been better 
addressed, where 
methylprednisone could 
have been used as a 
comparator 
✗only interim results 
were available 
✗small patient numbers 
=> uncertain size of 
effect in the absence of 
robust comparative 
evidence and immaturity 
of the data 
 
✗ DNL 
✗non-comparative 
study 
✗only interim results 
were available 
✗small patient numbers 
=> the robustness of the 
response shown in this 
study and its ability to 
be translated into a 
clinical benefit is 
uncertain, due to the 
small patient numbers 
and interim nature of the 
analysis 
 
 
 
✗ DNL 
✗non-comparative 
study 
✗only interim results 
were available 
=> efficacy hard to 
assess in view of the 
methods used. Limited 
clinical data obtained 
from the interim analysis 
✔  Provisional while 
awaiting complementary 
data: SMR moderate (no 
alternative drug) 
✔  Provisional ASMR 
V while awaiting 
complementary data 
 
Questions: 
 Are phase III trials preferred as primary evidence for the appraisals (e.g. as seen in 
the results)? 
 
 To what extent is evidence from phase II trials, subgroup analyses or ATU usage 
acceptable as primary evidence (e.g. criteria for acceptability? e.g.  trabectedin and 
ofatumumab)?  
 
 To what extent are indirect comparisons acceptable? (e.g. preference for indirect 
comparisons if direct comparative evidence weak? Define types of weaknesses) 
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 Is it common that the comparators included in the assessment are not deemed the 
appropriate ones? 
 
 To what extent can registry data be acceptable to proxy historical controls when no 
comparative data is available (e.g. as seen in the NICE appraisal for trabectedin)?  
 
 Sir Michael Rawlins discusses the criteria for acceptability of historical controls.10 
Would these be acceptable for your HTA agency and this approach in general for 
non-phase III evidence? Please explain. 
 
 
2. Non-primary evidence 
A number of non-primary non-phase III trials were reported in the HTA reports for the 
10 study drugs.  These, however, had very little influence on the final outcome.  
Outcomes from these trials were generally not reported, and when reported, the type of 
data provided was around safety (e.g. romiplostim, ofatumumab, eltrombopag), dosage 
research (e.g. eltrombopag) and historical controls (e.g. trabectedin). 
Questions:  
                                                 
 
10 In: Rawlins, M. (2008). De Testimonio: on the evidence for decisions about the use of therapeutic 
interventions. Clinical Medicine, 8, 579-588. 
In the context of HIV trials, the following requirements should be met for historical controls:  
• “there must be no other treatment appropriate to use as a control; 
• there must be sufficient experience to ensure that the patients not receiving treatment will have a 
uniformly poor prognosis;  
• the therapy must not be expected to have substantial side-effects that would compromise the 
potential benefit to the patient;  
• there must be a justifiable expectation that the potential benefit to the patient will be sufficiently 
large to make interpretation of the results of a non-randomised trial unambiguous; 
• and, the scientific rationale for the treatment must be sufficiently strong that a positive result would 
be widely accepted.” 
Cited from: Byar DP, Schoenfield DA, Green SB, et al. Design considerations for AIDs trials. N Engl J 
Med 1990; 323: 1343–48. 
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 How is non-primary evidence accounted for during the appraisal process, what 
type of information is provided, and are there any criteria in accepting this type of 
evidence (e.g. promise of another study)? 
 
 
3. Trial length 
In two cases the trial duration of the primary trials were deemed too short by some of 
the HTA bodies.  
• For imatinib, this was an identified concern for NICE and SMC (negatively 
influencing the opinion), but was not mentioned in the HAS recommendation.  The 
drug was not appraised by TLV. 
• This issue was also raised by all agencies for eltrombopag.  For HAS, eltrombopag 
received the same ASMR II rating as romiplostim (Nplate).  For the others, this 
had a negative influence on the opinions, where additionally, it was also confirmed 
as not long enough by clinical experts at NICE. 
 
Questions: 
 How is the appropriate trial duration determined, and under what circumstances 
could a trial considered too short be deemed acceptable (e.g. same length as 
comparator)? 
 
 Given that the appropriate trial length is discussed for the marketing authorisation 
(MA) stage, how are these MA determinants perceived within the HTA decision 
(e.g. degree of reliance, any differences in perspectives)? 
 
 
4. Primary endpoints 
Eltrombopag was appraised in all four countries based on the pivotal trial RAISE 
(phase III placebo-controlled RCT) and received diverging recommendations by the 
study countries (Table C-3).  
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Table C-3. HTA recommendations 
NICE SMC TLV HAS 
  REJECT  RESTRICT to 
patients with severe 
ITP and high risk of 
bleeding 
 RESTRICT for 
hospital use & 
reassessment in 2013 
 SMR important  
ASMR II 
 
 
The primary endpoint was “platelet response” and secondary endpoints included 
“WHO bleeding events” of different grades of severity (Table C-4). 
 
Table C-4. Bleeding events and their statistical significance in RAISE (pivotal 
trial for eltrombopag). 
 NICE SMC TLV HAS 
WHO bleeding event 1-4  
= all events 
    
WHO bleeding event 2-4  
= clinically significant events 
    
WHO bleeding event 3-4 
= gross and debilitating blood loss 
    
Legend:  significantly improved;  non-significantly improved. 
 
One of the reasons for rejecting the drug by NICE was that no significant differences 
between treatment groups in the low incidence of the most serious bleeding events 
(“WHO bleeding events grades 3 and 4”).  
 
Questions: 
 How is the relevant endpoint identified (e.g. trial’s primary endpoint, proxy for 
survival, most relevant to the patient)?  
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 The CT minutes indicate that the members discussed the existence of 
supplementary data concerning the effect of Revolade on bleeding compared with 
Nplate.  Given that both drugs were available under ATUs, one could speculate 
whether the outside expert had additional data from clinical use in France.  Is this 
data and/or clinical experience with drugs based on ATUs considered in the 
evaluation process? 
 
 
5. “Overall survival” versus progression-free survival 
A preference for “overall survival” was seen in a NICE appraisal (e.g. mifamurtide), 
where it was considered as the endpoint of interest despite “progression-free survival” 
(PFS) being the primary endpoint in the trial.  This had a negative influence in the 
opinion given it was not significantly improved (compared to PFS which was 
significantly improved positively influencing the assessments in other countries). 
In another case (e.g. imatinib), the secondary endpoint “overall survival” was not 
significantly improved.  This was one of the main reasons negatively influencing the 
opinion for NICE.  In contrast, for SMC and HAS, this was also raised as a concern, 
but was acceptable for SMC given the orphan status of the treatment, and for HAS 
given an on-going trial collecting additional data. 
Questions: 
 Does the CT have a preference for overall survival over progression-free survival, 
even in cases when overall survival is a secondary endpoint in the trial?  
 
 What criteria make that an uncertain clinical outcome is acceptable (e.g. on-going 
trial, rarity)? 
 
 
6. Surrogate endpoints 
The primary endpoints in 8 out of 10 cases were surrogate (e.g. substitute for the 
clinical endpoint of interest), which were predominantly validated with the exception 
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of “time-to-progression” for soft tissue sarcoma (trabectedin) and “platelet response” 
for ITP (eltrombopag, romiplostim). 
 
Questions: 
 Under what criteria for accepting surrogate endpoints (e.g. validated, when the 
relationship between surrogate and clinical endpoint is causal), which is a 
biomarker intended to substitute a clinical endpoint, the latter being ‘a 
characteristic or variable that reflects how a patient feels, functions, or survives’? 
 
 Are surrogate (validated or non-validated) endpoints more acceptable for orphan 
indications? 
 
 
 
PUBLIC HEALTH EVIDENCE  
This section seeks to understand how other evidence and considerations have 
influenced the decision processes, and how. 
  
7. Quality of life data 
Quality of life data was not present in 6 out of 10 cases, and in three other cases, it was 
only present in the assessments by SMC and NICE (eltrombopag, romiplostim and 
everolimus). 
 
Questions: 
 What type of quality of life data is accepted (e.g. from trials, registries, expert 
opinion, etc.), and preferred? 
 
 What are the implications for assessments when quality of life data is missing?   
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 How is quality of life data from different forms of evidence accounted for in the 
analysis of the public health value (intérêt de santé publique)? 
 
8. Innovativeness of the technology 
This research identified a number of instances where the treatment’s innovativeness 
was highlighted during the assessment (Appendix C-2).  No clear or uniform definition 
exists of the determinants of an innovative treatment.  Identifying cases where a 
treatment was recognised as innovative in practice may be a way forward to 
identifying these determinants. 
 
Questions: 
 
 Appendix C-2 lists the quotations coded from the HTA reports as recognising an 
“innovation”.  Do you agree with what was coded as pertaining to the innovative 
nature of the treatment in your country?  Any comments on how this was perceived 
in the other countries? 
 
 How does the orphan status of the drug reflect on innovation, and how does this 
impact the assessment and the ASMR rating?  Does this change depending on 
whether the drug is subject to fast-track consideration or to an ATU?  
 
 What are the criteria for recognising a technology as innovative (e.g. patient 
benefit, new class of drugs, etc.)?  Is administration benefit considered an 
innovation? 
 
 
9. Unmet need 
Unmet need in a given disease area may be considered among the determinants of a 
better ASMR (France) or price (UK).  This research identified a number of instances 
where the disease’s unmet need was highlighted during the assessment (Appendix C-
3).  Again, no clear or uniform definition exists of the determinants unmet need and 
one way of defining these could be by identifying previous cases. 
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Questions: 
 Appendix C-3 lists the quotations coded from the HTA reports as recognising an 
“unmet need”.  Do you agree with what was coded as referring to an “unmet need” 
in your country?  Any comments on how this was perceived in the other countries?  
 
 
 What are the criteria for recognising the “unmet need” of a disease (e.g. no 
treatments, few treatments, no curative treatment, etc.) and how do these influence 
the HTA evaluation of a drug meeting that need? 
 
 
 In Sweden, unmet need is contextualised by the degree of severity (e.g. the severity 
of a condition is defined by the consequences to the patient without the treatment 
under review), what do you think about that? 
 
 
 We assume that few comparators will be translated into a better ASMR.  How is 
unmet need accounted for and could there be double counting if accounted for 
separately from the ASMR.  
 
 
10. Disease severity  
A number of determinants of severity exist, which include the impact on quality of life 
and mobility, or considerations of life expectancy.11  There are two ways to include 
severity into HTA: through a weighing of the QALY (or other measures of HTA), or 
during the deliberative process of HTA.12  The second method would apply to our 
study countries as no specific weighing for severity in the outcome of HTA is seen. 
 
                                                 
 
11 Dolan P, Shaw R. A note on a discussion group study of public preferences regarding priorities in the allocation 
of donor kidneys. Health Policy. 2004; 68: 31-36. 
12 Garau M, Shah K, Towse A, et al. Assessment and Appraisal of Oncology Medicines: NICE's Approach and 
International HTA Experience. Report for the Pharmaceutical Oncology Initiative Group (POI), 2009. 
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This research identified a number of instances where reference to the severity of the 
disease was made during the assessment. 
 
Questions: 
 Appendix C-4 lists the quotations coded from the HTA reports as recognising 
“disease severity”.  Do you agree with what was coded as pertaining to disease 
severity in your country?  Any comments on how this was perceived in the other 
countries? 
 
 What are the criteria for recognising a disease as severe (e.g. life-threatening) and 
how do these influence the HTA outcome? 
 
 Are end-of-life treatments considered differently, and potentially qualify as severe 
cases (e.g. NICE end-of-life treatment)? 
 
 
11. Consistency across decision 
 Would it be conceivable for findings of innovativeness, unmet need and disease 
severity in the recommendations for the study drugs to constitute a precedent for 
how these matters are assessed in future recommendations? 
 
 In the appeals, has the consistency of considering these factors been a concern, and 
if yes, how have they been addressed?  
 
 
12. Public health value (ISP) and SMR 
 How are the following factors, accounted for in assessing the SMR, used to assign 
a higher or lower SMR? 
- efficacy & adverse events 
- place in the therapeutic strategy 
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- disease severity 
- preventive curative or symptomatic treatment 
- public health value (intérêt santé publique) 
 
 What is the weight of a public health value (ISP) in determining a drug’s SMR?  
Could the finding of an ISP (important, moderate, weak) increase the SMR of a 
drug that otherwise would have a lower SMR based on its clinical benefit?  Is there 
a framework with implicit weights for each criteria? 
 
 How are the following factors, accounted for in assessing the ISP, used to assign a 
higher or lower ISP? 
o Public health need 
o Impact of the treatment on the population’s health 
o Impact on the organisation of the health system 
o The particular ministerial plan under which the disease is designated as a 
priority 
 
 It appears that there were insufficient data to support a finding of public health 
value (ISP) for a number of the drugs.  Would better trial data on outcomes 
reflecting the impact of the treatment on the allocation of health system resources 
be valuable in the deliberative process for orphan drugs? 
 
 
DEALING WITH UNCERTAINTY  
We know that orphan indications are more difficult to appraise compared to more 
common indications, given it is more difficult to produce robust evidence due to the 
small sample sizes and heterogeneity of these conditions.  This, together with the high 
prices of these drugs to recoup R&D investments, results in orphan drugs being hardly 
ever cost-effective.  The question is whether more flexibility is given to accepting 
certain types of uncertainty when other types of evidence are presented, which is what 
we will try to understand in this section. 
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In a few cases, clinical uncertainties were deemed acceptable given the rarity of the 
condition: 
For eltrombopag, given it is an orphan drug destined to treat rare disease, the number 
of trial participants is considered large by TLV.  Quotation (translated): “The clinical 
studies of Revolade’s clinical efficacy demonstrates consistent data and relatively large 
number of patients included in the studies, given that ITP is a rare disease.” 
For trabectedin, NICE and SMC accepted that comparative evidence was limited given 
it is a drug that treats a rare condition.  Quotation: “The Committee appreciated that 
because soft tissue sarcoma is a rare condition, the evidence for the comparative 
effectiveness of trabectedin was limited.” 
For imatinib, SMC accepted the uncertain survival benefit given the rarity of the 
condition treated.  Quotation: “Although there were some limitations in the economic 
analysis in terms of the likely estimate of overall survival benefit, the economic case 
was considered to be demonstrated when the SMC modifiers, in particular those 
relating to medicines for orphan diseases, and the anticipated survival benefit 
associated with imatinib, were applied.” 
 
Question: 
 To what extent are certain types of uncertainties more acceptable given the rarity 
of the condition?  
 
 Do “other considerations” compensate for greater uncertainty for orphan drugs? 
Does a finding of ISP, even weak, compensate for clinical uncertainty? 
 
 
STAKEHOLDER INVOLVEMENT 
Who has input into the assessment process other than the manufacturer and the HTA 
body members? 
 
  
 
341 
Stakeholder input was mainly identified in the NICE appraisals, and in a few instances 
in SMC’s and is a direct result of the formal processes that exist (e.g. Public 
Involvement Programme (PIP) at NICE and the Patient and Public Involvement Group 
(PAPIG) at SMC).  No formal process for stakeholder input exists at TLV.  At HAS, 
participation of outside experts within the Transparency Committee was identified for 
all study drugs in the meeting minutes (procès-verbal), but the identification of the 
expert and the content of his/her advice was not recorded. 
The main type of information provided from patient and clinical experts was about 
“other considerations” and about clinical uncertainties.  
 
Questions: 
 What type of input do clinical experts and patient experts provide (e.g. 
uncertainties, clinical practice, evidence, assumptions, nature of the disease, living 
with the disease)?  
 
 How is their input accounted for (e.g. address uncertainty, participation in the 
deliberative process)? 
 
 Do clinical specialists have different conflict of interest requirements when dealing 
with small patient populations and the scarcity of specialists? 
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Appendix C-1: Study drugs & countries 
 
Generic 
name/Brand 
name 
Indication 
ICD10 
code1 
NICE 
England 
SMC 
Scotland 
TLV 
Sweden 
HAS 
France2 
Eltrombopag 
REVOLADE 
Thrombocytopenic 
purpura 
D2 
DNL 
TA205 
Oct 2010 
LWC 
625/10 
July 2010 
LWC 
3731/2010 
May 2011 
SMR 
important 
ASMR II 
June 2010 
Romiplostim 
NPLATE 
Chronic idiopathic 
thrombocytopenic 
purpura 
D2 
LWC 
TA221 
Apr 2011 
LWC 
553/09 
May 2009 
LWC 
833/2010 
Oct 2010 
SMR 
important 
ASMR II 
June 2009 
Everolimus 
AFINITOR 
Renal cell carcinoma 
(2nd line, advanced) 
C 
DNL 
TA219 
Apr 2011 
DNL 
595/10 
Mar 2010 
L 
853/2010 
Sep 2010 
SMR 
important 
ASMR IV 
Jan 2010 
Lenalidomide 
REVLIMID 
Multiple myeloma (3rd 
line) 
C 
LWC 
TA171 
Jun 2009 
LWC 
441/08 
Apr 2010 
L 
410/2010 
Jul 2010 
SMR 
important 
ASMR III 
Oct 2007 
Azacitidine 
VIDAZA 
Myelodysplastic 
syndrome 
D1 
LWC 
TA218 
Mar 2011 
LWC 
589/09 
Aug 2011 
NA 
SMR 
important 
ASMR II 
Apr 2009 
Imatinib 
GLIVEC 
Gastro intestinal 
stromal tumour 
(adjuvant, after surgery) 
C 
DNL 
TA196 
Aug 2010 
LWC 
584/09 
Aug 2010 
NA 
SMR 
important 
ASMR III 
Sep 2009 
Mannitol dry 
BRONCHITOL 
Cystic fibrosis  E 
LWC 
TA266 
Nov 2012 
DNL 
837/13 
Jan 2013 
NA 
SMR weak 
ASMR V 
Sep 2012 
Mifamurtide 
MEPACT 
Osteosarcoma C 
LWC 
TA235 
Oct 2011 
L 
837/13 
Jan 2013 
NA 
SMR 
insufficient 
DNL 
Nov 2010 
Ofatumumab 
ARZERRA 
Chronic lymphocytic 
leukemia 
C 
DNL 
TA202 
Oct 2010 
DNL 
626/10 
Jul 2010 
NA 
SMR 
moderate 
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ASMR V 
Oct 2010 
Trabectedin 
YONDELIS 
Soft tissue sarcoma C 
LWC 
TA185 
Feb 2010 
DNL 
452/08 
Jun 2011 
NA 
SMR 
important 
ASMR V 
Apr 2008  
Legend: NICE: National Institute for Health and Care Excellence (NICE); SMC: Scottish Medicines 
Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute Autorité de Santé; L: list; 
LWC: list with restrictions; DNL: do not list; NA: not applicable. 
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Appendix C-2. Quotations coded as an “innovation” in the HTA reports 
 
NICE SMC TLV
quotations translated
HAS
quotations translated
Eltrombopag Innovative: "cl inica l  experts  say that i t i s  an innovative treatment that 
mimics  the action of a  hormone…"
New class of drugs: "represents  a  new approach to therapy"
Oral administration: "benefi t of ora l  adminis tration 
recognised"
Oral administration: "the only treatment in 
that class  that can be taken ora l ly" 
First in class and oral administration: "the 
fi rs t ora l  thrombopotein receptor agonis t"
Romiplostim Adverse event profile: "i t has  a  good adverse-effect profi le, particularly 
in comparison with currently ava i lable treatments"
Improved clinical benefi t: "The Committee heard from the cl inica l  
specia l i s ts  that romiplostim may have benefi ts  over other active 
treatments  because i t produces  a  susta ined platelet response during "
New mechanism of action: "The Committee concluded that romiplostim 
has  a  novel  mechanism of action "
Step change: "romiplostim represents  a  s tep change for the treatment 
of ITP"
New class of drugs: "cons idered a  new class  
of drugs" + "i t i s  a  new principle for the 
treatment of ITP"
Everolimus
Lenalidomide Important advance: "lenal idomide i s  an important advance in the 
treatment of multiple myeloma and could be cons idered as  an 
a l ternative to bortezomib"
Provision: "lenal idomide could decrease 
the use of the heal th system given i ts  
adminis tration mode, a l though no 
evidence was  ava i lable to support this"
Azacitidine Important advance: "Committee recognised that azaci tidine represents  
an important change in the treatment of patients  with myelodysplastic 
syndromes, noting the substantia l  benefi ts  associated with i ts  use"
Imatinib Important advance: "imatinib treatment could represent a  
s igni ficant advance in therapy in patients  who are at high 
ri sk of tumour recurrence."
Mannitol dry Administration: "treatment burden i s  substantia l ly less  for an inhaler 
than for a  nebul i ser according to cl inica l  specia l i s ts  and patient 
experts ..... The Committee concluded that i t provided practica l  
advantages  over treatment with nebul i sers , but mannitol  as  an add-on 
therapy would not replace the use of nebul i sers , and so could not be 
cons idered a  s tep-change in treatment."
Administration: "i t i s  adminis tered as  a  dry powder 
inhalation, so may offer an important advantage over 
a l ternative treatments  which require nebul i sation."
Mifamurtide Important advance: "i t i s  cons idered a  s igni ficant innovation"
New mechanism of action: "the mechanism of action was  novel"
Potential valuable new therapy: "i t i s  a  potentia l ly va luable new therapy"
Ofatumumab New mechanism of action: "accordin to cl inica l  experts , i t may offer a  
s l ightly di fferent mechanism of action because i t targets  a  di fferent 
epi tope.
Trabectedin
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Appendix C-3. Quotations coded as an “unmet need” in the HTA reports 
 
NICE SMC TLV
quotations translated
HAS
quotations translated
Eltrombopag Unmet need: "..The Committee heard that patients  with a  low 
platelet count with a  pers is tent ri sk of uncontrol led bleeding 
have the greatest unmet need for treatment..."
Few treatment alternatives exist: "The Committee understood that 
options  for treatment of chronic ITP are l imited when 
conventional  treatments  fa i l  to reduce the ri sk of bleeding"
No treatment alternatives exist: "The guidel ine 
s tates  that there i s  no indication for treatment 
in adults  in whom there are no s igns  and 
symptoms and platelets  are greater than 
30x109/L"
Need for treatment options: "economic case was  
cons idered to be demonstrated as  el trombopag 
would offer an additional  treatment option "
No treatment alternatives exist: "No 
satis factory treatment options  for patients  
with chronic refractory ITP. "
Few treatment alternatives exist: "For these 
patients , treatment options  today are 
l imited."
Few treatment alternatives exist: "few 
therapeutic a l ternatives  exis t"
Romiplostim Unmet need: "Cl inica l  experts  advised that that there i s  s igni ficant 
unmet need"
Few treatment alternatives: "The Committee understood that there 
are few treatments  l i censed for the treatment of chronic ITP"
Few treatment alternatives: "l imited therapeutic 
a l ternatives  are ava i lable."
Need for treatment options: "romiplostim would be 
a  va luable addition to the range of ava i lable 
treatment options  for ITP"
Few treatment alternatives: "l imited 
therapeutic options"
No treatment alternatives exist: 
"There i s  no va l idated therapeutic 
a l ternative in these cl inica l  
s i tuations ."
Everolimus Few treatment alternatives exist: "The Committee heard from 
cl inica l  specia l i s ts  and patient experts  that there are l imited 
treatment options  for people with advanced... "
No treatment alternatives: "no a l ternative medicina l  products  exis t" 
No treatment alternatives exist: "No 
a l ternative medicina l  products  
exis t"
Lenalidomide Need for treatment options: "The Committee noted the importance 
that patients , thei r carers  and phys icians  placed on having 
effective options  to treat multiple myeloma at presentation and 
at subsequent relapses ."
No alternatives with similar benefits: "a l ternatives  not routinely 
ava i lable on the NHS"
Treatment alternatives exist: 
"medicina l  or non-medicina l  
treatment a l ternatives  exis t"
Azacitidine No alternatives with similar benefit: "fi rs t medicine 
to be l i censed speci fica l ly for the treatment of 
primary MDS"
Imatinib No treatment alternatives: "there are currently no adjuvant 
therapies  ava i lable for people fol lowing resection of a  GIST, and 
that watchful  wai ting i s  the current s tandard of care"
No treatment alternatives exist: "The current gold 
s tandard of treatment in primary resectable GIST 
i s  surgery with gross  margin resection and there 
i s  no accepted adjuvant treatment."
No treatment alternatives: "there i s  
no a l ternative medication"
Mannitol dry Unmet need: "The Committee concluded that there i s  an unmet 
cl inica l  need in patients  with rapidly decl ining lung function, 
particularly i f there are no other therapies  appropriate to offer 
the patient."
Need for treatment options: "the importance of treatment options  
for people with cystic fibros is  who have few a l ternative options ."
Unmet need: "The company has  suggested that 
there i s  an unmet need for an effective 
treatment in patients  who have fa i led to 
respond to, or are intolerant of, other 
treatments"
Need for treatment options: "high unmet need for 
effective therapies ."
Treatment alternatives exist: 
"therapeutic a l ternatives  exis t"
Mifamurtide Few treatment alternatives exist: "patient experts  and cl inica l  
specia l i s ts  s tated that there had been few developments  that 
had improved treatment outcomes  for osteosarcoma over the past 
20 years"
Treatment alternatives exist: 
"therapeutic a l ternatives  exis t"
Ofatumumab No treatment alternatives: "lack of treatment options  for patients  at 
this  s tage of disease"
Few treatment alternatives: "l imited treatment options"
Need for treatment options: " cl inica l  specia l i s ts  s tated that i t was  
important to have additional  treatment options , such as  
ofatumumab, later in the treatment pathway"
No treatment alternatives exist: "given the absence 
of any a l ternative treatment va l idated in 
extens ively pretreated patients  who are 
refractory to fludarabine and a lemtuzumab…."
No treatment alternatives exist: 
"absence of va l idated treatment 
a l ternatives"
Public health need: "improving the 
therapeutic management of chronic 
lymphcytoctic leukemia  i s  a  publ ic 
hea l th need"
Trabectedin No alternatives with similar benefit: "that treatment with trabectedin 
represents  an option for those patients  who would otherwise 
have no l i censed treatment options ."
Unmet need: "cl inica l  experts  advised that there 
i s  unmet need for effective second l ine 
treatments  in patients  with advanced soft ti s sue 
sarcoma who have good performance s tatus ."
No treatment alternatives: "no 
va l idated a l ternative drug 
treatment at this  s tage of the 
disease"
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Appendix C-4. Quotations around disease severity and the impact of living with the disease on the 
patient & surrounding
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Appendix D. Ethics Approval 
